Problems of Drug Dependence, 1984 : Proceedings of the 46th Annual Scientific Meeting by unknown
National
Institute on
Drug
Abuse
MONOGRAPH SERIES
Problems of
Drug Dependence
1984
Proceedings of the
46th Annual Scientific Meeting
The Committee on Problems
of Drug Dependence, Inc.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service Alcohol, Drug Abuse, and Mental Health Administration
Problems of Drug
Dependence, 1984
Proceedings of the 46th Annual
Scientific Meeting, The Committee
on Problems of Drug Dependence, Inc.
Editor: Louis S. Harris, Ph.D.
NIDA Research Monograph 55
March 1985
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Alcohol, Drug Abuse, and Mental Health Administration
National Institute on Drug Abuse
Office of Science
5600 Flshers Lane
Rockville, Maryland 20857
For sale by the Superintendent of Documents, U.S. Government Printing Office
Washington, D.C. 20402
NIDA Research Monographs are prepared by the research divisions of the
National Institute on Drug Abuse and published by its Office of Science. The
primary objective of the series is to provide critical reviews at research problem
areas and techniques, the content of state-of-the-art conferences, and integra-
tive research reviews. Its dual publication emphasis is rapid and targeted dissem-
ination to the scientific and professional community
Editorial Advisors
Martin W. Adler, Ph.D.
Temple University School of Medicine
Philadelphia, Pennsylvania
Sydney Archer, Ph.D.
Rensselaer Polytechnic Institute
Troy, New York
Richard E. Belleville, Ph.D.
NB Associates, Health Sciences
Rockville, Maryland
Gilbert J. Botvin, Ph.D.
Cornell University Medical College
New York, New York
Joseph V. Brady, Ph.D.
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Theodore J. Cicero, Ph.D.
Washington University School of Medicine
St Louis, Missouri
Sidney Cohen, M.D.
Los Angeles, California
Reese T. Jones, M.D.
Langley Porter Neuropsychiatrlc lnstltute
San Francisco, California
Denise Kandel, Ph.D.
College ot Physicians and Surgeons of Columbia University
New York, New York
Herbert Kleber, M.D.
Yale University School of Medicine
New Haven, Connecticut
NIDA Research Monograph Series
William Pollin, M.D.
DIRECTOR, NIDA
Jack Durell, M.D.
ASSOCIATE DIRECTOR FOR SCIENCE, NIDA
EDITOR-IN-CHIEF
Eleanor W. Waldrop
MANAGING EDITOR
Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857
Foreword
The National Institute on Drug Abuse presents once again to readers
of its Research Monograph series the Proceedings of the Annual
Scientific Meeting of the Committee on Problems of Drug Dependence,
Inc. NIDA and the CPDD share many interests and concerns in
developing knowledge that eventually will lessen the destructive
effects of dependence-producing substances on individual lives and
their costly burden on our society as a whole. As would be
expected, the two organizations work closely together.
CPDD's Annual Scientific Meetings gather the outstanding
investigators from many disciplines to discuss their ongoing
projects. Researchers from NIDA's own Addiction Research Center
report their findings here. In addition, the work of many other
CPDD members and meeting participants receives support through
NIDA's grant programs. The CPDD drug testing program to assess the
dependence potential and abuse liability of new compounds is also
NIDA-supported. Results of these tests, which seek analgesic drugs
free of abuse hazard, are included in each year's Proceedings.
A symposium on the neuroendocrine effects of substance abuse is
featured in Problems of Drug Dependence, 1984. In addition to papers
on chemistry and pharmacology, clinical pharmacology, treatment, and
epidemiology. It is gratifying to make available to drug abuse
professionals and to the public this yearbook of current research on
all aspects of the drug abuse field.
William Pollin, M.D.
Director
National Institute on Drug Abuse
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The papers in this monograph were presented or read by title at
the 46th Annual Scientific Meeting of the Committee on Problems of
Drug Dependence, Inc., in St. Louis, Missouri, June 4-6, 1984.
The CPDD, an independent, nonprofit organization, conducts drug
testing and evaluations for academic institutions, government, and
industry. Louis S. Harris, the editor of the monograph, is
chairman of the Department of Pharmacology, Medical College of
Virginia, Richmond, Virginia.
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Presentation to Kay Croker of
J. Michael Morrison Award for
Outstanding Achievement in Science
Administration in the Drug Field
Martin W. Adler
Michael Morrison was an exceptional young man who embodied all
those qualities one hopes to find in an administrator. When he
died about four years ago at the age of 36, Mike was Executive
Secretary of the Biomedical Research Review Committee at the
National Institute on Drug Abuse. Upon his death, his friends
and colleagues felt that the most appropriate memorial would be
an award honoring outstanding achievement as an administrator in
the drug field. The Committee on Problems of Drug Dependence,
Inc., agreed to administer the award and present it biennially.
This is the second such award.
Our awardee embraces all those qualities we so admired in Mike.
She is warm, dedicated, hard-working and extremely knowledgeable
in all areas of her work. Kay Croker has been with the American
Society for Pharmacology and Experimental Therapeutics since
1977, rising from the position of Editorial Assistant to
Administrative Secretary for the Executive Officer in 1982. To
give you some idea of what the members of ASPET think of Kay, at
the last business meeting of that society just two months ago,
the report of virtually every committee was followed by that
chairperson's singling out our awardee for special thanks for
the way she aided the committee in achieving its goals. All it'
seems to take are workdays that often extend 14 to 16 hours, a
flair for organization, a love for her job, and a warmth that
makes everyone comfortable.
For her outstanding achievements as as administrator, I am very
pleased and honored to present the J. Michael Morrison Award for
1984 to Ms. Kay Croker.
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Introduction of Nathan B. Eddy
Memorial Award Recipient—1984
Louis S. Harris
It gives me great personal pleasure to introduce this year's recip-
ient of The Nathan B. Eddy Award. Dr. Raymond Wilfred Houde was
born in New Hampshire and educated in New York, receiving both his
Baccaluareate and Medical degrees from New York University. After
a brief internship at Bellevue, he was on active duty with the
Navy from 1944-46.
He completed his residency in medicine at Memorial Hospital, a
connection he maintained until his retirement in 1982. From 1948-50,
he was a Research Fellow in Analgesia at Memorial Hospital and
Sloan-Kettering Institute. He used this time to spend a year first
in the Pharmacology Department at The University of Michigan and
then at the U.S. Public Health Service Hospital in Lexington,
Kentucky.
At Michigan, with Sam Irwin, a graduate student at that time, he
studied the effects of narcotics on reflex responses to nociceptive
stimuli in spinal animals. This interest was further pursued with
Abe Wikler at Lexington. It is noteworthy that Dr. Houde was the
senior author on the first paper delineating the usefulness of the
chronic spinal dog in evaluating analgesic and other centrally
acting drugs.
Following this training, Dr. Houde continued his uninterrupted
career at Cornell University Medical School and Sloan-Kettering,
rising through the ranks in both the Departments of Pharmacology
and Medicine with the encouragement of NBE. His research became
more clinical and he developed his first-rate team of Stan Wallen-
stein and Ada Rogers, who have remained together to the present.
Indeed, in his pioneering use of a nurse observer, etc., not only
did this team turn out some of the best clinical research in the
area of pain and analgesia, but they trained a host of clinical
pharmacologists, many of whom have gone on to highly productive
careers of their own. These include, to name a few, John Seed,
T. Weldon Bellville, Bill Forrest, Bill Beaver and more recently
Bob Kaikor.
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Dr. Houde has also well served the medical and scientific community
by his participation on numerous national and international commis-
sions and boards. Of particular note are his services to The
International, American and Eastern Pain Associations and The
Committee on Problems of Drug Dependence.
Dr. Houde is a modest, gentle man whose career may be summed
up by the following citation:
"Raymond Wilfred Houde -- compassionate physician, brilliant
clinical scientist. Your research into the nature of pain and
its relief has greatly benefited mankind."
The Committee on Problems of Drug Dependence is honored to name
you as the 1984 recipient of The Nathan B. Eddy Award.
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The Analgesic Connection: The
Nathan B. Eddy Memorial Lecture
Raymond W. Houde
First, I should like to thank the Committee for honoring me with
this award. To have been chosen to present the Nathan B. Eddy
Memorial Lecture is a very special honor and privilege for me.
Dr. Eddy was one of our strongest supporters, and he played an
important role in keeping our research team intact and on track,
I have very vivid memories of him at these meetings. I can still
almost feel his presence down there in the front row - gazing
downward in contemplation. At first, I used to think him asleep,
but soon learned the folly of that notion in the ensuing discuss-
ion period. But he was alway fair with us, and beneath that stern
and somber exterior I found him a warm and true friend.
I also want to thank those of you upon whose shoulder I have stood
to become visible for this award, and I am most grateful for a most
dedicated staff and group of associates. Most of you here know
Stan Wallenetein and Ada Rogers who have been with me almost from
the start. They and the other members of our research team,
including a secretary who has been with me almost as long, are the
ones who have kept it all together for these past 30 plus years.
It would be presumptuous for me to explain to you Dr. Eddy’s
involvement with the analgesic connection. However, I should like
to tell you how I became involved, for the circumstances have a
bearing on come of the studies we later conducted with the support
of this Committee. While serving as a medical resident at Memorial
Hospital after my discharge from the Navy at the end of World War
II, I was approached by two of our internists who asked me to
assist them in a study they had undertaken of some new strong
analgesics which had been developed by the Germane during the war.
Their study was being carried out in the manner in which studies
were usually done then and, too often, are still being done in the
same way today. It was conducted as an uncontrolled open trial -
and the observations were made in an unsystematic way by the busy
floor nurses whose other duties often took precedence over a study
in which they had little interest or commitment. Eventually, the
time came to put it all together for presentation at a meeting of
the New York Academy of Sciences, and you just know who pulled the
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short straw (Houde et al., 1948). I did not think then that I did
such a bad job under the circumstances - but a sharp-tongued
biostatistician named Bliss in the audience thought otherwise, and
I can leave it to your imagination as to how well. that discussion
period went for me. I vowed then and there that I had had it up to
here with analgesic studies.
I do not recall whether I had actually met Dr. Eddy then, although
he also presented a paper at the meeting which ‘included a rather
favorable report of a nationwide survey on the effectiveness of
oral metopon (methyldihydromorphinone) in cancer patients. We
were among the hundreds of physicians who submitted reports to him,
but our five patients must have been among the outliers in his data
on over 5,000 patients. But, I was not about to make a point of
that! To me, at that time, Dr. Eddy looked every bit as austere
and formidable as the good Dr. Bliss.
Sometime later, I was invited to attend a meeting between a number
of pharmaceutical company executives - including Maurice Tainter,
who chaired the Academy of Sciences meeting - and C.P. Rhoads,
Director of the Sloan-Kettering Institute, to set up an analgesic
study program at our hospital. Having been once burned, I wanted to
have nothing to do with it - but I was later induced to change my
mind by being offered a sabbatical and an opportunity to get
additional. training in pharmacology. It was then my good fortune
to have as my mentors, in succession: Drs. Seevers, Harris Isbell
and Abe Wikler - who were later to become, in the same sequence,
the first three, recipients of the Eddy Memorial Award.
My second meeting with Dr. Eddy was in November 1949. I had been
invited to attend a meeting of this Committee, known then as the
National Research Council Committee on Problems of Drug Addiction
and Narcotics, to present a report of the studies I had been
carrying out in spinal animals of the tail flick of the rat and
akin twitch of the dog and guinea pig, indices of pain commonly
used in laboratory animals for testing drugs for analgesic act-
ivity. The results of that early work led me to conclude that
these methods measured spinal reflexes upon which opiates acted and
that they were thus not true measures of the effects of these drugs
on pain perception. Rereading that report (Houde, 1949), I am
amused by my not-too-profound statement which read as follows:
Nevertheless comparison of the effect of medication before and
after operation showed that invariably the threshold rises were
appreciably greater in the intact than in the spinal animal for
any given dose of the drugs employed - an observation which we
have not been able to fully explain.
A lot of water has passed under that bridge, since that split
infinitive!
On my return to Memorial Sloan-Kettering, my efforts were directed
more to the development of a clinical research program than to my
studies with. spinal animals, which was then gradually phased out.
In the meantime, I had become acquainted with Harry Beecher and
impressed by his reports to this Committee at its annual scientific
meetings which I have attended regularly since 1951. In 1956, we
received the first in a long series of small annual grants from the
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Committee which served to keep our research team together and
greatly influenced the direction of our research.
Working at a large cancer center has tended to insulate us from
some of the problems of drug abuse. But it has also provided
unique opportunities to compare the effects of analgesics in a
variety of circumstances which have relevance to quest ions of
whether to restrict the use and availability of substances expected
to have abuse potential. Most patients with cancer will experience
some acute or chronic pain in the course of the disease or its
treatment, or from complications of the disease or treatment. Many
of these patients will also have organ dysfunction capable of
influencing the absorption, distribution, metabolic disposition or
elimination of particular analgesic drugs. Moreover, virtually all
patients with cancer are subject to a great deal of emotional
stress and the manner in which they contend with it will vary with
their backgrounds, personalities, and a wide variety of other
circumstantial factors. The need for effective analgesic
medications for these patients is undeniable and it is unlikely
that any single analgesic, or single class of analgesics, will fill
the bill. What is desirable or undesirable in an analgesic will be
influenced to a great degree by the clinical circumstances. The
role of the physician is to relieve both pain and suffering, and
side effects which may be considered adverse or undesirable in some
situations may be highly desirable in others. The goals of the
search for better analgesics are not out of step with those of the
quest for nonaddicting or nondependence-producing analgesics. I
have no allusions that we will ever find the panacea, but I do
believe that substantial progress has and will continue to be made
in the development of drugs that are more selective in their
act ions, or have different constellations of pharmacological
act ions, to provide greater flexibility in meeting medical needs.
We now recognize that many different classes of drugs are capable
of producing dependence, and compulsive drug-seeking behavior has
become more closely linked to their euphorigenic or other mood-
altering properties than to signs or symptoms of tolerance and
physical dependence. But euphoria is hardly an adverse side effect
to a patient dying of cancer, even though a sense of well-being may
seem inappropriate to the onlooker in that circumstance. Quite
understandably, most patients report that they feel better when
their pains are relieved and, at least in our studies of the
morphine-like opioids, the extent of mood elevation seems to
closely parallel the degree of pain relief. As we look across drug
classes, however, differences can be seen. This has been most
striking when comparing morphine to narcotic agonist-antagonist
analgesics - such as nalorphine, pentazocine, nalbuphine and
butorphanol - when pain relief was observed despite dysphoric
reactions in a substantial proportion of patients (Houde, 1979).
With somewhat more sensitive instruments, such as the mood
questionnaire which we have been employing recently, nonsteroidal
antiinflammatory drugs can also be distinguished from morphine in
terns of their relative lack of mood elevating actions in
equianalgesic doses. To what extent this constitutes a great leap
forward will of course depend upon when and how these drugs are
used clinically. The relative potentials or therapeutic indices of
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the nonsteroidal analgesics and the narcotic agonist-antagonists
are, in general, lower than those of the traditional opiates or
morphine-like opioids and, because of their potentially adverse
hematological and gastrointestinal side effects, the nonsteroidals
are particularly hazardous for some patients - particularly cancer
patients receiving chemotherapy.
In pharmacological terms, a statement of relative potency is
nothing more than an expression of the ratio of doses of two drugs
which produce a given effect. Its major function in the evaluation
of analgesics is that it allows one to compare drugs in terms of
their side effects, or adverse effects, at equianalgesic doses. On
the other hand, when speaking of efficacy, we are primarily con-
cerned with the maximal effect obtainable by increasing the dose
to the point of limiting side effects. To denote this, we have
used the term ‘relative potential’. Maximal or ‘ceiling’ effects,
are demonstrable only if one can demonstrate no further increases
in effect with increasing doses (Fig.1). In the clinical setting,
we have not found it possible to do this with morphine or its
surrogates because limiting side effects intervene before the log
dose-response curve flattens out. Although there are certain
criteria which must be met for a valid relative potency assay,
designing a study in that manner has undeniable advantages. First
of all, it forces the use of graded doses of the test or standard
drugs, and the responses to graded doses of a standard drug provide
a measure of the sensitivity of the assay. We strongly believe
that the ability to demonstrate that the subject population and
FIGURE 1. Conceptual representation of ‘relative potency’
‘relative ceiling effects’ and ‘relative potential’. The solid
regression lines of effect on log dose denote responses within
limiting adverse effects of hypothetical drugs A, B, and C, and the
dashed lines their projections beyond that level.
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method are capable of discriminating between a known active
standard and a placebo, or between graded doses of the standard,
should be an integral part of every study of the effects of drugs
on pain.
To illustrate this point, I should like to give a brief report on a
series of studies that we carried out with metopon, the long since
departed drug which had been the subject of Dr. Eddy’s report at
the New York Academy of Science meeting in 1948. Pre-clinical and
preliminary clinical trials were said to have demonstrated that the
oral and parenteral analgesic doses of this drug were essentially
the same, that tolerance and dependence developed more slowly than
to morphine, and that the drug was relatively free of adverse ef-
fects. From the results of the nationwide survey, Dr. Eddy con-
cluded that metopon hydrochloride, which was supplied as a 3 mg
capsule, was an effective oral analgesic for chronic pain due to
cancer, and that its use was accompanied by a “high incidence of
mental clarity and a low incidence of side effects.” He also com-
mented that tolerance to metopon developed more slowly than toler-
ance to morphine. In light of all this, we were intrigued by the
fact that the drug was hardly being used at all less than 10 years
later.
First we undertook to do a double-blind crossover study comparing
graded intramuscular doses of metopon to graded doses of morphine
and a placebo in a series of sequentially related experiments in
patients with pain due to advanced cancer (Houde and Wallenstein,
1957). In each of these experiments or “quintets”, as they were
called then, each patient received two doses of metopon which
varied in each quintet, 8 and 16 mg of morphine, and a saline
placebo, all in a randomized order. The patients were seen hourly
during the day by a single nurse, Ada Rogers, who recorded the
patients’ reports of pain intensity and administered the coded test
medication for moderate to severe pain. The patients’ responses
were evaluated in terms of the areas under the time-effect curves
for changes in pain intensity in each of the four experiments or
quintets. The data met the statistical requirements for a valid
relative potency assay and showed that, indeed, when administered
intramuscularly, metopon hydrochloride was over 3.5 times as potent
as morphine sulfate (Fig.2).
We then sought to determine whether orally administered metopon is
as effective as parenteral metopon when studied double-blind in the
same patient. As we had done in an earlier study of aspirin and
morphine, double-blind conditions were achieved simply by admin-
istering both a capsule to take by mouth and an intramuscular
injection when the patient required medication for pain (Houde and
Wallenstein, 1958). The results of that study, which was otherwise
conducted in the same manner as the comparison with morphine,
revealed that metopon was less than 1/5th as potent by mouth as it
was by intramuscular injection when tested in the same patients in
the same setting, and by the same method, double-blind. When the
results were reported to the Committee in 1958, Dr. Eddy was
gracious in his remarks but, I suspect, not totally convinced, for
shortly after that, he put our method to test in a study, with
Lyndon Lee, of the relative potency of parenteral oxymorphone and
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FIGURE 2. Dose response curves for intramuscular metopon and
morphine plotted in terms of the mean total scores for changes in
pain intensity over 6 hrs (the ordinate) and logarithm of the dose
(abscissa) for each of the four quintets, numbered in the order in
which they were done. The respective placebo scores are shown as
dashed lines.
morphine. We had assayed oxymorphone a few years before and
reported to the Committee that we found 1.12 mg of oxymorphone
equianalgesic to 10 mg of morphine and that the 95 per cent con-
fidence limits of our estimate were 0.90 to 1.65 (Houde and
Wallenstein, 1956). Dr. Lee’s study was conducted double-blind in
cancer patients at the Wayne County General Hospital in Michigan,
but, back in Bethesda, Dr. Eddy controlled the code and determined
the dose ratios’ to be studied. When their results were in, their
analyses revealed 1.02 mg of oxymorphone to be equivalent to 10 mg
of morphine with 95 per cent confidence limits of their estimate
similar to ours (Eddy and Lee, 1959). After that I knew we were
in with Dr. Eddy.
We also used the relative potency approach in a small short-term
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study of tolerance and cross-tolerance involving intramuscular
metopon and morphine in which an estimate of the relative poten-
cies of the two drugs was determined in a small group of patients
over a period of a week, and then half the group was placed on
repeated doses of morphine and the other half on repeated doses of
metopon for 7 to 8 days. Finally, in the third week, the drugs
were reevaluated for their relative potency as they had been in the
first week (Houde and Wallenstein, 1957). Only 13 patients
completed this little experiment, so that it was based on relative
potency estimates in only 6 and 7 patients, too few to provide a
definitive answer. However, the results were consistent in showing
that tolerance did indeed develop to metopon as well as to morphine
and that cross-tolerance between the two drugs was not complete.
TABLE I: Approximate equianslgesic mg doses of morphine (Mo) and
metopon (Me) based on crossover comparisons of graded
doses of each drug before and after chronic administra-
tion of each drug in two separate small populations of
tolerant patients with advanced cancer.
A similar study comparing methadone and morphine in a still smaller
group of 11 patients revealed a similar result. Because of the
relatively short length of stays of patients in active treatment
hospitals such as ours, it is extremely difficult to get together
a sufficient number of relatively stable patients for more definit-
ive studies of tolerance and physical dependence. However, it is
possible to identify patients who are relatively nontolerant and
others who are obviously tolerant to opioids, merely on the basis
of their recent past drug experience and the amount of drug that
they require for pain relief. It has, thus, been possible for us
to carry out parallel studies in two populations using the same
methodology and nurse-observers. This procedure has been particu-
larly useful in looking at interactions of agonist-antagonists,
such as pentazocine and morphine, where distinctly different
patterns are observed. In nontolerant patients, the effects of the
two drugs were found to be essentially additive, whereas in
tolerant patients, increasing the ratio of pentazocine to morphine
not only produced a progressive decrement in the analgesic effect
of the combination to the point of providing no analgesia but also
of precipitating withdrawal signs in some patients - an indication
that analgesic tolerance and physical dependence to narcotics go
hand in hand.
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Employing the same strategy, we undertook to test the hypothesis
that because of its reported greater euphorigenic properties,
heroin would prove to be uniquely effective in patients with
advanced cancer. To do this we carried out parallel studies in
nontolerant patients undergoing potentially curative surgery and in
narcotic tolerant patients with hopelessly advanced incurable
cancer. The drugs were administered intramuscularly and the
studies differed from those I have just described only in that we
employed visual analog scales in addition to our verbal categor-
ical scales of pain intensity and pain relief, and we also included
both a visual analog scale and a word pair questionnaire (adapted
from Lasagna et al., 1955) for measuring mood effects. The results
confirmed what was already well documented in the medical litera-
ture, namely, that heroin is approximately twice as potent as mor-
phine on a milligram basis, and that it has an earlier onset and
shorter duration of action than morphine. Moreover, though the
chronic pain patients with advanced cancer obtained less relief
than the postoperative patients from comparable doses of both
drugs, the analgesic potency of heroin relative to morphine was
found to be virtually the same in the two patient populations.
Also of interest was the fact that the effects on mood paralleled
the analgesic data, and this was shown very convincingly by the
results of the mood questionnaire (Kaiko et al., 1981).
We have, also, recently completed a double-blind comparison of the
relative oral to intramuscular potency of heroin hydrochloride
which revealed that it requires about 10 to 12 times as much heroin
by mouth to produce the same effect as when it is given by intra-
muscular inject ion. Based on our earlier studies of the oral/
parenteral potency of morphine in which we found that it required
almost six times as much oral morphine as intramuscular morphine to
produce the same analgesic effect (Houde et al., 1965). it appeared
to us that essentially all of the heroin given by mouth was being
converted to morphine before reaching the central nervous system.
That, in fact, was what we found in later studies of the bioavail-
ability of oral heroin since, when it was given by mouth in doses
as high as 60 mg, all that we were able to detect in the blood was
morphine, by an analytical assay method sensitive to 1 to 2 ng/ml
of heroin or 6-monoacetylmorphine, the other major metabolite of
heroin. On the basis of these results, it would seem that admin-
istering heroin by mouth is simply an expensive way of administer-
ing morphine which itself undergoes fairly extensive first-pass
metabolism. The failure to detect any striking differences in the
euphorigenic properties of intramuscular heroin and morphine also
leads me to believe that the passage of the bills now in Congress
to legalize heroin are more likely to compound the problems of the
DEA than to improve the management of the dying cancer patient. As
has also been recently reported (Inturrisi et al., 1984), heroin
does not bind to the opiate receptor, and its central act ions are
believed to be due to its being converted to 6-monoacetylmorphine
and morphine.
I should prefer not to close on this negative note. Actually, sub-
stantial progress has been made in developing drugs that have
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brought us closer to Dr. Eddy’s dream. Of perhaps greater import-
ance, the strides made in understanding the neuropsychophysiolog-
ical causes of pain have, in large measure, resulted from that
search for a strong nonaddicting analgesic and investigations of
the mechanisms of actions of the narcotic analgesics. Earlier Eddy
Award winners - specifically Bill Martin, Hans Kosterlitz, Eddie
Way, Avram Goldstein and Eric Simon - have all given you sterling
accounts of that research and it would be foolhardy for me to
venture into that territory. However, I hope that with these few
examples of my involvement with Dr. Eddy’s dream, I may have been
able to throw a bit of light on some of the more commonplace
aspects of the analgesic connection between the problems of drug
abuse and legitimate medical concerns,
Lastly, I should like again to thank the Awards Committee and all
of you for your forbearance in accompanying me in my journey down
memory lane.
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Opiate and Opioid Modulation of
Reproductive Endocrinology in the
Male and Female: Development
and Pregestational Aspects
Theodore J. Cicero
In this review, the influence of opiate drugs on reproductive
endocrinology in the male and female rodent will be reviewed.
Additionally. the possible role, and physiological significance, of
endogenous opioid peptidergic systems in modulating activity in the
regulatory systems involved in the release of luteinizing hormone
(LH) and LH-releasing hormone (LHRH) will also be evaluated. The
review has been divided into three major sections. In the first,
the influence of opiate drugs on reproductive endocrine parameters
will be discussed, particularly with respect to how the natural
evolution of these studies led to the hypothesis that endogenous
opioids represent an integral component of the hypothalamic
circuitry involved in LH/LHRH release. Second, the age- and sex-
related differences in the opioid-mediated control of reproductive
endocrinology will also be evaluated within the context that opioid
peptides may be involved in the onset of puberty and sexual
maturation. Finally, several recent studies will be discussed in
which the neuroendocrine maturation of offspring derived from drug-
naive females and males treated pregestationally with opiates have
been examined.
INFLUENCE OF OPIATES ON THE HYPOTHALAMIC-PITUITARY-GONADAL (H-P-G)
AXIS
Over the past 10 years, the effects of opiate drugs on the H-P-G
axis have been extensively examined in both the male and female of
virtually every species. To summarize this large body of
literature would not be possible here, but several recent studies
are available (Cicero 1980; Kalra 1982; Kalra and Kalra 1983). For
the purposes of this discussion, it is important to note only that
reproductive endocrinology is disrupted by both acute and chronic
opiate drug administration and that these compounds appear to exert
their primary effects by inhibiting the release of LHRH from the
hypothalamus. The precise manner in which the opiates inhibit the
release of LHRH has not been characterized, but it appears that
this action is mediated by opiate receptor(s) within the
hypothalamus. The existence of opiate receptors within the
hypothalamus, which apparently impinge in some fashion on LHRH-
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containing cell bodies, has led to the hypothesis that there may be
endogenous opioids present to interact with these; receptors and,
hence, play a role in the complex hypothalamic control mechanisms
involved in the release of LHRH. This hypothesis has been
impressibly supported by the following observations (which have
been fully discussed in the references listed above) (Cicero 1980;
Kalra 1982; Kalra and Kalra 1983). First, opiate antagonists
produce rapid dose-dependent increases in serum LH levels within
minutes after their subcutaneous administration; second, naloxone
competitively inhibits steroid-induced negative feedback control of
LHRH. Third, several endogenous opioids injected directly into the
cerebral ventricles depress serum LH levels, whereas antibodies to
several of these peptides increase LH levels. Fourth,
manipulations known to alter activity within the hypothalamic-
pituitary-LH axis produce changes in endogenous opioid contents in
the hypothalamus and pituitary and in opioid receptor
topographies. Finally, morphine and other opioids are just as
effective as testosterone in reversing the effects of castration on
the hypothalamic reserves of LHRH. Taken as a whole, these
observations suggest that opioid-containing neuronal pathways
represent an important component of the hypothalamic circuitry
involved in LHRH release and may represent an intermediate link
between the effects of steroids on the hypothalmus and their
inhibition LHRH.
DEVELOPMENTAL ASPECTS
The probable role of endogenous opioids in the regulation of
reproductive endocrinology has prompted several investigators to
examine whether alterations in opioid peptide-containing systems
are involved in sexual maturation and the onset of puberty in the
male and female rodent (Blank et al. 1979; Blank et al. 1979, 1980;
Ieiri et al. 1979; Schulz et al., 1982). In three of these
studies, the response to naloxone, an opiate antagonist known to
increase LH levels in the adult, has been examined in prepubescent,
adolescent and adult male and female rats and the LH-depressing
action of morphine has been evaluated in only one study. Aside
from this relative paucity of studies. few definitive conclusions
can be drawn from these published reports: the results are both
qualitatively and quantitatively different.
An inspection of these reports suggests that-numerous factors could
be involved in these discrepancies, including very small numbers of
subjects, the use of non-optimal drug doses and post-injection time
intervals and, finally, only selected time intervals during
development have been examined. Because developmental studies
offer a unique opportunity to more fully understand the
relationship of endogenous opioids to the control of LHRH/LH, we
have carried out a parametric study examining the age- and sex-
related differences in the LH response to a prototypic. Opiate
agonist (morphine) and antagonist (naloxone) in the rat.
Methods
Sprague-Dawley derived male and female rats were bred in our
laboratories (Fl generation of animals purchased from Harlan
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Industries, Indianapolis, Indiana) and maintained at a constant
environment of 22-25°C under a 12-hour light:dark cycle. At 80-90
days of age, one male and female were housed together for two
complete estrous cycles, at which time the males were removed and
the females permitted to carry to term. The dates of birth of the
offspring were recorded to the nearest 12 hours. Litters were
culled to 8 pups (4 males and 4 females) at 10 days of age and
weaned from their mothers at 21-24 days. Male and female offspring
were utilized at the following ages: 10, 15, 20, 25, 30, 35, 40, and
60 days of age. To minimize biological variation and provide
sufficient material for the multiple assays to be carried out, we
found it necessary to use 45 animals of each sex at days 10, 15, 20
and 25 (blood pooled from 3 animals for a total N of 15) and 15
animals at all older ages. At the appropriate intervals, rats were
injected with supramaximal doses of morphine (10 mg/kg), naloxone
(1 mg/kg) or saline, as determined in preliminary studies. They
were then killed by decapitation 2 hours after the injection of
morphine or 20 min after the administration of naloxone, the times
at which optimal decreases and increases in serum LH levels,
respectively, are found; half of the saline-injected animals were
killed at each post-injection time interval to control for possible
circadian rhythms. Serum was obtained and frozen at -2O°C until LH
radioimmunoassays (RIAs) were carried out. Once the foregoing
study was completed, an additional experiment was carried out in
which morphine and naloxone dose response curves were constructed
in both males and females at those intervals when morphine and/or
naloxone appeared to be least effective in the preceding studies.
Results
Effects of naloxone and morphine on serum LH levels. The effects
of saline, naloxone (1 mg/kg) and morphine (10 mg/kg) on serum LH
levels in male rats from 10 to 60 days of age are shown in Figure
1. The data depicted in this figure represent the pooled results
of two experiments (N=30 to 40). Neither naloxone nor morphine
affected serum LH at the earliest time interval examined (10 days
of age) in male pups. However, from 15 days to adulthood (60
days), morphine maximally suppressed LH levels to less than 25% of
control values, which was near the limits of detection of the
RIA. In marked contrast to these results, naloxone evoked no
statistically significant increase in serum LH levels from 10 to 30
days of age and, moreover, at 15 days of age, LH values were
significantly lower in naloxone-pretreated rats than they were in
controls. After 30 days of age, the LH response to naloxone
increased in a linear fashion to adulthood when naloxone-induced
increases in serum LH were 500% greater than in control animals
(i.e., saline-injected). As shown in figure 2, the patterns of
responses to naloxone and morphine were substantially different in
females. At 10 through 25 days of age, morphine failed to depress
serum LH levels. At 30 days a modest, but significant, suppression
of LH occurred which became progressively more intense to
adulthood; at 60 days of age LH levels in morphine-pretreated
female rats were approximately 60% lower than in controls. Thus,
two major sex-related differences in the response to morphine were
noted: females displayed a much later onset in appropriate LH
response to morphine (30-35 days versus 15 days) and the absolute
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FIGURE 1. The effects of saline, morphine (10 mg/kg) or naloxone
(1 mg/kg) on serum LH levels in male rats injected on the days
shown after birth.
depressions in LH were substantially less in females than they were
in males (50-60% versus >75%). As shown in figure 2, an even more
striking sex-related difference was found with naloxone. In
contrast to the male, in the female, naloxone produced extremely
large increases in serum LH at 10 (highly variable, however) and 25
days which were substantially greater than those observed at any
other time point. Interestingly, between days 10 and 25, the
antagonist did not influence serum LH levels at all. After the
naloxone-induced burst in serum LH levels at 25 days of age, it
remained highly effective in increasing LH levels, but the absolute
increase in LH declined gradually such that by 40-60 days of age,
increases in serum LH levels were only about 50% as large as those
observed at 10 or 25 days.
Dose-reponse curves for naloxone and morphine. In the previous
studies. only one dose of each drug was employed and animals were
killed at only one time interval. Although the doses and post-
injection time intervals were selected as optimal ones, the
possibility existed that this approach may have obscured the fact
that morphine and naloxone were simply less effective, rather than
devoid of activity, at the "critical" periods identified. To
evaluate this, dose-response curves for naloxone- and morphine-
induced changes in LH were constructed at those intervals
determined in the preceding studies at which there appeared to be a
complete refractoriness to the drugs. Our results demonstrated
that at 10 days of age, a point at which morphine (10 mg/kg) was
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FIGURE 2. Same as legend to Figure 1 except females were utilized.
ineffective in lowering serum LH levels in the male in the previous
studies (see figure 1). morphine dose-response curves revealed no
effect on LH at 5 or 10 mg/kg, but a significant depression was
found at a dose of 25 mg/kg. However, it should be noted that
morphine was quite toxic at this dose level, raising a question
regarding the significance of this fall in LH. In sharp
distinction to these results, morphine failed to depress serum LH
levels in 15-day-old females at any dose from 5-25 mg/kg. In
agreement with the previous studies (figures 1 and 2). naloxone
failed to increase serum LH levels over a wide range of doses in 30-
day-old males or 15-day-old females.
Concluding Remarks
The preceding results suggest that the responsitivity of the
opioid-mediated control of LHRH varies markedly during sexual
maturation and, moreover, is strongly sex-related. Whether our
results suggest that opioids are involved in the onset of puberty
and sexual maturation cannot be stated with certainty at this time,
but the "crltical periods" we have identified for the maturation of
naloxone and morphine appropriate responses appear to correlate
quite well with all other indices of sexual development.
The mechanisms involved in the differential sensitivity to naloxone
and morphine in males and females at different points in
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development have not been examined at all. However, two obvious
possibilities suggest themselves: differential time courses for the
appearance and/or functional activity of the relevant opioid
receptors or of the endogenous opioid(s) responsible for the
regulatlon of LHRH. No studies have directly examined these
relationships per se, but there are a number of reports in which
the ontogeny of opioid receptors and opioids have been examined
(Unnerstall et al. 1982; Khachaturian et al. 1983). Unfortunately,
these studies were not designed to focus on the "critical" periods
we have identified. Similarly, the literature regarding the
maturation of the H-P-G axis is not particularly germane for
several reasons: (a) few studies have examined time periods
equivalent to those utilized above; (b) most experiments have
examined only selected parameters; and (c) few studies have
compared males to females (see Kalra 1983).
A major goal of our current research efforts is to carry out these
necessary comparative studies in an effort to more fully
characterize the developmental aspects of the opioid-mediated
control of reproductive endocrinology. In addition to the obvious
significance of these studies at this basic level, our studies
could be quite significant from two additional perspectives.
First, our results suggest that the developing organism may be
particularly susceptible to opiates, or other drugs which influence
endogenpus-opioid function, during the prepubescent and adolescent
periods. Given the increasingly prevalent usage of such compounds
in human males and females during these critical points in their
sexual development, these experiments could have obvious clinical
significance. Second, if it can be demonstrated that specific
opioid peptides or opioid receptor subtypes show marked alterations
during the onset of puberty and sexual maturation, this could prove
to be one of the most definitive means of establishing the identity
of the endogenous opioid involved in LHRH release.
PREGESTATIONAL INFLUENCES OF THE OPIATES.
Although there are numerous studies of the adverse effects of the
administration of opiates to pregnant females, little attention has
focused on the deleterious effects of exposure of males to opiates
prior to or during mating. One particularly intriguing series of
studies, however, has been carried out by Or; Gladys Friedler which
indicate a potentially important pregestational effect of opiates
in male mice (Friedler 1974; Friedler and Crescenzi 1981; Friedler
and Wheeling 1979). She has found that exposing males to morphine
1 to 2 weeks prior to mating, followed by a 7-10 day drug-free
period, produces a number of anomalies in their offspring. They
also differ substantially in their response to opiate agonists and
antagonists as adults, but what is most interesting about her
studies is that these effects can be generated by as little as one
dose of morphine and can be transmitted from one generation to the
next.
In collaboration with Dr. Friedler, we have recently completed two
studies comparing the reproductive endocrine parameters in opiate-
derived adult male offspring versus normal controls (Friedler et
al. 1982). Our results are briefly summarized below.
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TABLE 1
Effects of Pregestational Morphine or Saline Administration
on Reproductive Endocrine Parameters
Methods
Adult male CO-l mice, 80-90 days of age, were injected with saline
or morphine, 50 mg/kg, twice daily for 8 1/2 days. After a drug
free period of an additional 8 1/2 days, the males were mated with
drug naive females. Animals were prepared in Or. Friedler's
laboratory, the subsequent offspring were coded by her, so that the
neuroendocrine studies could be carried out blind, and shipped to
my laboratory at 30-35 days. Only male offspring have been utilized
in the studies to date. After a 30-40 day equilibratior period in
our laboratories, the animals were divided into four groups:
saline-derived - sham-operated; saline-derived - castrated; opiate-
derived - sham-operated, and opiate-derived - castrated. Forty-
eight hours after the appropriate surgical procedure, the animals
were killed by decapitation and blood and tissue samples were
obtained. The reason for using both sham-operated and short-term
castrated animals was that massive deficits in the functional
activity of the H-P-G axis would be evident in both groups, whereas
more subtle differences might be apparent only in the castrates.
The following indices were measured: serum LH and testosterone
levels, hypothalamic LHRH content, and pituitary LH content. In
addition, opioid receptor profiles in brain and hypothalamus were
assessed. Finally, in a preliminary study, we evaluated whether
the LH responses of opiate-derived offspring to morphine and/or
naloxone were different than those observed in saline-derived
offspring.
Results
The results of these studies are briefly summarized in table 1. As
can be seen, in opiate-derived adult male offspring, serum LH
levels in sham-operated animals were approximately 20% lower than
those found in saline-derived offspring. but this deficit was
considerally more pronounced in castrated animals. The 10-fold or
greater increase in serum LH levels normally produced by castration
was significantly attenuated (<60%) in opiate-derived offspring
when compared to controls (see table 1) such that serum LH levels
were more than 70% lower in this group than they were in
controls. Accompanying these changes in serum LH, a modest
increase in the pltuitary content of LH was observed in morphine-
derived animals when compared to controls (table 1). Similarly,
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seminal vesicle weights and serum testosterone levels were lower in
opiate-derived animals than they were in controls, but neither of
these differences was statistically significant; no changes were
observed in hypothalamic LHRH (data not shown).
With regard to the opiold-mediated regulation of activity in the
hypothalamic-pituitary-LH axis, we found no alterations in µ, kappa
and delta receptor populations, respectively, in whole brain or
hypothalamus; competition and selective protection studies
confirmed these conclusions. On the other hand, in a preliminary
study, we observed a significant attenuation of the response to
both naloxone and morphine in opiate-derived offspring relative to
controls, Unfortunately, insufficient numbers of animals were
available to construct appropriate dose-response curves.
Concluding Remarks
The preceding results reinforce the prior conclusions of Frledler
and her colleagues ( Friedler 1974; Friedler and Crescenzi 1981;
Friedler et al. 1982) that pregestational opiate administration to
the male produces a number of adverse effects in their offspring.
The profound neuroendocrine disturbances we have observed in the
present studies represent perhaps the most significant anomalies
yet found in opiate-derived- offspring and suggest that
pregestational opiate administration to males produces substantial
and pervasive effects on the structural, biochemical and functional
integrity of their subsequent offspring. Although previous
studies have shown that opiates are quite toxic to developlng
Fetuses when given to pregnant females, the present results, and
the earlier work of Friedler et al. (1974, 1981, 1982), suggest that
pregestational opiate administration may be just as harmful and,
most significantly, that variables influencing the male at some
time prior to conception may be as important, or more important,
than those influencing the pregestational or gestating female. One
additional point should be emphasized in the studies of Friedler
and her colleagues. Specifically, she has noted that the adverse
effects she observes are not only evident in the Fl generation, but
can be transmitted from one generation to the next. These
intriguing observations defy a rational explanation at this time,
but have profound implications. We have no information as yet as
to whether the neuroendocrine effects we have observed in the
present studies can be passed along to subsequent generations or
for that matter if fertility and/or the capacity to fertilize is
effected.
With respect to the mechanisms involved in the pregestational
effects of the opiates, two interrelated phenomena must be
explained: what are the factors involved in the initial opiate-
induced insult to the male parent; and what are the. mechanisms
involved in the neuroendocrine deficits found in their offspring?
There is a complete void in the literature on both points. However,
in an ongoing series of studies in our laboratories we are
examining the influence of opiates on mature sperm. The rationale
for this strategy is that the treatment paradigm used by Dr.
Friedler involves administration of opiates 8-12 days prior to
mating. At this time, sperm in the vas deferens are fully mature
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and are stored there for up to 3 weeks before ejaculation. Thus,
it seems reasonable to postulate that adult sperm are adversely
affected by the administration of opiates. Although there is no
definitive evidence relevant to this point, several observations
suggest that opiates may indeed influence mature sperm function.
For example, it has been shown that opioid receptors are prevalent
in the reproductive tract, that opiates are found in semen after
their administration and, finally, that opioid peptides occur in
semen, the testes and the secondary sex organs (Cox and Baizman
1982; Margioris et al. 1983; Shaha 1984; Sharp and Pekary 1981;
Tsong et al. 1982). These observations indicate, at the very least,
that opiates can readily gain access to sperm and could potentially
exert adverse effects. In this connection, it should be noted that
in 1975 we found that methadone-maintained patients and heroin
addicts had significantly reduced sperm motility (>75%) when
compared to controls and a significant percentage of the sperm were
dead (Cicero et al. 1975).
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Acute Effects of Marijuana on
Pituitary and Gonadal Hormones
During the Periovulatory Phase
of the Menstrual Cycle
Jack H. Mendelson; Nancy K. Mello; Patricia Cristofaro;
James Ellingboe; and Richard Benedikt
INTRODUCTION
Experimental animal studies have demonstrated that pituitary and
gonadal hormones essential for normal female reproductive func-
tion are altered by acute administration of cannabis compounds.
Dose-dependent suppression (1 to 5 mg/kg) of luteinizing hormone
(LH) occurred within 1 h after acute administration of 9-tetra-
hydrocannabinol (THC) to ovariectimized rats (Marks 1973). Lower
doses of THC (62.5 mcg/kg) reduced LH concentrations by 42 to 68%
in ovariectimized rats (Tyrey 1980). THC (5 mg/kg) also inhibited
the periovulatory LH surge in intact rats and delayed ovulation
for up to 24 hours (Nir et al. 1977).
An intramuscular dose (2.5 mg/kg) of THC suppressed plasma LH
levels for 12 to 24 h in ovariectimized rhesus monkeys (Asch et
al. 1979). The magnitude of LH suppression was not correlated
with THC dose but the duration of LH suppression was dose related
(Smith et al. 1979a, b).
Acute doses (2 to 16 mg/kg) of THC produced decrements in plasma
prolactin levels in normal (Chakravarty et al. 1975) and ovariec-
timized female rats (Hughes et al. 1981). Prolactin surges in-
duced in female rats by electrical stimulation of the cervix were
delayed by intravenous administration of 4 mg/kg of THC (Hughes
and Tyrey 1982). THC administration also suppressed suckling-
induced prolactin surges in female rats (Tyrey and Hughes 1983).
A brief suppression of prolactin levels in male and female rhesus
monkey occurred after THC administration (Asch et al. 1979). THC
suppression of prolactin secretion was reversed by thyrotropin
releasing hormone which directly stimulates prolactin release
from the pituitary (Asch et al. 1979). Administration of gonado-
tropin releasing home (GnRH) restored normal ovulation in THC-
treated rats and also reversed THC inhibition of LH in monkey
(Smith et al. 1979a; Nir et al. 1973). These data converge to
suggest that THC inhibitory effects on pituitary release of LH
are due to drug effects upon hypothalamic neurons involved in
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regulation of pituitary hormone secretion.
Although there have been many studies of THC effects on reproduc-
tive hormones in human males (Bloch 1983), there are relatively
few data concerning cahnabis effects on female reproductive hor-
mones. We have been able to locate only one study on effects of
marijuana smoking on pituitary and gonadal hormones in human fe-
males. Bauman and coworkers (1979) conducted an outpatient evalu-
ation of 26 women, who reported marijuana use at least 4 times per
week and 16 age-matched controls who never used marijuana. Blood
samples were collected on days 1, 5, 10, 12 to 18, 20, 25, and 30
of the menstrual cycle. Marijuana users reported shorter menstrual
cycles and shorter luteal phases than controls. No significant
changes ware found in LH or estradiol levels in marijuana smokers
when compared to nonsmokers. However, prolactin levels were lower
in marijuana users. A major problem in evaluating these data is
that the study was carried out under outpatient conditions where
it was not possible to control for self-administration of alcohol
and other psychotropic drugs which might also affect pituitary
and gonadal hormone homeostasis.
Recently, we reported that acute marijuaha smoking suppresses
plasma LH levels in women during the luteal phase of the menstrual
cycle Mendelson et al. 1984). Prolactin levels following mari-
juana smoking also were significantly suppressed during the
luteal phase of the menstrual cycle Mendelson et al. 1984).
The purpose of the present study was to determine the acute ef-
fects of marijuana smoking on LH, estradiol, progesterone, and
prolactin in healthy adult female volunteers during the peri-
ovulatory phase of the menstrual cycle.  The women were studied
on a residential research ward to ensure that concurrent drug or
alcohol self-administration did not occur. This control is im-
portant since there is considerable evidence that chronic alcohol
abuse disrupts the menstrual cycle (Hugues et al. 1981; Mello et
al. 1983; Moskovic 1975) and that opiates inhibit secretion of
pituitary gonadotrophins and suppress gonadal steroid hormones
(Cicero 1980).
METHODS
Eight healthy adult females provided informed consent for partici-
pation in this study. These women were between 21 to 33 years
(mean age 26) and their man frequency of marijuana use was 14
times per month. All had normal physical examinations, medical
and mental history evaluations and normal laboratory (biochemistry
and hemogram) studies. No subject had any pastor current history
of alcohol or drug abuse and urine screens for drugs (opiates, bar-
biturates, tranquilizers, stimulants and depressants) were nega-
tive upon admission to the ward. All woman reported normal men-
strual cycles and none used birth control medication or intrauter-
ine devices. NO women had received any form of prescription med-
ication for at least one year prior to the study and none had
ever received gonadotrophins or steroids. Subjects were not preg-
nant as determined by the hCG beta subunit test.
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Marijuana cigarette administration and plasma sampling procedures
for pituitary gonadal hormones were identical for all subjects.
Subjects did not consume food for 12 h prior to the initiation of
each study which was begun at approximately 9:00 a.m. An indwell-
ing intravenous cannula with a heparin lock was connected to a
slow infusion of 5% dextrose in saline. Baseline blood specimens
were collected at 30 min intervals for 120 consecutive min prior
to administration of marijuana or placebo.
After baseline samples were collected, each women smoked a 1-g
marijuana cigarette containing 1.8% 9-THC. Standardized mari-
juana cigarettes were provided by the National Institute on Drug
Abuse. Subjects were instructed to take a deep inhalation of the
marijuana cigarette once every 30 sec and retain the inhaled smoke
for 2-4 sec. Under these conditions, subjects smoked the 1-g mari-
juana cigarette within to 12 min.
Blood samples were collected at 15, 20, 25, 30, 45, 60, 90, 120,
150, and 180 min after initiation of marijuana smoking. Blood
sample were centrifuged immediately following collection and
aliquots of plasma were stored at -70° C. for subsequent analysis
of LH, estradiol, and progesterone.
In order to determine effects of marijuana smoking on naloxone-
stimulated LH, 5 mq of intravenous naloxone was infused over
min at the same time as marijuana or placebo cigarette smoking in
2 women. Conditions of blood sampling and cigarette smoking were
identical to those described above. Placebo cigarettes were pro-
vided by NIDA.
LH was assayed as described previously (Mendelson et al. 1978).
Results are expressed as ng LER-907 standard ml/plasma. Mean
intra- and interassay CV's were 7 and 11%. Progesterone was
assayed without solvent extraction using kits purchased from
Radioassay Systems Laboratories, Inc., Carson, CA. The mean
intra-assay CV was 8.6%. Interassay CV's were 7.0 and 13.6% for
controls that averaged 27.6 and 1.12 ng/ml. Estradiol-17 was
assayed without extraction using kits purchased from Serono
Laboratories, Inc., Randolph, MA. Intra- and interassay CV's
were 6.0 and 7.3%.
RESULTS
Figure 1 shows LH, prolactin, estradiol and progesterone levels
prior to and following marijuana smoking. A 2-way analysis of
variance (ANOVA), with time as a repeated measure, revealed that
LH and prolactin levels decreased significantly (p <.01) as a
function of time. However, ANOVA also revealed a main effect of
marijuana smoking on plasma LH and prolactin levels. A small but
statistically significant pulse in LH and prolactin levels
occurred 20 min after initiation of marijuana smoking and persis-
ted for 45 min following marijuana smoking (p <.01) There were
no significant changes in plasma estradiol or progesterone levels
following marijuana smoking when compared with presmoking values.
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FIGURE 1: LH, prolactin, estradiol, and progesterone levels
( ± S.E.) prior to and following marijuana cigarette
smoking during the periovulatory phase of the menstrual.
cycle. indicates time of initiation of marijuana smoking.
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FIGURE 2: Plasma LH levels prior to and after IV naloxone
(5 mg) administration. Top panel (subject 18) - smoked
marijuana placebo cigarette concurrent with IV naloxone
administration. Bottom panel (subject 23) - smoked active
marijuana cigarette (1 g containing 1.8% 9-THC) concurrent
with naloxone administration.
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Figure 2 shows plasma LH levels prior to and following concurrent
administration of intravenous naloxone (5 mg) and acute marijuana
or placebo marijuana smoking. Intravenous naloxone produced a
significant increase (p <.01) in LH levels fran 100 to almost
150 ng/ml. The initial increment in LH levels following naloxone
administration and placebo marijuana cigarette smoking occurred
at 45 min and secondary LH pulses occurred at 100 and 120 min.
When naloxone administration and marijuana smoking occurred con-
currently, LH levels increased (p <.001) from approximately 100
to 250 mg/ml in 30 min. Two secondary LH pulses following con-
current marijuana and naloxone administration peaked at 300 and
400 ng/ml respectively within 120 min.
DISCUSSION
Smoking a single marijuana cigarette containing 1.83% THC produced
asmall but significant increment in LH and prolactin levels during
the periovulatory phase of the menstrual cycle. LH levels prior
to marijuana smoking in the 400 ng range and were consistent
with peak ovulatory LH pulse values recorded in normal females of
childbearing age. The small but significant marijuana-related
increment in LH and prolactin levels observed when basal LH levels
were high suggests that relatively small amounts of pyrolized
marijuana leaf have a strong stimulatory effect on LH and prolac-
tin release.
LH values prior to naloxone administration were in the 100 ng
range and consistent with levels found in normal women during
the early ascending or descending phase of the periovulatory LH
surge. This is the first report that naloxone stimulates LH dur-
ing the periovulatory phase of the menstrual cycle. These find-
ings are surprising since prvious studies using a continuous
infusion of naloxone indicate that LH is insensitive to naloxone
stimulation during the early and late follicular phase (Quigley
and Yen 1980; Quigley et al. 1980; Blankstein et al. 1981). Most
investigators have found that LH is most sensitive to naloxone
stimilation during the luteal phase of the menstrual cycle (Ropert
et al. 1981; Quigley and Yen 1980) and it has been suggested that
mid-cycle estrogen elevations increase the inhibition of LH by
endogenous opioid peptides and diminish the naloxone stimulatory
effect (Yen 1980). The apparent discrepancy between our findings
and previous reports probably can be reconciled by the fact that
we administered naloxone when LH levels were already elevated in
the periovulatory phase. Under these conditions, acute naloxone
administration produced a significant increase in LH.
The striking increment of LH levels following naloxone administra-
tion and current marijuana smoking suggests that cannabis compounds
may potentiate effects of gonadotrophin-releasing hormone during
the periovulatory menstrual cycle phase. Further studies will be
necessary to determine if this effect is specific for THC or may
be induced by other cannabis compounds in pyrolized marijuana leaf.
Additional studies are necessary to determine the site of action
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of  cannabis-induced potentiation of LH secretion during ovulation.
If cannabis compounds reliably potentiate LH secretory activity
during the periovulatory phase of the menstrual cycle, such com-
pounds may be efficacious for the treatment of some forms of in-
fertility in women.
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Feminization in Alcoholic Liver
Disease: The Role of Ethanol and
Alcoholic Liver Disease
David H. Van Thiel; Judith S. Gavaler; and Patricia K. Eagon
The following is a discussion of our present understanding of the
process of feminization of men with advanced alcoholic liver dis-
ease.
The first major step in our knowledge about this process was its
recognition as a process distinct from that of hypogonadism (Van
Thiel 1979). Specifically, alcoholic men with advanced alcoholic
liver disease (Laennec's cirrhosis) are both hypogonadal and
feminized. For feminization to occur, both chronic alcohol abuse
and advanced alcoholic liver disease must co-exist. Moreover,
hypogonadism is almost, if not always, a co-existing problem in
such feminized alcoholic men. In contrast, alcoholic men can man-
ifest overt hypogonadism in the virtual absence of any biochemical
and/or histologic evidence of either alcoholic liver disease or
feminization (Van Thiel et al. 1974; Van Thiel and Lester 1976).
Thus alcohol abuse per se leads to male hypogonadism. Feminiza-
tion requires both alcohol abuse and alcoholic liver disease.
Males with advanced nonalcoholic liver disease are not feminized
except very late in their disease course at a point in time when
they are essentially preterminal (Van Thiel 1979). Moreover, rats
with carbon tetrachloride-induced cirrhosis are neither hypogonad-
al nor feminized (Van Thiel 1980a). In contrast, alcohol-fed male
rats with minimal liver disease (fatty change) manifest severe
gonadal failure (Van Thiel et al. 1975; Van Thiel et al. 1979).
The manifestation of hypogonadism present in alcoholic men are
shown in table 1. Both advanced testicular atrophy and reduced
testosterone levels as shown in figure 1 are characteristic find-
ings in such chronic alcoholic men and frequently occur as noted
above in the virtual absence of important liver disease (Van Thiel
et al. 1974; Van Thiel and Lester 1976). Similar findings of tes-
ticular atrophy, loss of reproductive tissue, and reduced testos-
terone levels can be produced in either weanling or adult male
rats fed 5% alcohol which accounts for only 36% of their total
caloric intake but not in isocalorically matched control animals
(Van Thiel et al. 1975; Van Thiel et al. 1979). The alcohol-fed
rat model does not develop alcoholic hepatitis, hepatic fibrosis
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TABLE 1
Manifestations of Hypogonadism in Alcoholic Men
testicular atrophy
reproductive failure
reduced testosterone levels
prostate and seminal vesicle atrophy
reduced beard growth
reduced body hair (particularly sexual hair)
loss of muscle mass
"normal" to elevated gonadotropin levels
FIGURE 1A
Testicular histopathology in an alcoholic without liver disease
but with testicular atrophy H&E X 250.
or cirrhosis but does manifest alcohol-induced hypoqonadism. Thus
alcohol abuse per se, and not alcoholic liver. disease, is the pre-
cursor abnormality for alcohol-induced hypoqonadism.
Feminization of alcohol-fed male rats does not develop with this
model. Moreover, it is not apparent either in man or in experi-
mental animals in the absence of advanced (cirrhotic) nonalcoholic
liver disease. The manifestation of feminization seen in alco-
holic men with cirrhosis are shown in table 2.
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FIGURE 1B
Plasma sex steroid levels in alcoholic men. The cross hatched
area is the normal range. Points represent values for alcoholic
men.
TABLE 2
Manifestations of Feminization in Alcoholic Men
Biologic Biochemical
gynecomastia variably increased levels of estrogens
palmar erythema increases in prolactin levels
spider angiomata increases in sex steroid binding globu-
female escutcheon lin levels
body fat redistribution increases in estrogen stimulated neuro-
physin levels
increases in most transport proteins
(alpha and beta globulins)
When present in nonalcoholics these signs of feminization occur
very late in the course of the disease (preterminal) and are
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never as apparent as they are in alcoholics (Van Thiel 1979).
What is it then that distinguishes alcoholic liver disease from
nonalcoholic liver disease? What characteristics do alcoholics
with established cirrhotic liver disease have that alcoholics
without such liver disease lack? Finally, what are the biochemi-
cal events that effect estrogenization (feminization) and how does
alcoholic and nonalcoholic liver disease alter (amplify) this pro-
cess?
Schematic representative of how estradiol acts to produce femini-
zation (an estrogen effect).
I. Mechanism of Estrogen Action
The presently accepted model of how steroid hormones like estro-
gens effect their biological effects is shown in figure 2. The
FIGURE 2
lipophilic steroidal estrogen is produced by an endocrine organ or
tissue and circulates in the blood both in the bound (BE) and free
(FE) form. The vast majority of the plasma estrogen is protein
bound but it is the small fraction of free hormone which is avail-
able for interaction with and stimulation of steroid responsive
tissues. At the level of the steroid responsive tissue, the free
estrogen readily diffuses across the lipid plasma membrane and
35
enters the cytosol. Once within the cytosol, it interacts with a
variety of cytosolic proteins, one of which is the estrogen re-
ceptor (ER). The receptor protein characteristically has a high
affinity and low capacity for its ligand. In contrast, the other
estrogen binding proteins in cytosol have both a lesser affinity
and greater capacity for estrogen binding. As a consequence of
estrogen and receptor interaction, a transformational change
occurs in the receptor protein that allows it to be transported
across the nuclear membrane with its steroid ligand (ERE). With-
in the nucleus the complex interacts with DNA. As a result of
this interaction, the transcription of specific genes or RNA char-
acteristic of the specific hormonal effect, estrogenization oc-
curs. The mRNA so formed is transformed out of the nucleus and
effects the translation of a specific gene product (usually a pro-
tein) in the endoplasmic reticulum. The resultant newly synthe-
sized protein actually effects the process of estrogenization of
the cell.
II. The Role of Alcoholism
Alcohol ingestion results in a wide number of changes in the
liver as well as the rest of the body. Relevant to the present
discussion is the fact that chronic alcohol ingestion leads to
the induction of the microsomal enzyme, aromatase (Gordon et al.
1979a,b). Aromatase is the enzyme complex that converts C-19
androgens (testosterone) and proandrogens (androstenedione and
dehydroepiandrosterone) to C-18 estrogens (estradiol and estrone
respectively) (figure 3). Gordon et al. (1979a,b) have shown
that regardless of the specific nature of the androgen substrate,
aromatase activity is increased as a result of alcohol feeding.
As most of the aromatase activity in the body is in skin, fat and
muscle and not in the liver or body sites drained by the splanch-
nic circulation, the conversion of androgens to estrogens by
those nonhepatic tissues is increased as a consequence of alco-
holism. However, because alcoholism produces primary gonadal
failure in the absence of alcoholic liver disease, this induction
of aromatase activity by alcohol merely maintains "normal" plasma
estrogen levels in the face of overt androgen deficiency (figure
1B).
Additional consequences of alcohol abuse and its attendant hypo-
gonadism are that the cytosolic content of the estrogen receptor
is increased and that of the nonreceotor estrogen binding pro-
teins, particularly the male specific binding protein (MSBP) is
reduced. As a result, for any given cytosolic level of estrogen,
more estrogen is available for binding with the receptor and less
opportunity exists for nonreceptor interaction. The net result
is an amplification of the estroqen messaqe delivered to the cell
(nucleus) for any plasma and cytosolic level of the hormone. It
is important to note additionally at this point that only ste-
roidal estrogens bind to the MSBP and other nonreceptor estrogen
binding proteins while both steroidal and nonsteroidal estrogens
bind to the estroqen receptor (Eagon et al. 1980; 1981).
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FIGURE 3
Finally, it must be remembered that alcoholics do not drink etha-
nol but rather, they ingest alcohol-(ethanol) containing bever-
ages. Such beverages contain many substances other than ethanol
which are collectively termed "congeners" as well as the ethanol.
Table 3 shows a partial listing of the many kinds of substances
which comprise the recognized "congener" substances.
TABLE 3
Congener Substances Identified in Alcoholic Beverages
various aldehydes
various ketones
alcohol esters
various ethers
alcohols other than ethanol
salts
sugars
various organic acids
miscellaneous compounds
Recently we have considered the possibility that among the many
congener substances might exist phytoestrogens (nonsteroidal es-
trogens derived from plants) (Gavaler and Van Thiel 1983). In
this regard, it is well known that the major sources of phytoes-
troqens are seeds and grasses, the same materials which make up
the bulk of the nutrient material present in alcoholic beverages.
In addition, it is generally the case that ethanol has been the
solvent used to extract these phytoestrogens from their original
plant sources. Moreover, it should be added that phytoestrogens
not only can be found in alcoholic beverages as a result of their
leaching out of the grasses and seeds from which such beverages
are made but also can be added during the fermentation process
and some may be added purposefully as part of the aging process
(leached out of wood casks) or can be added for their flavor or
coloring characteristics.
This question of whether or not alcoholic beverages contain phy-
toestrogens has been addressed initiallybyexamining de-ethanol-
ized bourbon for an estrogenic effect using castrate female ani-
mals. In this rat model fed de-ethanolized bourbon, any increase
in uterine weight and/or suppression of castrate levels of LH
would suggest the presence of an estrogenic substance in the
material. Indeed, both effects were found (Gavaler and Van Thiel
1983). In subsequent studies, using de-ethanolized bourbon, we
have shown that it displaces radiolabeled estradiol from estrogen
receptor isolated from rat liver and uterus. In addition, we
have been able to show that the phytoestrogens, daidzen and bio-
chanin A (both isoflavanes) obtained commercially displace estra-
diol from these same receptors. Finally, we have accumulated
preliminary evidence that both formononetin and beta sistosterol
are present in de-ethanolized bourbon using gas chromatography -
mass spectroscopy techniques.
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III. The Role of Alcoholic Liver Disease
As discussed above, cirrhosis alone is not sufficient to produce
feminization (Van Thiel 1979). This fact is clearly demonstrated
by the failure of men with postnecrotic and biliary cirrhosis to
demonstrate evidence of feminization and the failure of male rats
with carbon tetrachloride-induced cirrhosis to have either in-
creased estradiol levels or reduced LH levels. In contrast, ani-
mals with portal hypertension and portosystemic shunting but with-
out cirrhosis have increased estrone and estradiol levels (Van
Thiel 1980b). This suggests that it is not cirrhosis but rather
the associated portosystemic shunting that leads to increased
estrogen levels and feminization in men with Laennec's cirrhosis.
Such men also have increased aromatase activity in nonhepatic tis-
sues such as fat, muscle, skin and possibly even the brain due to
allows for biliary excreted progestins and proandrogens and pos- 
their primary alcohol abuse. Portosystemic shunting in such men
sibly ingested phytoestrogens to escape hepatic clearance upon
being re-absorbed from the gut and instead allows them to circu-
late to peripheral extrahepatic sites where aromatase exists and
allows them to be converted to and act as estrogens (fioure 4).
FIGURE 4
Schematic representative of the interrupted enterohepatic circu-
lation in men with cirrhosis and portal hypertension.
It must be remembered also that men with Laennec's cirrhosis'are
not only cirrhotic and have portosystemic shunts, but also are
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alcoholic and have many, if not all. of the factors identified
above under the discussion of alcohol effects as well. Thus they
have an increased production of estrogen from androgen precursors,
a loss of cytosolic nonreceptor estrogen binding proteins, and an
enhancement of the cytosolic content of estrogen receptor protein.
These many factors, each acting alone as well as in concert, con-
tribute to the observed feminization. Thus cirrhosis and more
correctly portosystemic shunting allows the alcoholic with cir-
rhosis not only to achieve paradoxically "normal" estradiol levels
in the face of androgen deficiency but to achieve an actual es-
trogen excess. This estrogen excess, coupled with the alterations
described for the cytosolic estrogen binding proteins produced as
a result of alcohol abuse per se and the alcohol-induced hypogo-
nadism, all further amplify the estrogen effect and result in the
clinical manifestations of feminization or hyperestropenization.
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Effects of Delta-9-Tetrahydro-
cannabinol on Reproductive
Neuroendocrine Function in the
Female: Animal Studies
Lee Tyrey and Laura L. Murphy
There is now abundant evidence that exposure to
delta-9-tetrahydrocannabinol (THC), the primary psychoactive
cannabinoid of marijuana, can result in pronounced changes in the
secretion of anterior pituitary hormones. While the secretion of
each of the anterior pituitary hormones is to sane extent
influenced by THC (see Braude and Ludford 1984), which of the
recent research effort has focused on those hormones which
regulate reproduction. The motivation for this focus has arisen
in large measure from questions regarding the possible
reproductive consequences in humans from prolonged or repetitive
THC exposure through chronic use of marijuana, particularly since
that use is concentrated in age groups in or approaching their
prime reproductive years. The possibility of effects on
reproduction may have particular relevance to the female since
normal ovarian function is critically dependent upon appropriate
cyclic variations in the secretion of pituitary gonadotropins.
While there is no completely adequate substitute for
well-controlled studies with human subjects in establishing the
endocrine effects of marijuana use by humans, animal
experimentation aids the formulation of hypotheses for testing
with human subjects and plays an essential role in addressing
basic issues, such as mechanism of action, where human studies
are not feasible. A variety of animal models have been utilized
to good advantage by different investigators, but the laboratory
rat may possess particular value in this regard because of the
wealth of fundamental background information which has accumulated
from years of reproductive neuroendocrine research with this
species. That which follows is intended to illustrate sane of the
ways in which this animal mode1 has been manipulated to probe the
effects of THC on pituitary function, focusing upon the acute
effects of THC on luteinizing hormone (LH) and prolactin (PRL)
secretion in the female. There is no attempt to provide a general
review for which the interested reader is referred to a recent
monograph published by the National Institute on Drug Abuse
(Braude and Ludford 1984).
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LH AND PRL SECRETION IN THE RAT
Before proceeding to a discussion of the of feds of THC on the
pituitary reproductive hormones, there are several aspects of the
regulation of these hormones in the rat worthy of mention. During
most of the four- or five-day period of the estrous cycle, the
secretion of LH and PRL is held at a relatively low level and is
comparable to the secretion of these hormones in the male.
However, in the female this low “tonic” secretion is interrupted
in cyclic fashion by abrupt increases in the secretion of both LH
and PRL which, in spontaneous ovulators like the rat, are
attributed to the positive feedback effect of estrogen secreted
from preovulatory ovarian follicles. These cyclic “surges”
represent a stimulated mode of secretion which does not occur in
the male and which is generally considered to be governed by
regulatory processes distinct from those regulating tonic
secretion.
In the case of PRL, additional forms of stimulated secretion are
recognized in the rat which are characteristically different from
that which occurs during the normal estrous cycle. Stimulation of
the uterine cervix around the time of ovulation, such as would
occur with mating or mechanical probing of the vagina, reflexly
provokes the secretion of PRL in a series of diurnal and nocturnal
surges which occur twice daily for 10 or 11 days (Freeman et al.
1974; Smith and Neil1 1976). These PRL surges act to prolong the
life of the corpora lutea during early pregnancy. In the event of
infertile mating or following artificial stimulation of the cervix
the prolonged luteal function establishes a state referred to as
pseudopregnancy.
Another form of stimulated PRL secretion, common to both the rat
and the human, occurs in the lactating female in response to
suckling. This neuroendocrine reflex differs from that occurring
with cervical stimulation in the sense that the suckling reflex
requires reapplication of the stimulus for each. induced response,
whereas with cervical stimulation a single application of the
stimulus induces a series of responses continuing for several
days. Thus not only do the tonic and surge modes of hormone
secretion appear to be under differential regulation, but the
different forms of surge secretion also are likely to be governed
by different regulatory mechanisms functioning within the central
nervous system (CNS).
Just as the secretory patterns for LH and PRL appear to be
regulated differently, the manner in which secretion is controlled
by the hypothalamus is distinctly different for these two
hormones. The secretion of LH is stimulated through the action of
gornadotropin releasing hormone (GnRH) secreted into the
hypophysial portal circulation from nerve endings in the median
eminence. Increasing the level of GnRH stimulation at the level
of the pituitary thus provokes an increase in LH secretion (Sarkar
et al. 1976; Sherwood and Fink 1980). PRL secretion, on the other
hand, is tonically inhibited by the hypothalamus through the
action of one or more PRL inhibiting factors (PIF’s) released into
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the portal circulation, of which one is believed to be dopamine
(Neill 1980). A surge in PRL secretion therefore presumably
results at least in part from withdrawal of this tonic inhibition,
although the stimulative action of an as yet unidentified
physiological PRL releasing factor may also be involved. These
basic differences in the regulation of LH and PRL secretion should
be borne in mind during the following discussion of THC effects on
the serum concentrations of these two hormones.
EFFECTS ON TONIC HORMONE SECRETION
The detection of possible inhibitory effects on the tonic
secretion of LH in the female rat is complicated by the fact that
LH secretion is already very low during the intervals between
cyclic preovulatory surges of LH. A suitable model can be
created, however, when the negative steroid feedback on LR
secretion is interrupted by ovariectomy. The resulting
exaggerated episodic secretory pulses and tonically elevated serum
LH concentration provide a system which seems ideally suited for
the detection of potential inhibitory effects on LH secretion.
When ovariectomized rats fitted with indwelling atrial cannulae
were treated intravenously (iv) with THC during an interval when
blood samples were obtained every 10 min, the complete inhibition
of episodic LH secretory pulses and a consequent rapid decline in
serum LH concentration were readily apparent (Tyrey 1978; 1980).
The LH suppressive effect quickly followed acute iv treatment with
THC in doses of 0.5 to 8 mg/kg body weight (b.w.) , but it should
be noted that a similar inhibition, although of briefer duration,
has been observed following acute treatment with THC in doses down
to and including 62.5 mg/kg b.w. (Tyrey 1980). Treatment with the
vehicle used to deliver the THC, 10% propylene glycol and 1% Tween
80 in saline, had no notable effect on either the episodic
secretion or serum concentration of LH. In general, a
dose-response relationship could not be established for the degree
of LH suppression produced by THC treatment, although such a
relationship was evident for the duration of suppressed secretion.
Similar findings have been reported for the monkey (Besch et al.
1977) .
The tonic secretion of PRL also is suppressed in the
ovariectomized rat following acute treatment with THC. The
administration of THC in iv doses of 0.25 to 8 mg/kg b.w. resulted
in a pronounced reduction in the concentrations of PRL measured in
serum obtained 1 hr after treatment (Hughes et al. 1981). While
the 0.25 mg/kg b.w. dose produced less inhibition at 1 hr than did
the higher doses, it should not be concluded that the lowest doss
of THC was less effective in reducing PRL secretion since the
difference at 1 hr could merely reflect a rebound of PRL secretion
from an earlier more pronounced suppression in these animals. A
time course study with THC at 0.5 mg/kg b.w., the lowest dose
which was maximally effective at 1 hr, revealed that PRL secretion
was rapidly suppressed after drug administration in that a
significant decline in serum PRL concentration was already
apparent 10 min after injection of even this relatively modest
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dose of THC (Hughes et al. 1981).
EFFECTS ON HORMONE SURGES
Several years ago Nir et al. (1973), and later Ayalon et al.
(1977), convincingly demonstrated that the preovulatory surge in
LH secretion which occurs spontaneously during the afternoon of
proestrus in the rat can be blocked by appropriately timed
treatment with THC. When THC in a dose of approximately 10 mg/kg
b.w. was administered intraperitoneally (ip) prior to the expected
time of the LH surger either as a single injection (Ayalon et al.
1977) or divided into two equal doses administered 2 hrs apart
(Nir et al. 1973), the LH surge was prevented. Spontaneus
ovulation expected that night was prevented. Spontaneous
ovulation occurred in these blocked rats the following night,
approximately 24 hrs after the expected time.
The rise in serum PRL which occurs at the time of the gonadotropin
surge during the afternoon of proestrus also is blocked by THC
administered (ip) in doses of approximately 10 mg/kg b.w. (Ayalon
et al. 1977). However, suppression of this proestrous PRL surge
has been seen after treatment with much lower doses of THC
administered via the iv route. Even though the proestrous PRL
surge was already underway, a single iv injection of THC in a dose
of 0.5 mg/kg b.w. was quickly followed by an abrupt and pronounced
fall in the serum PRL concentration (Hughes et al. 1984).
The suppression of stimulated hormone secretion by MC is not
unique to the estrogen-dependent surges occurring during proestrus
since other modes of stimulated PRL secretion are inhibited by
acute exposure to THC. The effect of THC on the nocturnal PRL
surges occurring during pseudopregnancy was studied in rats in
which pseudopregnancies were induced by electrical stimulation of
the uterine cervix at the time of estrus (Hughes and Tyrey 1982).
Single iv injections of relatively large doses of THC (4 mg/kg
b.w.) just prior to the time of an expected nocturnal surge
delayed the onset of the surge by approximately 1 hr. However,
when THC exposure was extended by hourly injections of THC in
lower doses (1 mg/kg b.w.) throughout the interval of the expected
PRL rise, the surge was prevented altogether.
The effect of THC on stimulated PRL secretion induced in the
lactating mother by the suckling stimulus may be of particular
importance since this neuroendocrine reflex plays a critical role
in the maintenance of milk production. The treatment of lactating
rats with THC in single iv doses of 0.5 mg/kg b.w. prevented the
suckling-induced PRL surge in the majority of animals when the
drug was administered just prior to the onset of suckling (Tyrey
and Hughes 1984) . Even when the reflex surge in PRL secretion was
already underway as the result of suckling prior to the
administration of MC, the PRL surge was, nonetheless inhibited and
serum PRL concentrations declined in spite of continued suckling
by the pups (Tyrey and Hughes 1984).
LACK OF DIRECT PITUITARY EFFECTS
45
The simplest, most direct explanation which might account for the
ability of THC to inhibit the secretion of both LH and PRL in both
tonic and surge modes of release would be the direct inhibition of
hormone secretion at the level of the pituitary. The experimental
evidence, however, provides little support for that hypothesis
(Tyrey 1984). In the ovariectomized rat, exogenous GnRH injected
as an iv bolus during the time of maximal LH suppression induced
by prior THC treatment (1 mg/kg b.w.) provoked an immediate LS
surge of considerable magnitude (Tyrey 1978). This result, which
is consistent with those from other species (Smith et al. 1979;
Asch et al. 1979), indicates that the pituitary remains responsive
to the releasing activity of GnRH during THC-induced LH
suppression, but, of course, does not rule out the possibility of
an attenuation of that response. The latter seems unlikely,
however, since the LH response induced in THC-treated rats by a
moderate dose of GnRH (50 ng/kg b.w.) was comparable to that
produced by an equivalent dose administered to ovariectomized rats
pretreated with estrogen and progesterone, rather than THC, to
suppress the elevated serum LH levels (Tyrey 1978). The
steroid-pretreated ovariectomized rat is acutely sensitive to the
releasing action of GnRH and has been utilized for the bioassay of
GnRH activity (Ramirez and McCann 1963).
In the case of PRL, the unavailability of an accepted
physiological releasing hormone has required a somewhat different
approach to testing for possible direct pituitary inhibitory
effects. Advantage was taken of the fact that PRL secretion fran
anterior pituitary tissue removed from hypothalamic control
dramatically increases as a consequence of freedom fran tonic
inhibition, when hypophysectomized female rats bearing ectopic
anterior pituitary grafts beneath the kidney capsule were treated
(iv) with THC in a dose (1 mg/kg b.w.) which was maximally
effective in suppressing PRL secretion from the in situ pituitary,
no reduction in serum PRL concentrations was observed (Hughes et
al. 1981). Although MC similarly failed to demonstrate any
direct inhibition of PRL secretion from anterior pituitary tissue
incubated in vitro (Hughes et al. 1981), the in vivo results are
important since they provide evidence that neither THC itself nor
a circulating active metabolite acts directly on the pituitary to
inhibit PRL secretion.
CENTRAL NEUROENDOCRINE EFFECTS
Neurons which secrete the releasing and inhibiting hormones
regulating anterior pituitary function terminate throughout the
outer zone of the median eminence in conjunction with the primary
capillary loops of the hypophysial portal circulation. Since THC
does not have any pronounced effect at the pituitary level, it
seems reasonable to conclude that the drug alters pituitary
function through effects on the release of the hypothalamic
hormones into the portal circulation. How this might be
accomplished, of course, remains to be explained, but clearly
could involve action at several possible levels. At the most
fundamental level, THC could act directly on the neurosecretory
neuron in a way which might, for example, alter the hormone
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release mechanism at the axon terminal, alter the intraneuronal
transmission of the signal for that release, or even alter the
threshold for initiation of that signal within the neuron.
Alternatively, and perhaps more likely in view of the diversity of
THC’s neuroendocrine actions, the drug could affect, directly or
indirectly, the function of neurons which converge on the
neurosecretory units to modulate their level of functional
activity, clearly, identifying the level(s), and ultimately the
mechanism(s), of THC’s inhibitory effects on LH and PRL secretion
will be a difficult task, but the rat may prove especially
valuable in this area and some initial probes already have been
made utilizing this animal model.
The measurement of LH released in response to direct brain
stimulation was utilized to address the question of whether or not
endogenous GnRH release could be provoked during THC-induced LH
suppression. Earlier work had indicated that stimulation of the
medial preoptic area (mPOA) of the brain overcomes blockade of the
proestrous LH surge induced by a variety of drugs with different
pharmacological actions (Everett and Tyrey 1982). When cyclic
female rats were treated (ip) with a dose of THC (10 mg/kg b.w.)
which was sufficient to block the spontaneous LH surge and then
subjected to mPOA stimulation, an unambiguous LH surge was
recorded during the subsequent 90 min. Furthermore, the LH surge
induced by the preoptic stimulation was adequate to bring about
full ovulation in the majority of animals so stimulated. No
ovulations were recorded in control animals blocked with THC and
subjected to sham stimulation which included placement of the
electrode in the mPOA without the passage of current. While these
preliminary results from an ongoing study do not yet rule out the
possibility of some attenuation of responsiveness to stimulation,
they do indicate that the GnRH neurons remain responsive to
activation and are capable of a presumptive discharge of GnRH
sufficient to induce an LH surge during that time when the
spontaneous discharge of this signal to the pituitary is
apparently blocked by THC action. Since the intensity of mPOA
stimulation was relatively modest (Velasco and Rothchild 1973), it
seems unlikely that THC has any major blocking effect on
transmission of the release stimulus to the median eminence nerve
terminals or on the local release mechanism discharging GnRH from
those terminals.
The possibility that MC might inhibit PRL secretion through some
action in the median eminence, perhaps, for example, by promoting
an increased release of PIP, was investigated in animals subjected
to surgical deafferentation of the medial basal hypothalamus
(MBH). This approach took advantage of the observation by others
that the MBH could be disconnected from the remainder of the brain
without interrupting the tonic inhibitory control exerted over PRL
secretion by the hypothalamus (Blake et al. 1972; Turpen and Dunn
1976). If THC acts directly on the neurosecretory elements which
continue to function in the surviving hypothalamnic “island” to
maintain the tonic inhibition of PRL secretion, it might be
expected that THC would continue to exert an inhibitory effect on
PRL secretion in animals subjected to MBH deafferentation.
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However, a study utilizing rats subjected to complete
deafferentation of the MBH failed to provide evidence for a
decrease in serum PRL concentration following the iv
administration of THC in a dose of 0.5 mg/kg b.w. (Hughes et al.
1984), a dose which maximally inhibited PRL secretion in
nonlesioned animals (Hughes et al. 1981). Companion studies in
which only partial deafferentation of the MBH was produced in
cyclic rats by frontal cuts placed in the suprachiasmatic region
similarly resulted in a loss of the PPL suppressive effect
following THC administration (Hughes et al. 1984). Cuts in this
region were intended to interrupt afferent pathways into the MBH
from more rostral PRL regulatory centers believed to be
particularly involved in the regulation of PRL surges (Neill
1980). The results obtained thus far make it unlikely that THC
acts directly on the presumptive PIF secreting neurons of the MBH,
but rather suggest that the PRL inhibitory effect exerted by THC
depends upon rostral connections to the MBH, perhaps fran the
postulated rostral regulatory centers. It also should be noted
that, surprisingly, more rostral transections in the
suprachiamastic region not only prevented the THC-induced
suppression of PRL secretion, but also resulted in a preparation
wherein serum PRL increased immediately after THC administration
(Hughes et al. 1984). A similar PPL rise following THC treatment
also has been observed in ovariectomized rats subjected to frontal
cuts in the suprachiasmatic region (unpublished observations).
While the significance of this unexpected PRL stimulatory effect
of THC in lesioned animals remains to be explained, it is possible
that removal of a dominant inhibitory effect allows a stimulatory
action to be expressed.
SUMMARY
The rat experimental model has been utilized to demonstrate
pronounced suppressive effects of THC on the secretion of both LH
and PRL, a point of considerable interest since the tonic
secretions of these two hormones are regulated in opposite
fashions, that of LH requiring active stimulation, and that of
PRL, continued inhibition. Moreover, both the tonic and surge
modes of secretion of both hormones are inhibited or completely
blocked by THC action even though these different secretory modes
are presumed to be governed by different CNS regulatory
mechanisms. The most direct explanation for this broad inhibitory
capability of THC would be direct inhibitory action on the
pituitary cells secreting LH and PRL. However, experimental
evidence drawn from the rat model, consistent with that from other
species, provides no support for the possibility of direct
pituitary inhibition of significant consequence. Instead, the
evidence strongly favors the hypothesis that THC exerts its
neuroendocrine action centrally and thereby influences pituitary
function through alterations in the release of hypothalamic
hormones into the hypophysial portal circulation.
With the evidence favoring a central neuroendocrine mechanism for
THC action, the rat model becomes particularly valuable because of
the enormous body of information already available regarding
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neuroendocrine function in that species. Initial experiments with
the rat have failed to provide evidence supporting the possibility
of direct THC action on the hypothalamic neurosecretory neurons
terminating in the median eminence. Rather, the retention of GnRH
release capability during THC-induced LH suppression and the
apparent dependence of THC-induced PRL suppression on rostral
connections to the MBH are observations consistent with the
possibility of THC action at sites removed from the neurosecretory
neurons themselves. Thus, while definitive conclusions are not
yet possible, it seems reasonable that THC may act to alter the
activity of neuronal systems which normally serve to modulate the
functional level of neurosecretory neurons in the MBH. If this is
the case, potential sites of action through which THC might
influence pituitary function are not limited to the hypothalamic
region since THC effects could be conveyed into the MBH over
afferent pathways arising in widely distributed regions of the
CNS. In the case of PRL, the critical pathway may approach the
MBH from the rostral direction.
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This is the last annual report from the Lexington facility of the
ARC. By mid-July the unit will have transferred to the newly
remodeled facility of the ARC at Baltimore City Hospitals, where
we will join our clinical colleagues; and by the end of the sum-
mer, after 49 years of continuous operation at that site, we will
have closed out the Lexington facility. We hope you will all join
us next year to visit the new ARC, the dedication of which will be
held in conjunction with the meeting of the CPDD.
As in recent past years, I will review briefly this afternoon
several ongoing projects from our laboratory.
-ENDORPHIN-LIKE IMMUNOREACTIVITY IN HUMAN CENTENARIANS
For several years the Sanders-Brown Research Center on Aging at
the University of Kentucky and the Office of the Governor have
engaged in a joint program to identify and recognize centenarians
in the state. About 1 1/2 years ago the Center organized a broad
multidisciplinary study to investigate a number of biological and
social characteristics associated with the extreme longevity of
this unique group. We are participating in this study with an
interest in looking at present drug-taking patterns and also
plasma levels of -endorphin-like immunoreactivity in this group.
This afternoon I will report briefly on early results of the
endorphin study.
Because of the large number of blood studies to be done on these
subjects we could obtain no more than 0.5 ml of plasma. There-
fore, our first problem, and the one on which I will concentrate
in this report, was development of methodology sufficiently sensi-
tive for determination of -endorphin-like immunoreactivity in
small sample volumes. Most published methods, especially those
separating endorphin from lipotropin, use large sample volumes,
some as great as 20 ml. Based on preliminary information supplled
by New England Nuclear, an extraction procedure was developed
using three c.c. C18 Bond-Elut solid phase extraction tubes fitted
with filtration columns with an appropriate vacuum manifold.
The tubes were conditioned by pretreatment with methanol containing
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0.2% trifluoroacetic acid (TFA), 4X1 ml, followed by water with
0.1% TFA. Plasma samples of 0.1 to 1.0 ml containing 0.5% TFA
were added and the columns washed with water with 0.1% TFA, 2X1
ml. -Endorphin was eluted into small polypropylene tubes with
1.5 ml of methanol containing 0.5% TFA, and the extracts were
evaporated to dryness at room temperature under nitrogen.
-Endorphin-like immunoreactivity was determined by radioimmuno-
assay carried out in the tube containing the dried extract. The
I125 RIA kit from New England Nuclear was used with some modifica-
tion in the provided procedure. All steps of the assay were
carried out at 4°C using an ice bath, cold room, and refrigerated
centrifuge; silanized glassware or polypropylene was used
throughout. The extract was reconstituted with 0.1 ml of assay
buffer and 0.1 ml of antiserum (diluted to give BO of approx. 40%
bound) added with brief mixing on a Vortex mixer. Samples were
then preincubated for 72 hrs. in the cold followed by addition of
0.1 ml of I125 -endorphin and a further 24 hrs. incubation. 0.5
ml of charcoal suspension was then added to precipitate free
radiolabeled marker. After a 15-min incubation and centrifugation
the total supernatant was decanted and bound radioactivity counted
in a gamma counter. The standard curve ran from 1.25 to 25 pg
per assay tube; data were analyzed by using a log-logit transfor-
mation and constructing a linear curve. Using an 0.5 ml plasma
sample the sensitivity corresponding to the 1.25 pg added
standard was 10 pg/ml of plasma, representing overall extraction
and detection efficiency of approx. 26%. Concentrations below
10 pg/ml could be calculated, but were below the lowest run
standard.
-Endorphin-like immunoreactivity has now been determined by this
method in 23 centenarians; their ages range from 100-102 with mean
of 100.8 yrs.; 10 are male and 13 female. Mean concentration of
-endorphin-like immunoreactivity was 16.7 pg/ml with a range of
a calculated 2.1 pg/ml to 34.7 pg/ml. Although there is a great
deal of variability in reported methodologies and subject groups,
this appears to be within the range of reported normal values,
although probably near the lower end. We are continuing to
analyze this data and to accrue additional subjects.
COMPARATIVE METABOLISM OF 6-KETO OPIOIDS
During the last 5 years, we have been engaged in a comprehensive
study of the comparative metabolism of 6-keto opioids in humans
and several animal species. We studied the metabolism of 4
agonists (hydromorphone, hydrocodone, oxymorphone, and oxycodone)
and 2 antagonists (naltrexone and naloxone) in 6 human subjects
and dogs, rats, guinea pigs, and rabbits. The urinary excretion of
the parent compound and identifiable metabolites was measured
over the course of 6 days for humans and 2-3 days for animals.
The study is now sufficiently completed that some generalizations
have begun to emerge. From the mean human data it is apparent
that small structural differences greatly influenced the metabolic
profile. The change from N-ally1 (in naloxone) to N-cyclopropyl-
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methyl (in naltrexone) caused the drug to go from being metabo-
lized primarily to an inactive conjugate (naloxone glucuronide) to
being metabolized also in large amounts by keto-reduction to an
active metabolite (6 -naltrexol), which may partially account for
naltrexone's oral efficacy. Changes from 3-phenolic (as in hydro-
morphone and oxymorphone) to 3-O-methyl (as in hydrocodone and
oxycodone) greatly decreased the role of conjugation, increased
the role of N-demethylation, and increased the excretion of free
intact parent drug. Also, in going from 3-phenolic compounds,
which were selectively reduced to the 6- alcohol configuration,
to 3-O-methyl compounds, the stereoselectivity was completely
abolished and a 1:1 ratio of 6 - to 6 -alcohols was produced
during 6-keto reduction.
Comparative studies in laboratory animals in the six 6-keto
opioids have revealed some overall species trends in the metabo-
lism of these compounds. Humans showed a balanced metabolic
profile, with all pathways participating (conjugation, N-dealkyla-
tion, 0-dealkylation, 6-keto-reduction). The rat showed weak to
absent conjugation, N-dealkylation. and 6-keto reduction, and, in
general, appears to be a poor model for studying metabolism of
these compounds. The dog was an excellent conjugator with
moderate N-dealkylation and weak to absent other pathways. The
guinea pig was a very good 6-keto reducer, a poor dealkylator
and moderate in other pathways. The rabbit was generally balanced
across most pathways and appeared to resemble the human profile
more closely than the other species. The oxycodone data showed
that N-dealkylation does occur in the rabbit. It is apparent that
there are metabolic differences among all the species studied and
within species there are definitive trends across all 6 drugs.
Completion of the full analysis of the oxycodone data will complete
this study.
BEHAVIORAL PROPERTIES OF FENCAMFAMINE
Fencamfamine is a sympathomimetic central stimulant which has
recently appeared in the illicit drug market of the U.S. and is
being considered for scheduling by the World Health Organization.
At the last meeting of this Committee, we presented the results
of preliminary experiments demonstrating that fencamfamine
maintains i.v. self-administration behavior by beagle dogs.
Additional experiments to further characterize the behavioral
properties of fencamfamine have been conducted during the past
year, and the results are summarized in this report.
In the first experiment, the direct effects of fencamfamine on
schedule-controlled responding were studied. Four rats responded
under a multiple fixed-interval (FI) 300 sec, fixed-ratio (FR) 20
schedule of water presentation. Sessions were conducted daily,
Monday through Friday, with each rat. Each session consisted of
10 FI components alternating with 10 FR components. Five doses of
fencamfamine (0.1-10.0 mg/kg, i.p.) and six doses of cocaine
(0.1-30.0 mg/kg, i.p.) were tested. Drugs were typically
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administered on Tuesdays and Fridays; saline control injections
were given on Thursdays. Each dose was tested twice in each rat.
Fencamfamine and cocaine produced qualitatively similar effects
on performance under the multiple FI FR schedule of water presen-
tation. During the FI components, overall response rates first
increased, then decreased with increasing doses of either drug.
Peak increases were produced by 30.0 mg/kg fencamfamine and 10.0
mg/kg cocaine. During the FR components, overall response rates
were not appreciably different from saline until the highest dose
of each drug was tested, at which time responding was almost com-
pletely eliminated. The time course of drug effect was also
similar for fencamfamine and cocaine. Both drugs had relatively
rapid onsets of action, with similar declines over the remainder
of the session.
In the second experiment, the discriminative stimulus properties
of fencamfamine were studied. Four rats were trained to discrimi-
nate cocaine from saline in a two-lever drug discrimination task
on a fixed-ratio (FR) 10 schedule of water presentation. I.P.
injections of cocaine (3.0 mg/kg) or saline (0.1 ml/kg) were given
daily on a double alternation schedule. Each session began with
a 5-min blackout period, and was followed by 20 trials, or 30-min,
whichever occurred first. Trials were completed when the rat made
10 consecutive responses on the correct choice lever. Responses
on the drug-appropriate lever produced reinforcement following
cocaine injections, while responses on the opposite lever produced
reinforcement following saline injections.
Following acquisition of criterion performance (90% or greater
responses on the correct choice lever for eight consecutive
sessions), drug testing began.
cocaine (0.3-3.0 mg/kg) were tested;
Four doses of fencamfamine and
saline was also included in
the series. Ten consecutive responses on either lever produced
reinforcement during test sessions. Both fencamfamine and cocaine
produced dose-related increases in the percentage of responses
made on the cocaine-appropriate choice lever; fencamfamine was
approximately 1.5 times as potent as cocaine in producing
cocaine-like discriminative stimuli. Both drugs moderately
increased response rates above saline control values; only a dose
of 3.0 mg/kg cocaine slightly decreased rates.
In the third experiment, the effects of dopamine blockade on
fencamfamine self-administration were studied. Three purebred
beagle dogs, with histories of i.v. drug self-administration,
were given access to response-contingent drug injections under a
fixed-ratio with limited hold schedule of reinforcement. Experi-
mental sessions were conducted daily, Monday through Friday.
Each session consisted of 11 trials, each trial lasting a maximum
of 4 min; successive trials were separated by timeout periods of
10 min. During each trial, the 15th pedal-pressing response
produced a 15-sec i.v. drug injection. Each of five doses of
fencamfamine and cocaine (0.01-1.0 mg/kg) were tested for five
consecutive sessions, with treatment order arbitrarily determined
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for each dog. Following completion of the dose-effect curves.
the effects of presession treatment with the dopamine antagonist,
pimozide, on fencamfamine and cocaine self-administration were
assessed. Pimozide (30.0 mcg/kg, i.v.) was given 30 min before
the start of each session for five consecutive sessions for each
of the four doses of fencamfamine or cocaine (0.03-3.0 mg/kg).
Both fencamfamine and cocaine maintained self-administration
above saline control levels. There was an inverted U-shaped
relationship between the number of injections per session and dose
per injection; overall rates of responding and local rates of re-
sponding were also systematically related to dose per injection,
first increasing, then decreasing with increasing doses of drug.
For both response rate measures, at least one dose of fencamfa-
mine maintained higher rates than did cocaine. Presession treat-
ment with pimozide shifted the ascending portion of the dose-
effect curves approximately one-half log unit to the right; the
descending portion of the curves was not appreciably altered by
the administration of pimozide.
In the fourth experiment, the relative reinforcing properties of
fencamfamine and cocaine were assessed using a progressive-ratio
schedule of reinforcement. Three purebred beagle dogs, with
histories of i.v. drug self-administration, were given access to
a single response-contingent drug injection during each of three
1-hr. trials per day; these three trials were separated by time-
out periods of 3 hrs. The response requirement to obtain one
injection each trial was increased daily until the dogs failed to
complete the necessary fixed-ratio; i.e., until they reached a
"break-point". Several doses of fencamfamine and cocaine
(ranging from 0.6-3.0 mg/kg) were tested; drugs were delivered
i.v. over 30 sec. The order of testing was randomly determined
for each dog and saline was included in the treatment series.
All doses of fencamfamine and cocaine maintained self-administra-
tion behavior at FR values considerably above those obtained with
saline in all three dogs. In general, there was a positive rela-
tionship between dose per injection and FR value completed; that
is, with increasing doses of drug, higher "break-points" were
obtained. In all three dogs, fencamfamine and cocaine maintained
similar behavior; comparable fixed-ratio values were completed
with equivalent doses of each drug.
The results of these four experiments indicate fencamfamine and
cocaine share many behavioral properties. Both drugs have qual-
itatively similar effects on schedule-controlled responding;
fencamfamine produces cocaine-like discriminative stimuli; fen-
camfamine, like cocaine, maintains i.v. self-administration
behavior, and this behavior is altered by the administration of
the dopamine antagonist; pimozide; finally, both fencamfamine
and cocaine maintain similar FR values in a progressive ratio
paradigm. Thus, fencamfamine appears to be a highly reinforcing
drug that may be abused for its cocaine-like effects.
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PUPILLARY BEHAVIOR AS A NEURONAL MODEL TO STUDY THE SITE AND
MECHANISM OF ACTION OF ADDICTIVE DRUGS
One of the most demonstrative effects of morphine, besides anal-
gesia, is its ability to alter pupillary size-miosis in some
species (e.g., dog, monkey, human), but mydriasis in others (e.g.,
rat, cat). However, little is known about the site or mechanism
of action of morphine's pupillary effects. In these studies the
paralyzed cat preparation was used to study opiate effects on
three components of pupillary activity: size, light reflex, and
fluctuation. In this model the animal rests in a sling restraint
with a TV camera focused on one eye.. All pupillary activities
are measured continuously by an infrared video pupillometer con-
nected to a strip chart recorder and a computer.
In a typical experiment baselines of normal pupillary behavior
are obtained after dark adaptation for 30 and 60 min; drug is
usually administered intravenously at 60 min. The normal pupil
in this preparation oscillates at frequencies related mostly to
respiratory rate. The fluctuation amplitude is higher during
moderate mydriasis than during miosis. At specified intervals
a light reflex is obtained by flashing a light and measuring the
downward deflection. The typical effects 15 min after i.v.
administration of 0.5 mg/kg of morphine 60 min after dark adapta-
tion include: increase in pupillary size, inhibition of fluctua-
tion, and decrease in the amplitude of the light reflex.
Naloxone (10-30 µg/kg) antagonizes all three components of mor-
phine's effect.
The mean effect of morphine was determined in six cats in doses
of 0.06 to 15 mg/kg i.v. on the three components of pupillary
behavior. Morphine produced significant linear dose-related
changes in all three parameters. Levorphanol, but not dextror-
phan. produced morphine-like pupillary effects, suggesting mor-
phine receptor stereospecificity. Also, the pupillary effects
of morphine did not change two weeks following sympathectomy.
indicating that sympathetic pathways innervating the iris do not
appear to be involved in the pupillary effects of morphine in the
cat.
Single experiments that explore the role of released circulating
catecholamines in the mechanism of morphine's mydriatic effects
in the cat have now been completed. Preliminary results show
that after pretreatment with the -adrenergic blocking agent,
phentolamine, morphine-induced mydriasis was partially antago-
nized, suggesting that at least part of morphine's mydriatic
activity may be due to increased catecholamine release. Mydri-
asis occurred when 10 nmol of normorphine was microinjected into
the Edinger-Westphal nucleus of the rostra1 midbrain. This
suggests a possible central site of action for morphine mydriasis
involving the preganglionic parasympathetic neurons. Saline
injected into the Edinger-Westphal nucleus had no effect.
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To further explore the site of morphine's mydriatic action, the
effect of loperamide, 0.5 mg/kg i.v. was studied. This anti-
diarrhea1 compound does not cross the blood-brain barrier well,
but does have opiate properties in in vitro preparations.
Loperamide produced mydriasis, but with a much shorter duration
of action than the same dose of morphine. However, unlike
morphine, loperamide was completely antagonized by the
-adrenolytic, phentolamine. After pretreatment with both loper-
amide and phentolamine, morphine was still able to produce a
mydriatic effect. This preliminary data is consistent with
part of morphine's mydriatic action being indirect, that is to
increase the release of peripheral catecholamines which in turn
act on the smooth muscle of the iris, and part of morphine's
action being central. Experiments are currently underway studying
the effects of various prototypic opioids to explore the possible
opioid receptor interactions involved in opiate pupillary effects.
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During the past year, the clinical pharmacology research ward was
closed from April to September, 1983. During this time, the
ward was physically remodeled, and a computer system was installed
to permit the direct entry of subject and observer data via
terminals to the central processor (PDP-11). Despite the shutdown,
several studies were initiated and some of the results of these
completed or partially completed studies will be presented in
this report.
INVESTIGATION OF COMPULSIVE BEHAVIORS
Within recent years, there has been an increasing acceptance of
the concept that common mechanisms underlie the compulsive use of
a variety of substances. This concept follows from the obser-
vations that most substances of abuse serve as positive reinforcers.
and act as euphoriants in post-addict subjects. In addition, most
substance abusers abuse several drugs, often from different pharma-
cologic classes. The following two studies were conducted to
determine whether or not a non-drug controlled compulsive behavior
showed similar mechanisms with drug abuse. The strategies used
were based on those developed over the years at the Addiction
Research Center to study prototypic drugs of abuse (Jasinski,
Johnson and Henningfield, 1984).
Pathological Gambling
Winning at compulsive gambling has been compared to drug abuse
since the behavior may become compulsive; winning is exceedingly
reinforcing, and the gamblers self-report a drug-like euphoria
state looked on as a positive reinforcer. In the present experiment
nineteen volunteers with histories of compulsive gambling were
asked to simulate winning at gambling. This was done to learn
if an euphoric response accompanied winning, similar to that
produced by substances of abuse. In these studies, outpatient
subjects were given a series of psychometric tests. This included
anextensive drug history questionnaire which was modified to in-
clude a history of gambling. Then, on two separate occasions,
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they were administered the Addiction Research Center Inventory
(ARCI). One time they were asked to complete the ARCI as they
felt that day and on the other, they were asked to complete the
ARCI as they felt when they were winning at gambling. The use
of simulated tests has been shown to be a valid measure of euphoric
responses to drugs.
Of particular interest was the observation that the mean score
for the compulsive gamblers on the Psychopathy Scale of the MMPI
was 63.26. This compares with the mean score in normals of 43.62
and in the addict population of 68.21. The profile of responses
on the ARCI indicated that winning at gambling produced significant
responses on the Morphine Benzedrine Group (MBG), simulated opiates,
popularity, efficiency and Benzedrine Group Scales. This profile
is most similar to that produced by amphetamine and opiates.
Opiates, however, do not produce significant responses on the
Efficiency and Benzedrine Group Scale.
Overall, this clinical assessment of gambling indicated there were
some commonalities between gambling and drug abuse.. First, there
are positive early experiences associated with winning, elevated
psychopathy score, and within the subcultural areas enhanced
social status associated with winning. More importantly, the
winning is associated with an euphoric response as measured by
elevated MBG scale scores, a measure of drug-induced euphoria.
Abuse Liability of Glucose
These studies were done in four volunteers who had histories of
substance abuse. The purpose of these studies was to learn if
glucose given intravenously was an euphoriant. Our interest was
to learn if glucose ingestion compared with the model for compul-
sive behavior. A secondary purpose was to provide controls for
our studies on cerebral metabolism using rate of glucose turnover
as measured in Positron Emission Tomography.
In these studies, subjects were given 10, 20, and 40 mg of glucose
and saline, each infused over three minutes after a 12-hour fast.
Experimental procedures and the measures were those developed for
measuring the effects of intravenous boluses of nicotine. The
subjective behavior and physiologic measures were taken every 12
seconds, five minutes before, during, and after the infusion.
The glucose infusions were discriminated from saline infusions;
however, there was no alteration in mood. The effects of the glu-
cose infusions were disliked because of pain at the infusion site.
Infusions of glucose were physiologically active, since pupil
diameter, skin temperature and heart rate, and arm EMG all
increased. From these experiments we conclude that under conditions
and in populations where substances of abuse are psychoactive and
euphoriants, glucose did not produce euphoria.
60
AVERSIVE EFFECTS OF NICOTINE
One of our recent areas of investigation has been to investigate
relations between subjective effects and drug taking in operant
paradigms. Previously, we reported that euphoric and positive
reinforcing effects of nicotine were complexly related. Sub-
jective euphoria and reinforcing efficacy are both directly re-
lated to dose; however, over the course of a test session,
tolerance develops to the euphoric effects of the drug, whereas
preference for the drug over nicotine is unchanged. In the
presently reported study, the relationship between the aversive
properties of nicotine and subjective dysphoria were similarly
studied. During three-hour sessions, pressing one lever produced
nicotine injections and pressing the other lever blocked the
presentation of programmed injection. The subjects were three
volunteers who had failed to self-administer nicotine in excess
of placebo (saline).
The experimental paradigm is similar to that described previously
for self-administration of nicotine. Fifteen minutes before each
three-hour test session, a subject was given a single dose of the
drug which was to be presented during the subsequent test session.
One minute after the injection was given, the subject marked the
degree of any positive (euphoric) effects and the degree of any
negative (dysphoric) effects on positive and negative visual line
analogue scales, respectively. During the subsequent test session,
injections were programmed to occur at either 15-or 30-minute
intervals. By pressing one lever 10 times prior to the scheduled
injection, the stimulus lights were extinguished and the dose was
not delivered, At the start of the next day trial (15 or 30
minutes before injection), the stimulus lights were again turned on.
Subjective effects and operant avoidance behavior generally covaried.
The number of injections avoided was directly related to drug dose
in each of the three subjects tested. Similarly, scores on the
negative visual line analogue scale were somewhat more sensitive
to drug dose manipulations and were directly related to dose level.
INVESTIGATION OF OPIOID SUBCLASSES
Studies of the opioids, cyclazocine, and nalorphine in the chronic
spinal dog, in conjunction with human studies, suggested that the
effects of these drugs were mediated through receptors other than
the mu-type thought to mediate the effects of morphine (Gilbert
and Martin, 1976; Martin et al., 1976, Jasinski et al., 1970).
Martin proposed that ketocyclazocine represented a prototype of
one subclass, of opioids which act through stimulation of receptors
which he labeled “kappa”. We conducted studies to learn if the
pharmacologic profiles of morphine, ketocyclazocine, and cyclazocine
differed. We wished to know whether abstinent drug abusers could
discriminate among these three drugs. The design of the study
also included the administration of large doses of naloxone to
determine if naloxone is pharmacologically active. Our original
studies with naloxone revealed little pharmacologic activity at
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doses up to 30 mg (Jasinski, Martin, Haertzen, 1967). However,
in recent years, larger doses of naloxone have been used in clinical
and research medicine. The effects of these doses have been
attributed to antagonism of endogenous opioid substances.
Data are presented from the first five subjects who have completed
the study protocol. The measures included standard measures for
assessing the effects of single doses of substances of abuse.
They are the Single Dose Questionnaire for subjects and observers,
the full Addiction Research Center Inventory (ARCI) and selected
subscales, the Morphine Benzedrine Group (MBG), LSD and Pentobar-
bital-Chlorpromazine Alcohol Group (PCAG) scales. The physiologic
measures included blood pressure, pulse, temperature, and respira-
tory rate.
Some new psychometric measures were developed for inclusion in
this study. One is a scale which calls for a categorical-numerical
rating of 0, 1, 2, 3, or 4 in response to the question, "How much
do you feel the medicine?” Beside the “0” response, the word
‘hone” is written and beside the “4” response the word “maximum”
is written. No other prompt words appear, allowing the subjects
to scale the intensity of the feeling state.
The initial studies of ketocyclazocine prompted the development of
another scale, the Perception Scale, based on questionnaires
developed by Abramson and Isbell (Isbell et al., 1956) which are
useful for measuring the effects of LSD and hallucinogens. There
are 40 questions which reflect alterations in the five senses,
cognition, feelings of detachment, paranoia, and general mood. The
subject is confined to 10 categorical-numerical responses, the
digits 0-9, which represent the intensity of the particular feel-
ing state. The full questionnaire is scored by summing the
numerical responses. The scale is also broken down into subscales
which group questions probing one sense or mental process. These
subscales are scored individually.
Lastly, a drug discrimination procedure was introduced which called
for the subject to identify the drug 24 hrs after administration.
This was done by conducting the study in two parts, training and
discrimination. The training part consisted of giving intramuscu-
lar injections of morphine, 21 mg, ketocyclazocine, 0.85 mg,
cyclazocine, 0.7 mg, naloxone, 210 mg, and placebo in random order
identifying them only as A, B, C, D, and E. Subsequently, in the
discrimination phase, the subjects receive morphine, 15 and 30 mg,
ketocyclazocine, 0.6 and 1.2 mg, cyclazocine 0.5 and 1.0 mg,
naloxone, 150 and 300 mg, and placebo given in random order under
double-blind conditions. Twenty-four hours later the subjects
are asked to identify the unknown drug by writing the letter code
from the training phase which matches the unknown drug.
Further investigation was conducted into biochemical markers of
kappa and mu activity. Kappa agonists appear to inhibit ADH
release resulting in increased urine production while morphine,
a mu agonist, increases ADH release and decreases urine volume
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(Nutt and Jasinski, 1974). During the training phase of the
Experiment , plasma and urine were collected for ADH assay and
urine for determination volume and osmolarity per unit time.
Preliminary results indicate that morphine decreases urine output
and ketocyclazocine increases it.
RESULTS
The onset of action of ketocyclazocine is more rapid than cycla-
zocine or morphine. The activity of ketocyclazocine is apparent
at 15 minutes after administration and peaks at 30 minutes,
declining rapidly thereafter to baseline by three hours. Morphine
and cyclazocine did not reach peak activities until one hour
after administration and their effects were still present at 8 to
twelve hours.
Among the physiologic responses, morphine and cyclazocine caused
an increase in the supine systolic blood pressure, temperature
depression, and miosis. Only morphine caused a depression in
the respiratory rate. Ketocyclazocine caused an increase in the
supine systolic blood pressure and a decline in body temperature
was detected at the high dose only. Apart from these, it had no
other activity among these measures. The absence of miosis clearly
differentiated ketocyclazocine from cyclazocine and morphine.
The drug discrimination procedure of drug identification by letter
code demonstrated that the subjects could distinguish among the
five drugs that were administered. The results of the chi square
analysis rejected the null hypothesis of chance arrangement of
drug identifications with a p value much less than 0.05. The
subjects correctly identified the drugs 29 times out of 45 trials
(65%). Among the drug identification errors, ketocyclazocine was
cross-identified with cyclazocine six times but was not confused
with morphine. In contrast, cyclazocine was confused with placebo,
morphine, ketocyclazocine, and naloxone.
Morphine was significantly different from the placebo on the
“Feel the Drug, Opiate Symptoms, Subject’s Liking and MBG” scales.
It had no effects on the PCAG and LSD scales. Cyclazocine and
ketocyclazocine however, produced responses different from placebo
on the “Feel the Drug and LSD” scales with no significant responses
on the “Opiate Symptoms, Subject’s liking, MBG or PCAG” scales.
Thus, the pattern of responses of ketocyclazocine and cyclazocine
was identical. Analysis of the Perception Scale indicated that
morphine affected only the subscale relating to tactile responses.
Ketocyclazocine produced a striking response on the full scale
and had activity on the subscales of general effect, detachment,
auditory, tactile, dizziness, cognition, and paranoia. Exceptions
to its activity are the smell, visual, and taste subscales.
Cyclazocine also demonstrated significant activities on the full
Perception Scale at low and high doses. It had activity on the
general, detachment, tactile, dizziness and cognition scales but
only at the high dose. We conclude that cyclazocine is like
ketocyclazocine in its profile of subjective effects, especially
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at high doses; however, it is not identical to it. Morphine is
very different from ketocyclazocine. This is most clearly
distinguished by the profile of subjective effects. The profile
of physiologic effects less clearly discriminates among morphine,
ketocyclazocine and cyclazocine but important differences were
observed. The most important distinguishing physiologic measure
was pupil response in that it demonstrated that ketocyclazocine
was different than both morphine and cyclazocine.
Naloxone was pharmacologically active in these subjects at the
very large doses given in this study. The onset of effects was
noted at the 30-minute post-drug observation for the group. The
drug effects did not reach peak activity until one to two hours,
gradually resolving by about eight hours. The activity did not
appear dose-related because the peak effects and duration did not
change as a function of increasing dose. Naloxone caused few
changes in the subjective measures. It was significantly different
from placebo on the “Feel the Drug” scale. The full “Perception
Scale” measured differences between naloxone and placebo only
for the low dose. There were trends for significant responses
on the general and detachment subscales. There were also some
trends on the “Opiate Symptoms Scales.” The full scale, the
‘yawning”, and “high” symptoms all trended toward significance
with five subjects completed in the study. Naloxone did not
constrict pupils; however, the systolic blood pressure (supine
and standing) increased and body temperature was depressed compared
to placebo.
Thus, it is demonstrated that naloxone is a pressor in the absence
of hypotension. There was a trend for respiratory depression
and an increased pulse rate. On the basis of these studies, it
is concluded that naloxone is pharmacologically active at doses
of 150 and 300 mg when compared to placebo on both phsyiologic
and subjective measures. The profile and time course of effects
resemble a weak agonist rather than precipitated abstinence,
though the study is incomplete.
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Ira A. Liebson; and Scott E. Lucas
The Division of Behavioral Biology is the site of a group of
multifaceted research projects dealing with the behavioral
pharmacology of substance abuse. The general aim of this program
of research is to promote a fuller understanding of addictive
disorders and of their behavioral and biomedical foundations; in
particular, the laboratory focuses upon determinants of drug self-
administration and determinants of adverse drug effects. This aim
is pursued via systematic experimental study of the contributory
deterministic roles both of behavioral and of pharmacological
factors.
The range of research in the Division is illustrated in the
outline in Table 1. A major program of preclinical behavioral
pharmacology research is conducted within the animal laboratories
at the Medical School campus; in addition, a large clinical
research program is conducted, primarily on the campus of the
Francis Scott Key Medical Center. In both the animal and human
laboratory settings research focuses upon a similar array of
substance abuse related issues -- analysis of drug self-
administration behavior, evaluation of drug stimulus
characteristics via operant drug discrimination procedures, and
assessment of the behavioral and biomedical consequences or
sequelae of drug intake. In addition to these experimental
laboratory settings, the Division conducts related research in
various applied settings. These applied settings provide the
opportunity to examine the relevance outside the laboratory of
principles and relationships observed in the laboratory, and they
provide the opportunity to conduct controlled clinical trials of
treatment interventions for substance abuse problems.
This progress report will summarize the Division's work in these
areas over the past year.
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TABLE 1. Outline of Research Program and Settings
I. PRECLINICAL BEHAVIORAL PHARMACOLOGY
1.
2.
Drug Self-Administration
Drug Discrimination
3. Assessment of Drug Effects
II. CLINICAL BEHAVIORAL PHARMACOLOGY
A. Laboratory Settings
1. Drug Self-Administration
2. Drug Discrimination
3. Assessment of Drug Effects
B. Applied Settings
1.
2.
Drug Self-Administration
Assessment of Drug Effects
3. Treatment Intervention Trials
I. PRECLINICAL BEHAVIORAL PHARMACOLOGY
A. SELF-ADMINISTRATION
In the primate laboratory an experiment by Lukas, Griffiths and
Brady has examined the self-administration of a range of doses of
eight different opioid compounds. A substitution procedure was
used, in which baboons outfitted with intravenous catheters were
initially trained to self-administer cocaine (0.32 mg/kg/inj);
following stabilization of the cocaine performance an opioid test
dose was substituted for the cocaine for 12 - 15 days. The stable
cocaine performance was re-established prior to each test dose
substitution. Thus, these evaluations of opioid reinforcing
efficacy were conducted in subjects who were not opioid dependent.
Single injections were available once every three hours, so the
maximum possible was 8 self-injections per day.
The two agonists codeine and morphine and the three mixed agonist-
antagonists butorphanol, nalbuphine and pentazocine all showed
parallel ascending dose effect curves, but with morphine showing a
lower peak. Neither SKF 10,047 nor naloxone were self-administered
above vehicle levels. Self-administration of buprenorphine
occurred in only one of three animals, and showed a very shallow
dose-effect curve.
It is of interest that morphine, which Is recognized as a compound
of high abuse liability, maintained lower peak self-administration
than codeine, butorphanol, nalbuphine or pentazocine -- all of
which are considered to be of lower abuse liability.
Unfortunately we are not able to explain the basis for this
finding, but two possibilities are: first, that morphine's
reinforcing efficacy may be lower in the absence of physical
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dependence; or second, that morphine self-administration may be
suppressed by morphine's relatively greater potency in disrupting
operant behavior.
B. DRUG DISCRIMINATION
A second major area of activity within the animal laboratory has
been the use of the drug discrimination methodology to assess the
similarities and differences in the stimulus properties of various
compounds. In the drug discrimination procedure animals are
trained to make one operant response after having received a
specific training drug and to make a different operant response
after having received vehicle only. The response made after
receipt of test doses provides information concerning the stimulus
similarity of the test compound to the training compound.
Work by Ator, Griffiths, and Brady has examined the stimulus
generalization of a range of novel anxiolytics to standard
training drugs. Each of the test drugs was studied over a range
of doses. The results are summarized in Table 2. A "plus" mark
indicates the test drug showed stimulus generalization -- or
stimulus similarity -- to the training drug; a "minus" mark
indicates it did not; a blank indicates that particular condition
was not tested.
TABLE 2. Drug Discrimination Cross Generalization
Training Drug
Test Drug
Pentobarbital
Lorazepam
Triazolam
Zopiclone
CL 218,872
Buspirone
CGS 9896
PK 9084
Lorazepam
Baboon Rat
- -
+ +
+ +
+ +
+ +
- -
- -
- -
Pentobarbital
Baboon Rat
+ +
+ +
+ +
+
+
-
- -
-
Subjects were trained either in a lorazepam versus no drug
discrimination or In a pentobarbital versus no drug
discrimination. Both baboons and rats were trained in each
discrimination. It should be noted that there is cross-species
generality in all the conditions where It was tested.
An assymnetry was observed in the pentobarbital-lorazepam
discrimination. While both pentobarbital and lorazepam were
discriminated as being similar to pentobarbital, only lorazepam
was discriminated as being lorazepam-like; pentobarbital was not.
This assymmetry was replicated across species.
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Triazolam, a hypnotic benzodiazepine, showed a stimulus
characteristic profile similar to that of the anxiolytic
benzodiazepine lorazepam, not like that of the hypnotic
pentobarbital.
The remaining compounds in the table are all novel anxiolytics
with non-benzodiazepine structures. Despite their non-
benzodiazepine structures both zopiclone and CL 218,872 show a
profile of discriminative stimulus characteristics similar to the
benzodiazepines. Other data have indicated that these compounds
have anti-conflict or anxiolytic activity, and that they show
benzodiazepine binding.
The bottom two compounds -- CGS 9896 and PK 9084 -- are quinoline
derivatives that also show benzodiazepine binding and show
anxiolytic-like anti-conflict activity in preclinical studies.
However, neither of these was discriminated as having
benzodiaiepine-like stimulus properties.
The final compound -- buspirone -- is a piperazinyl derivative
which does not show benzodiazepine binding but which is reported
to have anxiolytic activity. It was not discriminated as being
either lorazepam-like or pentobarbital-like.
C. ASSESSMENT OF DRUG EFFECTS
A third activity in the animal laboratories has involved
assessment of the behavioral consequences of drug intake -- i.e.,
characterization of drug-produced performance disruptions. The
primary procedure being used is that of assessing the
psychophysical thresholds and reactlon times for stimulus
discrimination in baboons. This is done by training animals to
make specific operant responses when they detect a stimulus, and
then assessing the sensitivity and speed of their performance
following test dose administration.
During this year Lukas, Hienz, and Brady have completed a
comparative evaluation of diazepam and triazolam using this
psychophysics procedure. Diazepam produced dose-related elevations
of both auditory and visual, thresholds and reaction times. In
general, triazolam produced similar effects (except it did not
elevate auditory threshold), and it was approximately 100 times as
potent as diazepam.
There were marked differences in the time course of the
sensorimotor impalrments produced by the two drugs -- presumably
the result of long-acting metabolites following diazepam and not
triazolam. Following single high doses of diazepam, impairment was
detectable for up to 4 - 5 days. There was no residual day-after
effect following triazolam.
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II. CLINICAL BEHAVIORAL PHARMACOLOGY
A. LABORATORY STUDIES
1. Self-Administration
A drug self-administration methodology in the form of a behavioral
choice procedure is one of the bases of the laboratory's clinical
drug abuse liability testing program. In this procedure subjects
are given scheduled exposures to test compounds and are
subsequently permitted to choose which of those they prefer next
to receive. Use of the drug self-administration choice procedure
in clinical drug abuse liability assessments is illustrated in a
paper by Griffiths and colleagues reported elsewhere in this
volume. That report compares the reinforcing efficacies of
diazepam and oxazepam. Choice comparisons were conducted between
placebo and a range of doses of both diazepam and oxazepam as well
as between the two active drugs themselves. At comparably
sedating doses greater self-administration preference was
maintained by diazepam.
A second area of application of the clinical drug self-
administration methodology has been in study of the determinants
of tobacco smoking. A series of studies have investigated the
effects of various drug pretreatments upon smoking. Chait and
Griffiths have studied the effects of various methadone doses on
cigarette smoking among methadone maintenance patients who
participated in 2-hour smoking sessions after receiving either
placebo, dextromethorphan (as a taste blind) or one-half, one or
two times their usual methadone maintenance dose. Increasing
doses of methadone produced increases in various indices of
smoking -- including both behavioral measures and biological
measures of smoke absorption. This is the most recent in a series
of studies which have found cigarette smoking to be increased by a
range of drugs of abuse, including d-amphetamine, ethanol,
pentobarbital, and now methadone. In contrast, studies of
caffeine indicate that it does not affect smoking.
2. Drug Discrimination
During this year Preston, Bigelow, and Liebson have developed and
used with human subjects an operant drug discrimination procedure.
Opioid-dependent methadone maintenance subjects were trained in a
three-way drug discrimination between hydromorphone, naloxone, and
saline which were identified to them only by letter codes;
subjects were subsequently tested with a range of doses of the two
active compounds to assess their stimulus similarity to the
training doses. Results showed that the three-way drug
discrimination was rapidly learned and resulted in orderly'dose
effect relations. This human opioid drug discrimination procedure
appears promising for the clinical study of the opioid mixed
agonist-antagonists. This study is described in greater detail in
a separate report in this volume.
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3. Assessment of Drug Effects
A number of years ago the Committee awarded this laboratory
preliminary funds to develop clinical procedures for assessment of
abuse liability. The major procedure used in these evaluations is
assessment of the profile and time course of subjective and
behavioral effects of test compounds in experienced abusers.
Elsewhere in this volume two papers are presented which illustrate
the laboratory's application of these procedures to assessing the
abuse liability of benzodiazepines.
Griffiths and colleagues describe a comparative evaluation of
diazepam and oxazepam over a range of doses in experienced
sedative abusers. Figure 1 illustrates the time course of effects
on psychomotor performance. Interestingly, oxazepam, which is
pharmacokinetically the shorter acting of the two, had a much
slower onset and consequently a more protracted time course of
acute behavioral effects. Roache and colleagues report a
comparison of the benzodiazepine hypnotic triazolam with
pentobarbital, also with sedative abuser subjects. On the day
following drug administration subjects provided estimates of the
dollar value of the test dose. Interestingly, at dose ranges that
produced similar effects for both drugs on objective indices of
sedation and intoxication, subjects' subjective evaluations of
triazolam's reinforcing value were much lower than for
pentobarbital.
FIGURE 1. The time course of behavioral disruption following
oral administration range of a range of doses of diazepam or oxazepam
to sedative abuser subjects is shown. In this performance task.
subjects responded by touching randomly illuminated lights in a
circular array.
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B. APPLIED SETTINGS
1. Self-Administration
Studies in applied settings allow one to assess whether
relationships and principles observed in laboratory studies have
generalizable practical relevance in clinical settings, and they
allow one to assess whether there may be factors acting in
clinical settings which are being overlooked in laboratory
studies.
For some time this laboratory has been interested in whether the
construct of a drug's reinforcing efficacy or abuse liability is
related to the extent of the drug's self-administration by normal
patients in therapeutic contexts or whether this construct relates
more narrowly to the behavior of the somewhat deviant population
that engages in illicit drug abuse. Bigelow and Liebson have been
examining the self-administration of the phenylethylamine
anorectic-stimulant drugs using a behavioral choice procedure in a
therapeutic weight control clinic population. In these studies
overweight patients are exposed for one week durations to each of
two alternative drugs and are then allowed to choose the drug
which they will next receive. There is a one-week washout between
drug exposures and the cycle repeats for multiple choice exposures
for each subject. Figure 2 summarizes the results of three
experiments, each of which compared one of the phenylethylamines
to placebo. Diethylpropion, which has an amphetamine-like profile
of effects, maintains drug preference well above placebo levels;
chlorphentennine, which has a profile of effects that is more
fenfluramine-like, suppresses drug preference well below placebo
levels (interestingly, chlorphentermine has been discontinued from
production because of poor sales); phenylpropanolamine, the active
ingredient in over-the-counter diet aids, was not distinguished
from placebo. These data on preference in this applied clinical
setting are compatible with laboratory data concerning the
relative reinforcing efficacies of these drugs.
FIGURE 2. Mean percent choice for active drug versus placebo by
weight control outpatients is shown. In three separate experi-
ments placebo was compared to each of three phenylethylamine
anorectics.
72
A second applied setting in which drug self-administration is
studied is the methadone maintenance clinic. A study by Stitzer
and colleagues has used a behavioral choice drug self-
administration procedure to assess the reinforcing efficacy of
acute increases in the methadone dose. In this study patients
were offered, in a mixed order, the opportunity to choose between
various size methadone dose supplements and financial payments of
either $1 or $5. The percent of dose supplements chosen was
examined as a function of dose magnitude and as a function of
magnitude of the financial alternative. Graded dose-effect
relations were observed, with larger doses maintaining greater
drug preference, and the curve was shifted to the right by
increasing the magnitude of the financial alternative. The
demonstration that acute methadone dose supplements function as
reinforcers suggests the utility of incorporating such changes
Into contingent reinforcement behavioral interventions for the
promotion of therapeutic changes.
2. Assessment of Drug Effects
When patients enter methadone treatment one would like to dispense
a dose of methadone which is sufficient to suppress the opioid
abstinence syndrome but which is not so great as to produce acute
behavioral intoxication or behavioral impairment in Its own right.
Unfortunately no adequate procedure has been available for rapid
determination of the degree of opioid tolerance with which addicts
present. A recent study by Higgins and Stitzer has evaluated the
utility of an acute oral methadone challenge as a technique for
assessing degree of opioid tolerance. Participants were heroin
addicts applying for outpatient methadone detoxification; at
intake they were given a standard dose of 20 mg methadone orally
and were assessed over the course of 2 hours. Figure 3 shows the
relationship between the magnitude of their heroin habit --
measured in dollars per week reportedly spent for heroin -- and
the change in pupillary diameter constriction produced by the
methadone challenge. The correlation between the two was highly
significant, with r = -0.65. Thus, this methadone challenge
procedure appears to be a simple and effective technique for
estimating degree of opioid tolerance. A future prospective
clinical trial will assess whether tolerance levels at admission
are predictive of success in treatment.
3. Treatment Intervention Trials
One of the important aspects of drug dependence research which can
only be conducted in applied settings is, of course, the conduct
of therapeutic intervention trials. This has been one of the
major functions served by this laboratory's outpatient methadone
treatment research clinic. The results of three such treatment
intervention trials are reported separately elsewhere in this
volume. Stitzer and colleagues report the effects of methadone
dosage manipulations during detoxification. Higgins and
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FIGURE 3. Magnitude of pupillary constriction in response to an
oral 20 mg methadone challenge is shown as a function of dollars
per week reported spent for illicit heroin. Objects were out-
patient applicants for methadone treatment.
colleagues report the effects of using methadone dose alterations
as behaviorally-contingent reinforcers to encourage abstinence
from illicit drugs during detoxification. McCaul and colleagues
report on the comparative effects of diazepam and doxepin when
used as pharmacological adjuncts to methadone detoxification.
These studies will not be described here.
A final setting in which therapeutic intervention trials have been
conducted is in medical settings where patients with substance
abuse problems are seen for routine medical care. This is an
especially appropriate setting for studies of tobacco dependence
given its strong association with a wide variety of health
problems. Bigelow and Burling recently conducted a randomized
antismoking intervention trial among pregnant smokers attending a
hospital-based prenatal clinic. Women were randomized between a
usual care condition and a special intervention condition which
received a strong directive antismoking letter mailed to their
home from the clinic director. Results are shown in Figure 4; the
letter intervention produced a statistically significant increase
in smoking abstinence which was detectable at subsequent clinic
visits for up to ten weeks.
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FIGURE 4. Percent of patients abstinent from smoking is shown as
a function of treatment condition over successive clinic contacts.
Patients were pregnant women smokers attending an outpatient
prenatal clinic.
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Report From The University of
Chicago Drug Abuse Research
Center
Chris E. Johanson
Researchers associated with the Drug Abuse Research Center at the
University of Chicago have been investigating the biological and
behavioral mechanisms underlying the reinforcing properties of anorectics
for several years. Our evaluation of anorectic drugs includes measures
of their efficacy as anorectics as well as their neurotoxicity to
complement the assessment of dependence potential. We have expanded
our evaluation by using comparable procedures across species, including
humans. The goal of this research program is to develop and validate
procedures which can be utilized to develop safe anorectic agents with
lower dependence potential than those currently available. Even more
recently we have expanded our investigations to include anxiolytic drugs
with the same purpose. Because of our interests and background, we
were asked to participate in developing CPDD’s screening effort for
anorectic and anxiolytic drugs. This report includes a review of previous
work as well as preliminary results on compounds evaluated specifically
for CPDD.
The procedures typically used for compounds suspected or known to be
anorectic-like include measures of anorectic properties (food intake in
both rats and monkeys), drug discrimination with subjects (pigeons,
monkeys, and humans) trained to discriminate amphetamine from placebo,
and drug self-administration in monkeys and humans. Measures of
nenrotoxicity of repeated dosing in rats are included when possible.
Similar types of studies are done with anxiolytics but to date we have
only implemented drug discrimination studies in pigeons and monkeys
and self-administration studies in monkeys and humans. For procedures
where different species are used, an effort is made to have the protocols
as similar as feasible.
The use of multiple measures of drug action allows several kinds of
comparisons to be made which, when viewed as a whole, can aid in a
cost-benefit analysis of a compound. For instance, if the ED50 for
decreased food consumption is considerably lower than its ED50 for
discrimination, patients receiving the medication may not ever experience
any subjective effects which increase the likelihood of dependence
potential. In contrast, the opposite relationship is less desirable.
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ANORECTIC DRUGS
For purposes of illustrating our approach for anorectics, I will review
a series of animal studies on 7 anorectic drugs. Results with humans
wi l l  no t  be  inc luded .  These  d rugs  inc lude  d
phenmet raz ine  (PM) ,  d ie thy lp rop ion  (DEP) ,  maz indo l  (MZ) ,
-amphetamine (AMP),
methylphenidate (MP), fenfluramine (FF), and phenylpropanolamine (PPA).
These were selected because they include drugs with varying dependence
potential and varying neurochemical effects.
Anorectic Efficacy
Rats were given 15 minutes access to a milk solution each day and
their intake measured. Dose-response functions were obtained by
administering drugs (S.C.) 15 mins prior to the session. Rhesus monkeys
were given 2-hr access to food pellets each day and their intake
measured. Drugs were given lntragastrically 60 mins prior to the session.
Using ED50's for comparison, the rank ordering of potencies in both
rats and monkeys was: AMP MZ FF DEP PM MP. These
potencies correspond to the therapeutic dose. However, for PPA, there
was a marked difference in the efficacy and potency in the two species.
In rats, PPA had no effect in doses up to 128 mg/kg, whereas in the
monkey PPA was both a potent and efficacious anorectic. Our failure
to decrease food intake in the rat is in contrast to studies by Kornblith
and Hoebel (1976) in which doses of 5, 10 and 29 mg/kg of PPA produced
a significant decrease in food intake in rats. Further research is
necessary to determine what variables account for these differences.
Neurotoxicity
For the past 10 years we have worked in association with Dr. L. Seiden
to investigate the possible neurotoxicity of various anorectic drugs.
Amphetamines produce damage to DA neurons in several species which
strongly suggests that such changes would also occur in humans. What
is not known is whether the amphetamines are unique in this regard or
whether other anorectlc drugs produce similar effects.
A major problem In comparing drugs for their possible neurotoxic effect
is the selection of appropriate doses. The data on anorectic potency
in rats allowed the calculation of an ED50 dose for each drug which
could be used as the point of comparison for the selection of doses to
be tested for neurotoxicity. Generally, doses of 5, 10 and 20 times the
ED50 for suppression of food intake were selected for investigation,
although higher or lower doses might be tested if necessary. Half of
each daily drug dose was administered subcutaneously in two divided
doses at 0700 and 1700 hours for 4 consecutive days to a group of male
rats. Control rats were injected with the drug vehicle. Two weeks
after completing the 4-day treatment period, rats that survived the drug
regimen were killed for monoamine level determinations in specific areas.
There were marked differences in the effects obtained with the various
anorectic agents. AMP produced a decrease in the levels of DA and
5HT in certain regions of the brain including the striatum and
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hippocampus but had no effects on NE in any area. The minimal dose
(25 mg/kg) required to produce this effect was 20 times the ED50 dose
for suppressing milk intake. On the other hand, MP produced no effects
on the levels of DA, NE or 5HT at doses up to 5 times (50 mg/kg) its
ED50 for anorexia. Higher doses could not be evaluated because they
were lethal. MZ at a dose 40 times (120 mg/kg) its ED50 for anorexia
produced a small but significant decrease in NE levels in the hippocampus
and rest of brain. DEP at a dose 10 times (100 mg/kg) its ED50 for
anorexia produced a decrease in serotonin levels in the hippocampus and
rest of brain. FF also produced a long lasting depletion of serotonin in
the striatum, hippocampus and rest of brain at a dose (6.25 mg/kg) only
1.25 times the ED50 dose for anorexia. In the case of the other
anorectics, the minimal dose necessary to produce a prolonged
neurochemical effect varied from 10 (DEP) to 40 (MZ) times the ED50
dose. It would thus appear the fenfluramine is a significantly more
toxic drug than the other anorectics tested.
Drug Discrimination
The same compounds were evaluated in the drug discrimination paradigm
in pigeons trained to discriminate between 2 mg/kg (i.m.) AMP and
saline in a two-lever food-reinforced procedure and in monkeys trained
to discriminate 1 mp/kg (i.g.) AMP from saline in a two-lever shock
avoidance procedure. During test sessions, five of the anorectics
substituted for AMP in a dose-dependent manner in both species. For
pigeons the order of potency was MZ AMP = MP = PM DEP. In
monkeys the order of potency was: AMP PM MZ DEP MP.
In pigeons PPA also substituted but was the least potent. However, only
1 of 3 monkeys, at a dose of 100 mg/kg, responded on the drug-
appropriate lever. There was partial substitution of FF in pigeons but
none in monkeys.
Self-Administration
Rhesus monkeys have been used extensively to assess the dependence
potential of new compounds (Johanson and Schuster 1981). In general
drugs which are abused by humans are self-administered by monkeys
(Johanson and Balster 1978) and those which are not abused do not
maintain responding in monkeys. This concordance has led to the
acceptance of the self-administration paradigm as an animal model of
drug dependence (Thompson and Unna 1977). The dependence potential
of the anorectics reviewed in this paper has been evaluated extensively
both in our own laboratory as well as others.
Several studies have demonstrated that AMP maintains responding in
several species and under a variety of conditions (see Johanson and
Schuster 19 81). This is also true for MP (e.g., Wilson et al. 1971;
Johanson and Schuster 1975), PM (e.g., Wilson et al. 2971; Griffiths et
al. 1976; Woolverton, unpublished observations), DEP (e.g., Johanson and
Schuster 1977), and MZ (Wilson and Schuster 1976; Woolverton,
unpublished observations) but not FF (e.g., Woods and Tessel 1974;
Griffiths et al. 1976) or PPA (Woolverton, unpublished observations).
These results are in general agreement with the actual levels of abuse
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of these drugs and support the use of animal self-adminstration studies
as a means of predicting dependence potential.
ANXIOLYTIC DRUGS
Drug discrimination studies similar to those described above have also
been done in oxazepam-trained pigeons (i.m. route) and pentobarbital
(PB)-trained monkeys (i.g. route). During test sessions, several anxiolytics
substituted for the training drug while drugs from other classes (e.g.,
amphetamine) did not.
In order to evaluate the reinforcing properties of anxiolytics, the standard
substitution procedure with cocaine as the baseline drug has not been
adequate. For instance, in a study conducted by Bergman and myself,
only 3 of 11 monkeys self-administered diazepam. While this may
accurately reflect the dependence potential of this drug, it would be
difficult to differentiate anxiolytics with less reinforcing efficacy. On
the other hand, in that same study it was found that 5 out of 5 monkeys
maintained on a PB baseline self-administered diazepam. This had led
us to evolve a new strategy for testing the reinforcing properties of
anxiolytics. Such drugs are originally tested only in animals with a PB
baseline. If responding is maintained, monkeys on a cocaine baseline
may be tested.
In previous studies using monkeys on a PB baseline we have shown that
midazolam, triazolam, and flurazepam are self-administered by all
monkeys tested. Lorazepam and estazolam maintain responding in about
50% of the monkeys whereas enciprazene was not self-administered by
any of the monkeys tested.
CPDD COMPOUNDS
We have been sent 6 coded compounds from CPDD, 4 said to be
anxiolytics and 2 anorectics. To date these have been tested in drug
discrimination and self-administration. All compounds regardless of what
information we are given are initially tested in the drug discrimination
studies with pigeons, one group trained with amphetamine and a separate
group with an anxiolytic. The outcome of these studies determines what
further tests are done. If the drug is anorectic-like, further drug
discrimination studies are done with amphetamine-trained monkeys and
the reinforcing properties are evaluated in monkeys maintained on a
cocaine baseline. If, on the other hand, the drug is sedative-like, drug
discrimination studies are done in monkeys trained to discriminate PB
and the reinforcing properties are evaluated in monkeys maintained on
a pentobarbital baseline. If responding is maintained, a drug may be
tested using the alternative baseline in additional monkeys.
Anxiolytics
When the studies were completed, the four anxiolytics were revealed to
be diazepam, bromazepam, temazepam and halazepam. All four
substituted as a discriminative stimulus for oxazepam in pigeons and PB
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in monkeys hut did not substitute for amphetamine in pigeons. Three
of the compounds were similar in potency with halazepam being less
potent. All four compounds were self-administered in PB-baseIine
monkeys. In cocaine-baseline monkeys, a previous study showed that 3
of 11 monkeys self-administered diazepam. The other 3 anxiolytics were
tested in 2 cocaine-baseline monkeys. Bromazepam and temazepam
were not self-administered but halazepam was.
Anorectics
Only 2 compounds purported to be stimulant-like have been tested and
as yet the identity of these compounds is unknown. One of these drugs
(CPDD 5) substituted for AMP in both pigeons and monkeys but did not
substitute for oxazepam in pigeons. The second compound (CPDD 6)
partially substituted for AMP in both species but not for oxazepam in
pigeons. CPDD 5 was self-administered in 4 cocaine-baseline monkeys
whereas CPDD 6 was not. CPDD 5 was also self-administered by the
two PB-baseline monkeys. In one of these monkeys, intake was extremely
high and convulsions occurred. When that monkey was returned to the
PB baseline, increased sensitivity to its sedative effects were observed.
This same monkey also self-administered CPDD 6, tested after CQDD
5, but the second animal did not.
Summary
In summary, I have reviewed the results from 6 coded compounds we
have evaluated as part of CPDD’s efforts to expand into testing the
dependence potential of anorectics and anxiolytics. I have reviewed a
great deal of additional studies in order to place the results with the
test drugs into a broader context and also to demonstrate our experience
in evaluating these classes of drugs. Clearly the 4 anxiolytic drugs
were well characterized by our tests. The two compounds designated
as anorectics are still unknown to us. CPDD 5 appears amphetamine-
like, is self-administered, and in both tests is 1/10th as potent as
amphetamine. The results with CPDD 6, however, are less clear. In
the drug discrimination studies, it only substitutes for amphetamine in
some animals, and in monkeys has minimal reinforcing properties.
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Analgesics 3. Synthesis, Resolution, X-Ray
Structure Determination, Receptor Binding,
and Analgesic Properties of 3-Methyl-3-m-
Hydroxyphenylpiperidines With N-Substituent
Variation
Alice C. Cheng; Edward T. Uyeno; Lawrence Toll;
Christopher Keys; Dale Spangler; Joseph I. DeGraw;
Gilda H. Loew; Arthur Camerman; and Norman Camerman
Phenylpiperidines are an important class of compounds that
interact with opioid receptors. (Kugita et al., 1964, Jacoby et
al., 1974, Iorio and Casy 1975, Jacoby et al., 1981). Recently,
(Lawson, et al., in press) our laboratory has been involved with
the synthesis and pharmacological studies of several series of
3- and 4-phenylpiperidines. All these compounds were shown to
exhibit mixed analgesic agonist and antagonist activities.
Among the compounds studies, the 3-phenylpiperidines possess
optical activity. Because of the chirality, the agonist/antagonist
potency ratios observed could have resulted from different
activities of the enantiomers of the compounds in addition to
factors such as binding of different conformations or orientations
of the compounds at the receptor. In order to clearly address
this issue, the absolute configuration of the chiral center
should be taken into consideration. To the best of our knowledge,
no reports have appeared in which the actions of optically
active 3-(m-OH)phenylpiperidines have been examined for their in
vitro receptor binding and in vivo pharmacological activities.
Consideration of the general structural-activity relationship
(SAR) requirements of the receptor as well as steric, conforma-
tional or stereochemical factors may help to probe the nature of
the opiate pharmacophore and its mode of interaction with the
opioid receptors. Enantiomeric pairs are particularly useful
for such probing because they have identical physical properties
and thus, unless they undergo differential metabolism, pharmacologi-
cal differences may reasonably be attributed to receptor-associated
events. (Abdel-Monem et al., 1972, Sullivan et al., 1975). In
the present study, we have prepared the optical isomers of a
series of N-substituted-e-methyl-e-phenylpiperidine analogs
(shown in Table 1) in order to investigate their receptor
binding behavior and pharmacological activities.
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TABLE 1. Optical isomers of 3-phenylpiperidines
METHODS AND MATERIALS
1. Chemistry
The synthesis of racemic 3-methyl-3-(m-methoxyphenyl)piperidine
(1) follows the procedure of Kugita et al.,1 but with some
modification (Lawson et al., in press).
We found that (-)-D-tartaric acid was a convenient resolving agent
for the resolution of (±)-1; after three recrystallizations from
95% EtOH, a diastereomeric salt was obtained. The liberated
amine, upon conversion to the hydrochloride salt, gave a constant
specific rotation. The combined mother liquors containing
enriched (-)-1, obtained after resolution of (+)-1, when treated
with (+)-L-tartaric acid, led to the isolation of (-)-1, which
exhibits an opposite rotation of similar magnitude to (+)-1.
Determination of the optical purity of the enantiomers of 1 was
achieved by Mosher's method (Dale et al., 1969). Compound-(+)-1
was converted to the diastereomeric amides with optically pure
(-)- -methoxy- -trifluromethylphenylacetyl chloride. The
19F-NMR spectrum of these diastereomeric amides in CDCl3 displayed
two equally intense singlets at 6 9.38 and 8.58 ppm for the two
trifluromethyl resonances. The amide generated from (+)-1
displayed a major signal at 8.58 ppm and a minor one at 6 9.38
ppm, while integration of the two peaks showed a ratio of 96 to
4. This, coupled with the specific rotations of two
enantiomers establishes that they are equally-resolved and
suggests that they are nearly optically pure.
Direct N-alkyiation of the enantiomers of 1 with the three
appropriate alkyl halides yielded the desired N-substituted
compounds (m-OCH3 of 3,4,5) (Lawson, et al., In press). A
reductive alkylation, using formaldehyde and sodium cyanoborohy-
dride, was employed in the preparation of the N-methyl analog
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(m-OCH3 of 3,4,5) (Lawson et al., In press). The arylmethyl
ethers were cleaved by boron tribromide to give the resolved
target compounds (2,3,4,5).
2. Opiate Receptor Binding Assay and Data Analysis
Opiate receptor binding assays were erformed essentially as
described by Pasternak et al., (1975). Briefly, rat whole brain
homogenates were prepared, preincubated at 37°C for 1 hr and
resuspended in Tris ph 7.7 at 6.7 mg tissue per ml. Receptor-
binding incubations contained 1.8 ml tissue suspension, 0.1 ml
labeled ligand (usually 1.0 nM) and unlabeled drugs in a total
volume of 2.0 mL. The tubes were incubated in triplicate at
25°C for 45 min prior to filtration,
In the present studies, self- and cross-competition experiments
were conducted for 4 labeled ligands, at two different concentra-
tions of labeled ligand. This yields a four-by-four "matrix" of
competitive inhibition behavior. For each pair of enantiomers
inhibition of all 4 labeled ligands was performed. Data obtained
from binding studies were analyzed by a modified version of the
program LIGAND (Munson and Rodbard 1980) which predicts the
receptor binding affinities and capacities using weighted
nonlinear, least squares regression analysis.
In the procedure used, all self- and cross-competition studies
involving the four labeled ligands were analyzed together
assuming a 1-, 2-, 3-, and 4-site model of receptor binding, and
results were compared for statistical significance and other
indications of reliability. Inhibition data for each of the 4
enantiomeric pairs of N-substituted-3-methyl-e-(m-OH)phenylpiperl-
dines were then added to the matrix obtained for the labeled and
unlabeled ligands, and the data reanalyzed simultaneously for
self-consistent receptor binding affinities and capacities.
Again, 1-, 2-, 3-, 4-site models for receptor binding were
systematically explored.
3. Animal Testing
Analgesic potencies of the chemicals and the reference drug
(morphine sulfate) were determined by the mouse writhing test,
developed by Koster et al. (1959) and Blumberg et al. (1965).
The writhing test was chosen as a measure of analgesic activity
since these compounds were suspected of having antagonist
activity. The median effective doses (ED50) were derived from
the dose-response curves, and the 95% confidence limits were
calculated according to the graphic method of Litchfield and
Wilcoxon (1949).
Antagonism of morphine analgesia to the tail-flick response was
used to evaluate the antagonist potency of our test compounds.
In this tail flick assay, the radiant heat method described by
D'Amour and Smith (1941) and Harris et al. (1969) had been
adapted for use in our laboratory.
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RESULTS
Using the computer program LIGAND, a three- and four-site
receptor model yielded a self-consistent set of receptor binding
affinities and capacities that were statistically much more
significant than either a one- or two-site model, but were not
significantly different from each other. Results for the three-
site model are shown in Table 2 for naloxone,
D-ala2-D-leu5enkephalin (DADL), dihydromorphine (DHM), ethylketocy-
clazocine (EKC) and the four pairs of resolved 3-phenylpiperidines.
As can be seen by the four standard opioid ligands, sites labeled
"µ" and " " can be discerned by high affinity of naloxone and
DADL respectively. The third site we have chosen to label " ",
however, is not characterized by a high affinity for EKC, which
has been called a prototypical ligand. Several other investigators
however, have noted a lack or limited number of kappa receptors
in rat brain (Snyder and Goodman 1980, Gillan and Kosterlitz
1982). This third site contains a much greater number of
binding sites than the other two, and may in fact represent a
composite of several opioid sites.
The 3-phenylpiperidines are u-selective, binding with highest
affinity at µ and lowest at . For the µ site, the affinities
range from 18.4 to 424 nM for the (+) enantiomer and from 46.5 to
351 nM for the (-) enantiomer. There is no striking difference
in affinity between (+) and (-) enantiomers at any site for any
compound.
The similarity in affinities of the enantiomer pairs is in
contrast to the striking differences obtained in the mouse acetic
acid writhing and antagonism of tail flick analgesia tests (Table
3). The most obvious difference is apparent in the antagonist
assay. For all four pairs, the (+) isomers show activity, while
the (-) isomers are inactive up to 80 mg/kg (300 µmol/kg). In
contrast to the fused-ring opiates, the (+)-N-phenethyl analog
(+)-5 is the most potent antagonist. This compound is 6.5 times
less-potent than nalorphine and 8-10 times more potent than the
other 3-phenylpiperidines tested. For analgesic agonist activity,
the N-methyl and N-phenethyl analogs display no stereospecificity,
while the (-) isomers of the allyl,3, and cyclopropylmethyl, 4,
are at least 10 times more potent than the (+) isomers. In fact,
the (+)-N-cyclopropylmethyl analog, (+)-4 , was inactive as an
analgesic.
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TABLE 2. Receptor affinities and maximum binding capacities for
a three-receptor site model
DISCUSSION
The major finding in our study of binding affinities and analgesic
and antagonist activity of resolved 3-(m-OH)phenylpiperidine
compounds is that while receptor affinities do not vary signifi-
cantly between enantiomers at any site, all of the antagonist
activity resides in the (+) isomer of each enantiomeric pair.
Some stereospecificity is also apparent in the analgesic activity
of the N-cyclopropylmethyl and N-allyl analogs, but not in
N-methyl or N-phenethyl compounds. These results indicate that
determination of receptor affinity, at least at the sites we have
characterized, is not sufficient to predict differences in
agonist or antagonist activity.
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TABLE 3. Analgesic and narcotic antagonist potencies of
resolved 3-methyl-3-m-hydroxyphenylpiperidine
with N-substituent variation
a
b
c
d
Inhibition of acetic acid induced writhing.
Antagonism of tail-flick inhibition induced by morphine sulfate
(21.08 µmol/kg, s.c.)
Compounds showed no significant antagonist activity up to dose of
80 mg/kg.
Showed no significant activity at a dose of 707.21 µmol/kg.
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FIGURE 1. Postulated 3-phenylpiperidine agonist and
antagonist pharmacophores
Based on energy calculations, binding affinities and agonist and
antagonist activities of racemic 3- and 4-phenylpiperidine
compounds, we have postulated three possible qualitatively
different receptor binding orientations that can lead to agonism
and antagonism (Fig.1) (Lawson et al., In press; Burt and Loew
1984). In these binding modes, an overlap with only the cationic
amine nitrogen of morphine (Pharmacophore I) will lead to agonism
while an overlap of only the m-OH-phenyl with morphine's
phenyl-OH will produce antagozism (Pharmacophore II). Thus mixed
agonist/antagonist activity could by accounted for by a single
compound binding in a bimodal fashion as in Pharmacophores I and
II. N-R variations could then modulate the extent of binding of
each isomer in each mode, but in a manner different from that in
fused ring opioids. By contrast, if the 3-phenylpiperidines bind
in a Pharmacophore III mode with a simultaneous overlap with
morphine's amine nitrogen and m-OH-phenyl group, we would expect
N-R variations to modulate agoNism and antagonism in a manner
similar to that in fused-ring opiates.
For the 3-methyl-3-phenylpiperidines, Pharmacophore I or II could
involve -axial or 4-equatorial conformers with a piperidine
chair. Pharmacophore III involves a piperidine boat conformer,
which, while of higher energy than a chair, cannot be ruled out
for the receptor site interactions.
The results presented here are most consistent with the
hypothesis that different receptor binding modes lead to
agonism and antagonism. All (-) isomers are pure agonists and
thus would seem to bind preferentially in an orientation without
a m-OH-phenyl overlap (Pharmacophore I), prohibiting antagonist
activity. The (+) isomers appear to bind in a bimodal fashion
with agonist activity initiated by binding in Pharmacophore I and
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antagonist activity initiated by binding in Pharmacophore II.
The N-R substituents modulate the extent of binding in each mode.
They, however, do not modulate agonist/antagonist activity as in
fused-ring opioids. In fused-ring opiates, N-methyl compounds
rarely show antagonist activity. Also, the N-ally1 and
cyclopropylmethyl substitutions in this series do not increase
antagonist activity as they do in the fused-ring opiates. Thus,
Pharmacophore III with simultaneous cationic amine and
hydroxy-phenyl overlaps is probably not involved in the binding.
The surprising finding of strict stereospecificity for antagonism
but not agonism should provide clues to additional spatial
requirements for antagonist activity of 3-phenylpiperidines other
than m-OH- overlap with morphine at the µ opioid receptor. In
the two different enantiomers in Pharmacophore II orientation,
the amine-N of the piperidine is displaced relative to the
crucial m-OH phenyl group. Apparently, only one of the amine
positions is compatible with local receptor subsite interactions.
Preliminary X-ray structure determination of the (+)-enantiomer
of the m-OCH3 nor analogue, 1, reveals that the series of active
antagonists derived from this compound have a S-configuration as
shown in Pharmacophore II (figure 1). Moreover, as shown in this
Pharmacophore. it was found that the piperidine ring has a chair
conformation and the phenyl ring is equatorial. These X-ray
results support the conclusion that bimodal piperidine chair
Pharmcophores (I and II), rather than a boat conformation
(Pharmacophore III), are involved in receptor interactions. The
X-ray determination of the absolute configuration of the active
enantiomer further defines the relative position of the crucial
amine and phenyl groups in the antagonist binding mode.
EXPERIMENTAL SECTION
Resolution of (±)-1. The free base 1 (8.9 g, 43.5 mmol) in
a so ute EtOH 70mL) was treated with a solution of (-)-tartaric
acid (7.5 g, 50 mmol) in 95% EtOH (55 mL) and the resulting
mixture was allowed to stand overnight at room temperature. The
salt which formed (7 g) was filtered. After two
recrystallizations from 95% EtOH, the enantiomerically pure salt
was obtained. The free base was liberated by extracting a pH 10
solution of the tartrate salt with Et2O (3 x 50 mL). After
drying over K2CO3, the solvent was concentrated under vacuum to
58 mL, and ether saturated with dry HCl was added drop-wise at
0°C to precipitate
(c=0.5, MeOH) + 11.0°.
the HCl salt of (+)=1: mp 188-190°C; [ ] D
2 5 °
The combined mother liquors containing
amine 1 enriched with (-)-1 were worked up to yield the pure base
which was treated with (+)-tartaric acid, and the resulting salt
was recrystallized 3 times to yield the enantiomerically pure
product in 37% yield.
188-190°C; [ ]D
25° (c=0.5, MeOH) - 10.8°.
The hydrochloride salt (-)-1 had a mp of
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Evidence for Separation of Anesthetic Activity
From Prototypic Phencyclidine Action in Drug
Discrimination by Molecular Modification of
Dioxadrol, a Phencyclidine-Like Dissociative
Anesthetic
Ernest A. Harrison, Jr.; Michael F. Rafferty; Kenner C. Rice;
Cyrus R. Creveling; Gail D. Winger; James H. Woods; and
Arthur E. Jacobson
Phencyclidine (1, PCP, figure 1) was synthesized in the late 1950’s
and found to produce many novel pharmacological and behavioral
effects (Chen et al. 1959). Among these was an ability to provide
a surgical level of anesthesia with little compromise of
respiration or cardiovascular function (Chen and Weston 1960).
Unfortunately, PCP produced dysphoric dissociative effects in an
unacceptably large percent of the people to whom it was given and
its use as an anesthetic was discontinued.
Abuse of PCP has become a serious problem in this country and has
caused a resurgence of interest in PCP-like compounds (Henderson
1982, and ref. cited therein). PCP and related compounds have
been shown by several laboratories to interact with binding sites
or receptors in mammalian brain tissue (Zukin and Zukin 1979;
Vincent et al. 1979; Hampton et al. 1932; Rafferty et al. 1984).
We, and others, have found that this interaction occurs with
reasonably high affinity. Structural specificity and
stereospecificity have been demonstrated (Jacobson et al.; Marwaha
et al. 1981). and the in vitro affinities of many ligands are in
good accord with their in vivo PCP-like actions (Rafferty et al.).
We are attempting to characterize the PCP receptor through the
synthesis of varied molecules which might have higher affinity or
act as antagonists, and we have recently reported the synthesis of
an affinity ligand able to bind specifically and irreversibly to
the PCP receptor (Rafferty et al. 1984). In our initial efforts to
discern molecular requirements for interaction with the PCP
receptor, we have hypothesized that the dissociative effects of PCP
are mediated through its receptors in the CNS, but that its
anesthetic effects may not occur through interaction with that
receptor. Thus, compounds which may structurally resemble the
PCP-like anesthetics hut which do not interact with the PCP
receptor may afford us anesthetics without dysphoria.
In 1966, Hardie and colleagues synthesized a large number of
4-(2-piperidyl)-1,3-dioxolanes; compounds which bear little
structural resemblance to PCP. One of these, dioxadrol, exists in
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four isomeric forms: alpha (+), alpha (-), beta (+) and beta (-).
The alpha (+) and alpha (-), and the beta racemate have potent
local anesthetic effects as measured in the rabbit corneal test,
and one, dexoxadml, the alpha (+) enantiomer, had analgesic
effects in the rat hot-plate test as well. It was given a clinical
trial where it was demonstrated to have analgesic effects but
produced dissociative effects very similar to those produced by PCP
in a substantial number of patients to whom it was given (Lasagna
and Pearson 1965). Dexoxadrol has subsequently been shown to have
stimulus properties in common with PCP in squirrel monkeys. It
also had limited reinforcing properties in rhesus monkeys, its i.v.
presentation producing rates that were above those maintained by
vehicle but generally lower than those maintained by PCP (Brady et
al. 1982). It has also been shown to bind to the PCP receptor
(Hampton et al. 1982) at least as well as PCP (table 1). As shown
in figure 1, dioxadrol has two oxygen atoms in its structure.
FIGURE 1. Structures of PCP (1) and dexoxadrol (dioxadrol, 2),
and synthesis of 1,1-diphenyl-3-(2-piperidyl)cyclopentane (3 ) and
1,1-dicyclohexyl-3-(2-piperidyl)cyclopentane (4 ).
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We have posed the question of whether these oxypen atoms are
necessary for the PCP-like pharmacological actions of dexoxadrol
and whether a compound without those oxygen atoms would have
anesthetic activity. In order to answer this question, we have
synthesized 1,1-diphenyl-3-(2-piperidyl)cyclopentane (3 , figure 1).
a cyclopentyl analog of dioxadrol, lacking the ether oxygens in
dioxadrol’s dioxolane ring, measured its interaction with PCP
binding sites in vitro, and discerned its similarity to ketamine in
a drug discrimination assay. The local anesthetic property of this
compound was evaluated as well using hatrachotoxin binding as an
indicator (Creveling et al. 1983, 1984: McNeal et al. 1984). We
have also obtained the dicyclohexyl analog 4 (1,1-dicyclohexyl-3-
(2-piperidyl) cyclopentane) as a by-product-in the synthesis of 3,
and measured its effects in PCP binding and in the local anesthetic
assay.
CHEMISTRY
The synthesis of 1,1-diphenyl-3-(2-piperidyl)cyclopentane (3) and
1,1-dicyclohexyl-3-(2-piperidyl)cyclopentane (4 ) are shown in
figure 1: details of the synthesis will be described elsewhere.
Their structure was assured by infrared, nuclear magnetic resonance
and mass spectroscopy, and by elemental analysis. Compounds 3 and
4 are disstereomeric mixtures; work is in progress on their
separation.
BIOLOGY
Batrachotoxin binding - The specific binding of [3H]BTX-B (20 nM,
14 Ci/mmol) to a bindinq site in voltage dependent sodium channels
in a nreparation of synaptoneurosomes (Hollingsworth et al. 1994)
from guinea pig cerebral cortex was measured in the presence of
optimal concentrations of scorpion venom as previously described
(Creveling, et al. 1983 and 1984; McNeal et al. 1984).
non-specific binding (23%) was determined in the presence of 300
uM veratridine.
Phencyclidine binding assay -
(Sprague-Eanley, Taconic Farms) was homogenized for 20 sec in 30
Freshly excised rat forebrain
vol ice cold 5 mM Tris.HCl, pH 7.4 (Brinkmann Polytron homogenizer,
setting 6). The homogenate was centrifuged at 30,000 x G for 15
min at 4°C, and the pellet resuspended in 30 vol fresh ice cold
buffer. The tissue was again centrifuged, and the resuspension and
pelleting steps repeated a total of three times. The final washed
tissue pellet was then suspended in 80-100 vol of fresh buffer and
kept on ice. The assay mixture consisted of 50uL 3H-PCP solution
(final concentration 8 nM specific activity 43.5 Ci/mmole, New
England Nuclear), 50 uL buffer, 10 uM PCP (the latter was added to
determine nonspecific binding), and 900 uL tissue preparation for
a final volume of 1.0 mL. Compounds were added to the buffer in
various concentrations for assessment of their displacement of
3H-PCP from the brain. The assay mixtures were incubated at 5°C
for 60 min. Separation of bound ligand was accomplished by
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filtration of the assay mixture through Whatman GF-B filters which
had been soaked for a minimum of tvo hours in a solution of 0.2%
polylysine (MW 150,000-300,000, Sigma) to minimise filter binding
of the 3H-PCP. The filters were then vaahed with 2 x 5 mL aliquots
of ice cold buffer. After removing as much liquid as possible from
the filters by suction, the filters were transfered to
scintillation vials, followed by 8 mL cocktail (Beckman Redisolve).
The vials were shaken for 30 min, and allowed to stand for an
additional 30 min or longer before counting. The IC50 values
presented are the average of two separate experiments (each
concentration was run in triplicate).
Drug Discrimination - Rhesus monkeys that had been trained to
discriminate sc injections of either 1.0 or 1.8 mg/kg of ketamine
were used to evaluate the stimulus properties of compound 3. The
details of the training and testing procedure have been described
elsewhere (Bertalmio et al. 1982; Solomon et al. 1982). During
daily sessions, these monkeys were seated in operant conditioning
chambers that were equipped with a stimulus light, two response
levers and a food receptacle. Ten minutes following the injection
of ketamine or a sham injection, the stimulus light was
illuminated, and 100 consecutive responses on the appropriate lever
were reinforced with delivery of ten 300 mg Noyes banana flavored
pellets. The appropriate lever was the right lever if 1.0 or 1.8
mg/kg ketamine had been injected, and the left lever if a sham
injection had been given. The stimulus light was turned off after
100 appropriate responses had been made, or after 5 min had passed,
which ever came first. If, as was usually the case, responding was
completed in less than 5 min, the monkey remained in a blackout
period until the 5-min period was completed. A series of 15-min
trials, each consisting of a 10-min blackout and a maximum 5-min
opportunity to respond, was presented during each daily session.
Ketamine was administered on the penultimate trial of a training
session, and responding on the right (ketamine appropriate) lever
was reinforced on this and the final trial. From zero to four sham
trials preceded the ketamine injection, and responding on the left
(sham appropriate) lever was reinforced during these trials.
During tests of the discriminative effects of compound 3, 100
consecutive responses on either lever was reinforced during each
trial of the test session. Increasing doses of compound 3 from
0.03 to 0.32 mg/kg were given in a cumulative fashion, one
injection preceding each 10 min blackout period of a trial.
RESULTS AND CONCLUSION
The binding of the various compounds to the PCP receptor can he
seen in Table 1, in comparison with PCP and dexoxadrol.
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TABLE 1. The affinity of compounds to the phencyclidine receptor
in rat brain.
C O M P O U N D IC50 (nM)
Phencyclidine (1) 95
Dexoxedrol (2) 89
Cyclopentane analog (3) >1000a
Dicyc lohexyl analog (4) >2000
a) 86% inhibition at 10 uM, 47% at 1 uM
Neither the diphenyl-cyclopentane analog of dioxadrol (3 ) nor the
dicyclohexyl-cyclopentane derivative (4) binds to the PCP receptor
with any degree of potency. In accord with the binding data, drug
discrimination experiments indicate that compound 3 does not act as
a PCP-like cue to ketamine-trained animals at doses from 0.03 to
0.32 mg/kg. Monkeys trained to discriminate ketamine from sham
injection did not respond on the ketamine-appropriate lever when
given increasing doses of compound 3. The rates of responding were
not suppressed at the doses tested: the relative inaolubility of
the compound precluded testing at higher doses. Animals might have
generalized to ketamine if higher doses could have been tested.
There is, also, a remote possibility that one of the four isomers
of 3 is potent in this assay since the diastereomeric mixture in
the oxalate salt which was examined biochemically and in vivo
appears to be about a 4:1 mixture from thin layer chromatography.
Work is in progress on their separation.
Compounds 3 and 4 were tested for their local anesthetic properties
by interaction with the voltage-dependent, batrachotoxin binding
site in sodium channels. Most local anesthetics have good affinity
at that binding site. It was found that compound 3 was about half
as potent au dibucaine and that the dicyclohexyl compound 4 was
equipotent with dibucaine in that assay: they are among the most
potent compounds which have been tested. Although compounds 3 and
4 are diastereomeric mixtures it is, a priori, unlikely that one of
the isoners will be seen to be very much more potent than the
others; little stereospecificity has been noted, heretofore, in
this asaay.
These preliminary data indicate, however, that one or both of the
oxygen atoms in dioxadrol is essential for interaction with the PCP
receptor. In conclusion, it appears that while the ethereal
oxygens are important for the PCP-like dysphoric activity of
dexoxadrol, the in vitro local anesthetic effects persists in the
absence of these atoms.
94
R E F E R E N C E S
Bertalmio, A.J., Herling, S., Hampton, R.Y., Winger, G.D. and Woods,
J. H. A Procedure for rapid evaluation of the discriminative effects
of drugs. J of Pharmacological Methods, 7:289-299, 1932.
Brady, K.T. , Woolverton. W.L. and Balster, R.L. Discriminative
stimulus and reinforcing properties of etoxadrol and dexoxadrol in
monkeys. J Pharmacol Exp Ther, 220:56-62, 1982.
Chen, G., Ensor, C.R., Russel, D. and Bohner, B. The pharmacology
of 1-(1-phenylcyclohexyl) piperidine HCl. J Pharmacol Exp
Ther, 127:241-250, 1959.
Chen, G.M. and Weston. J.K. The analgesic and anesthetic effect of
1-(1-phenyl cyclohexyl) piperidine HCl. Anesth Analg,
39:132-137, 1960.
Creveling, C.R., McNeal, E.T., Lewandovski, G.A., Rafferty, M.,
Harrison, E.H., Jacobson, A.E., Rice, K.C. and Daly, J.W. Local
anesthetic properties of opioids and phencyclidines: Interaction
with the voltage-dependent, hatrachotoxin binding site in sodium
channels. J Neuropeptides, in press, 1984.
Creveling, C.R., McNeal, F.T., Daly, J.U. and Brown, C.B.
Betrachotoxin-induced depolarization and [3H]batrachotoxin-A
20-alpha-benzoate binding in a vesicular preparation from guinea
pig cerebral cortex: Inhibition by local anesthetics. Molec
Pharmacol, 25:350-358, 1983.
Hampton, R.Y., Medzihradsky, E., and Woods, J. H. Stereospecific
binding of phencyclidine in brain membranes. Life Sci,
30:2147-2154, 1982.
Hardie, W.R., Hidalgo, J., Halverstadt, I.F. and Allen, R.E.
4-(2-Piperidyl)-1,3-dioxolanes with local anesthetic, spasmolytic,
and central nervous system activity. J Med Chem. 4:127-136, 1966.
Henderson, C. Phencyclidine. A widely abused but little underatood
psychotomimetic agent. TIPS, 3(6):248-250, 1982.
Hollingsworth, E.B., McNeal, E.T., Burton, J., Wiliams, R.J.,
Daly, J.H. and Creveling, C.R. Characterization of a filtered
synaptoneurosome preparation from guinea pig cerebral cortex.
J of Neurochem, in press, 1984.
Jacobson, A.E., Harrison, E.A. Jr., Rafferty, M.F., Silverton, J.H.
Stereospecific interaction of dexoxadrol to phencyclidine binding
sites. The absolute configuration of dexoxadrol. In preparation.
Lasagna, L. and Pearson, J.W. Analgesic and psychotomimetic
properties of dexoxadrol. Proc Soc Exp Biol Med, 118:352-354,
1965.
95
Marwaha, J., Palmer, Y., Hoffer, B., Freedman, R., Rice, K.C.,
Paul, S. and Skolnick, P. Differential electrophysiological and
behavioral responses to optically active derivatives of
phencyclidine. Arch Pharmacol 315:203-209, 191.
McNeal, E.T. , Lewandovski, G.A., Daly, J.W. and Creveling, C.R.
[3H]Batrachotoxin-A 20-alpha-benzoate binding to voltage-sensitive
sodium channels: A rapid assay for local anesthetic activity.
J Med Chem, in press, 1984.
Rafferty, M.F., Jacobson, A.E., Rice, K.C., Skolnick, P. and Woods,
J.H. Quantitative relationship between the binding of PCP and PCA
derivatives to sites in rat brain and their in vivo activities. In
preparation.
Rafferty, M.F., Jacobson, A.E., Rice, K.C. and Mattson, M. A highly
specific alkylating agent for the [3H]phencyclidine binding site in
rat brain. Science, in review, 1984.
Solomon, R.E., Herling, S., Domino, E.F. and Woods, J.H.
Discriminative stimulus effects of N-substituted analogs of
phencyclidine in rhesus monkeys. Neuropharmacol, 21:1329-1336,
1982.
Vincent, J.-P., Kartalovski, B., Geneste, P., Kamenka, J.M., and
Lazdunskl, M. Interaction of phencyclidine (“angel dust”) with a
specific receptor in rat brain membranes. Proc Natl Acad Sci
U.S.A., 76:4678-4602, 1979.
Zukin, S.R. and Zukin, R.S. Specific [3H]-phencyclidine binding in
rat central nervous system. Proc Natl Acad Sci U.S.A.,
76:5372-5376, 1979.
AUTHORS
Ernest A. Harrison, Jr., Ph.D.
(Guest Worker on sabbatical leave from the Department of Chem.,
The Pennsylvania State University, York Campus, York, PA 17403)
Michael F. Rafferty, Ph.D.
(Guest Worker. Presently at Warner Lambert Pharmaceutical Research
Division, Ann Arbor, MI 48106)
Kenner C. Rice, Ph.D.
Arthur E. Jacobson, Ph.D.
Medicinal Chemistry Section, Laboratory of Chemistry
And: Cyrus R. Creveling, Ph.D.
Laboratory of Bioorganic Chemistry
NIADDK, National Institutes of Health
Bethesda, MD 20205
Gail D. Winger, Ph.D.
James H. Woods, Ph.D.
University of Michigan, Department of Pharmacology
Ann Arbor, MI 48109-0010
96
Dose Effect and Preference
Comparison of Diazepam and
Oxazepam
Roland R. Griffiths; George E. Bigelow; Ira A. Liebson;
and John D. Roache
Two experiments were undertaken to provide information about
possible differences in the abuse liability of diazepam and
oxazepam. The experiments were conducted in a residential hospi-
tal research ward setting with male human volunteers with his-
tories of sedative drug abuse. In both experiments, oral doses
were administered every third day under double-blind conditions.
In the first experiment, the effects of diazepam (10-160 mg) and
oxazepam (30-580 mg) were studied. Dose-effects with area under
the time-action curve data (AUC) showed diazepam to be 2.6 to
5.7 times more potent than oxazepam on various psychomotor,
cognitive, staff-rated, and subjective measures. Comparison of
relative potencies showed diazepam to be relatively more potent
in producing liking than in producing psychomotor and cognitive
effects. Diazepam produced greater peak effects than oxazepam
on a number of staff-and subject-rated measures, including liking.
Onset of effect was more rapid and time to maximal effect was
shorter (1-2 h vs. 4-12 h) with diazepam than oxazepam, while
time to offset of effect was similar for the two drugs. Diazepam
was categorized as producing barbiturate-like subjective effects
(38.3%) more frequently than was oxazepam (13.8%), while oxazepam
was identified as placebo more often than diazepam. Repeated
administration of 160 mg diazepam and 480 mg oxazepam showed that
AUC liking was greater for diazepam than oxazepam, and that
tolerance to psychomotor and cognitive effects occurred with
oxazepam but not diazepam. This study suggests that diazepam may
have a higher abuse liability than oxazepam.
In the second experiment, the effects of and preference for
placebo, osazepam (480 mg), and diazepam (40, 80, and 160 mg) were
studied. After an initial exposure to the letter-coded test
drugs, a series of choice days was scheduled on which subjects
chose between two available drug alternatives. Compared with
oxazepam, diazepam produced greater liking (area under the time-
action curve), peak liking and euphoria and was judged to be of
greater monetary street value. Diazepam was categorized as
producing barbiturate-like subjective effects more frequently than
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was oxazepam (54 vs. 21%), whereas oxazepam was identified as
placebo more often than diazepam (32 vs. 4%). Diazepam was
associated with a more rapid onset of effect than was oxazepam,
and this rapid onset was repeatedly cited by subjects in poststudy
written comments as being a desirable feature of the drug effect.
In choice tests, 80 and 160 mg of diazepam were preferred to
480 mg of oxazepam on 62.5 and 91.7% of the choice tests, respec-
tively. In choice tests between placebo and drug, placebo was
never preferred to diazepam; however, placebo was preferred to
oxazepam on 21.4% of choice tests. Overall, these results extend
the results of the first study suggesting that diazepam has a
higher abuse liability than oxazepam.
A C K N O W L E D G E M E N T
This work was supported by U.S. Public Health Service Research
Grant R01 DA01022.
AUTHORS
Roland R. Griffiths, Ph.D.
George E. Bigelow, Ph.D.
Ira A. Liebson, M.D.
John D. Roache, Ph.D.
Department of Psychiatry
The Johns Hopkins University School of Medicine
Baltimore, Maryland 21205
98
Effects of b-FNA in Drug-Naive and
Morphine-Dependent Rhesus
Monkeys
Debra Gmerek and James H. Woods
The ß-fumarate methyl ester of naltrexone, ß-FNA (Partoghese et
al. 1980) has been reported to be a selective nan-equilibrium
opiate mu receptor antagonist and reversible kappa receptor
agonist in vitro (Takemori et al. 1981; Ward et al. 1982a) and in
vivo (Messing et al. 1982; Ward et al. 1982b). These properties
would make ß-FNA very useful as a pharmacologic probe. However,
the pharmacology of this interesting compound has not yet been
characterized extensively. In this work, we have studied ß-FNA by
observing its overt behavioral effects in drug-naive and morphine-
dependent rhesus monkeys. It was compared to the chemically
related narcotic antagonist naltrexone. ß-FNA appears to reach
sites in the central nervous system after systemic administration
in small amounts compared to naltrexone; we find ß-FNA to be an
insurmountable mu receptor-selective antaqonist in the rhesus
monkey.
MATERIALS AND METHODS
Subjects
Mature rhesus monkeys (Macaca mulatta) (3.0-5.5 kg) trained to
receive S.C. injections were housed in groups of 3-6. Monkeys
made dependent by administering morphine (3 mg/kg, s.c.) every 6
hours for a minimum of 3 months were stereotaxically implanted
with a stainless steel cannula (Plastic Products) for intracere-
broventricular (i.c.v.) injections as described previously (Gmerek
et al. 1983). Cannula placements were verified by radiography.
The overt behavior of the monkeys was monitored by two experienced
observers familiar with the individual animals. The appearance
and actions of the monkeys were recorded every 30 min by checking
the presence or absence of particular behaviors and signs on a
score sheet. Muscle relaxation is evaluated in terms of the
position the monkeys take while sitting still (TABLE 1). Stupor
refers to the response of the animals to envrronmental stimuli.
Withdrawal severity grades were made as described previously
(Villarreal 1973; Woods et al. 1979) such that higher numerical
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scores correspond with an increasing number and severity of
withdrawal signs. The morphine-dependent and normal monkeys were
tested weekly.
TABLE 1. Scale by which monkeys were graded for general
muscle relaxation.
Grade
0
Appearance
No observable muscle relaxation
1 Slight facial relaxation, jaw
slackening, shoulder droop
2 Pronounced facial relaxation, jaw
slackening, shoulder droop
3 Monkey must brace himself to sit up
4 Monkey cannot sit
Compounds and Injections
ß-FNA (Dr. D. Zimmerman, Eli Lilly Co.), morphine sulfate (Merck)
and naltrexone HCl (Endo) were dissolved in warm distilled water.
Ethylketazocine methanesulfonate (Sterling-Winthrop) was dissolved
in a minimal volume of lactic acid and diluted with distilled
water. Doses refer to the particular salt. Subcutaneous injec-
tions were given in volumes of 0.1-1.5 mls. The monkeys were
injected every 30 min with increasing doses of the test agents
such that the total cumulative dose increased by ½- or ½-log
units. Intracerebroventricular injections of aseptic solutions
were given in volumes of 100 ul, during which time the monkeys
were placed in a restraining chair.
RESULTS
Normal Monkeys
Cumulatively administered ß-FNA (1.0-10 mg/kg, s.c.) produced
stupor and muscle relaxation grades of A and 1, respectively, at
10 mg/kg. The animals (n=6) were at their pre-injection level of
appearance and behavior twenty-four hours after 10 mg/kg B-FNA
administration.
The effect of naltrexone pretreatment on morphine-induced muscle
relaxation is shown in figure 1. Naltrexone (1 mg/kg) caused the
expected shift to the right in the morphine dose-effect curves
when given 1 hr before morphine, but, when given as a 24-hr
pretreatment, even 10 mg/kg of naltrexone was ineffective in
antagonizing morphine. Similarly, naltrexone attenuates morphine-
induced stupor when given as a 1-hr, but not as a 24-hr pretreat-
ment (Gmerek and Woods 1984). In contrast; 24-and even 48-hr pre-
treatment with ß-FNA (10 mg/kg) antagonized morphine-induced
muscle relaxation (figure 2). Morphine-induced stupor is also
attenuated by 48-hr pretreatment with ß-FNA (Gmerek and Woods
1984). Twenty-four hr pretreatment with ß-FNA did not antagonize
ethylketazocine-induced muscle relaxation (fig. 3), however,
Thus, ß-FNA was selective in its ability to antagonize the overt
behavioral effects of morphine but not EKC.
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FIGURE 1. The effect of cumulative morphine alone (solid lines), 1
hr after 1 mg/kg naltrexone (dashed lines), and 24 hr after 10
mg/kg naltrexane (dotted lines) on muscle relaxation in normal
monkeys (n=6). Each horizontal segment represents the percent of
monkeys (from 0-100%) showing the level of muscle relaxation
indicated as described in table 1.
FIGURE 2. The effect of cumulative morphine alone (solid lines)
and after 24-hr (dashed lines) or 46-hr (dotted lines) pretreat-
ment with 10 mg/kg ß-FNA on muscle relaxation in normal monkeys
(n=6).
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FIGURE 3. The effect of cumulative ethylketazocine (EKC) alone
(solid lines) and 24 hr after 10 mg/kg. ß-FNA on muscle relaxation
in normal monkeys (n=6).
Morphine-Dependent Monkeys
Single doses of ß-FNA (1, 3.2 and 10 mg/kg, s.c.) precipitated
withdrawal in a dose-related fashion in morphine.-dependent
monkeys. Table 2 compares the dose of naltrexone and ß-FNA
required to precipitate withdrawal of equivalent severity after
s.c. and i.c.v. administration. Subcutaneously administered ß-FNA
was significantly less potent than S.C. naltrexone in its ability
to precipitate withdrawal, whereas i.c.v. ß-FNA was more potent
than i.c.v. naltrexone. Taking into consideration the weight of
the monkeys (i.e., converting mg/monkey, i.c.v. to mg/kg, i.c.v.)
ß-FNA was approximately 16,000 times more potent by i.c.v. than
s.c. administration. In contrast, naltrexone was essentially
equipotent by the two routes.
TABLE 2. Duration of withdrawal of equivalent severity
in morphine-dependent monkeys (n=6).
*In the presence of normal maintenance doses of
morphine (3 mg/kg, S.C. every 6 hr).
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The time-course of precipitated and natural withdrawal was deter-
mined by monitoring the monkeys until they ceased to show signs of
abstinence. During this time the monkeys continued to receive
their normal maintenance doses of morphine (3 mg/kg, S.C. every 6
hr). ß-FNA-precipitated withdrawal lasted substantially longer
than that precipitated by naltrexone or produced by 14 hr morphine
deprivation (TABLE 2).
In order to assess the relative reversibility of ß-FNA and nal-
trexone, morphine was qiven (cumulative doses of 1, 3, 10, 17.5,
32, 56, 100, 185, 320 mg/kg, s.c.) at 30-min intervals beginning 1
hr after the precipitation of equivalent levels of withdrawal by
S.C. naltrexone or ß-FNA. Dependent monkeys undergoing 14-hr
natural withdrawal were treated similarly. A cumulative dose of
17.5 mg/kg morphine completely suppressed the withdrawal elicited
by naltrexone (0.01 mg/kg, s.c.) or by 14- hr abstinence. An
equivalent level of withdrawal induced by ß-FNA (10 mg/kg, s.c.)
was slightly attenuated by 320 mg/kg morphine. These monkeys had
dilated pupils, slight stupor and mild muscle relaxation, but
continued to show other signs of withdrawal. Morphine also did
not suppress i.c.v. ß-FNA (0.003 mg) precipitated withdrawal
(Gmerek and Woods 1984). Thus, ß-FNA-induced withdrawal was
essentially insurmountable.
DISCUSSION
Using observational methods in drug-naive rhesus monkeys, we have
shown that ß-FNA is a long-lasting antagonist of morphine  but not
the kappa agonist EKC. In dependent monkeys, ß-FNA precipitates
long-lasting withdrawal which is insurmountable by subsequent
morphine administration. We also find that there is a large
s.c./i.c.v. potency difference for ß-FNA.
Naltrexone is effective as an antagonist of the acute behavioral
effects of the mu agonist morphine (vida supra) and as well as the
kappa agonist EKC (Gmerek and Woods 1984) in normal monkeys.
ß-FNA, however, at the time it was an effective antagonist of mor-
phine-induced muscle relaxation, did not antagonize EKC-induced
muscle relaxation. This suggests that, in agreement with Ward et
al. (1982b), ß-FNA appears to be a selective mu antagonist in
vivo. ß-FNA also has a long duration of action. The withdrawal
elicited by ß-FNA in morphine-dependent monkeys lasted about twice
as long as a similar level of withdrawal precipitated by naltrex-
one. The duration of ß-FNA-induced withdrawal is in agreement
with the results of Aceto et al. (1984) and may correspond with
the length of time required to regenerate new opiate receptors.
However, a long duration of actions is only indirect evidence of
irreversibility, and may be misleading (see Woods et al. 1984).
The ability of morphine to overcome ß-FNA precipitated withdrawal
was therefore examined. In contrast to natural abstinence and
that precipitated by the competitive antagonist naltrexone, as
well as naloxone, Win 44,441, MR 2266 and cyclazocine (Gmerek
1984), ß-FNA-precipitated withdrawal could not be completely
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suppressed by subsequent morphine administration. This provides
evidence of the insurmountability of ß-FNA in vivo.
There are a number of possible explanations for the large potency
difference of ß-FNA according to route of administration (i.e.,
s.c. or i.c.v.). The first is that ß-FNA may be metabolized after
systemic injection. The possibility that ß-FNA is inactivated
cannot be discounted. A second possibility is that B-FNA has
difficulty penetrating the blood-brain barrier. However, ß-FNA is
thought to pass the blood-brain barrier readily (Dr. P. Porto-
gehese, personal communication). A third possible explanation for
the low potency of ß-FNA after S.C. injection is that there may be
a significant amount of non-brain site binding, such as to plasma
proteins. This would thereby lower the concentration of ß-FNA
available to enter the central nervous system after systemic
administration.
In summary, large doses of ß-FNA are required in order to be
effective after S.C. administration. However, ß-FNA does appear
to be a mu-selective insurmountable antagonist in the rhesus
monkey.
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Experimental Assessment of the
Relative Abuse Liability of
Triazolam and Pentobarbital
John D. Roache and Roland R. Griffiths
There has been increasing interest io assessing the abuse liability
of benzodiazepines relative to the barbiturates and determining
whether there are differences between individual benzcdiazepiones in
terms of abuse liability (Griffitbs & Roache, 1984). The of the best
validated human experimental methodologies for providing information
relevant to abuse liability is to evaluate tbe subjective and/or
reinforcing effects of psychoactive substances in subjects with
histories of drug abuse. Commonly, the abuse liability of a test
drug is inferred by the degree of subjective “euphoric” effects the
test drug may produce in comparison to a standard drug of known abuse
liability such as pentobarbital (Jasinski et al., 1982, 1983).
Subjective “euphoric” effects are often assessed through the use of
standardized factor scale questionaires such as the Addiction
Research Center Inventory (ARCI) or through single item ratings such
as a question of drug liking (Griffiths et al., 1983, 1984).
The present report describes findings from a recent study which
compared the effects of triazolam (TZ) (a benzodiazepine hypnotic)
and pentobarbital (PTB) in subjects with histories of sedative drug
abuse. The experimental approach involved both the assessment of the
liability for abuse (likelihood) through the use of subject rating
scales and the assessment of the liability of abuse (associated
hazard) through the use of objective performance measures and subject
ratings of task perfomance.
M E T H O D S
Using a double-blind, 9 X 9 latio square design, the effects of
placebo, TZ (0.5, 1.0, 2.0, 3.0 mg), and PTB (100, 200, 400, and 600
mg) were examined in nine male volunteers (20-40 yrs; 70-100 kg)
living cm a residential research ward. All subjects bad documented
histories of drug abuse and were not physically dependent at the time
of the study. The daily experimental protocol ran from 0800-2200 hrs
during which time subjects participated in procedures, completed
questionaires, and performed tasks similar to those in former
studies from this laboratory which have been previously described in
detail (Griffiths et al., 1983, 1984). Each day, subjects were Not
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permitted to eat solid foods until 1300 hrs and the placebo vehicle
was administered as an unsweetened powdered fruit drink mixture at
1000 hrs. After a 4-7 day acclimation period, test doses of placebo
or drug were administered in the vehicle on every second day. Data
were analyzed by ANOVA coupled with Duncan's New Multiple Range Tests
for post-hoc comparisons. Relative potencies were calculated by the
method of Finney (1964).
R E S U L T S
Both TZ and PTB produced comparable degrees of dose-related
impairment as measured by staff (observer) ratings of drug effect and
drug-induced drunkenness and also by two objective measures of
psychomotor performance, circular lights and a computerized version,
of the digit-symbol-substitution task (DSST) (a psychomotor task
involving a cognitive component). A similarly rapid onset of action
was observed with both TZ and PTB although the peak effect of PTB
(2-3 hrs) lagged somewhat behind that of TZ (1-2 hrs). TZ tended to
produce greater peak effects than PTB but had a shorter duration of
action (< 8 hrs) than PTB (> 12 hrs). Analysis of peak effect and
area under the time-action curve (AUC) data from these staff ratings
and objective performance measures indicated that the dose-effect
curves for the two drugs were parallel and roughly comparable;
relative potency calculations indicated that TZ was approximately 200
times more potent than PTB (the range across these measures was
159.24-273.94).
In contrast to the similarity in the effects of TZ and PTB observed
with staff ratings and the above-mentioned performance tasks, subject
ratings of drug effect and drug-induced drunkness indicated that TZ
produced effects of a reduced magnitude and a distinctly shorter
duration (4-6 hrs for TZ and 12 hrs for PTB). The reduced subject
ratings of TZ’s duration resulted in significant drug differences
with the AUC data; the peak effect differences were not significant
althougb relative potency calculations indicated a reduced potency
differential (134.77-153.61) between TZ and PTB. A possibly related
observation was obtained with the subject estimates of performance on
the circular ligbts and DSST tasks. Subjects were “blinded” as to
their actual scores on these tasks but were asked to estimate how
well they did by placing a mark on a 100 mm visual analog scale
labeled from "much worse" to "much better" than normal. With this
measure, subjects consistently underestimated the degree of
impairment produced by TZ, whereas they more accurately estimated
the degree of PTB-induced impairment.
Two additional performance tasks utilized in the present study were
an immediate and a delayed recognition memory task. With both tasks,
memorization occurred at 1.5 hrs post-drug; with the delayed
recognition task, subjects were tested the following morning after
drug effects had dissipated, whereas, with the immediate recognition
task, subjects were tested within minutes of acquisition. With both
tasks, TZ produced significantly greater amnestic effects than PTB;
with the delayed test, even the 0.5 mg dose of TZ produced nearly
maximal effects.
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In order to assess the liability (likelihood) for abuse of TZ,
several subject rating scales were utilized in the present study.
One rating scale involved the use of a five-point scale cm which
subjects could repeatedly rate the degree to which they liked the way
the drug made them feel throughout the 24-hr post-drug period.
Analysis of the AUC data for this measure indicated that TZ was less
well liked than PTB. Examination of the peak effects showed that
there was a nonosignificant tendency for PTB to result in a greater
peak degree of drug-liking than TZ and the relative potency
calculation showed that TZ was 122.16 times more potent than PTB on
this measure. Three other rating scales were completed by subjects
at 0830 hr of the morning following the day on which drug was
administered. At this time, subjects were asked to rate (on a 100 mm
visual analog scale) the degree to which they “liked” or “would
choose to take again” the “drug you took yesterday”, and were asked
to estimate the monetary street value of yesterday’s drug. With all
three of these scales, PTB was generally rated higher than TZ
although the drug differences were not statistically significant.
The 400 and 600 mg doses of pentobarbital were consistently rated
higher than the 3.0 dose triazolam on the visual analog ratings of
liking and choose to take again. With the estimated street value,
600 mg of pentobqarbital was rated as worth $8.06 (± 2.90, S.E.M.)
whereas 2.0 and 3.0 mg of triazolam were rated as wrth only $4.88
(± 1.78, S.E.M.) and $3.42 (± 1.01, S.E.M.) respectively; the
difference between 600 mg pentobarbital and 3.0 mg triazolam was
significant. Relative potency calculaticms showed that with these
three rating scales, TZ was found to be 91.23-122.26 times more
potent than PTB.
DISCUSSION
The present study provides important information relevant to the
assessment of the abuse liability of TZ by providing within-subject
comparisons to PTB in a procedure which enabled the simultaneous
examination of measures of subjective effects and objective
behavioral perfomance. The results clearly indicate that with acute
dosing, TZ has a lower liability (likelihood) for abuse than PTB.
This conclusion is based upan the finding that subjects with
histories of drug abuse rated TZ as being less well liked, having a
lower street value, or as being a drug they would be less likely to
choose to take again. The relative potency calculations showed that
in comparison to PTB, TZ was relatively less potent in producing
these effects (relative potency range: 91.23-122.26) than in
producing performance impairment (relative potency range: 159.24-
273.94). While the likelihood of abuse of a drug is dependent on
other factors besides reinforcing properties (i.e., availability),
the value of a subject rating scale is in the extent to which it
predicts “pleasant” subjective effects which may be related to
reinforcing properties. The subject rating scales utilized in this
study are presumed to reflect reinforcing properties of drugs in that
if the drug effect is “liked” or thought to have “street value” then
one would predict that the drug may be self-administered.
Also important to abuse liability assesment is a determination of
the liability of abuse, in other words, the deleterious (hazardous or
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toxic effects) cousequences of abusive drug usage (Brady & Griffiths,
1982). Clearly, the greatly reduced likelihood of respiratory
depression with TZ has to be considered an advantage of TZ. However,
the results of the present study indicate that with regard to
perfomance impaiment, TZ may have a liability greater than that of
PTB. The finding that in comparison to PTB, subjects under the
influence of TZ rated themselves as less affected and less impaired
even though they were similarly impaired (by objective criteria).
suggests that under-estimation of impairment my be greater with TZ.
The role of drug-induced amnesia in abuse liability is unclear.
Certainly, the dramatic amnestic effect observed with even the lowest
dose of TZ indicates a greater liability associated with its use. It
is also possible that such au effect may influence the reinforcing
properties of TZ; for example, several subjects spontaneously
indicated that they would not use this drug on the street because
they could not remember what happened and would Dot like to wake up
in jail not khowing what they had done. Therefore, it is possible
that amnestic effects of TZ my reduce the liability for abuse for
some individuals.
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Behavioral Dependence in Rhesus
Monkeys Following Chronic THC
Administration
P. M. Beardsley; R. L. Balster; and L. S. Harris
The principal behaviorally active component within cannabis
products is delta-9-tetrahydrocannabinol (THC). Over the last
two decades there have been conflicting reports whether or not
a withdrawal syndrome is associated with abstinence from THC.
Many studies have been unable to observe behaviors character-
istic of withdrawal from THC (e.g., Chesher and Jackson 1974;
Dewey et al. 1972; Harris et al. 1974; Leite and Carlini 1974;
McMillan et al. 1970) while others have been able to do so (e.g.,
Deneau and Kaymakcalan 1971; Fredericks and Benowitz 1980; Jones
and Benowitz 1976; Stadnicki et al. 1974). There are a number
of differences between those studies which have and have not
been able to observe abstinent behaviors including differences
in dosing regimen, species of subjects tested, and route of
administration. Perhaps the crucial variable responsible for
the inconsistent observation of withdrawal-associated changes,
however, is that different behaviors are monitored from study
to study for detection of withdrawal effects. For example,
when behaviors characteristic of the stereotypical withdrawal
syndromes associated with the narcotics or the sedative-
hypnotics are monitored, abstinent syndromes are not observed
(Dewey et al. 1972). In some studies, however, that have
examined performance of learned behaviors as the method for
detecting abstinent-specific changes, withdrawal effects have
been observed (e.g., Branch et al. 1980). In general, the
sensitivity of the baseline used to monitor THC withdrawal
changes may be the determining factor whether or not they are
observed. Baselines composed of schedule-controlled behavior
can be used as sensitive instruments to assess both the effects
of drug administration and the effects of discontinuing a
drug’s administration. For example, marked alterations in
schedule-controlled behavior, indicative of withdrawal, have
been demonstrated following the discontinued administration of
morphine in rhesus monkeys and rats (Ford and Balster 1976;
Holtzman and Villarreal 1973; Thompson and Schuster 1964),
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of phencyclidine in rhesus monkeys (Slifer et al. 1984), and
following abstinence from prolonged ethanol drinking in rats
(Ahlenius and Engel 1974). In this study we report the effects
during abstinence from continuous infusion regimens of THC on
schedule-controlled behavior of rhesus monkeys.
M E T H O D S
Four adult, male rhesus monkeys (Macaca mulatta) served as sub-
jects. Each monkey had been used in a previous study involving
the effects of intravenous phencyclidine administration and
withdrawal (Slifer et al. 1984). All of the monkeys had been
drug free for at least 3 months prior to the start of the
present experiment. The animals were individually housed in
enclosed, fiber glass cubicles (0.8m x 0.8m x 1.0 m) equipped
with filtered ventilation systems. Each monkey wore a
stainless steel tubular harness with a connected spring arm.
The spring arm was attached to the rear of the cubicle. The
harness and spring arm prevented the monkey from leaving the
cubicle but allowed free movement within the cubicle. The
monkeys were -surgically prepared with chronically indwelling
catheters under phencyclidine-pentobarbital anesthesia. The
silicone rubber catheter (0.8 mm lumen) was inserted into
either a femoral, internal jugular, or external jugular vein.
The distal end of the catheter was passed subcutaneously to an
exit point on the animal’s back. The external catheter was
then threaded through the spring arm and out the rear of the
cubicle where it was connected to a syringe infusion pump.
Within the cubicle, two response levers were located on the
clear Plexiglas door at the front of the chamber. Two red and
one white 28v lamps were mounted above each lever. A food
hopper was located between the response levers. Events within
the chamber were controlled and recorded by solid-state
programming equipment located in adjacent rooms.
The monkeys had extensive experience pressing the right lever
for banana pellets under either a FR 100 (Monkeys M321 and
6189) or a FR 150 (Monkeys M320 and 7623) schedule of
reinforcment. Responses on the left lever did not have
scheduled consequences. The monkeys could obtain banana
pellets according to their respective reinforcement schedules
during four daily, 30-min sessions that began at 4:00 p.m.,
10:00 p.m., 4:00 a.m., and 10:00 a.m. During each session the
lights above the right lever were illuminated. In addition, a
white-noise alarm was sounded at the start of each session and
was terminated by the first press of the right lever.
Following surgery, saline was continuously infused via the
catheters at a rate of 1.0 ml/hr. After a minimum of three
days, saline was replaced with a solution of Emulphor 620, 95%
ethanol, and 0.9% saline in a ratio of 1:1:8, respectively.
This concentration was chosen since it is able to serve as a
vehicle for up to 20 mg/ml of THC (Carney et al. 1977).
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Vehicle solutions were replaced by 0.05 mg/kg/hr THC following
five days of stable food-reinforced responding. After 10 days
of 0.05 mg/kg/hr THC infusion, vehicle was again administered
until behavior recovered. This procedure involving predrug
vehicle for at least 5 days, 0.05 mg/kg/hr THC for 10 days,
followed by postdrug vehicle was repeated for Monkeys 7623.
M321, and 6189 (referred to as the Second Determination).
Monkey M320 was additionally tested under a 16-day drug regimen
of 0.05, 0.075. 0.113 and 0.169 mg/kg/hr THC for 2, 2, 2, and
10 days, respectively.
Routine housekeeping (cubicle cleaning, watering. and animal
inspections) was performed between 7:00 and 8:30 a.m. daily.
Solution changes occurred at 2:00 p.m., tvo hours prior to the
first session of the day. It vas estimated that this syringe
change time vould enable the nev solution front to arrive at
the catheterized vein concurrently with the start of the 4:00
p.m. session. Stock solutions of THC (100 mg/ml) were prepared
using a solvent composed of Emulphor 620 and 95% ethanol in a
1:1 concentration. Working drug solutions were prepared using
approprlate amounts of stock solution dissolved in 0.9% saline.
R E S U L T S
Response rates during the final day of THC administration were
higher than on the final day of predrug vehicle administration
for Monkeys 7623 and M321 during Determinations 1 and 2, and
for M320 during Determination 1 and during his 16-day regimen
(see table 1). Monkey 6189 responded at a lover rate on the
last day of THC administration than on the last day of predrug
vehicle during Determination 1; however, this was atypical of
his overall performance. Usually the response rate of Monkey
6189 on drug days vas within the range of his predrug response
rates during both determinations. While the monkeys were
receiving THC administration it was often difficult to detect
observable drug effects in the gross behavior of the animals.
The finding that response rates vere either equal to and often
higher than predrug vehicle rates, in addition to the
observation that few changes in gross behavior vere observed
during THC administration periods, provides evidence that
these regimens of THC administration vere not particularly
debilitating.
Table 1 shows that within 48 hours following vithdrawal of 0.05
mg/kg/hr THC there occurred sharp reductions in response rates
to below predrug and drug levels for Monkeys 7623, M321, and
6189 during both the First and Second Determinations. Monkey
M320 did not shov reductions in response rates comparable to
the other monkeys following the 10-day 0.05 mg/kg/hr regimen;
hovever, response rate reductions to near-zero levels occurred
within 72 hours following the 16-day drug regimen in this
monkey.
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TABLE 1
Monkey
7623
M321
6189
M320
7623
M321
6189
M320
The Effects of Delta-9-THC Administration and Withdrawal
on Food- aintained Responding
(mean dally lever presses/sec)
Final Day Final Day Withdrawal Day
PreDrug Vehicle T H C 1 2 3 10
2.9
1.7
2.2
2.2
2.3
2.1
2.1
2.9
Determination 1
3.1 3.2 0.8 0.2 1.8
2.5 2.1 0.2 0.2 0.0
1.0 0.4 0.7 0.5 1.5
2.5 2.8 2.8 2.7 2.9
Determination 2
2.8 2.6 0.5 0.8 2.5
2.7 2.9 0.2 0.3 1.4
2.1 0.8 0.6 0.9 1.5
16-Day Regimen
3.0 2.8 0.3 0.0 1.7
Figure 1 shows daily mean lever presses per second for Monkey
7623 during the First and Second Determinations. Response rates
within Determination 1 during the predrug and drug periods were
similar and usually exceeded 2.75 lever presses/sec. On the
first day of withdrawal during Determination 1, the mean response
rate was still within the range of response rates observed
during the drug period. During the second day of withdrawal,
hovever , response rates dropped sharply and decreased again on
the third day of withdrawal to below 0.25 lever presses/sec.
Thereafter response rates increased through the 16th day of
vithdrawal, whereupon lever pressing rates began to restabilize
at around 2.5 responses/sec. Similar effects vere seen during
Determination 2 except response rates slightly increased from
the predrug to the drug period and maximum reductions in
response rates were seen by the second day of withdrawal.
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FIGURE 1. Effects of continuous i.v. infusion
arid vithdrawal of delta-9-THC on responding
maintained by food presentation for Monkey 7623.
Each point is the mean of four daily 0.5-hr food
sessions. Filled symbols: First Determination.
Unfilled symbols: Second Determination.
DISCUSSION
Three of the four monkeys shoved marked withdrawal disruption of
their food-maintained responding following a 10-day regimen of
0.05 mg/kg/hr of THC. Monkey M320, who did not show response
rate changes upon withdrawal following the 10-day regimen, did
so when the dose and duration of contact with THC was increased.
It is important to note that these drug regimens did not involve
debilitating administrations of’ the drug as evidenced by the
fact that response rates usually were maintained or increased
during the drug period relative to the predrug period. In
fact, a regimen-involving 0.05 mg/kg/hr (i.e., 1.2 mg/kg/day)
is within the range of drug administration observed in some
chronic users of cannabis products (LeDain et al. 1972)). It
is surprising that histories involving such low doses of THC
are sufficient for generating withdraval-reduction of food-
naintained responding in the magnitude observed in the present
experiment, although other studies involving the use of labor-
atory animals and human subjects have observed reductions in
food intake following discontinuation of the administration of
THC and cannabis products (Deneau and Kaymakcalan 1971; Jones
and Benowitz 1976; Greenberg et al. 1976).
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The underlying behavioral mechanisms responsible for the THC
withdrawal-reduction in food-maintained responding are unclear.
At least two mechanisms are possible. One possibility is that
the monkeys were incapacitated during withdrawal such that most
operant behavior (including lever pressing for food) was sup-
pressed. If this had occurred other marked changes in behavior
would likely have been evident. However, behaviors indicative
of motor incapacitation were usually not seen. Also, when
reeponding for food did occur during vithdrawal, local responee
rates during each FR were often as high as predrug local responee
rates. If the monkeys had been suffering from motor incapaci-
tation, local response rates should have been dramatically
reduced. A second possibility is that the disruption is specific
for food-maintained responding due to some type of anorexia.
Often in routine observations done during withdrawal. however,
the monkeys would eat banana pellets offered to them by hand.
Neverthelees, this observation does not eliminate the possi-
bility that anorexia did contribute to the behavioral mechanism
responsible for response-rate reductions. Additional research
needs to be conducted to clarify what behavioral mechanisms of
action were responsible for the response-rate reductions seen
during withdraval.
The suppression of responding following the discontinued admini-
stration of delta-9-THC was an effect seen in all four monkeys.
Disruption of operant responding following termination of chronic
drug administration is evidence for behavioral dependence
(Schuster and Thompson 1969). This study has demonstrated that
monkeys can become behaviorally dependent upon delta-9-THC and
has provided another example of the utility of using operant
baselines to assess the effects of withdraval from drugs.
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Alcohol Self-Administration as a
Function of Menstrual Cycle Phase
N. K. Mello; M. P. Bree; and J. H. Mendelson
INTRODUCTION
Recently we reported that female rhesus monkeys are an excellent
model for studying the effects of alcohol on reproductive function
(Hello et al. 1983). During chronic alcohol self-administration,
female rhesus monkeys develop derangements of reproductive function
similar to those seen in alcoholic women (Mello et al. 1983).
Alcohol dependence in women and female rhesus monkeys has been
shown to be associated with amenorrhea, anovulatory cycles, and
luteal phase inadequacy (Hugues et al. 1980; Moskovic, 1975;
Ryback, 1977; Hello et al. 1983). In the context of these endo-
crine studies, we also examined the co-variance between alcohol
self-administration and menstrual cycle phase in female rhesus
monkeys.
Clinical studies of women with alcohol problems have consistently
shown that drinking tende to increase during the premenstrual phase
of the menstrual’cycle (Podolsky, 1963; Belfer and Shader, 1976;
Belfer et al. 1971). Patients who reported premenstrual tension
used alcohol to attempt to decrease or modulate the unpleasant
symptoms associated with the premenstruum. To date, there have
been no empirical studies of the temporal concordance betveen
drinking, mood, and hormonal changes associated with the menstrual
cycle in female alcoholics or in problem drinkers (cf. Mello, 1980
for review).
Although there is abundant clinical evidence that dysphoric mood
states in women are correlated with certain menstrual cycle phases
(Moos, 1969; Smith, 1975; Steiner and Carroll, 1977), the reality
of the premenstrual tension syndrome has often been challenged on
methodological as well as idealogical grounds (Wilcoxon et al.
1976; Rubinow and Roy-Byrne, 1984). For example, it is sometimes
argued that women experience discomfort because they have been
taught that they should feel premenstrual tension and anxiety
(Ruble, 1977). At the other end of the spectrum are those who
postulate that the cyclic changes in pituitary gonadotroplns and
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ovarian steroid hormones which define the phases of the menstrual
cycle may contribute to changes in affective states (Bardwick,
1975; Dalton, 1964; Steiner and Carroll, 1977; Reid and Yen, 1981).
How subjective changes in feeling states are influenced by ex-
pectancy or modulated by concurrent changes in pituitary and
gonadal hormone secretory patterns is unknown. It is not known
if any phase of the menstrual cycle is associated with discomfort
in female monkeys. However, any consistent covariance between
alcohol self-administration and menstrual cycle phase in monkeys
could not reasonably be attributed to learning or expectancy
factors.
METHODS
Sexually mature female Macaque monkeys (4.6 to 7.5 kg) were housed
individually in a room with adult males. A 12-hour light-dark
cycle (7 a.m. to 7 p.m.) was in effect. During adaptation to the
laboratory, monkeys were maintalned on ad lib food and water.
Daily supplements of fresh fruit, vegetables and multiple vitamins
were given throughout the study. Vaginal swabs were done daily to
determine the onset and duration of menstrual bleeding. Blood
samples were collected two or three times each week for radioim-
munoassay of pituitary and gonadal hormones and to determine levels
of alcohol in blood. Details of radioimmunoassay and blood alcohol
analysis methods have been published (Mello et al. 1984a). Monkeys
were periodically evaluated with laboratory tests to monitor the
status of liver function, lipid and carbohydrate metabolism, elec-
trolyte homeostasis and hematologic function.
Each monkey had a prior history of occasional alcohol exposure in
studies of the acute effects of alcohol on pituitary gonadal hor-
mones (Mello et al. 1984a) but had been alcohol free for at least
three months prior to initiation of the behavioral studies. All
monkeys appeared to have normal ovulatory menstrual cycles as
indicated by a mid-cycle luteinizing hormone (LH) surge and subse-
quent elevation in progesterone levels.
Monkeys were trained to work for food in an operant paradigm on
gradually increasing response requirements on a variable ratio (VR)
schedule in which the number of responses required for each rein-
forcement varied irregularly. An average of 16 responses (VR 16)
produced a brief stimulus light (S+) and a 1 gram banana pellet.
When response behavior was stable, a second order schedule was used
where only a brief stimulus light (S+) was delivered after comple-
tion of each VR 16 response requirement. After four consecutive VR
16 components were completed, both the brief stimulus light and a
food pellet were delivered. This is a second order fixed ratio
(FR) of 4 schedule with VR 16 components (FR 4 [VR 16:S]).
Once food-maintained responding was stable, each monkey was sur-
gically implanted with an intravenous catheter under ketamine
anesthesia (25 mg/kg/i.m.) using aseptic procedures. Eight to 10
days after surgery, monkeys were given access to alcohol during
menstruation or the late luteal phase of the menstrual cycle.
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Monkeys learned to self-administer alcohol intravenously on the
same operant schedule of reinforcement used for food acquisition.
An average of 64 responses was required for each food pellet or
alcohol injection (0.12 g/kg/inj) under a second order schedule of
reinforcement (FR 4 [VR 16:S]).
Food and alcohol each were available during four l-hour sessions
each day. Food sessions began at 11 a.m., 3 p.m., 7 p.m., and 11
p.m.; alcohol sessions at 12 noon, 4 p.m., 8 p.m., and 12 midnight.
The conditions of food and alcohol availability and time out (when
responses had no programmed consequence) each were associated with
a colored stimulus light (S+) projected on a translucent Plexiglas
response key. Each session lasted for one hour or until 65 food
pellets or 20 alcohol injections were delivered. Complete details
of the apparatus and basic operant paradigm used in our previous
studies of drug self-administration have been published (Mello and
Mendelson, 1978).
Alcohol self-administration data are reported for 30 menstrual cy-
cles from six females. Since chronic high dose alcohol self-
administration-often resulted in amenorrhea (Mello et al. 1983),
only cycles of average length which terminated in menstruation were
selected for analysis. The average pre-alcohol control cycles and
the alcohol self-administration cycles, were not significantly
different by t-test analysis.
Animal maintenance and research was conducted in accordance with
the guidelines provided by the Committee on Laboratory Animals
Facility and Care, the National Research Council Institute of
Laboratory Animals Resources. The facility is licensed by the U.
S. Department of Agriculture; The health of the monkeys was
periodically monitored by a consultant veterinarian from the New
England Regional Primate Center.
RESULTS
Thirty menstrual cycles were divided into four sub-groups according
to the average dose of alcohol self-administered during each cycle.
Only the low (0-1.5 g/kg/day) and moderate (1.5-3.0 g/kg/day) alco-
hol dose groups maintained normal menstrual cycles as indicated by
a mid-cycle LH surge and subsequent rise in progesterone. Although
the high intermediate (3.0-4.0 g/kg/day) and high (4.0-5.5 g/kg/
day) dose groups had cycles that terminated in menstruation, analy-
sis of pituitary and gonadal hormones indicated that these were not
normal ovulatory menstrual cycles. Average daily alcohol doses
above 3.0 g/kg consistently resulted in suppression of ovulation
and luteal phase inadequacy as inferred from the absence of a
mid-cycle LH surge and low basal levels of progesterone throughout
the cycle.
The low dose group took significantly fewer alcohol injections at
mid-cycle than during menstruation and the late luteal phase
(p < .01). Exactly the opposite pattern occurred in the high-
intermediate dose group. Monkeys self-administered more alcohol at
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mid-cycle than during menstruation (p < .001) or the mid-luteal
phaee (p < .05). The high dose group self-administered more
alcohol during both mid-cycle and the late luteal phase then during
menstruation (p < .01) whereas the moderate dose group self-admin-
istered equivalent amounts of alcohol at each menstrual cycle
phase.
Figure 1 shows the average number of alcohol injections self-
administered during menstruation (days 1 through 5), at mid-cycle,
and during the last 5 days prior to menstruation combined for all
four dose groups. It is evident that alcohol self-administration
was relatively constant across the menstrual cycle. There were no
significant differences in the average number of alcohol injections
per cycle phase, considered independently of dose as evaluated by
t-tests for two means.
DISCUSSION
Alcohol self-administration by female rhesus monkeys did not
co-vary systematically with menstrual cycle phase in a sample of
30 menstrual cycles. These data do not support the hypothesis,
derived from clinical data, that alcohol self-administration
increases at the premenstruum in comparison to other menstrual
cycle phases (cf. Hello, 1980). There was no consistent tendency
to increase or to decrease alcohol self-administration as a func-
tion of menstrual cycle phase.
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Although alcohol-dependent rhesus monkeys develop derangements of
reproductive function similar to those seen in alcoholic women
(Mello et al. 1983). the temporal pattern of alcohol self-
administration does not increase at the premenstruum in rhesus
females as in alcoholic women (Podolaky, 1963; Belfer and Shader,
1976; Belfer et al. 1971). Other than those self-report data,
there have been no direct observations of drinking patterns in
women during the menstrual cycle on a clinical research ward, but
these studies are currently underway in our laboratory. Parallel
studies of the concordance of marihuana smoking with menstrual
cycle phase in women also have failed to show increased drug use at
the premenstruum (Mendelson, Personal Communication, 1984).
However, until completion of studies of alcohol use patterns in
human females using objective behavioral measures, the generality
of these alcohol self-adminiatration data in rhesus monkey cannot
be evaluated.
At present, it is difficult to determine if the observed differ-
ences between rhesus monkeys and alcoholic women are primarily
attributable to species differences, to methodological differences
(observed behavior versus self-report measures) or to the impossi-
bility of ascertaining the presence or absence of something analo-
gous to a premenstrual tension syndrome in rhesus monkey. It does
seem reasonable to conclude that the hormonal variations which
define the menstrual cycle are not reliably associated with
increases or decreases in alcohol self-administration in rhesus
monkey.
In addition to clinical reports of increased drinking during the
premenstruum, it has also been reported that women develop higher
blood alcohol levels at the premenstruum than during menstruation
or cycle days 13 through 18 (Jones and Jones, 1976a and b). These
data seemed persuasive arguments that drinking patterns might be
modulated by menstrual cycle phases (cf. Mello, 1980 for review).
However, recent studies in human females failed to find differences
in peak blood alcohol levels at the premenstruum, menstruation and
cycle days 12 - 15 in nine women given sufficient alcohol to pro-
duce peak blood alcohol levels of 103 mg/dl (Hay et al. 1984). We
also failed to find differences in blood alcohol levels following a
standard dose of alcohol (1.5, 2.5 and 3.5 g/kg) in female rhesus
monkey as a function of menstrual cycle phase (Mello et al. 1984b).
The present report of stable alcohol self-administration patterns
across the menstrual cycle is consistent with previous reports of
stable blood alcohol levels following a standard dose of alcohol
across the menstrual cycle (Hay et al. 1984; Mello et al. 1984b).
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Food Deprivation Produces
Persistent Increases in Self-
Administration Behavior During
Cocaine Extinction
Marilyn E. Carroll
INTRODUCTION
Drugs have been shown to maintain higher rates of self-administration
behavior when they are presented along with exteroceptive stimuli that
have acquired conditioned-reinforcing properties. When these stimuli
are presented when the drug is not available, they facilitate respond-
ing that was previously rewarded by drug infusions (e.g., Goldberg, 1975).
There are several areas of study suggesting that interoceptive changes
may be as likely as exteroceptive changes to be associated with the
reinforcing effects of drugs. For example, the presence or absence of
food, liquid, or shock is discriminated by interoceptive changes pro-
duced by drug administration (Barry, 1974) and by food or water depri-
vation (Capaldi and Davidson, 1979). lnteroceptive stimuli associated
with intravenous infusions of saline and saline-dextrose infusions (Mad-
den, Oei and Singer, 1980; Karoly, Winger, lkomi and Woods, 1978; Schus-
ter and Brady, 1964) or noncontingent drug infusions (DeWit and Stewart,
1981, 1983) facilitate responding that was previously rewarded by drug
infusions.
The purpose of the present experiment was to examine the effect of
interoceptive stimuli associated with food deprivation on drug-seeking
behavior once drug access has terminated. Food deprivation markedly
enhances the initiation and maintenance of drug-reinforced behavior
(Carroll, 1982). This finding has been generalized across species,
drug classes and routes of administration (Carroll and Meisch, 1984).
Previous studies have also ruled out many possible explanations such as
a general increase in activity or liquid intake, differential effects
of food or no food in the stomach on absorption and distribution of the
drug and anorexigenic effects of certain drug classes (Carroll and
Meisch, 1984). However, mechanisms underlying food deprivation-induced
increases in drug intake are unclear. The specific hypothesis that was
tested in the present experiment was that interoceptive stimuli related
to food deprivation become associated with the reinforcing effects of a
drug, and these stimuli later function as conditioned reinforcers to
elicit drug-seeking behavior.
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METHODS
Animals
Twenty-three adult male Sprague-Dawley rats weighting between 450 and
520 g were used as subjects. The rats were divided into an experimen-
tal group (E) and four control groups (C-1, C-2, C-3 and C-4). All
groups consisted of five rats except group C-l which contained three
rats. Each animal was implanted with an intravenous jugular catheter
according to methods previously described (Carroll, France and Meisch,
1981). The rats were housed in a room with the temperature maintained
at 25° C. They always had free access to water, and food availability
was determined by the experimental procedure.
Apparatus
The rats were individually housed in octagonal operant chambers contain-
ing two levers (with lights above each) and a house light (Carroll et al.,
1981). Responses on the left lever activated the lever light and an in-
fusion pump for 5 sec delivering approximately 0.15 ml of saline or co-
caine (0.1 mg/kg). Responses on the right lever were counted, and they
activated the lever light for 5 sec, but they did not produce an infusion.
Procedure
After surgery, the rats were allowed to recover in the operant chamber
for at least 48 hr. Subsequently, 24-hr sessions were run continuously
for 41 consecutive days. At 10:00 a.m. data were recorded; trays,
pumps, feeders and water bottles were maintained, and experimental con-
ditions were changed. The experiment was divided into three phases:
Training, Extinction and Testing. The procedures for the five groups
differed only in the Training and Extinction phases (See Table 1). The
experimental group (E) was given continuous access to cocaine infusions
(0.1 mg/kg) under a fixed-ratio (FR) 1 schedule; that is, each infusion
was contingent upon a lever press. All five rats began to self-administer
cocaine after only a few hours in the operant chamber. During the Train-
ing phase, the rats were food satiated (S) or deprived (D) during succes-
sive 24-hr sessions according to the following 11-day sequence: S, S,
D, S, S, D, S, S, D, S, S. During food satiation sessions, food was freely
available; during food deprivation sessions, only 8 g of food was pro-
vided at the start of the session. At the start of the 10-day Extinc-
tion phase, saline was substituted for cocaine, and the rats were contin-
uously food satiated. Throughout the subsequent 20-day testing phase,
the rats continued to receive saline under an FR 1 schedule, and they
were food deprived (8 g) every third day.
To evaluate the importance of food deprivation during the initial Train-
ing phase with cocaine, Group C-1 received the same training sequence
as the Group E, except they were not food deprived. To determine whether
the results of Group E could be attributed only to food deprivation exper-
ience during training, Group C-2 was treated as Group E except they re-
ceived saline instead of cocaine during the Training phase. After recov-
ery from surgery, this group was given brief exposure to cocaine self-
administration in order to train the lever-press response and to generate
an elevated rate of saline-maintained behavior that would be comparable
to that of Group E. Cocaine was available until at least 25 infusions
were obtained; this usually occurred within 24 hr. Food was freely avail-
able during this brief exposure to cocaine. Group C-3 was used to assess
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the importance of the contingency between responding and cocaine infu-
sions. This group received the same number of cocaine infusions as Group
E over the II-day Training phase, but infusions were not contingent upon
upon lever-press responses; they were automatically programmed by a com-
puter to be delivered according to tne same pattern as Group E. Responses
were counted, and they resulted in illumination of the lever light, but
they did not result in infusions. Before the Extinction phase, in order
to train the lever-press response, Group C-3 received access to cocaine
under an FR I schedule until 25 Infusions were obtained. Subsequently,
saline was available under an FR 1 schedule for the Extinction and Test-
ing phases of the experiment as in the other groups. Group C-4 was treat-
ed identially to Group C-3, except this group was food deprived (12g/day)
during the 10-day Extinction phase in an attempt to extinguish the effect
of stimuli associated with food deprivation.
Table 1. EXPERIMENTAL DESIGN
RESULTS
Figure 1 shows substantial increases in cocaine-maintained respondmg
and infusions during the Training phase. Responses on the activity
lever did not differ as a result of the feeding condition. During the
Extinction phase, responding declined to low levels; however, when food
deprivation conditions were reinstated during the Testing phase, respond-
ing increased nearly seven fold. Group C-l also showed decreased re-
sponding when saline was substituted for cocaine, but when they were
food deprived during testing there were no increases in responding.
Group C-2 showed a small gradual increase in saline-maintained respond-
ing throughout the three experimental phases, but there were no speci-
fic increases due to food deprivation. These results suggest that ele-
vated responding due to food deprivation in the Testing phase was due
to the specific combination of food deprivation and cocaine access dur-
ing the Training phase. Group C-3 automatically received the same num-
ber of infusions as Group E during the Training phase; however, since
infusions were not contingent upon responding, these rats responded at
very low rates during the Training phase. When they were allowed one
session of FR 1 access to cocaine after the Training phase, the group
obtained a mean of 46.3 infusions within 1.2 sessions. When saline was
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Figure 1. Effects of food satiation (S) and deprivation (D) on drug-
lever responses ( ), infusions ( ) and activity-lever responses ( ).
Points in the left frames represent 11 consecutive sessions of the
Training phase. In Groups E and C-1 lever pressing was reinforced by
cocaine (0.1 mg/kg); in Group C-2 lever-pressing was reinforced by sa-
line, and in Groups C-3 and C-4 lever presses were counted but had no
programmed consequences. The break along the abscissa represents a 10-
day extinction period during which the rats received access to saline
contingent upon lever-press responses (FR 1), and they were either food
satiated (E, C-1, C-2 and C-3) or food deprived (C-4). During the Test-
ing phase (right panels), all rats received FR 1 access to saline, and
they were food deprived every third day. Each point represents a mean
(± S.E.) of five rats except Group C-1 which consisted of three rats.
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substItuted for cocaine during the Extinction phase, there was an ini-
tial increase in responding for a day or two in some rats, but respond-
ing decreased and remained at low levels. During the Testing phase,
responding remained low, but it nearly doubled during food deprivation
sessions. There were no systematic differences in responding during
10-day Extinction phase among the first four groups (E,
C-1, C-2 and C-3); thus, the differences that occurred among these
groups during the Testing phase were attributed to differing experimen-
tal conditions during the Training phase. The results of Group C-4
were mixed. Two of the rats responded in a manner similar to those in
Group C-3. Response rates increased during food deprivation, but only
during the first three food deprivation cycles. The other three rats
showed no increase in saline-maintained responding during food depriva-
tion. The results of this group indicate that when extinction (saline
substitution) initially occurred while the stimuli associated with food
deprivation were present, food deprivation was less likely to produce a
high rate of saline-maintained responding than if extinction occurred
during food sat ration.
DISCUSSION
The results of this experiment indicate that the specific combination
of drug-reinforced behavior and food deprivation produced a high rate
of cocaine-reinforced behavior as well as a high rate of saline-main-
tained responding when the food deprivation condition was reinstated
during the Extinction phase. During the Testing phase the probability
of responding was increased such that if drug had been available, relapse
behavior would have likely occurred. The control groups showed that
food deprivation or a history of cocaine self-administration alone was
not responsible for the reinstatement of high rates of behavior. Also,
the contingency between lever-press responding and cocaine infusions
was an important determinant of the result.
A tentative explanation of the current results IS that interoceptive
stimuli associated with food depravation become paired with cocaine
injection, and they come to function as conditioned reinforcers. The
results of Group C-4 support this hypothesis. When stimuli associated
with food deprivation were present throughout the 10-day Extinction
phase, the ability of these stimuli to subsequently control self-admin-
istration behavior was substantially reduced. Similar results have
been reported earlier in a comparison of the effects of presenting (or
not presenting) exteroceptive drug-paired stimuli during extinction
(Goldberg and Gardner, 1981). Subsequent reinstatement of the drug-
related stimuli temporarily restored high rates and patterns of respond-
ing only when these stimuli had not been presented during extinction.
A problem with explaining the food deprivation effect by such a condi-
tioning process is that i.v. drug intake increased during the first food
deprivation session; there had been no specific previous pairings of
food deprivation and drug effects. This suggests that conditioned in-
creases in drug self-administration occurred almost immediately after
the onset of the interoceptive effects of food deprivation. There are
parallels for this type of rapid, one-trial learning in the taste aversion
literature (Carroll and Smith, 1974; Domjan, 1977), whereby a pairing
also exists between two interoceptive stimuli: ingestion of a substance
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and an altered physiological state which can be produced by a variety
of agents. A crucial variable for taste aversion learning is the nov-
elty of the taste solution. Similarly, food deprivation is defined in
the present study as a relatively novel condition for a free-fed labor-
atory animal. Thus, stimuli associated with food deprivation may be
especially salient and easily paired with reinforcing effects of drugs.
An implication of the current results for the prevention and treatment
of drug dependence is that internal stimuli, such as those associated
with food deprivation, may contribute to the persistence and relapse of
drug use. There are a few anecdotal reports of a relationship between
fasting and an increased rate of drug dependence. For instance, a
starvation study conducted during World War II revealed a substantial
increase in the use of caffeine, nicotine and other substances in men
maintained at reduced body weights (Franklin, Schiele, Brozek and Keys,
1948); the high rate of coca leaf chewing among the Quechua Indians of
the Peruvian high plateau diminished when ordinary sparse diets were
replaced by well-balanced meals, and returned when the sparse diets
were resumed (Hanna and Hornick, 1977); and a higher than normal rate
of drug dependence is reported among bulimic patients who intermittently
fast and binge (Pyle, Mitchell and Eckert, 1981). Self-imposed fasting
is also associated with the chronic use of some drugs such as ampheta-
mine, cocaine and phencyclidine. These observations and the results
from laboratory animal studies suggest that further research is needed
to evaluate the role of food deprivation and other interoceptive events
in the etiology of drug dependence.
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Parameters of Intracranial Self-
Administration of Cocaine Into the
Medial Prefrontal Cortex
N. E. Goeders and J. E. Smith
The neuronal substrates of cocaine reinforcement have been under
investigation with pharmacological lesion, place-preference con-
ditioning, and intravenous and intracranial self-administration
procedures. Intravenous cocaine self-administration is attenua-
ted hy drugs that interfere with dopaminergic (DeWit and Wise
1977) and cholinergic (Wilson and Schuster 1973) neuronal activ-
ity, but enhanced with noradrenergic neuronal blockade (Goldberg
and Gonzalez 1976). The locus of dopaminergic involvement has
been suggested since 6-hydroxydopamine (6-OHDA) lesions of the
nucleus accumbens decrease intravenous self-administration
(Roberts et al. 1980) without affecting heroin intake in the
same animals (Pettit et al. 1982). These data suggest the dopa-
minergic innervations of the nucleus accumbens to be central to
the processes mediating cocaine reinforcement. However, 6-OHDA
lesions of this region do not attenuate cocaine place-preference
conditioning (Spyraki et al. 1982), and the content of dopamine
(DA) in the nucleus accumbens does not correlate with the degree
of deficit seen in intravenous self-administration after similar
lesions of the ventral tegmental region (Roberts and Koob
1982). Kainic acid lesions of this region which spare the dopa-
minergic innervations also decrease intravenous cocaine self-ad-
ministration (Zito et al. 1983). These data suggest that multi-
ple systems may he involved in the brain processes associated
with cocaine reinforcement. Intracranial self-administration
studies were initiated to determine the direct role of neuronal
systems in cocaine reinforcement. Cocaine was found to be self-
administered into the medial prefrontal cortex but not into the
nucleus accumbens or ventral tegmental area (Goeders and Smith
1983). The parameters of this self-administration have been
further investigated to determine the expanse of the potential
site of action and the role of various neurotransmitter
receptors.
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Method
Adult male Fischer F-344 rats were initially stereotaxically
implanted with 22-gauge guide cannulae into the medial
prefrontal cortex (10.05 mm anterior, 0.6 mm from the midline
and 2.1 mm below the surface of the brain; Konig and Klippel
1967). One group of rats was allowed to self-administer cocaine
directly into the medial prefrontal cortex, while one group was
given response-independent infusion of [3H]-cocaine at a dose
and schedule equivalent to the maximum rate of
self-administration to determine the expanse of the potential
site of action.
The drug was intracranially delivered with electrolytic microin-
fusion transducer systems (figure 1) that mount directly onto
the guide cannulae using previously described procedures
(Goeders and Smith, 1983; Goeders et al. 1984).
Figure 1. The electrolytic microinfusion transducer
system used for intracranial administration and self-
administration experiments (from Goeders et al. 1984)
Copyright 1984, Ankho International Inc.
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Radioactive Spread of [3H]-Cocaine: Rats were given either 10,
20, or 40 (N=3 per condition) response-independent infusions of
[3H]-cocaine into this region on a random time 4-minute schedule
which was equivalent to the maximum rate of self-administra-
tion. Each infusion contained 100 pmoles and 2,200 counts per
minute of [3H]-cocaine. Immediately following the last infu-
sion, the animals were frozen in liquid nitrogen and the heads
removed and stored at -7O°C. The heads were warmed to -20°C,
the brains removed, cut into 1 mm coronal sections and each sec-
tion cut into 1 mm cubes using a eyepiece grid and stereomicro-
scope. Each tissue cube was placed in a counting vial, 100 ul
of O.1N NaOH added and stored overnight to dissolve the brain
tissue. 100 ul of O.1N HCl and 6 ml of scintillation cocktail
were added to each vial and the radioactivity determined by
liquid scintillation spectrophotometry.
Intracranial Self-Administration - Role of Neurotransmitter
Receptors
Six rats were used to determine the role of cholinergic, dopami-
nergic and noradrenergic neurons in the intracranial self-admin-
istration into the medial prefrontal cortex. After stable base-
lines of self-administration (8-hr sessions every third day)
were obtained and dose-effect relationships assessed, three rats
were exposed in a random order to each of four drug conditions.
Equimolar concentrations of atropine (cholinergic muscarinic an-
tagonist), propranalol (alpha adrenergic antagonist), SCH 23390
(D1 dopamine receptor antagonist) or sulpiride (02 dopaminergic
receptor antagonist) were added to the cocaine injection solu-
tion and the intake and patterns of self-administration moni-
tored.
Results
The self-administration of cocaine into the medial prefrontal
cortex was dose-dependent and directed responding (Goeders and
Smith 1983). The radioactive spread data demonstrates that the
infused cocaine was localized in the medial prefrontal cortex
(figure 2). At the maximum injection number and longest time
point, sixty-seven percent of the total recovered radioactivity
was located in the 1 mm cube containing the injection cannulae
tip, with 93% within 1 mm of this site. This suggests that the
self-administered cocaine is exerting its effects in the target
area and not diffusing to other brain areas. Only 2.5% of the
total infused radioactivity was recovered in the brain. Blood
removed from the superior saggital sinus region did not show
counts above background. This suggests cocaine is rapidly
cleared from the injection site.
The neurotransmitter antagonists were either ineffective, had a
direct effect or a delayed effect on cocaine self-administration
(table 1). Sulpiride decreased the rate of self-administration
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Figure 2. Location of [3H]-cocaine infused into the medial
prefrontal cortex at a rate equivalent to the highest rate of
selt-administration. The values represent the percent in that 1
mm cute of the total radioactivity recovered In the brain.
Values are means for three animals. Standard deviations were
omitted for space limitations but were 10-15% of each mean.
Table 1
Percent of Baseline Cocaine Interinfusion Intervals for the
Intracranial Self-Administration of Cocaine Plus
Equimolar Concentrations of Each Antagonist
Percent of Baseline Interinfusion Intervals
First Second
Post- Post-
Treatment Treatment
Antagonist Baseline Day of Session Session
Atropine 100 ± 14 99 ± 1 160 ± 9† 100 ± 14.3
Propranalol 100 ± 27 106 ± 28 98 ± 14 85 ± 5
SCH 23390 100 ± 13 123 ± 29 177 ± 13† 121 ± 8
Sulpiride 100 ± 10 319 ± 83† 464 ± 280 112 ± 74
Values are means ± standard deviations for N=3. Significance
of the differences determined With Student’s t-tests were:
†p<0.01.
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that was consistent with patterns of intake seen when the dose
was lowered from the optimum level. This effect was still seen
three days later, but had disappeared by the second post-drug
session (6 days). Atropine and SCH23390 did not have a direct
effect on the day of administration but did on the first post-
drug session (3 days later). The patterns of self-administra-
tion were similar to those seen when the dose was increased.
These effects dissipated by the next session. Propranalol had
no effect on self-administration. Phenoxybenzamine was tested
in one animal and also had no effect.
Discussion
The intracranial self-administration of cocaine into the medial
prefrontal cortex is the result of the actions of the drug at a
small site at the tip of the injection cannulae. The injected
drug is rapidly cleared from this site, resulting in a decrease
in the concentration at the receptor subpopulation initiating
the reinforcing properties resulting in the stimulus that leads
to the next infusion. Dopaminergic D2 receptors appear to be
directly involved in the initiation of these reinforcing proper-
ties, while muscarinic cholinergic, alpha adrenergic, beta adre-
nergic, and D1 dopaminergic receptors are not. However, the D1
and muscarinic cholinergic receptors appear to be indirectly in-
volved since blockade results in a delayed effect that resembles
increasing the dose of cocaine. The role of serotonergic and
GABAergic receptors is currently being assessed. These data
suggest several possible synaptic receptor configurations at the
self-administration site that may have general implications in
brain reinforcement processes.
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Evaluation of Intramuscular
Meptazinol and Morphine in
Cancer Patients With
Postoperative Pain
Robert F. Kaiko; Stanley L. Wallenstein; Ada G. Rogers;
Annemarie Canel; Benjamin Jacobs; and Raymond W. Houde
Development of analgesics with the effectiveness but not the unde-
sirable effects of morphine has prompted evaluations of selected
agonist-antagonist analgesics. Meptazinol, m-(3-ethyl-1-methyl-
hexa-hydro-1H-azepin-3-yl) phenol HCl, is one of these. Since
initiation of evaluations in 1.975, there have been reports of its
use in pain of obstetrics (Nel et al. 1981; Nicholas and Robson
1982); renal colic (Robson 1983); surgery (Cohen et al. 1983; Dos
Santos-Pereira 1980; Gibbs and Johnson; Hedges et al. 1980; Moyes et
al. 1979; Paymaster 1976; Paymaster 1977; Paymaster 1983; Saviano et
al. 1980; Slattery et al. 1982; Verschraegen and Rolly 1979); cancer
(Staquet 1978); myocardial infarction (Sonecha et al. 1983; and
other indications (Coutinho 1982). It has been compared with other
drugs, including buprenorphine (Harmer et al. 1983), meperidine
(Harmer et al. 1983; Hedges et al. 1980; Nel et al. 1981; Nicholas
and Robson 1982; Paymaster 1977; Paymaster 1983; Slattery et al.
1981), morphine (Cohen et a1. 1983; De Rosayro et al. 1981; Harmer et
al. 1983), omnopon (Moyes et al. 1979), and pentazocine (Paymaster
1977; Staquet 1978; Verschraegen and Rolly 1979). Reviews indicate
that IM meptazinol differs from IM morphine: a relative potency in
the range of 1/10, a faster onset and shorter duration of analgesia,
a lower abuse potential, and different side effect profile (Robson
1982; Stephens et al. 1978). Meptazinol is reported to produce less
respiratory depression (Jones 1983; Jordan et al. 1979; Jordan et
al. 1979; Slattery et al. 1983; Slattery et al. 1982), and to have
benign effects on the cardiovascular system (Budd 1976; Camu and
Rucquoi 1983; DeRosayro et al. 1981; Moyes et al. 1979; Paymaster
1977). It also has been reported to produce a low occurrence of CNS
side effects (e.g., euphoria, restlessness, hallucinations, dysphor-
ia) (Evans et al. 1983; Robson 1983) and constipation (Stephens et
al. 1978), although nausea and vomiting are not uncommon (Nicholas
and Robson 1982; Paymaster 1976; Richens et al. 1983; Stephens et
al. 1978). It has also been suggested that meptazinol is unique in
being a mu-1 receptor selective opioid analgesic (Spiegel and
Pasternak 1984).
Previous clinical studies were primarily efficacy evaluations and
do not provide valid estimates of relative potency. The primary
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objective of this study was to determine the analgesic potency of IM
meptazinol relative to morphine in moderate to severe postoperative
pain. Secondary objectives were to assess side effects and effects
on selected aspects of mood.
M E T H O D S
Methods adhered to the principles of design and procedure previously
reported (Houde et al. 1960; Wallenstein and Houde 1975). Patients
were seen hourly, with an additional observation at 1/2 hr following
study drug, by a nurse-observer who recorded reports of pain, relief,
and mood. At the time of study drug and at 2 hrs, patients also
completed an adaptation (Kaiko et a1. 1981) of a mood questionnaire
(Lasagna et al. 1962). Concomitant signs and symptoms and volun-
teered side effects were also recorded. Observations were continued
for 6 hrs or until baseline pain returned. The assay consisted of
equi-log-spaced doses of IM meptazinol (50,100 and, 200 mg) and
morphine (4, 8, and 16 mg). Each patient received 2 study treat-
ments, each on a different day: a lower dose of one drug and an
upper of the other, or the middle dose of each on a double-blind,
randomized basis, and balanced for order. Analyses of variance for
twin-crossover assay (Finney 1964) were employed.
RESULTS AND DISCUSSION
The completed assay incorporated 102 completing patients and 26
patients who dropped out. Table 1 summarizes the results of the
relet ive potency calculations. In terms of peak effects, 120 to
155 mg meptazinol is equianalgesic with 10 mg morphine; in terms of
total effects, 175 to 245 mg of meptazinol is equianalgesic to 10 mg
of morphine. The difference in peak and total equianalgesic doses
indicates that meptazinol provides a shorter duration of analgesia
for a given peak effect. At comparable peak effects as provided by
morphine, meptazinol provides peak relief at less than 1 hr in com-
parison to between 1 and 2 hrs following morphine. The faster onset
is accompanied by a shorter duration of action (Table 2).
Table 3 details the significant changes between baseline and 2 hrs
in terms of the contrasting mood words for each study treatment.
Only morphine provided significant mood improvements and in a dose-
related manner. Meptazinol provided only for a few significant
changes and these were toward negative feelings. In terms of anal-
gesia at 2 hrs (not shown) 100 mg meptazinol is equivalent to 4 mg
morphine and 200 mg meptazinol is equivalent to 8 mg morphine.
The percentage of patients with side effects (Table 4) was dose-
related for both drugs and in a comparable range, but with a steeper
slope following meptazinol. When occurrence is expressed in terms
of the number of effects, it becomes apparent that meptazinol
results in more side effects except at the 50 mg dose. Most common
to morphine (Table 5) was eleepiness followed far behind by groggi-
ness, dry mouth, and sweating. Most common to meptazinol was nausea,
followed closely by sweating, sleepy, and dizzy. There were more
reports of side effects exclusive to meptazinol than to morphine,
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TABLE 1. Mean IM meptazinol milligram dosages (with 95% confidence
intervals) equianalgesic with 10 milligram of IM morphine.
ESTIMATE OF ANALGESIA PEAK TOTAL
Pain intensity decrease Mean 95% C.I. Mean 95% C.L.
Categorical . . . . . . . . . . . 120 (80-170) 175 (125-270)
"Tursky" . . . . . . . . . . . . . . 140 (90-215) 190 (130-310)
Visual analog . . . . . . . . . 150 (95-240) 180 (115-305)
Pain relief
Categorical ........... 155 (105-245) 225 (155-400)
Visual analog . . . . . . . . . 155 (105-245) 245 (160-455)
TABLE 2. Mean (SE) time (hr) to peak analgesia (visual analog pain
relief) and to remedication following IM morphine and meptazinol.
Morphine
4 mg . . . .
8 mg . . . .
16 mg . . . .
All doses
Meptazinol
50 mg . . . .
100 mg . . . .
200 mg . . . .
All doses
PEAK TIME
1.1 (0.14)
1.3 (0.17)
1.8 (0.22)
1.4 (0.11)
0.87 (0.11)
0.96 (0.16)
0.87 (0.10)
0.94 (0.07)
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
REMEDICATION TIME
3.6 (0.52)
4.7 (0.37)
6.2 (0.84)
4.8 (0.36)
3.1 (0.24)
3.7 (0.39)
4.1 (0.50)
3.6 (0.22)
TABLE 3. Significant (P<0.05) changes (0 to 2 hr) in selected
aspects of mood following IM morphine and meptazinol.
CONTRASTING PAIRS Morphine Meptazinol
+ 4 mg 8 mg 16 mg 100  mg 200 mg
Shaky Serene 0.66 1.13
Restless Peaceful 0.97 1.10
Nervous Calm 1.06
Alone Sociable 0.97 0.63 1.03
Serious Amused 0.85 0.97
Uneasy At ease 0.90
Heavy Buoyant 0.55 0.81 -0.57
Blue Cheerful 0.77
Apathetic Enthusiastic 0.71 -0.90
Sad Happy 0.71
Pessimistic Optimistic -0.60
TABLE 4. The occurrence of side effects (SE) following IM morphine
and meptazinol in moderate to severe postoperative pain.
Dose
No. administrations
No. with SE
Percentage with SE
No. of SE reports
No. of SE/patient
Morphine Meptazinol
4 mg 8 mg 16 mg 50 mg 100 mg 200  mg
37 45 34 39 39 37
12 22 22 7 19 27
32% 49% 65% 18% 49% 73%
19 32 58 12 59 129
0.51 0.71 1.71 0.31 1.51 3.48
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and among these were some particularly disturbing effects.
In conclusion, relative to IM morphine in moderate to severe pain in
postoperative cancer patients: a) 120 to 155 mg of IM meptazinol is
equivalent to 10 mg of IM morphine in terms of peak analgesic
effects; meptazinol provides a more rapid onset and a shorter dura-
tion of analgesia, such that 175 to 245 mg of meptazinol is equiva-
lent to 10 mg of IM morphine in terms of total analgesic effects; b)
while morphine improves selected aspects of mood in a dose-dependent
manner, meptazinol has a negligible or negative effect on mood; c)
side effect occurrences are dose-related and particularly disturbing
in about 15% of patients following doses of meptazinol which are
equianalgesic with commonly employed doses of IM morphine for
moderate to severe pain; d) for a given degree of analgesia, the
overall effects of meptazinol are less satisfactory than those of
morphine. The latter conclusions are in apparent contradiction to
those of many previous reports. In reviewing that literature, and
in examining our patient sample for characteristics which might be
associated with such differences, our tentative explanation for the
differences lies in the fact that previous studies rarely extended
the dose of IM meptazinol beyond 100 mg.
TABLE 5. Side effect profile of IM morphine and meptazinol
Exclusive to
Morphine (13 pts.)
Disoriented 2
Apathetic 1
Feels sad 1
Crying 1
Itching 1
Palpitations 1
Ear pressure 1
Constricted pupil 1
Dyspepsia 1
Common to
both drugs:
Sleepy
Groggy
Dry mouth
Relaxed
Feels Jumpy
Headache
Inj. pain
Irritable
Nausea 5 25
Sweating 6 24
Dizzy 3 19
Vomiting 2 10
Stom. cramps 2 3
Lightheaded 1 9
Floating 1 7
Weak 5 7
Blurred vis. 2 6
Feels hot 3 5
Shaky 1 3
Vis. halluc. 1 2
M S M E P
38 20
7 5
6 5
4 1
4 2
3 2
2 2
1 1
Exclusive to
Meptazinol (20 pts.)
Feels faint 5
Tachycardia 1
Hypotension 1
Pale 1
Pressure in stomac 4
Tightness in throat 1
Frightened 3
Loss of control 2
Ominous feeling 1
Warm 4
Flushed 2
Hot flashes 1
Hypertension 1
Nervous 1
Restless 1
Respiratory depress. 1
Numbness and ting- 1
ling in face
Lips feel numb 1
Numbness in arm 1
Eyes big for sockets 1
Eyes tearing 1
Eyelids feel puffy 1
Rhinorhhea 1
Nose congested 1
Diarrhea 1
Difficulty sleeping 1
Slurred speech 1
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Analgesic Efficacy of Intra-
muscular Flunixin Meglumine
Compared to Meperidine: A
Preliminary Report
Abraham Sunshine; ltic Zighelboim; Nancy Olson;
Ana De Castro; and Eugene Laska
Flunixin is an aniline derivative of nicotine acid with analgesic,
antipyrettc, and anti-inflammatory properties. In animal models, flunixin
meglumine, the n-methyl glucamine salt, was found to be essentially
bioequivalent to flunixin in terms of pharmacologic activity and
absorption characteristics when given orally. However, its analgesic
potency was much greater than that of flunixin by the subcutaneous and
intramuscular routes. This finding appears to be related to the faster
absorption of the salt compared to the free acid. In the same animal
models flunixin meglumine given by these routes was generally more
potent than meperidine, codeine and pentazocine, and comparable to
morphine.4
The present clinical trial was, to the best of our knowledge, one of the
first to be conducted to assess the analgesic efficacy of flunixin
meglumine in man. Our objective was to evaluate single, parenteral
doses of 20, 40, and 80mg of flunixin, compared to 50 and 100mg of
meperidine and placebo when administered to hospitalized patients for
the control of moderate to severe pain following various gynecological
surgical procedures.
M E T H O D S
The study was a double-blind, parallel group, single-dose design.
Patients who were able to communicate meaningfully with the nurse-
observer and who gave written informed consent to participate in the
study were considered. Patients were included in the trial if they had
either moderate or severe pain secondary to cesarean section or gyn-
ecological surgery which required treatment with a parenteral analgesic.
AU subjects were between eighteen and seventy-five years of age.
Patients were excluded if they were breastfeeding, had any complicating
illness, or had received any other investigational drug within 4 weeks
prior to enrollment in the study. Patients with a history of drug
dependence or known allergic sensitivities to the test medications were
also excluded.
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Patients were stratified according to moderate or severe baseline pain
and were then randomly assigned to receive either placebo, meperidine
50 or 100mg, or flunixin meglumine 20mg, 40mg, or 80mg.
When the patient’s pain intensity was either moderate or severe, study
medication was administered by the nurse-observer. The same nurse-
observer interviewed the patients at the time the medication was
administered at a half hour. one hour and hourly thereafter for four
hours. If the patient was asleep at a scheduled interview time, she was
awakened. At each observation, the patient was asked to assess the
intensity of her pain, and also to classify her degree of pain relief. If
a patient reported inadequate pain relief before the first hour, a
conventional analgesic was given and she was removed from the study.
If a patient was remedicated with a conventional analgesic after the
first hour she was included in the statistical analysts. At the completion
of the study, patients were also requested to give their global evaluation
of the study medication.
The statistical analysis utilized standard methodology3. Several sum-
mary measures of analgesia were derived from the interview data. Pain
Intensity Difference (PlD) is the difference between the pain intensity
score at an observation point and the baseline intensity. SPID is the sum
of the hourly PID scores, weighted by the time interval between
observations, and is an estimate of the area under the time-effect curve.
The variable TOTAL is the sum of the hourly relief values, also weighted
by the length of the time interval between observations. A comparison
was made among the six treatments using a one-way analysis of variance
(ANOVA) to test the hypothesis of no difference between treatments for
all parameters2. If the ANOVA was significant at the 0.05 level, tests
were performed to investigate pairwise differences between treatments
using Peritz’ modification of the Neuman-Keuls procedure.1
RESULTS
One hundred and ninety patients were entered in the study and all are
included in this preliminary report. Each of the treatments was given
to a group of 30 to 32 patients. Mean scores for the various measures
of analgesia and significant treatment differences are described in Table
1, and time-effect curve for PID is shown in Figure 1. All three doses
of flunixin and meperidine 100mg differed significantly from placebo on
many hourly and summary parameters. Meperidine 50mg was signifi-
cantly more effective than placebo only at the half-hour and one-hour
readings. After the second hour, there was a decrease in the level of
analgesia for meperidine whereas flunixin remained effective throughout
the entire period of observation. At the later hours, flunixin 80mg was
statistically more effective than both doses of meperidine. For SPID.
TOTAL, Time to Peak and the global assessment of study drug, all active
drugs were significantly more efficacious than placebo with the
exception of meperidine 50mg which, for some of the variables was not
significantly different from placebo. The average of the responses of
the three doses of flunixin was superior to the average of the two doses
of meperidine for the third and fourth hour variables, SPID, and TOTAL,
but was inferior at the half-hour reading. Relative potency and dose
response analyses are in progress and will be reported at a later date.
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Thirty patients reported adverse effects. The most frequently reported
adverse effect with the three flunixin treatments was pain or discomfort
at the injection site, while with the meperidine treatments dizziness and
sweating were more frequently reported. In addition, one patient who
received 50mg meperidine reported difficulty breathing and a sharp pain
in the thorax area. Two patients who received placebo also complained
of pain at the injection site.
DISCUSSION AND CONCLUSION
Flunixin 20, 40 and 80mg and meperidine 100mg were all found to be
effective analgesics. Flunixin 80mg was significantly more effective
than meperidine 50mg for several analgesic measures including SPID and
TOTAL. In addition, flunixin 80mg was significantly better than
meperidine 100mg at the fourth hour. Flunixin 20 and 40mg was
significantly better than meperidine 50mg for several variables, par-
ticularly for those of the third and fourth hours.
Globally flunixin 80mg at half-hour is less effective than 100mg of
meperidine, at one-hour it is approximately equivalent and thereafter has
a higher mean effect. The 20 and 40mg doses have mean responses
similiar to meperidine 100mg. During the third and fourth hours, there
were statistically significant differences for all doses of flunixin in
comparison to meperidine.
The availability of a non-steroidal anti-inflammatory drug for parenteral
administration with efficacy in the range and possibly more effective
than meperidine has many advantages. It makes available a potent
analgesic which is a non-narcotic, a non-respiratory depressant, a non-
inhibitor of cough, and non-sedating. It would be advantageous in
clinical use for patients with pulmonary insufficiency and patients in the
immediate post-operative condition where cough and respiratory depres-
sion may be a problem.
In summary, the flunixin, a non-steroidal anti-inflammatory drug is an
effective parenteral analgesic that has a role to play in clinical
situations requiring analgesics of strengths equivalent to meperidine.
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TABLE 1. Measures of Analgesic Efficacy
Variable Placebo
N=32
Meperidine Meperidine
50mg 100mg
N=30 N=32
Flunixin Flunixin Flunixin
20mg 40mg 80mg
N=32 N=32 N=32
Pain Intensity
Differences (PID)
1/2 hour
1 hour
2 hours
3 hours
4 hours
SPID
0.56 1.14 P 1.38 P 1.03 P 1.06 P 0.97 P
0.72 1.24 P 1.50 P 1.38 P 1.41 P 1.64 P
0.75 1.10 1.44 P 1.50 P 1.38 P 1.76 P
0.72 0.86 1.13 1.53 P,M 1.53 P,M 1.70 P,M
0.66 0.48 0.69 1.25 P,M,H 1.25 P,M,H 1.49 P,M,H
2.77 3.64 4.69 P 5.48 P 5.39 P 6.24 P,M
TOTAL 4.23 5.69 7.22 P 8.25 P 8.19 P 9.46 P,M
Time to Peak 121.90 84.80 55.30 P 71.30 P 76.90 P 74.50 P
Global Evaluation
of Test Drug 0.97 1.45 1.75 P 1.84 P 1.69 P 2.00 P
P=Significantly more effective than placebo, p 0.05
M=Significantly more effective than meperidine 50mg, p 0.05
H=Significantly more effective than meperidine 100mg, p 0.05
TABLE II. Incidence of Adverse Effects
Adverse Effects Placebo Mep Mep F l u Flu Flu
50mg 100mg 20mg 40mg 80mg
N=32 N=30 N=32 N=32 N=32 N=32
Difficulty Breathing 1
Dizzy 2 6 1
Drowsy 1
Injection Site Pain 2 3 4 3
Sleepy 1
Sweating 3 2 3 1
Thorax Discomfort 1
No. of Pts. Reporting
Adverse Reaction 2 5 8 5 4 6
Mep = meperidine
Flu = flunixin
Figure 1: Time effect curve for mean PID scores are calculated by
subtracting the mean pain intensity score for each observ-
ation point from the pain intensity at 0-hour.
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Three-Choice Discrimination in
Methadone Maintenance Patients:
Hydromorphone, Naloxone, and
Saline
Kenzie L. Preston; George E. Bigelow; Maxine L. Stitzer;
and Ira A. Liebson
Recent data indicate that drug acting at the various opioid recep-
tors produce discriminable stimulus effects which make it possible to
use behavioral drug discrimination testing procedures as a basis for
classifying drugs with respect to the similarity of their pharmacolo-
gical actions. It has been demonstrated that a number of infrahuman
species can not only reliably discriminate opioid drugs from saline
over a range of doses but also can discriminate between opioid drugs
which act at different opioid receptors (for review see Herling and
woods, 1981). Althouh a two-choice discrimination (drug vs.
placebo) is the more frequently used methodology, a three-choice
discrmination (drug 1 vs. drug 2 vs. placebo) has also been success-
fully used to study opioid stimulus effects. The results of these
three-choice discrimination studies were compatible with findings in
other animal studies using a two-choice discrimination paradigm
(White & Holtman, 1983).
The purpose of the present study was to develop drug discrmination
procedures for use in human volunteers. Although subjective effect
measures such as true/false questionnaires, adjective rating scales,
and questionnaires concerning similarity of a test drug to previously
used street drugs have been very useful in describing the effects of
various drug classes, it appears likely that a drug discrimination
paradigm could be successfully combined with the collection of these
traditional subjective effect measures to obtain finer and more com-
plete descriptions of the subjective effects of psychoactive drugs.
The addition of drug discrimination to human behavioral phamaco-
logical studies could provide direct comparison of the effects of
study drugs to standard drugs with less dependence on each subject’s
own unknown and unique street drug history.
In this initial pilot study we trained methadone maintenance volun-
teers in a three-way drug discrimination procedure to discriminate
between the effects of saline, hydromorphone, and naloxone—i.e.,
between no pharmacological effect, no opioid/mu-agonist effect, and
a withdrawal/mu-antagonist effect. Following this discrimination
training dose-effect functions were determined for the two active
training compounds.
151
M E T H O D S
Subjects: The participants were three adult male methadone mainte-
nance patients who gave written informed consent and who were paid
for their participation. The subjects reported prior narcotic addic-
tion of 12 to 16 years duration and participation in a methadone,
maintenance program for two to eight years. The subjects lived on an
eight-bed inpatient research unit throughout their participation in
the study. Two subjects were maintained on methadone hydrochloride
50 mg daily, the third subject on 40 mg daily; methadone doses were
given at 6:00 p.m. daily.
Drugs: The training drugs were saline (0.5 ml), hydromorphone HCl 10
mg, and naloxone HCl 0.15 mg. Hydromorphone powder (Knoll Pharmaceu-
ticals) was dissolved in bacteriostatic saline to the desired concen-
tration; naloxone 0.4 mg/ml (Endo) was diluted to the desired concen-
tration with bacteriostatic saline. Doses were given in a volume of
0.5 ml intramuscularly. Doses of each drug are expressed in terms of
the salt. Training drugs were identified to subjects only by arbi-
trary letter codes. For each subject these drug letter codes were
randomly determined, but remained unchanged throughout the protocol.
Drug was administered under double-blind conditions.
General Methods: The study proceeded in three phases: Training/
Acquisition, Test of Acquisition, and Test Drug Discrimination. Dis-
crimination training was conducted on sessions 1-6, during which the
subject received, in random order, 2 sessions of exposure to each of
the two active training drugs and to placebo. During these training
exposures each drug was identified to the subject by letter code
prior to drug administration. The subject was instructed to attend
carefully to the drug effects and to try to discriminate precisely
among them; he was informed that in each session be would be able to
earn money by correctly identifying the administered drug by letter
code. In sessions 7-12 acquisition of the discrimination was tested
by exposing the subject in randomized block order to the training
doses of each of the three training compounds to determine whether
the subject could correctly identify them by letter code. In these
test-of-acquisition sessions the subject received feedback about the
code of the administered training drug after the session. This test-
of-acquisition procedure was also repeated between test sessions dur-
ing the subsequent testing phase to insure continued correct discri-
mination. Beginning with session 13, a series of test sessions was
conducted on alternate days, separated by one test-of-acquisition
session in which one of the training drugs was given. During this
testing phase four doses of each active training drug (including the
training dose) and saline were tested twice each in randomized block
order. Following each test session the subject did not receive feed-
back of the correct drug identification. All 3 subjects completed
the protocol through session 12. One subject completed the entire
study protocol.
Experimental Session: A TRS-80 Model I microprocessor, located in an
experimental roan, was programmed to present all questionnaires in a
prearranged and timed sequence, store the subject’s responses, and
print a data output following each session. At the beginning of each
152
experimental session, the subjects completed the subjective report
forms. The scheduled drug was then administered. During the initial
training sessions the subject was informed of the drug’s identifying
letter code at the time of injection. The subject remained under
observation for ten minutes and then completed the post-drug discri-
mination and subjective effect testing. Post-drug testing lasted for
one hour and consistent of 3 repeating 20-minute cycles followed by a
final subjective effect form. At the end of test-of-acquisition
sessions a sealed envelope was opened, and the staff informed the
patient of the letter-code identify of the administered drug; follow-
ing test sessions the card said only that the session had been a test
session and that the identity of the drug could not be revealed.
Discrimination Procedures: Drug discrimination data were collected
in three ways. In each procedure only correct responses were con-
verted to monetary reinforcement for the subject. As one component
of each assessment cycle the subject made a discrete choice, naming
by letter code (A, B, or C) the drug he thought he had received. A
second component asked the subject to distribute 50 points between
one or more of the three drug choice alternatives depending upon how
certain he was of the identity of the administered drug. In a third
component the subject responded on a fixed interval 1 sec schedule on
computer keys designated with drug letter codes to earn points. Dur-
ing each 8.5-minute operant responding component, points could be
earned for each of the 3 choice drugs by pressing the key correspond-
ing to that drug however, a 10-sec delay occurred whenever the sub-
ject switched from one key to mother (a changeover delay, used to
discourage ill-considered switching among alternatives).
Subjective Effect Measures: Subjective effect measures included:
(1) the 49-item Addiction Research Center Inventory (ARCI) Short
Form, which contains the MBG scale ("euphoria"), the LSD scale
("dysphoria") and the FUG scale ("sedation"); (2) a 32-item adjec-
tive rating scale containing an opioid agonist scale (to detect
opioid-like effects) and an antogonist scale (to detect opioid with-
drawal-like effects), which the subject rated on a 5-point scale from
0 (no effect) to 4 (maximum effect); (3) quantitative visual analog
scales to indicate the degree of drug effects, drug liking, "good"
and "bad" effects, and subjective "high" on a scale from "not at all"
to "extremely".
Data Analysis: The results of the discrimination training (discrimi-
nation of the training doses following two exposures to each training
drug) are reported as mean percent correct identifications from ses-
sions 7-12. The results of the subjective effect measures are re-
ported as the mean of overall scores (average from four exposures to
each drug in sessions 1-12) for each individual subject; mean change
from pre-drug scores is reported for ARCI scales and adjective check-
list scales. A repeated treasures analysis of variance (ANOVA) was
conducted, and Duncan's multiple range test was performed where
appropriate. Effects were considered statistically significant if
p < 0.05.
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RESULTS
The results from the discrimination training and test of acquisition
trials for the three subjects enrolled in this portion of the study
are shown in Table 1 and 2. The discrimination between the three
training drugs was readily learned, and few errors were made in iden-
tifying the training doses during the test of acquisition sessions
(7-12). Table 1 shows percent correct identifications for each of
the three drugs for each of the three discrimination measures. Nalo-
xone 0.15 mg was most consistently correctly identified. The results
of the three discrimination measures were similar for each drug.
Table 1
Percent Correct Identifications in the Discrimination Measures
for Test of Acquisition Trials
Hydromorphone Saline Naloxone
Discrete Choice 75.0 (11.8) 73.6 (12.0) 93.3 (5.4)
Point Distribution 75.0 (11.8) 73.6 (12.0) 93.3 (5.4)
Operant Responding 76.6 (11.8) 85.5 ( 5.8) 93.3 (5.4)
Standard errors are given in parentheses, N = 3
Table 2
Results of Subjective Effect Measures from Training and
Acquisition Trials
Hydromorphone Saline Naloxone
Visual Analogue Scales1
Drug Effect (Strength) 39.6 (13.2) 5.9 (4.7) 58.7 (11.3)
Linking 67.5 ( 0.3)* 0.8 (0.5) 0.9 ( 0.6)
Good Effects 64.4 ( 9.9)* 1.9 (1.5) 0.2 ( 0.1)
Bad Effects 0.0 ( 0.0) 4.9 (4.0) 73.5 ( 6.1)*
High 37.4 (15.2) 0.9 (0.7) 0.0 ( 0.0)
Adjective Rating Scales1
Agonist (Morphine-like) 16.7 ( 2.3)* -3.7 (2.3) 6.3 ( 3.0)
Antogonist -0.6 ( 1.4) 1.3 (1.1) 20.8 ( 0.5)*
(withdrawal-like)
Addiction Research Center Inventory2
MBG Scale (euphoria) 5.9 (1.4)* -0.5 (0.5) -0.9 (0.8)
PCAG Scale (sedation) -l.6 (2.0) 0.4 (0.3) 3.1 (0.5)
LSD scale (dysphoria) -1.1 (0.2) 0.4 (1.1) 3.4 (1.4)
Standard errors are given in parentheses. * - significantly differ-
ent from saline, p < 0.05, 2-tailed Duncan’s Multiple Range Test.
1 = 30 min post injection. 2 = 70 min post injection.
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The results of the measures of subjective effects produced by the
training drugs in sessions 1-12 are shown in Table 2. Significant
treatment effects were produced on three of the five visual analog
scales: “liking” [F(2,4) = 32.4, p = 0.005], “good effects”
[F(2,4) = 25.5, p = 0.007]. and “bad effects” [F(2,4) = 66.1,
p = 0.002]. Hydromorphone produced significantly greater “liking”
and “good effects” scores than both saline and naloxone, while sub-
jects reported significantly greater “bad effects” for naloxone than
for saline and hydroamorphone. The results of the adjective checklist
agonist and antagonist scales also showed significant treatment ef-
fects: agonist scale [F(2,4) = 12.9, p = 0.02] and antogonist scale
[F(2.4), 97.2, p = 0.001]. Hydromorphone significantly increased
agonist scale scores compared to saline; naloxone significantly in-
creased antagonist scale scores compared to saline and hydromorphone.
Two scales from the Addiction Research Center Inventory showed signi-
ficant effects of treatments: LSD scale [F(2,4) = 7.2, p = 0.048]
and MBG scale [F(2,4) = 8.6, p = 0.037]. Naloxone produced signifi-
cantly greater scores on the LSD scale than did hydrawrphone.
Hydromorphone significantly increased MBG scale scores compared to
both saline and naloxone. Naloxone also produced an increase in the
PCAG scale, though this effect did not reach significance.
Dose effects functions for hydromorphone and naloxone on discrimnina-
tion measures and subjective effects measures have been determined in
one subject thus far. Orderly dose response functions for the dis-
crimination of both hydromorphone and naloxone resulted with all
three discrtimination components. Figures 1 and 2 show the results
omvrrl the operant responding discrimination treasure. Saline was cor-
rectly identified in all test of acquisition trials in which it wds
presented. Hydromorphone 2.5 and 5.0 mg produced 40 to 50% correct
identifications while the training dose (10 mg) and 14 mg produced
100% correct identifications. Naloxone 0.037 mg was identified as
saline in each presentation; naloxone 0.075 mg was identified as be-
ing naloxone in 50% of the identifications. Naloxone 0.15 mg (the
training dose) and 0.20 mg produced 100% identifications as naloxone.
The two active test drugs also produced similar (but complementary
and contrasting) orderly dose-dependent effects upon the various sub-
jective report measures. The results also agree with those found in
the discrimination training and test of acquisition sessions reported
above for three subjects. Hydromorphone produced dose-dependent in-
creases in visual analog scale ratings of “drug effect”, “good ef-
fects” (Figure l), “high”, and “liking”. Virtually no “bad effects”
were reported for hydromorphone. Hydromorphone also produced dose-
dependent increases in the agonist scale of the adjective checklist,
but no increases in the antagonist scale. On the ARCI only the MBG
(euphoria) scale was increased. Naloxone produced dose-dependent
increases on the visual analog scales for “drug effects”, and “bad
effects” (Figure 2); there were no increases in “high”, “good ef-
fects”, or “liking” following naloxone administration. Naloxone pro-
duced dose-dependent increases in the antagonist scale of the adjec-
tive checklist, but no increases in the agonist scale. There were no
consistent naloxone effects on any scales of the ARCI.
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FIGURE 1. Hydromorphone Dose Response Curves (N = 1) for percent
identifications as hydromorphone in operant responding discrimination
measure, visual analog scale scores, and adjective checklist scale
scores. Data from test drug discrimination trials (13-40), average
of 2 determinations.
FIGURE 2. Naloxone Dose Response Curves (N = 1) for percent identi-
fications as naloxone in operant responding discrimination measure,
visual analog scale scores, and adjective checklist scale scores.
Data from test drug discrimination trials (13-40), average of 2
determinations.
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DISCUSSION
The results of this pilot study show that it is possible to adapt for
human laboratory use the same general procedures of drug discrimina-
tion training which have been used so successfully and productively
in the animal laboratory. The three-way opioid discriminations of
agonist versus antagonist versus saline were rapidly learned by the
methadone-dependent volunteer subjects, and orderly dose-effect rela-
tionships were observed in this human opioid drug discrimination
testing. A number of different measures of drug discrimination
appear to be effective, including a “percent of drug lever” operant
response measure, which is commonly used in animal studies.
This behavioral drug discrimination testing was readily integrated
with collection of traditional clinical pharmacology measures of sub-
jective drug effects, and these data, too, showed orderly and compar-
able dose-effect relationships. This drug discrimination paradigm is
not meant to replace traditional measures of subjective drug effects,
but to serve as an additional source of information, which might
prove to be more sensitive to low doses of drugs and which might
allow better comparison between drugs within a single pharmacological
class which have considerable overlap in subjective effects, such as
might be expected with the mixed opioid agonist/antagonist analgesics.
In addition, use of this paradigm in combination with measures of
subjective drug effects will allow interesting comparisons of human
and animal drug discrimination studies and the relationship between
drug discrimination and verbal descriptions of drug effects. Over-
all, this drug discrimination paradigm appears to be a useful experi-
mental procedure for studying the similarities and differences among
the wide variety of available opioid compounds.
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Maternal Drug Use and the
Effectiveness of Pharmacotherapy
for Neonatal Abstinence
Sandra L. Tunis; Donna M. Webster; Joseph K. Izes;
and Loretta P. Finnegan
Infants undergoing neonatal abstinence due to maternal drug use
have been commonly treated with paregoric, phenobarbital or
diazepan. This study was designed to test the effectiveness of
each of these agents in the control of abstinence symptomatology.
The relationship of the type of maternal drug use to the effec-
tiveness of the treatment was also examined. The subjects
included 134 infants born at Thomas Jefferson University Hospital
who were treated for abstinence after careful assessment with a
scoring system. Infants with serious medical complications were
finally eliminated from the study. A series of least squares
linear regression analyses was performed using the treatment
drug, type of maternal drug (opiates, non-opiates, or both), and
the interaction of treatment and maternal drugs as predictors of
whether or not a second pharmacotherapeutic agent was needed in
order to control abstinence symptomatology. Treatment was con-
sidered effective if control was obtained by the use of a single
agent. Results revealed that if maternal drug use was limited to
non-opiates, phenobarbital therapy was a significant predictor of
successful treatment. Treating an infant with diazepam, however,
significantly predicted the need for a second agent, regardless
of maternal drug use. Paregoric was a significant predictor of
successful treatment if maternal drug included opiates or a com-
bination of opiates and other drugs. However, paregoric was also
a significant predictor of unsuccessful treatment if the mother
abused only non-opiates. Conclusions of the data are as follows:
1) an abstinence scoring system is essential in the assessment of
any infant undergoing abstinence, 2) evaluation of the drugs used
prenatally will permit more specific drug choices for treating
neonatal abstinence, 3) combining a scoring system with specific
drug recommendations provides a more objective method of manage-
ment, 4) paregoric is most efficacious if the infant has prenatal
exposure to opiates or a combination of opiates and other agents,
5) phenobarbital is most efficacious if the infant is prenatally
exposed to non-opiates only and finally, 6) diazepam is not an
appropriate drug for neonatal abstinence either from prenatal
exposure to opiates only, opiates and non-opiates or non-opiates
only.
AUTHORS’ AFFILIATION Thomas Jefferson University,
Department of Pediatrics, Philadelphia, Pennsylvania
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Double-Blind Comparison of
Desipramine and Placebo in With-
drawal From Cocaine Dependence
Forrest S. Tennant, Jr., and Anita L. Tarver
ABSTRACT
Desipramine was compared with a placebo under double-blind con-
ditions to determine if it is effective treatment for withdrawal
from cocaine dependence. Eleven (11) subjects received desipra-
mine and 11 received placebo. There was no significant statistical
difference between groups in self-report on effectiveness; retention
in treatment; cessation of cocaine use; or suppression of withdrawal
scores. Although desipramine appears to be no more effective than
placebo in withdrawal from cocaine use or suppression of withdrawal
scores, it may be useful in the long-term treatment of this condition.
INTRODUCTION
Desipramine has recenly been suggested as a possible treatment for
cocaine dependence.1,2 This tricyclic antidepressant produces as
great or greater degree of selective blockage of norepinephrine
re-uptake as any other antidepressant.3 Chronic cocaine administra-
tion to animals and in vivo has been shown to deplete neuronal
norepinephrine levels.4 Based on this information, it was be-
lieved that desipramine may be an effective treatment agent for
chronic cocaine dependence, and an open clinical trial plus
anecedotal reports have indicated this may be an effective treat-
ment.1,2 Reported here is a double-blind, placebo-controlled
clinical trial to determine if desipramine may be effective
in withdrawal from cocaine dependence.
METHODS
Twenty-two (22) cocaine-dependent subjects were admitted to a
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special cocaine research unit located in Eastern Los Angeles County
(West Covina). In order to be admitted to the study, the subject
had to have a perception that cocaine dependence existed to the
point that medical withdrawal was necessary. All subjects also
had to meet the following criteria: multiple daily cocaine use
for the previous one month; no other drug or alcohol dependency;
absence of any illness requiring medication; and presence of co-
caine in plasma or urine. One-half (11) of subjects were randomly
assigned to desipramine and one-half (11) to placebo groups. Sub-
jects attended the clinic daily for the first five days and then
two times per week for as long as five additional weeks for a max-
imal study time of six weeks (42 days.) Desipramine and placebo
were prepared in identical unmarked capsules. Each active capsule
contained 25 mg. of desipramine. Neither subject nor clinical staff
were aware of contents of capsules. The first day's dose was one
capsule given four separate times so that a subject receiving active
medication would consume 100 mg in 24 hours. Daily dosage was
raised to a maximum of six capsules or 150 mg of desipramine in
24 hours if the subject complained that medication was ineffective.
On each day of attendance subjects were asked if the medication
"worked," reduced cocaine craving, gave energy, prevented depression,
and assisted sleep. One nurse observer determined a withdrawal
score for each of the first five days of the study by assigning a
numerical score to 14 symptoms: 0 for absent; +1 for mild; +2 for
moderate; and +3 for severe. The following symptoms were assessed:
anorexia; diaphoresis; insomnia; irritable; anxiety; lethargy;
nausea; diarrhea; depression; headache; difficulty concentrating;
cocaine craving; myalgia; and mental confusion. A urine specimen
was taken every other day of attendance during the first week and
every day of attendance after the first week. The qualitative
presence of cocaine in each urine sample was determined by
immunoassay technique.5
If a subject felt their assigned medication was ineffective, they
could drop out of the study or be given doses of desipramine.
RESULTS
Study groups appeared comparable with the exception that all females
received desipramine. (Table One) All subjects were chronic cocaine
users who believed themselves to be dependent and in need of medical
withdrawal treatment. Self-report effectiveness for reduction of
craving, providing energy, preventing depression, and assisting sleep
showed no difference between the two groups with the exception that
the placebo group reported more assistance with sleep. (Table Two)
Drop-out rate, mean days retained in treatment, and number of
subjects who converted urine from cocaine positive to negative, and
total number of cocaine negative urine tests were not statistically
different. (Table Two) In addition, the mean daily withdrawal score
for each group during the first five days was not statistically
different for any day, and the overall mean daily withdrawal score
for the first five days was almost identical (6.0 versus 5.9).
All appeared to clinically benefit from it and they voluntarily
continued it for periods ranging from one to six months. The only
side effect reported by either group was dry mouth in two desipra-
mine subjects.
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DISCUSSION
Although all females were assigned in blind, random fashion to the
desipramine group, it is highly improbable that statistical outcome
has been affected. Even if some poor-performing females had been
assigned to the desipramine group, performance data between compari-
son groups is so similar that enough variance with different group
assignments could probably not be achieved to affect statistical
outcomes. Clinical performance of placebo and desipramine groups
appeared to be essentially identical by subject self-report, drop-
out rate, retention, withdrawal suppression, and cocaine use as
detected by urine test. The only difference between groups
appeared to be that more subjects in the placebo group reported
ability to sleep. No significant side-effects were reported to
occur in the desipramine group even though it was administered,
in some cases, within only a few hours following cocaine usage.
Desipramine is a potent re-uptake blocker of norepinerphrine.3
Cocaine appears to deplete neurons of norepinephrine.4,6 Prior
to this study, we had hoped that desipramine's ability to block
the re-uptake of norepinephrine would make more norepinephrine
available to receptor sites and facilitate withdrawal from
cocaine dependence. It may be that cocaine depletes central nervous
system norepinephrine so much that desipramine cannot be effective
in the acute phase of withdrawal from cocaine dependence. Marked
norepinephrine depletion has been demonstrated in animals that were
administered cocaine on a chronic basis. In addition, another
recent, unreported study by us suggests that norepinephrine is
markedly depleted in cocaine-dependent persons, since urinary 3-
methoxy-4-hydroxyphenylglycol (MHPG) was very low in study subjects.
Imipramine, which partially converts to N-desmethyl-imipramine, the
active metabolite of desipramine, has been shown to lower MHPG ex-
cretion. It is, therefore, possible that further lowering of nor-
epinephrine by desipramine could be the explanation for the placebo
group reporting more ability to sleep. Demonstration that desipra-
mine is no more effective than placebo in the acute withdrawal from
cocaine dependence raises questions about the usefulness of all
tricyclic antidepressants for this condition. We observed, however,
that desipramine appeared to be clinically helpful to some subjects
after the acute withdrawal phase of cocaine dependence had ended.
TABLE ONE
DEMOGRAPHIC AND DRUG USE
CHARACTERISTICS OF STUDY GROUP
Desipramine Placebo
N=11 N=11
Stat Sig
Males
Females
Age Range (Years)
Mean Age (Years)
7 (63.6%) 11 (100%) P < .05
5 (45.4%) 0 (O%) P < .05
18 - 35 19 - 36 NA
28.0 29.3 PNS
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TABLE ONE
(Continued)
Desipramine
Employed
Married
Range Overall Cocaine Use
(Years)
7 (63.6%)
4 (36.4%)
1 - 14 yrs.
Mean Overall Use of Cocaine
(Months)
49.4
Mean Reported Amount Used
per day (gms)
1.32
TABLE TWO
RESULTS AND OUTCOMES OF TREATMENT
Desipramine
N=11
Feels Medication Does Following:
"Works"
Reduces Cocaine Craving
Gives Energy
Prevents Depression
Assists Sleep
Dropped out in First Week
Mean Days in Treatment
Urine Tests Absent of Cocaine
No. Who Converted Urine from
Cocaine Positive to Negative
Switched to Known Desipramine
Following Drop-Out from Study
Mean Per Day Withdrawal Score
During First Five Days of
Treatment
6 (54.5%) 7 (63.6%)
7 (63.6%) 7 (63.6%)
0 ( 0%) 3 (27.3%)
6 (54.5%) 5 (45.5%)
3 (27.3%) 5 (45.5%)
5 (45.5%) 5 (45.5%)
12.0 14.8
39 of 61 47 of 67
(63.9%) (70.1%)
9 (81.8%)
3 (27.3%)
6.0
8 (72.7%)
5 (45.5%)
5.9
Placebo Stat Sig
6 (54.5%) PNS
4 (36.4%) PNS
2 - 10 yrs. N A
66.2 PNS
1.54 PNS
Placebo Stat Sig
N=11
PNS
PNS
PNS
PNS
P < .05
PNS
PNS
PNS
PNS
PNS
PNS
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Platelet Serotonin Transporter in
Cocaine Patients
Charles A. Dackis; Marcy A. Pasternak Dackis;
David Martin; A. L. C. Pottash; and Mark S. Gold
INTRODUCTION
Cocaine is a potent euphoriant which has become a growing
medical and social problem. While the euphoriant properties of
this drug are well known, there is less appreciation of
cocaine-associated depressive states. Depressive syndromes
occurring after the abrupt discontinuation of cocaine are
particularly frequent and may lead to “self-medication with
cocaine and the perpetuation of cocaine abuse. While it is not
clear in all cases whether depressive symptoms preceded or
resulted from cocaine abuse, such syndromes may require specific
treatment. At present there are no laboratory measures with
proven reliability that are specific for depression in cocaine
patients. A reliable test for depression in cocaine abusers
might be useful in order to distinguish between pre-existing
depression and cocaine-induced affective changes. One recently
reported laboratory measure for major depression is the platelet
serotonin transporter (PST). Since cocaine itself could affect
this measure, however, the specificity of the PST must be tested
in cocaine abusers who are not depressed. This study addresses
PST findings in nondepressed cocaine patients.
The PST measure relates to the indolamine theory of depression
which states that depression can result from a deficiency of
serotonin in the neuronal synapse. Numerous measures of
serotonin metabolism have previously been shown to be abnormal
in certain patients with major depressive illness. These
include cerebral spinal fluid (CSF) 5-hydroxyindoleacetic acid
(5HIAA), and plasma and CSF tryptophan levels (Ashcroft and
Sharman 1960; Van Praag and Korf 1971; Goodwin et al. 1977;
Bridges et al. 1976; d’Elia et al. 1979). The most recent
serotonin measure, the PST, involves the uptake of serotonin by
platelets and serves as a peripheral model for serotonin uptake
in brain serotonin nerve endings (Sneddon 1973; Stahl and
Meltzer 1978; Pletscher 1968). This measure has been suggested
to have diagnostic reliability for depression based upon low PST
values in endogenously depressed patients (Meltzer et al.
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1981). Decreased platelet serotonin uptake in depressed
patients was found by Heltzer and his colleagues (Meltzer et al.
1981; Meltzer et al. 1983). Malmgren found similar results when
comparing endogenously depressed patients with those who were
nonendogenously depressed and with normal controls (Malmgren et
al. 1981). Kaplan and Mann (1982) have also found platelet
uptake of serotonin in depressives to be significantly lower
than in controls. However, the specificity for depression of
the PST has not been addressed in patients with other
conditions, such as cocaine abuse.
Cocaine has been reported to alter serotonin and other
neurotransmitter metabolism in a number of ways (Dackis and
Gold 1984). In animal studies, cocaine reduces brain serotonin
concentrations acutely. (Pradhan et al. 1978a) and this reduction
may contribute to behavioral effects of the drug (Pradhan et al.
1978b). Cocaine also inhibits the synthesis of serotonin (Knapp
and Mandell 1972; Schubert et al. 1970) leading to a reduction
in serotonin turnover. Reduced serotonin turnover has been
hypothesized to result from increased stimulation of
postsynaptic serotonin receptors (Friedman et al. 1975))
representing a compensatory regulatory mechanism. Cocaine also
blocks serotonin reuptake (Friedman et al. 1975; Ross and Renyi
1969), leading to increased synaptic levels of serotonin.
Whether this potentiation of serotonin neurotransmission leads
to compensatory turnover reductions remains unclear.
It is obvious from animal studies that cocaine exerts a number
of significant effects on serotonin function in the brain. It
is quite possible that serotonin systems are likewise disrupted
in human cocaine abusers. For this reason. as well as
previously discussed considerations regarding the diagnostic
reliability for depression of the PST, we decided to investigate
this measure in cocaine patients. Our hypothesis was that; as
in animal studies, serotonin reuptake would be inhibited in
humans chronically exposed to cocaine, and that this would be
reflected in low PST values.
METHODS
Subjects: Subjects consisted of 24 cocaine patients and 28
normal controls. All subjects were free from a present or past
DSM-III diagnosis of major depression as determined by a careful
psychiatric interview. Cocaine patients had a current DSM-III
diagnosis of cocaine abuse and were free of other substance
dependence. The DSM-III diagnosis of cocaine abuse was
confirmed in all cases by either blood or urine levels of
cocaine on admission. PST assays were performed within 5 days
of admission on cocaine patients.
PST Assay: Specimens for the determination of PST were
collected in BD yellow top vacutainers containing ACD (Acid
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Citrate Dextrose) as an anticoagulant. The tubes were spun at
200 x g for 10 minutes in a refrigerated centrifuge set at
4-10°C. Once spun, the platelet rich plasma was carefully
removed with a polypropylene transfer pipet and placed into a
conical 10 ml polypropylene tube. Adequate buffer was added to
double the volume of the harvested platelet rich plasma and the
resulting concentrations of platelets were determined in
triplicate by a Baker MK-4/HC electronic platelet counter. The
method of determining PST is a modification of a method
previously described (Arora and Meltzer 1981). Radioactive
serotonin was diluted with buffer to achieve
concentrations varying from 3.75 x 10-5M to 1.00 x 10-6M.
final
The diluted platelet rich plasma was preincubated for 10 minutes
at 37°C and then 300 uL aliqots were combined with 600 uL of
buffer and 100 uL of varying concentrations of radiolabelled
serotonin. These tubes were incubated for 2 minutes at 37°C
then immediately placed in an ice bath to stop the reaction.
Tubes were centrifuged at 0-4°C at 14000 g in a microfuge
(Fisher Model 235A), the supematant discarded and the platelet
pellets washed with 700 uL of buffer to remove any radiolabelled
serotonin not transported by the platelets. The pellets were
then solubilized in 500 uL of ScintiGest (Fisher Scientific) at
50°C for 2 hours. Once solubilized, the platelet pellet was
transferred to a scintillation vial containing 7.0 mls of
SintiVerse II (Fisher Scientific) and counted in a Beckman IS
7500 liquid scintillation system. Uptake for each concentration
of radiolabelled serotonin transported into aliquots of platelet
rich plasma was then determined as maximum velocity. Values
obtained by using Lineweaver Burk Analysis (Lineweaver and Burk
1934) data was expressed as “serotonin units” defined as
molecules of serotonin transported per platelet (5-HT/platelet x
105). Inter- and intra-run coefficients of variation (C.V.)
for split control samples were less than 10.0 percent. All
above operations, including the preparation of the platelet rich
plasma, were carried
loss of activity.
out in the shortest time possible to avoid
RESULTS
PST values of the cocaine and normal control groups were
compared by means of a two-tailed student’s t-test. PST values
in cocaine patients (16.3 ± 5.7, mean ± SD) were lower than
those of normal controls 727.2 ± 11.5, mean ± SD). This
difference was statistically significant (t=4.86, df=50, p<
0.001).
DISCUSSION
Our data indicate that the PST is extremely low and therefore
not specific for depression in cocaine abusers. Al though none
of the cocaine abusers were clinically depressed, their PST
values were extraordinarily lower than seen in our control
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subjects. low PST values in patients suspected of cocaine abuse
may even indicate the need for plasma or urine testing for
cocaine and a careful drug history. The clinician should
cautiously interpret PST results in cocaine users, and perhaps
in other untested conditions. The current findings suggest the
need for further research regarding the specificity of the PST
measure and militate against its diagnostic use for depression
in cocaine patients.
If the PST serves as an accurate model of central serotonin
neuronal reuptake, our low PST values in cocaine users would
imply a potentiation of central serotonin neurotransmission in
these patients. This finding would be consistent with reports
that cocaine blocks reuptake in animals (Friedman et al. 1975;
Ross and Renyi 1969). Cocaine-induced neurotransmitter
disruptions, such as reuytake blockade, could persist well
beyond the last cocaine dose and exert pressure on brain
homeostasis. As such, this disruption could contribute to
abstinence symptoms in areas influenced by serotonin functions,
such as sleep, locomotor activity, mood, appetite regulation, and
aggression (Kiter and Youngblood 1978; Fuller 1982).
We anecdotally observed several predictable symptoms after
abrupt cocaine discontinuation which may represent a withdrawal
syndrome. These symptoms included depression, anergia,
irritability, and craving for cocaine. Neurochemical effects of
cocaine, such as changes in serotonin reuptake, could be related
to “psychological” tolerance and withdrawal commonly encountered
in cocaine abuse. Further research is required to determine
whether PST abnormalities in cocaine users are pre-existing or
result from cocaine abuse. A longitudinal study of PST in
recently abstinent cocaine users could clarify this question.
Our recently abstinent cocaine abusers and certain depressed
patients appear to share low PST values. It is possible that
mood changes seen during and after cocaine use vary with
serotonin uptake measures. This possibility is interesting in
light of the fact that several antidepressant medications block
serotonin uptake and that this blockade has been theorized as
the mechanism of antidepressant action. Depressed patients
abusing cocaine may differ from nondepressed cocaine abusers
with respect of the PST. PST inhibition may also recover in
accordance with depressive symptoms seen after cocaine is
discontinued. These speculations require further investigation.
In conclusion, our findings indicate that, as a marker of major
depression, the PST probably lacks adequate specificity in
cocaine abusers. This test must be carefully interpreted when
used diagnostically for depression in cocaine addicts because
cocaine abuse itself profoundly influences the PST measure. Low
PST values in cocaine abusers suggest an additional
pharmacological effect of cocaine which could further our
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understanding of cocaine abuse and the mechanism of cocaine
induced mood alterations.
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Impact of Talwin NX
Edward C. Senay and Janice R. Clara
INTRODUCTION
During the decade of the seventies, remarkable changes occurred in
the heroin scene in the Chicago area. White heroin, with a distri-
bution network centered in the black ghetto, was replaced with
brown heroin, with the distribution network now shifted to the
Hispanic community. In addition to the change in control of the
distribution network, increased efforts by law enforcement agencies
appeared to cause longer periods of unavailability of quality
heroin.
It is tempting to speculate that the longer periods of unavail-
ability of quality heroin created a vacuum into which “T’s and
Blues” flowed. During this decade Chicago area treatment programs
experienced such a dramatic rise in the intravenous use of pentazo-
cine and tripelennamine, known as “T’s and Blues”, that by the
end of this time, almost one half of the heroin addicts in treat-
ment were frequent users of “T’s and Blues”. In addition, ten
percent of the addicts in Chicago area treatment programs at this
time were considered to be primary ‘T’s and Blues” abusers, many
of whom did not use heroin frequently and some had never used
heroin at all.
By 1978, pentazocine ranked fifth among drugs coming to attention
in Chicago area emergency rooms. Illinois reacted to this dramatic
increase in abuse by scheduling pentazocine as a schedule two drug
in 1979. Sterling-Winthrop reacted by formulating Talwin Nx, a
combination of pentazocine, 50 mg. and naloxone, 0.5 mg.
The work we describe in this paper was undertaken in the Spring of
1983 to study the effects of the introduction of Talwin Nx. At
this time, according to reports from Chicago area treatment pro-
viders, demand for treatment of the primary pattern of “T’s and
Blues” was diminishing; none the less, clinical encounters with
primary abusers of the combination occurred, and “T’s and Blues”
were a familiar and apparently enduring part of the drug scene in
Chicago.
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M E T H O D
We conducted this study at the University of Chicago Drug Abuse
Rehabilitation Program. Groups of subjects were interviewed in
the following periods:
Phase 1 - May 20th to June 7th, 1983 (N = 34)
Phase 2
Phase 3
- June, 15th to July 14th, 1983 (N = 92)
- August 24th to August 26th, 1983 (N = 24)
When the data from these periods was examined it was decided that
additional data would be obtained. Interviews were then conducted
in the second part of the study in the following periods:
Phase 1 - October 6th to October 17th, 1983 (N = 50)
Phase 2 - November 14th to November 18th, 1983 (N = 40)
Phase 3 - December 5th to December 9th, 1983 (N = 60)
The research subjects were recruited for this study by the Univer-
sity of Chicago Drug Treatment Clinic’s clients and staff. Each
subject was assigned a number to assure complete anonymity; also
no identifying information was obtained from the subjects which
could associate them with the study in the future. One researcher
conducted all the interviews and did not interview the same sub-
ject twice.
All subjects were administered identical questionnaires in a stan-
dardized format. Questions concerning heroin use were included
in the questionnaire to make it appear that our focus of interest
was on multiple drug use patterns rather than exclusively on “T’s
and Blues”. In this way we hoped to avoid bias.
Each subject was paid $10.00 per interview. Interviewing lasted
approximately fifteen minutes per subject. Subjects were also
required to submit urine samples which were tested for the pres-
ence or absence of pentazocine. Subjects were informed at the
beginning of their interviews that their street drug patterns were
to be studied.
In the second part of the study we incorporated additional measures
to further validate our findings. In the initial stages of part 2,
difficulty was experienced in obtaining subjects who were willing
to bring in a Talwin tablet to the clinic. We therefore instituted
a “finder's fee”. This fee consisted of paying “finders”; for ex-
ample, clients of the clinic or subjects who had already been in-
terviewed, $5.00 for each subject they secured for the study. In
this part of the study we also selected urine samples on a random
basis for canprehensive analysis. We also required each subject
to present a Talwin tablet to the researcher in order to gain
entrance into the study. We added this measure to ensure that
subjects had at least a peripheral relationship with the illegal
distribution system. None of the subjects claimed to be using
Talwin on a prescribed basis for a medical condition in either
part of this study.
* A copy of the questionnaire can be obtained from the authors by
written request.
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RESULTS
The results of this research are reported in the tables below.
Table 1 depicts the results of the questionnaire from the three
phases of the study.
TABLE 1
Questionnaire Data (Part 1)
Phase 1
May 20 to
age of respondents
Race: Black
White
June 7
N=34
32
86%
14%
65%
3 5 %
Phase 2
June 15 to
July 14
N=92
28
100%
Sex: Male
Female
7 9 %
2 %
1) age of first use of
“T’s B’s”
age of first use of heroin
27 29
21 20
2) number of years in life
using “T’s B’s” 2
months or more during
the year and at least
3 x a week during use 6 (N=30) 5 (N=90)
3) number of uses per sub-
ject of “T’s B’s”
last month (30 day
month)
number of uses per
subject per day
57 (N=31) 36
2 1
4) number of uses per
subject of heroin last
month (30 day month)
number of uses per
subject per day
20 (N=24)
.6
15 (N=73) 15 (N=22)
.5 .5
5) Quality of “T’s B’s”
(% of responses):
Would not touch it (bad news) 9 %
Worse than ever 3 8 %
Same as ever 3 2 %
Better than ever 12%
Best it’s ever been 9 %
15% 4 %
49% 67%
30% 25%
5 % 4 %
1 % 0 %
Phase 3
August 24 to
August 26
N=24
40
100%
88%
13%
33
19
7 (N=23)
4 9
2
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TABLE 1 (continued)
% of positive Talwin Screens 29% 8 % 0 %
(5 continued)
% of subjects reporting
various forms of Talwin
use:
Yellow - (Talwin Nx)
Peach (Talwin 50)
Blue (Talacen) 1 4 % 9 % 3 %
Other (Talwin compound) 5 % 3 % 0 %
6) Quality of heroin, % of
responses:
Would not touch it (bad news) 0 % 14% 11%
Worse than ever 24% 31% 4 5 %
Same as ever 40% 16% 14%
Better than ever 24% 36% 27%
Best its ever been 12% 3 % 0 %
1 1 %
7 0 %
14%
7 4 %
26%
71%
Table 2 depicts the data analyses for the three phases of Part 2
of the research.
TABLE 2
Questionnaire Data (Part 2)
Phase 1 Phase 2 Phase 3
October 6 to November 18 to December 5
October 17 November 18 to December 9
age of subjects
Race: Black
Caucasian
Sex: Male
Female
1) age of first use of ‘T’s
B's"
age of first use of heroin
N=50 N=40 N=60
33 35 33
100% 100% 100%
0 % 0 % 0 %
76% 70% 78%
24% 30% 22%
27 28 27
20 21 21
2) number of years in life
using “T’s B’s” 2 months
or more during the year and
at least 3 x a week during
use 6 5 5
173
TABLE 2 (continued)
3) number of uses per subject
of ‘T’s B’s” in the
previous month (30 day
month) 60
number of uses per subject
per day 2
4) number of uses of heroin
per subject in the previ-
ous month (30 day month) 41 (N=41)
number of uses per subject
per day 1.4
5) Quality of Talwin, % of
responses:
35
1.2
37 (N=37)
1.2
42
1.4
23 (N=56)
.8
Would not touch it (bad news) 4
Worse than ever 46
Same as ever 48
Better than ever 2
Best it’s ever been 0
% of subjects reporting
various forms of Talwin
use:
Yellow (Talwin Nx) 9 0 %
Peach (Talwin 50) 6 2 %
Blue (Talacen)
Other (Talwin Compound)
6) Quality of heroin, % of
responses:
Would not touch it (bad news) 0 2
Worse than ever 29
Same as ever 34
Better than ever 34
Best its ever been 3
% of positive Talwin Screens 10%
% of positive Talwin pill
analyses 100%
3
65
27
5
0
87.5%
45%
2.5% (White)
3
38
46
13
0
2
58
35
5
0
93%
27%
3 % 2% (59 urines)
52
37
9
0
100% 100%
The majority of the subjects interviewed were black males with a
mean age of 33 years. “T’s and Blues” use began approximately at
29 years of age for these subjects and continued at a rate of
approximately three times a week or more for at least two months
each year for approximately six years. The age of their first use
of heroin was approximately 20 years. This figure was consistent
across all six phases of the research.
Table 3, in which we combined categories from Table 1 and 2 to
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highlight changes, illustrates the subjects’ changing perception of
“T’s and Blues” and heroin as the study progressed.
TABLE 3
Comparison of Qualities of Talwin and Heroin
Bad news Better than ever
worse than ever Same as ever best its ever been
Quality of Talwin % % %
Part 1 Phase 1 47 32 21
Phase 2 64 30 5
Phase 3 71 25 4
Part 2 Phase 1 50 48 7
Phase 2 68 27 5
Phase 3 60 35 5
Quality of Heroin
Part 1 Phase 1 24 40 36
Phase 2 45 16 39
Phase 3 59 14 27
Part 2 Phase 1 29 34 57
Phase 2 31 46 13
Phase 3 54 37 9
By the conclusion of Part 1 of the study over 70% of the subjects
perceived “T’s and Blues” to be “worse than ever” or “bad news”.
This level of dissatisfaction with “T’s and Blues” continued
throughout the second part of this study.
According to the reports of the subjects, particularly in the
later periods of the study, “T’s and Blues” were no longer used
as primary intoxicants. They were then primarily used as
“boosters” for poor quality heroin. Since the perceived quality
of heroin decreased in the latter part of the study, many of the
subjects felt that they needed to increase the number of sets of
“T’s and Blues” injected along with heroin in order to obtain
intoxication.
The increase in the use of Talwin Nx from May to December may have
been partially due to the scarcity of peach colored Talwin and its
high cost, $12 to $20 a set for a T-21 (original Talwin without Nx)
and blue, relative to $7 a set for a Talwin Nx and a blue.
Many of the subjects stated that Talwin Nx, known to them as
“footballs”, “bananas”, or “butterballs” were not as potent as
T-21’s. One subject described the effects of Talwin Nx as follows:
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"With the originals (peach colored T-21), I used to get a good nod
and be able to wake up in the morning and feel cool, now with
Talwin Nx I feel jittery when I wake and I have to go out and look
for dope, i.e. heroin.”
Following use of “T’s and Blues”, subjects also reported a high
incidence of dysphoric side effects including nausea, paranoia,
diarrhea, abscesses, darkening and burning of the skin, increased
agitation, and seizures. In some instances, seizure activity was
a concomitant to the increased dosage levels of “T’s and Blues”.
Several of the subjects interviewed in this study used more than
four sets of “T’s and Blues” on an individual basis per injection.
The majority of subjects, however, hesitated in using such a large
number of sets for fear of unpleasant effects.
It is important to add that the compounds present in the urines
analyzed via comprehensive urine screens indicated the subjects
used a variety of drugs. Of the thirty urines analyzed via com-
prehensive urine screens in the second part of the study, urine
specimens were positive for the following compounds:
#01 - acetaminophen; cannabinoids
#02 - cannabinoids; unident material (unidentified)
#10 - ethanol
#15 - acetaminophen; ethanol
#20 - quinine; ethanol
#25 - norpropoxyphene; ethanol; cannabinoids
#30 - quinine; ethanol; cannabinoids
#35 - quinine; ethanol; cannabinoids
#40 - pentazocine; tripelennamine; quinine; ethanol
#45 quinine; ethanol; cannabinoids
#50 - ethanol
#55 - codeine; methadone; cannabinoids
#60 - salicylates; acetaminophen; codeine; quinine;
cannabinoids; benzodiazepine metabolites
#65 - ethanol; cannabinoids
#70 -codeine; chlordiazepoxide; cocaine; benzoylecgonine;
quinine
#75 - ethanol
#80 - methadone; cocaine; benzoylecgonine; cannabinoids
#85 - acctaminophen; ethanol
#90 - ethanol; cannabinoids
#95 - clean
#105 - insufficient urine; not tested
#115 - ethanol; cannabinoids
#120 - codeine; propoxyphene; ethanol
#125 - ethanol
#130 - benzodiazepine metabolites
#135 - phencyclidine; cannabinoids
#140 - clean
#145 - cannabinoids
#150 - ethanol; tripelennamine; antihistamine; valium
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One hundred fifty Talwin Nx tablets were purchased in Part 2 of
the study. Of the 150 tablets, 30 were analyzed to test for the
presence or absence of pentazocine, and 100% of these analyses were
positive for pentazocine.
DISCUSSION
The data obtained in this study suggests that the inclusion of a
small dose of naloxone substantially alters the street patterns of
abuse of the Talwin and Pyribenzamine combination. The demand for
treatment for primary abuse of this combination declined dramati-
cally following the introduction of Talwin Nx in the Spring of
1983. There were also marked changes in the experiences obtained
from the use of T’s and Blues and in the frequency with which this
combination was used as a primary source of intoxication.
Studies of this nature are difficult because of the multiple drug
use patterns of so-called “street people”. Our broad screen
urines revealed substantial evidence of such drug use in the cohort
studied. In addition, changes in the supply and potency of heroin
affected users’ drug select ions.
The situation is also made difficult by the fact that many users
of “T’s and Blues” and heroin have minimal or nonexistent degrees
of pharmacologic dependence on opioids. This alters substantially
the response to intravenous naloxone. If there is no opioid
dependence, then the experience of taking Talwin Nx will be quite
different than if opioid dependence is present.
Reports from treatment programs in the Chicago area indicate that
demand for treatment of the primary abuse of T’s and Blues is
practically nonexistent at this point. For example, the perinatal
program which focused on pregnant T’s and Blues users. at the
Chemical Dependence Unit at Northwestern University had to be
terminated because no pregnant addicts are being encountered now
who are primary users of “T’s and Blues”. Reports from treatment
providers across the Chicago area are quite consistent in this
regard.
There is evidence from both formal and Informal channels that the
introduction of Talwin Nx appears to have the effects hoped for
when it was introduced; namely, reduction in primary abuse of
Talwin and Pyribenzamine. Further studies are needed to document
the persistence or perhaps reversal of this trend.
AUTHORS
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Contingent Methadone Dose
Increases as a Method for
Reducing Illicit Opiate Use in
Detoxification Patients
Stephen T. Higgins; Maxine L. Stitzer;
George E. Bigelow; and Ira A. Liebson
Outpatient methadone detoxification is a common treatment for opiate
dependence, but is often found to be ineffective in achieving even
snort-term abstinence. Typically, patients drop out of treatment or
relapse to the use of illicit opiates prior to completion of the
detox (Canada, 1972; Stitzer et al., 1981; Wilson et al., l974).
Stitzer et al. (1981), for example, reported that 80% of their pa-
tients relapsed to illicit-opiate use prior to or shortly after the
completion of a 90-day detox. Such high rates of relapse have been
reported both for individuals who periodically used illicit opiates
throughout the detox as well as those who were initially abstinent
(Stitzer et al., 1983a). In general, then, outpatient methadone de-
toxification is typically ineffective, and methods for increasing its
clinical efficacy should be identified if the use of this treatment
modality is to continue.
One method for increasing abstinence from illicit opiates and also
achieving greater retention in treatment has been to include
contingency-management procedures in the cietox (Hall et. al., 1979;
McCau1 et al., l984). For example, McCaul et al. (l984) provided
patients enrolled in a 90-day detox with $10.00 and a take-home dose
contingent on each opiate-free urine sample delivered during twice
weekly testing. The contingency achieved (1) an increase in the
overall percentage of opiate-free urines, (2) an increase in the
maximum number of consecutive opiate-free urines individuals pro-
vided, and (3) an increase in treatment retention. The purpose of
the present study was to further investigate the use of contingency-
management procedures with individuals enrolled in outpatient metha-
done detoxification. More specifically, in this study we investi-
gated the effectiveness of contingent methadone-dose increases in
reducing illicit-opiate use and increasing treatment retention. Con-
tingent methadon-dose increases have been used to reduce illicit-
opiate use in methadone maintenance patients (Stitzer et al., 1983b),
and could prove to be a more economically feasible procedure than
providing money for opiate-free urines during outpatient methadone
detoxification.
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M E T H O D
Patients. Thirty-five male patients dependent on illicit opiates
were enrolled in a 90-day or 13-week detoxification program across an
11-month period. Patients had to provide 50% or more opiate-free
urines during the first 3 weeks of the detox to be eligible for the
present study. Twenty-seven of the 35 patients met this criterion
and the remaining eight patients were assigned to another study.
Procedures
Attendance and urinalysis. Patients reported to the clinic 7 days a
week and were terminated from treatment when they missed any 3 conse-
cutive days at the clinic. Urine samples were collected on Monday,
Wednesday, and Friday and were immediately tested via an onsite Emit
system for the presence of opiate drugs. Additionally, one randanly
selected sample each week was sent out to an independent laboratory
for each patient throughout the detox. These samples were tested
using thin layer chromatography (TLC) analysis for both opiate and
nonopiate drugs. All specimens were collected under staff observation
to prevent patients from providing bogus urines. Missed urine speci-
mens due to clinic absences were counted as opiate positives.
Contingency-management procedure. Patients were randanly assigned to
one of three treatment groups, which became effective on Day 22, the
first day of Week 4. The three treatment groups were a contingent
methadone-dose increase group, a noncontingent methadone-dose
increase group, and a control group. The procedural differences
between the groups were as follows: 1) Members of the contingent
group (N = 9) could increase their clinic dose of methadone by 5, 10,
15, or 20 mg on a daily basis, but only if their most recent urine
sample was free of opioids other than methadone. 2) Members of the
noncontingent group (N = 8) had the the same amount of extra methadone
available to them as the contingent group, but could receive daily
dose increases independent of their urinalysis results. 3) Members
of the control group (N = 10) could not receive dose increases. Dose
increases were always voluntary and they were available from Day 22
(Week 4) through Day 77 (Week 11) of the 90-day detox.
Methadone-dosing regimen. Patients drank their methadone daily under
nursing supervision. Methadone doses were mixed with cherry syrup
and administered under double-blind conditions. Dose increases were
added to the clinic dose by the nurse upon request. During the
first 3 weeks of the detox, all patients were stabilized on 30 mg of
methadone. Beginning in Week 4 the methadone dose was reduced in
alternating 2 and 3 mg steps until 0 mg was reached at the end of
Week 9. Thereafter, control subjects received only cherry syrup as
their clinic dose. Members of the contingent and noncontingent
groups also received cherry syrup as their clinic dose during Weeks
10 and 11, but still had the doss increases available to then during
this period; When the dose increases were discontinued on Day 78,
the clinic dose for the contingent and noncontingent group members
was increased to 15 mg and reduced again to 0 mg in 5 mg decrements
every 3 days. This was done to prevent an increase in withdrawal
symptoms after opportunities for dose increases were discontinued.
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Data analysis. Data for the three groups are presented for treatment
retention, clinic attendance, and urinalysis results. Al 1 patients
enrolled in the study were included in the treatment-retention
analysis. However, only those patients who were retained in treat-
ment into Week 8 of the detox (78% of the total sample) were included
in the analyses of clinic attendance and urinalysis results. Early
dropouts were excluded because we were especially interested in com-
paring the treatment groups during the later segment of the detox when
the methadone dose fell below 10 mg (i.e., Weeks 8 through 11). It is
during this period that high rates of relapse to illicit-opiate use
often occur. Clinic attendance and urinalysis results were analyzed
in two-week blocks for those who remained in treatment into Week 8.
Patients discontinued from treatment during or after Week 8 were in-
cluded in later analyses by assigning them their average score from
the two-week block during which they terminated treatment.
RESULTS
Treatment retention. The percent of individuals in the three treat-
ment groups discontinued during each two-week block of the dose
increase intervention procedure is presented in Table 1. In the
contingent group, zero terminations occurred during Weeks 4-5, 22% or
two of the original nine group members terminated treatment during
Weeks 6-7, zero terminated during Weeks 8-9, and 22% or two more of
the original nine terminated treatment during Weeks 10-11. In total,
44% of the contingent group members terminated treatment during the
intervention period and 56% completed it. In the noncontingent group,
zero terminations occurred during Weeks 4-5, 25% or two of the origi-
nal eight members terminated during Weeks 6-7, and 13% or one group
member terminated during Weeks 8-9 and Weeks 10-11, respectively. In
total, on-half of the noncontingent group numbers completed the
intervention. In the control group, 10% or one of the original 10
group members terminated treatment during Weeks 4-5, 10% more at
Weeks 6-7, and 30% more terminated during Weeks 8-9 and 10-11, re-
spectively. In total, 80% of the control group terminated treatment
prior to completion of the intervention period. These differences
across groups were hot statistically significant, but the trend is
clearly one of the two dose-increase groups engendering greater
retention in treatment than the control group. Note that the two
individuals in each group who terminated treatment prior to Weeks 8-5
are not included in the clinic-attendance and urinalysis results
reported below.
TABLE 1
Percent of Subjects Terminating Treatment
Study Weeks
Treatment Groups 4-5 6-7 8-9 10-11
Contingent 0 22 0 22
Noncontingent 0 25 13 13
Control 10 10 30 30
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Clinic attendance. Figure 1 depicts the percent of clinic absences
during the dose-stabilization and intervention periods. The three
groups exhibited similar levels of clinic absences during the dose-
stabilization period; however, the control group exhibited a higher
percent of clinic absences during the intervention period than either
the noncontingent or contingent groups. A mixed two factor analysis
of variance with repeated measures showed significant repeated
measures (df = 4,72, F = 10.68, p < 0.01) and interaction (df = 8,72,
F = 2.24, p < 0.05) effects. Post-hoc analyses using the Scheffe
test indicated the control group was absent from clinic siyificantly
more than both the contingent (p < 0.01) and noncontingent (p < 0.05)
groups at Weeks 8-9 and Weeks 10-11. The differences between the
noncontingent and contingent groups were not statistically signifi-
cant.
Urinalysis results. Figure 2 depicts urinalysis results for the
three treatment groups. During the dose-stabilization period (Weeks
2-3), all three groups were similar, presenting in the range of 12-
15% opiate-positive samples. Although the control group presented a
higher percentage of opiate-positives than the two dose-increase
groups during Weeks 4-5 and 6-7, the three groups most clearly
separated from each other during Weeks 8-11 when the clinic dose of
methadone fell below 10 mg. A mixed two factor analysis of variance
with repeated measures revealed significant treatment effects
(F = 3.8, df = 2,72, p < 0.05) and significant repeated measures
effects (F = 8.5, df = 4,72, p < 0.01). Post-hoc analyses using the
Scheffe test indicated that the contingent group presented a signifi-
cantly lower percent of opiate-positive urines than the control group
at Weeks 8-9 (p < 0.001) and 10-11 (p < 0.01). The noncontingent
group presented a lower percent of opiate-positive urines than the
control group during Weeks 8-9 (p < 0.10). The contingent and
noncontingent groups also differed (p < 0.10) from each other in the
average percent of opiate-positive urines presented at Weeks 8-9.
Post-hoc analysis of the repeated measures effect using the Scheffe
test indicated the control group presented a significantly
(p < 0.01) greater percent of opiate-positive urines at the end of
the intervention (Weeks 10-11) than they did prior to the interven-
tion (Weeks 2-3 ). The noncontingent group also showed a significant
(p < 0.05) increase in opiate-positive urine tests over this time.
In contrast, the contingent group did not present a significantly
higher percent of opiate-positive urines at Weeks 10-11 than at
weeks 2-3.
DISCUSSION
The results from this study suggest that contingent methadone-dose
increases may be ah effective means for reducing illicit-opiate use
in outpatient methadone patients. The contingent group was clearly
superior to the control group in presenting fewer opiate-positive
urines, an effect that was most apparent during the middle of the
detox when the clinic methadone dose was substantially reduced for
the control group. The differences between the non-contingent and
control groups were not as clear, but the trend for the former to
present fewer opiate-positive urines was consistent. The differences
between the noncontingent and contingent groups in the percent of
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FIGURE 1. Average percent of missed clinic appointments
during consecutive two-week study periods. Percentages
are based on seven appointments per subject per week.
FIGURE 2. Average percent of opiate-positive urine tests
during consecutive two-week study periods. Percentages
are based on three urine tests per subject per week.
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opiate-positive urines presented were only marginally significant at
Weeks 8-9, but the trend was consistently one of the contingent group
exhibition greater treatment effects. This trend is particularly
interesting because it implicates the conjoint role of the contin-
gency and the pharmacological properties of methadone in reducing
illicit-opiate use in the contingent group. In fact, more opportuni-
ties existed for noncontingent group members to obtain extra metha-
done than for members of the contingent group because noncontingent
group members could do so even after providing opiate-positive urines.
Basic research studies have demonstrated the reinforcing efficacy of
methadone in nonhumans (Schuster & Balster, 1971) and in human opiate
addicts (Stitzer et al., 1983c). The effects obtained with the con-
tingent group in the present study illustrate now the reinforcing
efficacy of methadone can be utilized to maintain abstinence from
illicit-opiate use in opiate addicts.
The reinforcing efficacy of methadone was further suggested in the
present study by the lower percentage of clinic absences in the
contingent and noncontingent groups relative to the control groups.
Although the maximum methadone-dose increase permitted (20 mg) is not
particularly high for experienced opiate users, the availability of
this amount of extra drug was sufficient to engender a higher rate of
clinic attendance in the two dose-increase groups. Maintaining a
high rate of clinic attendance is important not only for suppressing
illicit-drug use. but also because clinic staff are provided a
greater number of opportunities to counsel patients in psychiatric,
employment, and other drug-and nondrug-related areas.
Although this study is still ongoing and the data are preliminary,
the effects obtained to date are consistent with the existing
literature showing the efficacy of contingency-mnagement techniques
in methadone treatment of opiate dependence. The use of contingent
Methadone-dose increases appears to have promise as a clinical method
for reducing illicit-opiate use in outpatient methadone programs.
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Naltrexone in Addicted Physicians
and Business Executives
Arnold M. Washton; Mark S. Gold; and A. Carter Pottash
ABSTRACT
Naltrexone was administered to 114 opiate-dependent business exec-
utives and 15 opiate-dependent physicians as part of a comprehen-
sive outpatient aftercare program following inpatient detoxifica-
tion using clonidine. Over 80% of patients successfully completed
at least six months of treatment without relapse or re-addiction
and were still drug-free at 12-18 months follow-up. Patients who
completed at least six months of treatment were more likely to be
opiate free at follow-up than patients who had dropped out at an
earlier point in the program. This study demonstrates that nal-
trexone can be an extremely useful and appropriate treatment for
highly motivated middle/upper class addicts when administered
within the context of an intensive high-expectation program.
INTRODUCTION
During the past two decades, opiate addiction has spread to the
middle and upper class segments of American society. Contrary to
established stereotypes, addicts now include many who are corp-
orate executives, business owners, health professionals, and others
who hold responsible jobs, earn substantial incomes, and do not
commit crimes to obtain drug supplies. Unfortunately, the treat-
ment needs of this addict subgroup are not adequately met by the
existing publicly supported treatment system. Treatment with meth-
adone or in methadone clinics is usually unacceptable to middle/
upper class addicts and may be distinctly contraindicated in many
cases because of the social stigma, identification by government
agencies, and exposure to drug-related crime. Public drug-free
programs pose similar problems. The typical middle/upper class
addict desires complete abstinence and prefers treatment in a
private setting.
We now report the successful use of naltrexone in addicted physi-
cians and business executives who were treated in our intensive
programs at Regent and Fair Oaks Hospitals. This study afforded a
unique opportunity to evaluate the efficacy of naltrexone in ad-
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diets who were socio-economically advantaged, with valuable jobs
or careers, and strongly motivated for treatment by a combination
of internal and external factors.
METHODS
Patients
The patients in this study were admitted to Regent or Fair Oaks
Hospital during the time period from February 1979 to February
1981. All had been addicted to opiates for at least two years.
The subgroup of 114 business executives represent all opiate-
dependent patients admitted during the specified time period who
met the following criteiia: (a) employed in a "white collar" job,
family or self-owned business, or professional; (b) earning at
least $20,000 per year; (c) successfully completed the inpatient
treatment program and started outpatient aftercare treatment with
naltrexone. The average age of this subgroup was 30 years, 92%
were white males, and their average income was $42,000 per year.
The subgroup of 15 physician addicts represent all opiate-depen-
dent physicians admitted for treatment during the specified time
period who successfully completed the inpatient program and start-
ed naltrexone aftercare. All were white males and their average
age was 38 years.
Treatment Protocol
The first phase of treatment consisted of a 4-10 week inpatient
program on a highly structured and intensive specialized unit at
Regent or Fair Oaks Hospital. The inpatient program included
initial detoxification using clonidine as well as daily partici-
pation in group therapy, individual therapy, peer group meetings,
educational classes, and physical exercise. Where appropriate,
the patient's spouse or family participated in joint meetings and
in aftercare planning: All patients were inducted onto naltrexone
during the final two weeks of inpatient treatment.
The inpatient program was presented to patients as the initial
step in a longer term recovery plan designed to foster continued
abstinence and address the psychological aspects of their addic-
tion through changes in lifestyle, interpersonal relationships,
and behavior patterns. In this regard, all patients signed an
aftercare treatment contract before leaving the hospital stipu-
lating naltrexone maintenance, group therapy, individual therapy,
family/couples therapy, and drug abstinence verified by random
urine checks for at least six months after hospital discharge.
RESULTS
Table 1 shows that 70 patients in the business executive subgroup
completed at least six months of naltrexone treatment in the out-
patient aftercare program. An additional 23 patients discontinued
naltrexone before six months but remained opiate free and partici-
pated in the outpatient program for at least six months.
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Table 1
ADDICTED BUSINESS EXECUTIVES
(N=114)
Completed at least six months
of naltrexone and therapy
Number Percentages
70 61
Completed less than six months
naltrexone, but stayed opiate
free and in therapy for at
least six months
23 20
Re-addicted or status
unknown at six months
21 19
These patients were all drug free, employed, and functioning
reasonably well when they discontinued the medication. Reasons
for stopping the naltrexone included generalized concern about
potential long-range health consequences, a felt need to remain
opiate-free "on their own" without pharmacologic assistance, and
side effects of stomach upset, sleeplessness, and nervousness
that they attributed to the medication.
At 12-18 months, 64% of the 93 available patients were still
opiate free and 36% were either known to be re-addicted or lost
to follow-up. Those who had stayed in the program for at least
six months on naltrexone and/or with drug-free urines were more
likely to be opiate free at this point than those who had dropped
out before six months.
Table 2 shows that in the subgroup of physician addicts, 11 pa-
tients completed at least six months of naltrexone treatment and
an additional two patients discontinued naltrexone at an earlier
point in treatment but nonetheless remained opiate-free and parti-
cipated in the outpatient program for at least six months.
Table 2
ADDICTED PHYSICIANS
(N=15)
Numbers Percentages
Completed at least six months
naltrexone and therapy
11 74
Completed less than six months 2 13
naltrexone, but stayed opiate
free in therapy for at least
six months
Re-addicted, rehospitalized 2 13
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The remaining two patients relapsed and required additional in-
patient treatment. At 12-18 months, all 13 patients who had suc-
cessfully completed at least six months of treatment were still
opiate-free and continuing their successful return to medical
practice.
DISCUSSION
Our findings demonstrate the highly successful use of naltrexone
in motivated middle and upper class addicts suggesting that nal-
trexone may be the treatment of choice for such patients. Naltrex-
one retention rates in these patient subgroups were approximately
two to five times greater than those reported in other studies
(Hollister, 1978; Bradford et al., 1979). The relative success of
our patients may be attributable in part to their being more so-
cially and economically advantaged than most previous naltrexone
research subjects and to the fact that they entered treatment, with
good job, career, and family supports. They had a great deal to
lose by continuing their drug use and also had a history of being
able to function well before their addiction to opiates. These
motivational factors in combination with our highly structured,
high-expectation program contributed to their overall success.
This explanation is consistent with previous studies that have
identified some of the favorable criteria associated with success
in naltrexone treatment. For example, addicts with higher pre-
treatment levels of psychosocial functioning and those with non-
drug-using spouses have shown better retention in naltrexone
treatment (Resnick and Washton, 1978; Parwatikar et al., 1976).
Similarly, programs that have administered naltrexone in conjunc-
tion with a high level of rehabilitative services (e.g., counsel-
ing, psychotherapy, urine screening) have usually produced greater
retention and drug-free success rates (Stone-Washton et al., 1982;
Hurzeler et al., 1976).
The length of time in naltrexone treatment appears to have an im-
portant influence on treatment outcome. For example, in a one-year
follow-up study, Resnick and Washton (1978) found that whereas
only 2% of 208 former naltrexone patients were still opiate-free
following less than three months on naltrexone, 31% of 59 patients
were opiate-free after 3-24 months of naltrexone treatment. Simi-
larly, our data showed that patients who completed at least six
months of naltrexone treatment were more likely to be opiate-free
at follow-up than patients who dropped out of treatment shortly
after hospital discharge. While compliance with naltrexone treat-
ment may have contributed in part to our patients' success, the
subgroup who discontinued naltrexone before six months but remained
in the aftercare program was also successful. This finding suggests
that for at least some of our patients the nonpharmacologic compo-
nents of our structured aftercare treatment program (i.e. therapy,
group meetings, urine checks) may have been more the crucial fac-
tors in determining outcome.
Naltrexone appears to be an especially useful and appropriate
treatment for the physician addict. With the protection of nal-
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trexone, the physician addict can return to the practice of
medicine and continue the rehabilitative process despite recur-
rent life stress and continued access to drugs. We have found that
hospital administrators, licensing boards, and other authorities
responsible for the future of the physician addict tend to feel
more comfortable about allowing the patient to resume medical
practice when naltrexone is a mandatory part of the recovery plan.
Our finding that 13 of 15 physician addicts (87%) successfully
completed the outpatient program, re-entered medical practice,
and were still drug free at one year follow-up compares very
favorably with previous reports (Wall, 1958; Green et al., 1981;
Modlin and Montes, 1984) showing that between 27% and 72% of
physician addicts are able to resume their careers following
treatment. While further work is needed to determine the best
treatment for this subgroup of opiate addicts, the use of nal-
trexone should clearly be an important feature of the addicted
physician's recovery plan.
Naltrexone appears to be a well-suited, well-tolerated, and well-
accepted treatment for the motivated addict who is able to use
the time previously spent on drug involvement on career develop-
ment and lifestyle change. The recent FDA approval of naltrexone
for marketed prescription use allows for the treatment of opiate
addicts by private physicians and in private medical facilities,
thus bringing the treatment of these patients further into the
mainstream of medical practice. This may remove a significant
obstacle to treatment for many middle/upper class addicts who
otherwise prolong their addiction in the process of trying to
avoid public treatment facilities.
FOOTNOTE
1. An earlier version of this manuscript was published in Advances
in Alcohol and Substance Abuse, 4(2): 48-51, 1984, and is reprinted
with permission of Haworth Press, Inc.
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Outpatient Methadone Detoxification:
Effects of Diazepam and Doxepin
as Adjunct Medications
Mary E. McCaul; Maxine L. Stitzer; George E. Bigelow; and
Ira A. Liebson
In recent years, there has been increasing interest and research
in the use of adjunct medications during opiate detoxification.
Although use of supplemental medications to control withdrawal
symptomatology has received general clinical application for many
years, there had been little systematic research in the area prior
to reports of the significant anti-withdrawal effects of the
alpha-2-adrenergic agonists clonidine and lofexidine (Gold et al.
1978,1980,1981; Washton and Resnick 1980).
The present adjunct medication study compared the effectiveness of
doxepin and diazepam on a variety of outcome measures during out-
patient opiate detoxification treatment. Clinically, anti-anxiety
and anti-depressant medications, either prescribed by the program
or illicitly obtained, are often used by detoxification clients to
control withdrawal symptoms. Two factors would support the choice
of these medications in this population. First, many of the
symptoms associated with opiate withdrawal resemble those of anxi-
ety and depression, including restlessness, sleep disturbance,
muscle ache, fatigue, and irritability. Second, these medications
have a relatively high safety level and a relatively low level of
side-effects, making them particularly well suited for outpatient
use.
The procedures in the present study differed from those generally
used in other adjunct medication-research in several important
ways. First, the dosing schedule included both acute and chronic
dosing regimens, designed to assess the effects of a range of
doses on several dependent variables. Second, the adjunct medica-
tion regimen was superimposed on a gradual rather than an abrupt
methadone detoxification schedule, allowing the assessment of the
effectiveness of the adjunct medications in the most commonly used
clinical procedure. Third, the present study utilized a wide
variety of outcome measures, including continued illicit opiate
use, other drug use, clinic attendance, adjunct medication refusal
rate, and symptomatology.
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METHODS
Subjects. Approximately 50 subjects were enrolled in a 90-day or
13-week outpatient detoxification. Subjects were eligible for
detox on the basis of a documented history of opiate use and urin-
alysis evidence of current opiate use. During the first three
weeks on the program, urine specimens were collected twice weeky
on Mondays and Fridays and analyzed for the presence of opiates.
Clients were selected for the present study if at least half of
the specimens were opiate free. Approximately half of the en-
rollees met this criterion; the remaining clients either dropped
out of treatment prior to study assignment or were assigned to an
alternative study because of their high initial levels of Illicit
opiate use. Drug use was used as a selection criterion in this
study since the effects of the pharmacological intervention could
be obscured if subjects were chronically supplementing their
methadone dose with additional opiate drugs.
Subjects averaged 30 years old, were generally single, separated,
or divorced, and had worked 17 out of the last 24 months. Sub-
jects reported an average of 4 to 7 years of continuous opiate use
prior to this treatment enrollment. Although the diazepam group
was significantly younger than the doxepin group, there were no
other significant dffferences between the two study groups on
demographic characteristics.
Procedures. All doses of methadone were mixed with a cherry syrup
vehicle and administered under double-blind conditions by clinic
nursing staff. All clients were stabilized on 40mg per day of
methadone during the first three weeks of the study. The metha-
done dose was then decreased in 10mg steps at the beginning of
weeks 4 and 5. This initial 20mg dose decrease was expected to
engender measurable levels of symptomatology prior to the acute
phase of the adjunct medication protocol. The methadone dose was
further decreased 4mg per week over the next 5 weeks; subjects
were then maintained on cherry syrup vehicle only for the final 4
weeks of the detox. Dosing for the adjunct medications was
changed from acute to chronic when the methadone dose reached 4mg
in week 9 of the detox.
At the beginning of week 5, subjects were randomly assigned to
receive either doxepin or diazepam. Both drugs were dispensed in
once-daily dosage forms, doxepin as Sinequan and diazepam as the
sustained-release Valrelease. Capsules were available each day at
the time of methadone administration. All medications were dis-
pensed in opaque orange capsules under double-blind conditions.
Subjects had the opportunity to decline each daily dose without
influencing the future availability of the medication; however, if
chosen, the capsules had to be ingested at the clinic under nurs-
ing supervision. During weeks 5 through 8, subjects were exposed
to a dose range of either doxepin (0, 25, 50 and 75 mg) or diaze-
pam (0, 15, 30 and 45 mg) in a random order. During this acute
dosing phase, each dose was administered on two consecutive days
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with at least a three-day placebo wash-out between active doses.
Subjects were informed at the start of the acute dosing period
that they would receive both active medication and placebo
("blanks") but that, as the detox continued, the frequency of
active doses would increase.
Each day during weeks 9 and 10, subjects had the opportunity to
ingest the intermediate dose of their assigned drug (diazepam 30mg
or doxepin 50mg). At week 11 during this chronic dosing period,
if subjects had reported an increasing level of withdrawal symp-
tomatology without reports of significant side-effects from the
study medication, the drug dose was increased from the intermed-
fate dose to the high dose administered during the acute dosing
phase (diazepam 45mg or doxepin 75mg). During the final week of
the detox, the adjunct medication dose was decreased and then
discontinued.
Several standard clinic procedures were used to collect data on
the dependent variables. Daily attendance records were maintained
by the clinic nurses; subjects were discharged when they missed
three consecutive days at the program. Throughout the detox, all
subjects provided urine specimens on Monday, Wednesday, and Friday.
These specimens were tested using an on-site MIT system for the
presence of supplemental opiate drugs. Finally, all subjects
completed symptomatology reports at each clinic visit.
RESULTS
Treatment retention was measured as the number of days subjects
remained active in the clinic without missing three consecutive
days. There was a significant difference between the two medica-
tion groups in the proportion of subjects who completed the 90-day
detox. Specifically, 5 out of the 10 diazepam subjects but only 1
out of the 13 doxepin subjects successfully completed the 13-week
detoxification protocol (Z=2.29; p<.O5). Mean number of days in
treatment was 74.1 days (S.D.=22.5) for diazepam subjects and 65.5
days (S.D.=17.9) for doxepin subjects. Although on the average
diazepam subjects remained in treatment over a week longer than
doxepin subjects, this difference is not statistically significant
due to large within-group variability. Results for the remaining
dependent measures are based on 8 out of the 10 diazepam subjects
and 9 out of the 13 doxepin subjects who remained at the clinic
for at least 9 weeks and entered the chronic dosing phase of the
study.
Clinic attendance was similar in the two medication groups during
the baseline and acute dosing phases of the study. During weeks 2
through 8, subjects in both groups missed 10% or less of their
clinic visits. During the chronic dosing phase of the detox. the
rate of missed clinic days increased in both groups; however, the
"no show" rate was lower for diazepam subjects (13%) than for
doxepin subjects (22%).
During both phases of the study, subjects in the diazepam group
193
FIG. 1. Percentage of opiate-positive EMIT urine tests
for doxepin and diazepam subjects during successive weeks
in the detox. Data points represent the total number of
opiate-positive specimens provided during each week divid-
ed by the total number of specimens possible (N X 3).
Specimens missing as a result of subjects’ not attending
the clinic were treated as opiate-positive results. The
broken lines following weeks 4 and 8 represent the intro-
duction of the acute and chronic dosing periods for ad-
junct medications.
were more likely to refuse their capsules than were subjects in
the doxepin group. Subjects in the doxepin group refused only
three capsules out of all the occasions on which they were avail-
able. In contrast, subjects in the diazepam group refused approxi-
mately 20% of available capsules during the acute dosing phase of
the detox and 13% during the chronic dosing phase.
The percentage of opiate-positive specimens for each treatment
group throughout the detox is presented in figure 1. Less than
25% of specimens were opiate-positive during baseline weeks 2 - 4.
Starting in week 5 at the introduction of the adjunct medications,
rates of opiate-positive specimens diverged for the two treatment
groups. During the acute dosing phase, the mean rate of opiate-
positive test results was 46% for doxepin subjects and 28% for
diazepam subjects. Rates of supplemental opiate use increased for
both groups during the chronic dosing phase of the study when the
methadone dose had reached Omg; however, this increase was more
dramatic in the doxepin group than in the diazepam group. The
mean percentage of opiate-positive specimens increased to 63% for
the doxepin group and to 37% for the diazepam group. The overall
increase in the opiate-positive rate for diazepam subjects was in
large part accounted for by the single-week increase in week 11 of
the detox.
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Withdrawal symptoms were measured using a 20-item self-report
questionnaire on which each symptom was rated on a lo-point scale
of increasing severity. Each subject's average symptom score
during weeks 2 through 4 was subtracted from his mean symptom
score during subsequent weeks to yield a difference-from-baseline
symptom score for each subject during weeks 5 through 13 of the
detox. These difference-from-baseline scores were averaged across
subjects within each treatment group to provide a weekly mean
difference-from-baseline symptom score for each medication group.
There was a difference between the two medication groups in the
patterning of symptomatology scores during both the acute and
chronic phases of the study. Doxepin subjects reported no change
from baseline in symptom scores during the 4-week acute dosing
period; symptom scores then steadily increased during the chronic
dosing phase when the methadone dose had reached 0mg. In con-
trast, diazepam subjects showed an immediate increase in symptoms
at the start of the acute dosing period; however, symptom scores
then remained relatively stable throughout the remainder of the
detox.
DISCUSSION
Subjects assigned to the diazepam treatment group were more likely
to complete detoxification treatment, attended the clinic more
regularly and had fewer opiate-positive urine specimens than sub-
jects assigned to receive doxepin during the detox. It is inter-
esting that the diazepam group had a generally improved outcome in
comparison to the doxepin subjects on several clinical indicators
of treatment success despite their higher capsule refusal rate and
their more rapid onset of withdrawal symptomatology complaints.
The high drop-out rate for doxepin subjects has made systematic
comparison of the two groups difficult during the final two weeks
of the detox. This comparison is of particular interest for the
percentage of opiate-positive urine tests since the outcomes di-
verge most dramatically during the final weeks of treatment when
methadone has been discontinued at the clinic. In earlier re-
search at this clinic using a similar methadone detoxification
protocol (McCaul et al. 1984). approximately 75% of specimens have
been opiate positive during the last 2 to 3 weeks of the detox;
this historical rate of opiate-positive specimens is appreciably
above the diazepam group rate at the end of the current detoxifi-
cation protocol.
The results of the present study indicate that diazepam admin-
istration during outpatient opiate detoxification may improve
treatment outcome on several clinically important variables.
Furthermore, experiences of the nursing and clinical staffs during
this research suggest that adjunct medication administration can
be well controlled in an outpatient setting with relatively few
complaints of untoward incidents resulting from the study medica-
tion and relatively low risk of medication diversion by the study
participants.
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Effects of a Dose Increase on
Chronic Opiate Use During
Methadone Detoxification
Maxine L. Stitzer; Mary E. McCaul; George E. Bigelow; and
Ira A. Liebson
The purpose of the present study was to evaluate the effects on
illicit opiate drug use and treatment retention of administering
high methadone doses during detoxification treatment to chronic
opiate supplementers. The rationale for this treatment approach
was based on previous reports which indicated that higher metha-
done doses are associated with less illicit opiate drug use during
maintenance treatment (Gossop et al. 1992; Ling et al. 1976;
McGlothlin and Anglin 1981) and on a previous uncontrolled study
with chronic opiate supplementers which showed that opiate posi-
tive urine samples were reduced following a 20 mg blind dose
Increase (Stitzer et al. 1984). In the present study we planned
to expose patients to methadone doses which would provide an
adequate blochade of opiate drug effects while suppressing the
withdrawal symptoms which might result from cessation of illicit
drug use.
METHODS
Twenty-six male opiate-dependent subjects participated. Their
average age was 29 years and they had been continuously addicted
to opiates for an average of about eight years. Racial composi-
tion was 43 percent black and 57 percent white. Half (54%) of the
subjects had been previously enrolled in methadone detoxification
or maintenance programs, while half were new to methadone treat-
ment. These subjects represent 25 percent of the 104 admissions
to outpatient detoxification which occurred between January 1982
and August 1983 at the Behavioral Pharmacology Research Unit.
Subjects selected for the present study showed more than 50 per-
cent opiate-positive urinalysis test results during treatment
weeks 2 and 3 when all detox patients were maintained on a stable
methadone dose. Patients with 50 percent or fewer opiate positive
urinalysis tests participated concurrently in other detoxification
studies.
Procedure
Subjects were enrolled in a 90-day (13-week) outpatient detoxifi-
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cation treatment program. Methadone dose was initially stabilized
at 30 mg/day during treatment weeks 1 - 3. At the end of week 3,
patients width more than 50 percent opiate-positive urine tests
were randomly assigned to one of two blind dosing regimens. As
shown in Table 1, subjects in the control group received 30 mg/day
methadone from week 4 through week 10 of the detox; the dose was
then reduced in 10 mg steps at the start of weeks 11, 12, and 13.
Methadone dose in the experimental group was increased to 60 mg/day
during study weeks 4 and 5. This dose was then lowered by 10 mg
steps at the start of study weeks 6, 8, 10, 11, and 12. Thus,
experimental subjects received doses at or above the original
stabilization dose throughout week 10 of the 13-week detox.
TABLE 1. Methadone Dosing Schedules
Treatment Week
1
2
3
4
5
6
7
8
9
10
11
12
13
Methadone Dose (mg)
Experimental
30
30
30
60
60
5 0
50
30
40
30
30
10
0
Control
3 0
3 0
3 0
30
3 0
30
30
30
30
30
20
10
0
Subjects ingested methadone daily in a cherry syrup vehicle under
nursing supervision. Doses were prepoured and delivered under
single-blind conditions. Clinic attendance was not mandatory, but
missed clinic visits resulted in missed medication opportunities.
Urine samples were collected three times weekly (Monday, Wednesday,
Friday) and analyzed for opiates using an on-site EMIT system
(Syva Corp.).
Measures
No treatment outcome measures were analyzed: 1) Treatment re-
tention. Patients were terminated from treatment after missing
three consecutive medication opportunities. The number of treat-
ment days prior to termination provided the measure of treatment
retention. 2) Opiate-positive urines. Percent of thrice weekly
urine tests which were positive for opiate drugs on the EMIT sys-
tem was determined for each treatment group during successive
two week study periods. Missing samples were counted as opiate
positive.
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RESULTS
Treatment Retention
Substantial between-group differences in treatment retention are
reflected in median durations of enrollment which were 80 days
(I.Q. range = 50 - 90 days) and 41 days (I.Q. range = 28-86
days) for the experimental dose increase [N = 13) and control
(N = 15) groups, respectively. This difference was not signifi-
cant in a Maim-Whitney U Test. Average treatment retention was
68.3 days (SEM =6.8 days) for the experimental group and 53."
days (SEM = 7.0 days) for the control group. The between-group
difference for average treatment days was also not significant
(t = 1.4-1, df = 24, n.s.).
Opiate-Positive Urines
Urinalalysis data were analyzed for the 11 experimental and 10 con-
trol subjects who remained in treatment through stud', week 5.
During dose stabilization, experimental and control subjects
averaged 80 percent and 87 percent opiate-positive urine tests,
respectively. During study weeks 4 and 5, when experimental sub-
jects were receiving 60 mg/day methadone and where the impact of
the dose increase treatment was expected to be greatest, the
percent of positive urine tests for the control group was unchanged
(83% positive) while the percent of positive tests for the experi-
mental dose increase group dropped to 62 percent. Although the
between-group difference in number of opiate-positive tests was
not significant in an analysis of covariance (t = 1.9, df = 1,19,
p < 0.20), the experimental group did show a marginally signifi-
cant decrease from their own baseline in opiate-positive mine
tests (correlated t = 2.59, df = 10, p < 0.05).
Examination of individual subject data revealed that the treatment
effect was primarily due to two experimental subjects who reduced
their opiate-positive sample rate by more than 50 percent follow-
ing the dose increase; none of the control subjects showed re-
ductions of this magnitude. Overall, 6 of 11 experimental sub-
jects (55%) and 5 of 10 control subjects (30%) delivered fewer
opiate-positive urine samples during the two 60 mg dose increase
weeks than during the preceding two dose stabilization weeks.
Five control and seven experimental subjects remained in treatment
for 10 weeks or longer. This subgroup showed 75 - 80 percent
opiate-positive urine tests during initial dose stabilization
(weeks 2 and 3). Control subjects continued to deliver about
70 percent positive urine specimens throughout the 15 week treat-
ment program, for the experimental dose increase group, opiate-
positive tests decreased to 60 percent during study weeks 4 and 5
when their methadone dose was 60 mg/day, decreased further to 50
percent during weeks 6 and 7 when the methadone dose was 50 mg/dav
and then remained at about 50 percent through study week 11, at
which time the methadone dose had decreased to 20 mg/day. Percent
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opiate-positive tests rapidly increased for this group during the
last two study weeks when the methadone Jose was 10 mg or less,
returning to the high levels observed during the initial dose
stabilization portion of the study. Five of the seven experi-
mental subjects who remained in treatment through week 10 showed
a decrease in urine positive tests during this time. Specifically,
these subjects reduced their opiate-positive urine test rate by at
least 40 percent from their own baseline rate and maintained the
reduction for at least Tour weeks during the intervention.
DISCUSSION
This study showed that raising the methadone dose to levels
characteristic of maintenance treatment (50 - 60 mg/day) during
the early weeks of a detox program resulted in improved treatment
retention and decreased rates of opiate-positive urine test re-
sults in chronic opiate supplementers. Subjects in the experi-
mental dose increase group remained in treatment for about two
weeks longer on the average than did control subjects, while
median treatment retention was twice as long for the experimental
dose increase group (86 days) as for the control group (41 days),
but neither difference was statistically significant due to within
group variability. Since methadone appears to be a reinforcing
drug for treatment patients (McCaul et al. 1982; Stitzer et al.
1983), longer treatment retention would be predicted for subjects
who receive more methadone.
Opiate-positive tests were reduced by approximately 20 percent
from control levels during the first two weeks of the dose in-
crease treatment and the effect persisted throughout a substantial
portion of the detox in a subgroup of patients who remained in
treatment for 10 weeks or longer. These results are consistent
with those from a previous uncontrolled study with chronic opiate
users (Stitzer et al. 1984) in which dose was raised from 30 mg
to 50 mg per day for two weeks during the initial phase of detox
treatment and also consistent with differences in opiate-positive
urine rates reported for maintenance patients on higher versus
lower doses of methadone (McGlothlin and Anglin 1981).
Although the dose increase procedure had a noticeable impact on
opiate-positive rates, the clinical importance of the reductions
noted is questionable. The effect was small in magnitude and
inconsistent across subjects. For example, only two subjects
showed a substantial initial reduction in opiate-positive rates
following the dose increase and only five of the original thirteen
subjects benefitted at any point. More importantly, the experi-
mental subjects as a group were delivering 50 - 60 percent opiate-
positive urines throughout the detox. It can be argued that this
positive urine test rate still represents a substantial amount of
continuing illicit opiate use. Thus, it appears that a substan-
tial methadone dose increase given in the context of detoxifica-
tion treatment does not have a sufficiently large effect on
illicit opiate use of chronic opiate supplementers to be by itself
a clinically useful procedure.
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Assessment and Extinction of
Conditioned Withdrawal-Like
Responses in an Integrated
Treatment for Opiate Dependence
Anna Rose Childress; A. Thomas McLellan; and
Charles P. O’Brien
INTRODUCTION
Wikler's (1948) original observations of opiate withdrawal-like
responses in drug-free patients have stimulated almost four
decades of research on opiates and Pavlovian conditioning
processes (O'Brien et al. 1983). The results of this work
indicate that conditioned withdrawal-like and opiate-like
responses occur in both animals and humans (Eikelboom and Stewart
1979; Grabowski and O'Brien 1980). Addict patients often
experience drug craving and/or withdrawal-like changes in skin
temperature, pupillary dilation, etc., in response to drug
related slides, videotapes (Teasdale 1973; Sideroff and Jarvik
1980) or cook-up paraphernalia (Ternes et al. 1979). Cur own
research has demonstrated that opiate withdrawal-like responses in
humans can be conditioned to an arbitrary conditioned stimulus
(O'Brien et al. 1977).
Prom this accumulated evidence it seems clear that conditioned
withdrawal-like phenomena exist, but their actual incidence and
clinical importance remain controversial. Wikler (1948) felt
that Conditioned withdrawal-like responses constituted a common
'disease de novo' in opiate addicts, and a primary cause of
relapse. This view has been challenged by recent interview data
(McAuliffe 1982) suggesting that conditioned withdrawal-like
phenomena are relatively uncommon and seldom lead to opiate
use/relapse.
Our research center (O'Brien et al. 1983) is currently develop-
a set of procedures 1) to determine the actual incidence of
conditioned withdrawal-like phenomena in opiate-dependent
patients, 2) to attempt extinction of these responses, and 3) to
examine their postulated role in clinical outcome, include
relapse (Wikler 1948). At the previous Proceedings (Childress
et al. 1983) we reported preliminary results of our attempts to
measure and to extinguish conditioned withdrawal-like responses
in several pilot patients. The current paper updates those
findings and discusses several methodological changes which we feel
will permit more accurate assessment of these responses, more
effective extinction, and thus, a more meaningful evaluation of
their contribution to clinical outcome in our patients.
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METHODOLOGY
Design Considerations - In our initial attempt to elicit and to
extinguish conditioned withdrawal-like responses (O'Brien et al.
1979) we asked patients maintained on an opiate antagonist
(Naltrexone) to undergo double blind cook-up and unreinforced
self-injection rituals. Opiate administration was either omitted
(saline trials) or pharmacologically blocked due to the antagonist
treatment. Though cook-up and self-injection stimuli were potent
elicitors of withdrawal-like responses, the procedure itself
produced such strong dysphoria, withdrawal and craving that most
patients refused to participate after only a few trials. Even
though no subject completed extinction, there was some suggestion
that patients who completed more trials had somewhat better
outcomes at six-month follow-up than other non-extinction
Naltrexone patients (O'Brien et al. 1979).
For our next extinction attempt (the current protocol) we tried to
modify the earlier procedure in ways that should increase patient
comfort and compliance: 1) patients were given early trials with
series of drug-related stimuli as a prelude to the highly
evocative cook-up and self-injection ritual; T) each extinction
trial was followed by 15 minutes of deep relaxation training to
allow the patient to 'wind down' from any discomfort or craving
triggered by exposure to the drug related stimuli.
As another consideration, we recognized that an extinction
procedure-even if well-tolerated by patients--would address only
the conditioned factors of their disorder. If the significant
psychological, social and vocational components of addiction
were left untreated, the possible clinical benefits of the
extinction could be overshadowed and perhaps not even measurable.
With this in mind, we decided to integrate our laboratory-derived
extinction procedure with professional psychotherapy, a clinical
treatment which would address the non-conditioned features of the
addiction and which had previously produced pervasive therapeutic
benefits for our clinical population (Woody et al. 1981).
Subjects - The subjects for this ongoing study are male veteran
methadone patients from the Drug Dependence Treatment Unit of the
Philadelphia Veterans Administration Medical Center. Patient
volunteers are recruited through. direct contact or referral from
their drug counselor. All patients are clinically screened to
rule out diagnosis of major thought disorder (schizophrenia) or
organic brain syndrome. Patients who are diagnosed as having
only anti-social personality disorder (In addition to their drug
dependence diagnoses) are also screened from the study, since
such patients were previously found unresponsive to psychotherapy
(Woody et al. 1981).
Procedure - Patients eligible for the Study are randomly assigned
to one of three treatment groups. The clinical outcome of patients
receiving cognitive-behavioral psychotherapy, extinction, and
relaxation (CE group) will be compared against two control groups:
one group receiving therapy and relaxation, but no extinction (CT
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group), and a standard treatment control group which receives
extra drug counseling and educational/control materials (DC
group). Professional attention, session length, and small
payments contingent upon session attendence are equivalent for all
treatment groups.
Laboratory Measurement of Conditioned Withdrawal-Like Responses -
Prior to treatment, at the end of treatment, and at 1 and 6 month
follow-up points, each patient's conditioned withdrawal-like
responses are assessed in laboratory measurement sessions. All
laboratory sessions are conducted in an environmentally-
controlled, electrically-shielded recording chamber. Physio-
logical measures include skin temperature, galvanic skin
resistance (GSR, a general arousal index), heart rate, respiration
and blood pressure. These physiological measures (except blood
pressure) are continuously recorded on a polygraph and then
converted to computer storage for later analysis.
In addition to the physiological measures, patients are asked to
rate the degree of subjective high, craving or withdrawal they
experience in response to test stimuli.
Both physiologica1 and subjecttve responses are measured under two
types of stimulus conditions: Neutral and Drug-Related
patient experiences both conditions, acting as his own control.
For either stimulus condition, the following sequence obtains;
lasting approximately one hour: 1) Resting Baseline; 2) Video-
tape (Neutral or Drug-Related); 3) Baseline; 4) Activity (Neutral
or Drug-Related); and 5) Baseline.
The neutral videotape features a nature story, the neutral (the
drug-related) activity allows patients to play a computerized
"pong" game. The drug-relatedvideotape features a cook-up-shoot-
up ritual; the drug-related activity requires patients to go
through a mock cook-up and tie-off, with optional self-injection
of saline. Previous research in our center has shown pre-
injection (drug preparation and cook-up) stimuli to be powerful
elicitors of conditioned withdrawal-like responses (Ternes et al.
1979).
Extinction - Each hour-long treatment session for patients in the
extinction group begins with 30 minutes Of psychotherapv, followed
by approximately 10 minutes of exposure to extinction stimuli.
Each session ends with 15-20 minutes of relaxation, guided by
audio cassette. Extinction stimuli include self-produced verbal
imagery ("drug stories"), audiotapes of drug talk, color slides of
cook-up-shoot-up rituals, videotapes of drug purchase, cook-up and
injection, and finally,
cook-up/tie-off procedure.
handling of drug objects in a mock
With exception of the self-produced
'drug-stories', extinction stimuli are not individualized, but are
the sane for all patients. Saline self-injection, the final
member of the extinction series, is encouraged but optional. For
each patient, the ordering of extinction stimuli across sessions
is the same, and we employ a fixed trials procedure which
determines the number of exposures to each stimulus category.
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Data for the extinction trials is currently based on the Within-
Session Rating Scale (1982), a quantified subjective report
listing 24 withdrawal-like and 24 high-like symptoms. The WSRS
is administered before and immediately after exposure to the
extinction stimuli. We have begun to record skin temperature
during treatment sessions, which will allow us even
the course of extinction across sessions and to compare subjective
with physiological responses.
Extinction sessions for outpatient subjects are conducted three
times weekly, with 32 sessions comprising a complete course of
treatment. We have also begun the same study with inpatients
undergoing gradual methadone detoxification over a four-week
period. For these inpatients, extinction trials are conducted
five times weekly, for a total of 22 treatment sessions.
Daily methadone is administered immediately after measurement or
extinction sessions so that its onset effects will not interfere
with physiological or subjective measures.
Clinical Outcome Measures - Prior to treatment, at the end of
treatment and at 1 and 6 month follow-up points, each patient is
given a series of inventories to assess clinical status,
psychiatric complaints, drug use and problems associated with the
drug use. The following clinical measures are used: 1) Addiction
Severity Index (McLellan et al. 1978); (2) Beck Depression
Inventory (Beck and Beck 1972); (3) Hopkins Symptom Check List-90
(Derogatis et al. 1974). These instruments and their use as out-
come measures is more fully described elsewhere (Woody et al.
1981).
RESULTS
Pre-treatment Laboratory Measurements - Data from the pretreatment
Laboratory sessions is based primarily on 25 additional patients
who have entered treatment since our initial report (Childress
et al. 1983).
Physiological - In measurement sessions, patients continue to
respond to drug-related stimuli with a variety of physiological
responses, including, an increase in arousal (a decrease in GSR)
and transient, non-specific changes in heart rate and respiration..
A Kline-linked decrease in skin temperature - has remained the most
reliable and specific index of a conditioned withdrawal-like
response. Analyses of variance performed on the group data
(n = 25) showed an overall statistically significant effect.
(p < .001) of interval (neutral vs. drug-related stimuli) upon
skin temperature. The overall average decrease in skin
temperature to drug related stimuli is approximately 4°F. As
before, about a third of our patients, "responders," show marked
decreases in skin temperature (often eater than the 4°
average) which seem specific to drug-relate stimuli.
Similar to our preliminary findings, approximately one third of
our recent patients are 'non-responders'--they show little or no
temperature reduction to standardized drug-related stimuli in the
laboratory setting. The remaining patients are more difficult to
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characterize, but several fall into the category of 'non-specific
arousers', showing mild arousal patterns to both neutral and drug-
related activities, but no differential response in skin
temperature or the other physiological measures.
me standard drug stimuli, and 207. report actual subjective with-
Subjective - About 50% of the patients report Increased craving to
drawal . These figures are similar to our pilot data, but somewhat
higher. There is a modest positive correlation (r = .25) between
subjective reports of craving and reports of withdrawal. Only a
few patients (8%) report increased subjective high to drug-related
stimuli during pretreatment laboratory testing.
Though subjective craving is modestly correlated with skin
temperature (physiological change) (r =.23), subjective withdrawal
is not wall correlated with skin temperature change (r = -.06,
not sig.).
Extinction - Of 16 patients randomly assigned to the Extinction
(CE) group, 8 completed 20 or more extinction trials. The
extinction data presented here are based on these 'treatment
completers'.
Subjective Craving - As shown in Figure 1, patients in the
extinction (CE) treatment group show an initial increase in
craving (following presentation of drug-related stimuli) which
tends to diminish with repeated extinction sessions. The overall
reduction in craving in the extinction group across sessions is
statistically significant (p < .001). The amount of craving
experienced by the extinction patients is significantly greater
(p < .001) than that reported by patients in the other treatment
groups who are not exposed to drug-related stimuli (see DC control
group in Figure 1) .
Subjective Withdrawal - Patients in the extinction sessions
experience a significant increase ( p < .001) in subjective with-
drawal-like symptoms to the drug-related stimulus presentations,
and they experience significantly more withdrawal-like symptoms
than patients in treatment groups who do not receive exposure to
drug-related stimuli. Withdrawal-like symptoms are relatively
persistent in sane patients, particularly those who occasionally
give themselves 'conditioning' trials with illicit opiates. There
is no significant overall reduction in withdrawal symptoms over
trials, though about half of our 'responders' do show relatively
complete extinction of subjective withdrawal-like symptoms within
the allotted treatment sessions.
With use of less evocative stimuli as a prelude to cook-up trials,
patients have been able to tolerate the procedures quite well and
none left the study due to withdrawal discomfort..
Subjective High - Extinction patients  occasionally report an
increase in subjective high in response to drug-related stimuli,.
but there is no statistically significant pattern among treatment
group or across trials.
206
FIGURE 1. Reduction in craving co drug-related stimuli
as a function of repeated exposures across
sessions in patients given extinction (CE).
Note reemergence of craving when cook-up
rituals are begun, in session 16.
Post-treatment Laboratory Testing
Physiological - Taken as a group, the extinction patients show
moderate attenuation of the initial skin temperature response
following extinction (6°F Decrease pre-treatment, 2°F
decrease post treatment). Patients in the control groups do not
exhibit any systematic change in the-temperature response.
Subjective - Craving is reduced to 0 in 80% of the extinction
patients, suggestive of extinction. This pattern is not seen in
the therapy-but-no-extinction comparison group.
Clinical Outcome - Based on analyses of variance performed on
data from the ASI and psychiatric rating scales, all treatment
groups are showing improvements at 6 month follow-up points, but
improvement is greater in the two groups receiving professional
psychotherapy. The pattern of improvements in the two therapy
groups (decreased psychiatric symptoms, etc.) is similar to that
found in our previous studies of psychotherapy with opiate-
dependent patients (Woody et al. 1981), but less pronounced. At
this juncture there is no significant difference in outcome
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between patients receiving psychotherapy and extinction versus
those receiving therapy and control activities, but no extinction.
As discussed below, this result probably says less about the
benefits of extinction than about the difficulties of developing
an effective extinction procedure and of choosing an appropriate
design in which to test for its effects.
SUMMARY AND COMMENTS
Recent data have generally been consistent with our pilot
findings: a significant proportion--33 to 40%--of opiate-
dependent patients show a time-linked decrease In skin-temperature
in response to standard drug-related stimuli, suggestive of
conditioned withdrawal. Patients' physiological changes are often
accompanied by subjective craving and withdrawal, but the
correlation among these measures is modest. Though craving seems
to diminish with repeated exposure to drug-related stimuli, with-
drawal-like symptoms are often persistent and slow to extinguish.
Our current design initially assumed that most patients would show
conditioned craving and withdrawal to our standard stimuli and
that our current procedure would be adequate to produce complete
extinction for these 'responders.' As It turned out, not all
patients respond to our standard stimuli, and our extinction
procedure Is not completely effective for those who do. Given
these two findings, our current design does not permit the best
test of the potential clinical benefits of extinction.
Our rich experience during the first phase of this project has
stimulated several procedural changes which should increase our
accuracy in determining the incidence of these conditioned
better assessment of their potential clinical benefit. These are
phenonena, our effectiveness In extinguishing them, and permit a
as follows:
1) Individualize eliciting (drug-related) stimuli - We Initially
chose to use standard (the same for all patients) stimuli for
practical and experimental reasons. However, their use may have
resulted In an underestimate of the incidence of conditioned
craving and withdrawal, and in less relevant extinction for many
patients. Our experience now suggests that some of the most
powerful conditioned stimuli may be individualistic - e.g., a
patient may experience extreme craving at the sight of a paycheck
stub. In the next phase of our study, the patient and therapist
will select a group of Individualized drug-related stimuli and
Incorporate them Into the extinction series.
Earlier in the project we briefly considered a design change that
would pre-select 'responders' to standard stimuli and then assign
them to the current treatment groups, Including extinction.
However, this approach would fail to address - or even discover -
conditioned craving and withdrawal which may be elicited by
individualized stimuli.
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2) Incorporate mood-related stimuli - In the course of our study
we observed that many apparent 'non-respenders' may exhibit
craving or conditioned withdrawal-like symptoms in response to
drug stimuli if they are tested In a certain emotional state
(i.e. anxiety, depression, etc.). We now suspect that, for sane
patients, mood states may have become an integral part of the
conditioned stimulus complex which elicits craving/withdrawal
(Poulos et al. 1981), and that drug-related stimuli alone are
sometimes insufficient to elicit the complete conditioned
response. Effective extinction might necessitate trials
administered while the patient is in problematic mood states
(perhaps induced by suggestion) which help trigger craving/
withdrawal.
3) Increase the number of extinction sessions to allow for
relatively complete extinction. A trials-to-criteria format may
be useful If individual variability Is too great to permit a
fixed trials procedure.
4) Assess the Impact of adding extinction to drug counseling, not
Just psychotherapy. Under the possibility that extinction can add
measurable benefits to the treatment of the opiate-dependent
patient, it would be important to develop this procedure in a way
that can be used in a number of standard treatment settings.
5) Employ an abstinent patient population - Since the presence of
methadone (or any opiate) can attenuate the expression of
conditioned withdrawal-like responses, It would be very
informative to assess and to attempt extinction of these responses
In a drug-free population. Though drug-free patients are usually
difficult to retain in treatment, this population offers the most
appropriate opportunity for determining the contribution of
conditioned responses to relapse from an abstinent state.
With these procedural modifications, we  anticipate a fuller under-
standing of the nature of conditioned craving and withdrawal and
a better assessment of the role of these responses In opiate use
and relapse.
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Benzodiazepine Dependence of
Several Years Duration: Clinical
Profile and Therapeutic Benefits
Forest S. Tennant, Jr., and Edward A. Pumphrey
ABSTRACT
Twenty-two (22) patients with long-term benzodiazepine dependence
ranging from 3.5 to 13 years (Mean 7.4 years) were referred to us
for evaluation and treatment. Daily dosages ranged from 10 to 100
mg (Mean 43.8 mg) of diazepam or its equivalent. Psychiatric
diagnosis by DSM-III criteria revealed that 13 (59.1%) had schizo-
phrenic disorder; 7 (48%) had generalized anxiety disorder, and 2
(9.1%) had manic depression. Only one patient could be totally
withdrawn and remain abstinent from benzodiazepines without
substituting another psychotherapeutic drug. Benzodiazepine
dependence appeared therapeutic in the majority of these patients
since psychotic symptoms, anxiety, or alcohol abuse were reduced.
Based on these observations and other studies, we suggest that
long-term benzodiazepine dependence should not always be discontin-
ued, since the patient may have severe underlying psychiatric and
medical illnesses that are therapeutically well controlled.
INTRODUCTION
Benzodiazepine dependence has been recognized in recent years.1-3
There is, however, considerable uncertainty as to why this condi-
tion occurs and how it should be clinically managed. Some recent
reports suggest that select patients therapeutically benefit from
long-term dependence upon benzodiazepines, while others show that
there may be an abuse problem among populations who misuse a
variety of other drugs and alcohol.4-10 Most reported cases of
benzodiazepine dependence have occurred with high, daily dosages,
although some reported cases have taken doses at or near normal
therapeutic dosage ranges.11,12  Another area of uncertainty has
been whether symptoms observed after cessation of dependence al-
ways represent true withdrawal symptoms, or a recurrence or
exacerbation of symptoms that existed prior to initiation of
use.2,4 Reported here is a study of 22 consecutive patients who
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were referred to us with benzodiazepine dependence of 3.5 to 13
years duration. These patients were evaluated to identify underly-
ing psychiatric and medical conditions. Attempts were made to
withdraw some patients, and all were followed for periods ranging
from 6 to 24 months to assess outcome. Observations of these
patients suggest etiologic reasons for long-term benzodiazepine
dependence and provide some guidelines for clinical management of
this condition.
METHODS
Each patient was given a complete physical examination, health
questionnaire, drug history, and a psychiatric assessment based on
the Diagnostic Statistical Manual of the American Psychiatric
Association, 3rd Edition (DSM-III). Specific inquiry was made as
to previous psychiatric treatments, attempts to withdraw from
benzodiazepines, alcohol abuse, reasons for beginning benzodiaze-
pine use, and whether the patient wanted to attempt withdrawal.
Whenever possible, previous medical records were obtained for
review and family members were interviewed. A urine sample was
collected and analyzed by immunoassay to document that benzodiaze-
pines were being used, and an alcohol breath test, was done on each
patient.13 Patients who desired to withdraw were administered
propanolol, phenobarbital, and/or hydroxyzine over a period of 30
days in a manner described in other studies, or they entered into
a schedule of progressive, declining dosages of benzodiaze-
pines.8,14,15 Patients who did not desire to withdraw were
maintained with their benzodiazepine of choice after they signed a
written consent form which described the risks and benefits of
long-term dependence. During the first 30 days of evaluation and
treatment,, patients were seen. two to five times per week for the
purposes of medication adjustment and assessment of psychiatric
status. After this period, each patient was followed at least
every 30 to 90 days by telephone communication, regular clinic
visits, and/or consultation with the referring physician. In
those patients who totally withdrew, various psychotherapeutic
medications were administered depending on which specific
psychiatric symptoms were present.
documented by urine test analysis.13
Benzodiazepine abstinence was
RESULTS
This group of patients presented a clear profile of significant
psychiatric and medical disease, as well as social difficulties.
(Tables 1,2) Only 5 (22.8%) were employed and 7 (31.8%) were
married. Medical records, self-report history, and/or family
interviews documented that the majority had experienced previous
psychiatric hospitalization (14; 63.6%) and psychotic episodes
(13; 59.1%). Previous alcohol abuse and suicide attempts were
reported by 7 (31.8%) and 6 (27.3%), respectively. Patients in
some cases had a poor recollection and/or understanding as to why
they originally started benzodiazepines, and the following were
212
given as reasons: "nervous", 7 (31.8%); "stress", 4 (18.2%);
"nervous breakdown", 3 (13.6%)) "help cope", 3 (13.6%); medical
problem, 3 (13.6%); and unknown, 2 (9.1%). The three benzodiaze-
pines used in descending order of frequency were diazepam, lorazepam,
and chlordiazepoxide (Table Three). Diazepam dosages ranged from
10 to 100 mg per 24 hours (Mean 43.8; SD 29.1). Patients reported
using benzodiazepines from 3.5 to 13 years (Mean 7.4; SD 3.72).
The longest period of abstinence within the overall period of use
which was reported by a patient was six months. Current use of
benzodiazepines was confirmed in all patients by urine testing.
All patients had previously attempted to totally withdraw only to
resume use following discharge. Twelve (12; 54.5%) desired to
withdraw at the time of our initial evaluation. Review of medical
records and interviews of patients and family members indicated
that the following psychiatric illnesses were present by DMS III
criteria: schizophrenic disorder 13 (59.1%); generalized anxiety
7 (31.8%); and manic-depression 2 (9.18%) (Table Two). Patients
had a wide variety of medical conditions and were taking a variety
of therapeutic agents. Four (18.2%) indicated that they were
currently abusing alcohol. Of the 12 patients who attempted
withdrawal, three (3; 25.0%) desired to restart benzodiazepines
within 10 days (Table Four). Six of the nine (66.7%) who withdrew
developed psychotic symptoms, and three required hospitalization
to control hallucinations and/or delusions. Three of these six
did not develop psychotic symptoms until they were abstinent 30
days or more. Eight of the nine (88.9%) who completely withdrew
required, within 90 days, administration of an antidepressant or
antipsychotic agent, or the reinstitution of a benzodiazepine to
control symptoms.
DISCUSSION
The clinical profile of patients studied here exhibits a variety
of many serious psychiatric and medical conditions. There was no
support found for the sometimes popular notion that normal,
healthy individuals become dependent on benzodiazepines.16-18
Found among these patients were long histories of psychotic
illness, suicide attempts, psychiatric hospitalization, alcoholism,
medical conditions, and social instability as evidenced by a
relative lack of marriage stability and employment. A high
percentage of these patients (10 of 22; 45.5%) did not desire to
even attempt withdrawal because they believed that benzodiazepines
were essential for adequate mental and social function. A recent
study shows that normal adults, when given diazepam and placebo
under blind conditions, prefer placebo.19 Epidemiologic surveys
show that less than 2% of persons prescribed a benzodiazepine
continue to use it for more than one year.20 Patients who choose
to take benzodiazepines for very long periods, such as the ones in
this study, should, therefore, be viewed as a special subgroup who
probably have chronic psychiatric illness and who may likely
benefit from benzodiazepine dependence. An important finding in
this group of patients was the large number who had documented
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histories of psychotic illness and who, by clinical evaluation,
met DSM-III criteria for schizophrenic disorder. Six of nine
(66.7%) patients who attempted withdrawal developed psychotic
symptoms within 90 days, and three required hospitalization to
control symptoms. Psychotic symptoms have previously been reported
to occur during benzodiazepine withdrawal and they have generally
been believed to simply be a part of a withdrawal syndrome.22-23
Three of our patients did not develop psychotic symptoms until
after 30 or more days of benzodiazepine abstinence, so it is very
unlikely that their symptoms were related only to a withdrawal
syndrome. It is, therefore, possible that at least some previous
reports of psychosis following benzodiazepine withdrawal represent
recrudescence of an underlying psychiatric disorder, or they are
individuals prone to psychosis that is triggered by withdrawal.
There have been a number of recent studies which show that
benzodiazepines can control psychotic and manic symptoms in many
patients just as they appeared to do in some of our cases.26-30
Benzodiazepines have proven effective enough in schizophrenia that
some are now calling for reassessment of their use in treatment of
this illness.31 Considering the notorious side-effects of
hepatitis, extrapyramidal effects, and tardive dyskinesia which
frequently result from use of phenothiazines and neuroleptics, the
benzodiazepines, with their low incidence of side effects, may be a
preferable alternative for control of schizophrenia and mania in
many patients. Some patients in this study were apparently never
recognized as schizophrenic, but they empirically discovered that
benzodiazepines could control their symptoms. This study and
others on benzodiazepine withdrawal provide some clinical
guidelines for treatment of the patient who has taken
benzodiazepines for a long period. Tyrer and Owen attempted to
withdraw patients who were taking therapeutic doses of diazepam
for three months.15 They found that gradual tapering of the daily
dose over a 12-week period was successful for many patients,
although some patients experienced enough psychiatric symptoms
that withdrawal could not be accomplished. Most patients reported
here took much higher doses of benzodiazepines for several years.
In addition, they appeared to therapeutically benefit since
psychosis, mania, anxiety, and alcohol abuse were reasonably well
controlled. If withdrawal is to be attempted in a patient who has
taken benzodiazepines for a very long period, it should be done
gradually with the realization that continued administration of
benzodiazepines may be therapeutically required to adequately
control underlying psychiatric illness.
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TABLE ONE
DEMOGRAPHIC AND HISTORICAL CHARACTERISTICS
OF PATIENTS WITH LONG-TERM BENZODIAZEPINE DEPENDENCE
N = 22
Female
Male
White
Employed
Married
No. With Previous Psychiatric Hospitalization(s)
No. With Previous Psychotic Episodes
No. Who Have Attempted Suicide(s)
Smoke Cigarettes
Alcohol Abuse in Past
No. Previously Attempted Inpatient Benzodiazepine
No.
15
7
21
5
7
14
13
6
14
7
Withdrawal
No. Desired Withdrawal From Benzodiazepines
6 (27.3%)
12 (54.5%)
TABLE TWO
CLINICAL PROFILE OF
LONG-TERM BENZODIAZEPINE DEPENDENCE PATIENTS
N = 22
Psychiatric Diagnosis by DSM-III Criteria
Schizophrenic Disorder 13 (59.1%)
Generalized Anxiety Disorder 7 (31.8%)
Manic Depression 2 (9.1%)
No. Who Reported Current Alcohol Abuse 4 (18.2%)
No. Who Currently Used Additional Psychotherapeutic 6 (27.3%)
Drugs
No. With a Concurrent Medical Condition
Hypertension
Gastrointestinal Disease
Musculo-Skeletal Disease
Obesity
Dermatologic Disease
Respiratory Disease
5 (22.8%)
5 (22.8%)
4 (18.2%)
2 ( 9.1%)
2 ( 9.1%)
2 ( 9:1%)
No. Who Currently Used Medication(s) For a Medical
Condition 10 (45.4%)
(68.2%)
(31.8%)
(95.5%)
(22.8%)
(31.8%)
(63.6%)
(59.1%)
(27.3%)
(63.6%)
(31.8%)
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TABLE THREE
BENZODIAZEPINE AND DOSAGES USED IN DEPENDENCE
N = 22
Length of Dependence (Range in Years)
Mean Length Dependence (Years)
Drug of Dependence
Diazepam (No.)
Dosage Per Day (Range in mgs)
Mean Dosage Per Day (mgs)
Lorazepam (No.)
Dosage Per Day (Range in mgs)
Mean Dosage Per Day (mgs)
Chlordiazepoxide (No.)
Dosage Per Day (Range in mgs)
Mean Dosage Per Day (mgs)
3.5-13
7.4 (SD 3.7)
16 (72.7%)
10 - 100
43.8 (SD 29.1)
4 (18.2%)
4-30
11.0 (SD 12.7%)
2 (9.1%)
20-100
60 (SD 56.6)
TABLE FOUR
OUTCOMES OF 12 PATIENTS
WHO ATTEMPTED WITHDRAWAL*
No.
-Attempted Withdrawal But Restarted Benzodiazepines
Within 10 days 3 (25.0%)
Completed Withdrawal But Developed Psychotic
Symptoms Within 30 Days 3 (25.0%)
Completed Withdrawal But Developed Psychotic
Symptoms Within 30 to 90 Days 3 (25.0%)
Completed Withdrawal But Developed Anxiety
Symptoms Within 30 to 90 days 3 (25.0%)
Completed Withdrawal But Began Alcohol Abuse
Within 30 Days 3 (25.0%)
Completed Withdrawal But Required Restarting
Benzodiazepines or Other Psychotherapeutic
Drug to Control Psychosis, Anxiety, and/or
Alcoholism 8 (66.7%)
Completed Withdrawal and Not Taking Any
Medications at End of 90 Days 1 ( 8.3%)
* Numbers add to more than 12 since some patients experienced
more than one type of outcome.
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The Addiction Severity Index in
Three Different Populations
A. Thomas McLellan; Lester Luborsky; Charles P. O’Brien;
Harriet L. Barr; and Frederick Evans
INTRODUCTION
During the past ten years, our research group1 has evaluated a
number of different treatments for both alcoholism and drug
addiction. Using a comprehensive evaluation instrument developed
at our center (McLellan et al, 1980), we have concluded "that
alcohol and drug abuse treatments can produce significant,
pervasive and substantial positive changes..." (McLellan et al.,
1982, p. 1427) not only in the target problems of alcohol and drug
use, but in the important ancillary problems of employment,
criminal behavior, and psychiatric symptomatology; i.e., his
"psychiatric severity" based on a structure admission interview
(McLellan et al., 1983. p. 624).
As a test of generality of our earlier conclusions with the male
veterans, the present study was undertaken in three other Centers
selected for diversity of their patient populations, using the same
instruments and procedures developed for our previous studies. We
had previously performed an extensive evaluation of our assessment
instrument (the Addiction Severity Index) in these samples and had
concluded that it was both reliable and valid for general use.
This report will be presented in two parts, each focusing on an
important evaluation issue within the field of substance abuse
treatment:
1. Do patients admitted to these centers show improvement follow-
ing substance abuse treatment? Are these improvements comparable
to those seen in our earlier studies of male veterans?
2. To what extent are the outcomes from these treatments predicta-
ble from pre-treatment information? What type of information is
most predictive among treatment centers and among various segments
of the patient population?
Three treatment centers participated in this research:
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Philadelphia VP Substance Abuse Treatment Unit - offers methadone
maintenance, narcotic antagonist, drug-free outpatient and/or
abstinence-oriented therapeutic community treatment to eligible
male veterans.
Eagleville Hospital and Rehabilitation Center - is located twenty-
five miles from Philadelphia and offers abstinence-oriented thera-
peutic community treatment to alcohol- and drug-abusing patients in
a combined residential setting.
Carrier Clinic - a psychiatric treatment facility located twelve
miles from Princeton, New Jersey; all treatment is inpatient,
abstinence-oriented, therapeutic community.
All three programs offer a number of ancillary support services to
substance abuse patients and are approved by the Joint Commission
on Accreditation of Hospitals.
Subjects - A total of 181 voluntary subjects were recruited from
the three Centers at the time of their admission to treatment.
Fifty-seven male, drug-dependent subjects were recruited from the
Philadelphia VA. Sixty subjects participated from the Carrier
Clinic; 15 female alcohol, 22 male alcohol, 15 female drug and 9
male drug-dependent. Sixty-four, subjects participated from the
Eagleville Rehabilitation Center; 11 female alcohol, 10 male
alcohol, 19 female drug and 19 male drug-dependent.
As indicated above, one major reason for selecting the three
Centers was the diversity of their patient populations. For
example, Eagleville subjects were younger than Philadelphia VA or
Carrier patients (mean ages = 31,33,35 respectively). In addition,
88 and 73 per cent of Carrier and Eagleville patients
(respectively) were white as compared with 42 percent of
Philadelphia VA patients. Forty-two and 53 per cent of
Philadelphia VA and Carrier patients (respectively) had been
married, as compared with only 8 per cent of Eagleville patients.
Carrier patients had an average monthly income from employment of
$1300, 7% received welfare income, and fewer than 10% had been
arrested. In contrast, Philadelphia VA subjects averaged $800 per
month from employment, 39% received welfare income and 57% had been
arrested. The average monthly income for Eagleville patients was
less than $600, 44% received welfare income, and 72% had been
arrested.
In the interest of brevity, only the data for the drug-dependent
patients will be presented here.
Data Collection - Admission evaluations were based on data from the
Addiction Severity Index (ASI). The ASI is a structured,
40-minute, clinical research interview designed to assess problem
severity in seven areas commonly affected in substance abusers:
medical condition, employment, drug use, alcohol use, illegal
activity, family relations, and psychiatric condition.
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Two types of measures result from the collected data in each prob-
lem area. First, the interviewer assimilates the objective and
subjective data to produce a global, ten-point rating of the
severity of each problem area.
The second type of measure available from the data in each ASI
problem area is a mathematically derived composite score developed
from interellated items within each ASI problem area and is similar
to a factor score. An ASI copy with administration manual is
available from the senior author.
Follow-Up Data - All follow-up evaluations were done through ASI
interviews by an independent research technician. six months fol-
lowing treatment admission. Ninety-nine (84%) of the 118 drug-
dependent patients were recontacted and received a follow-up
interview.
STUDY I - EVALUATION OF TREATMENT EFFECTS
As one standard means of assessing treatment effectiveness, we
compared a range of patient status measures from the ASI. at
treatment admission and again at Six-month follow-up. Prior to
performing these comparisons, we divided the Drug Dependent (N=99)
sample into groups based upon treatment center. Admission to
follow-up comparisons were then made using the paired t-test
procedure. The results are presented in Table 1.
There were clear and expected differences in problem severity among
the three patient subgroups at treatment admission, precluding
meaningful between-center comparisons following treatment, although
similar patterns of status change were seen among patients from the
three Centers. For example, all groups showed significant (p < .05
or less) improvements in drug use. psychiatric symptomatology and
family relations. Two of the three groups also showed significant
improvements in employment, alcohol use and illegal involvement.
Only the Carrier Clinic patients showed a significant reduction in
medical problems over the six-month period.
The nature and extent of these changes are most clearly seen in the
data for the combined drug-dependent sample (last two columns).
For example, these patients reduced their days of opiate use by
80%. and showed reductions of 85% in stimulant use, 60% in depres-
sant use and 57% in days of alcohol intoxication. Increases of 83%
and 85% respectively were seen in the number of days employed and
in the income earned, with corresponding decreases of 83% in days
of criminal activity and 90% in illegal income.
STUDY II - PREDICTION OF OUTCOME RESULTS
Given the data from Study I indicating that patients treated in the
three treatment Centers showed substantial and pervasive improve-
ments, it was logical to ask what types of pre-treatment
information might be most related to these improvements. This
question was important to our research group since we had
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previously performed a prediction-of-outcome study in an earlier
sample of male veterans, using the ASI (McLellan et al., 1983).
Thus, we were interested in whether the same types of pre-treatment
information would again be predictive of outcome in a more diverse
patient population and whether the ASI (which had not been used in
this prognostic manner with patients other than male veterans)
would be useful in this context. The subjects and methods of data
collection were those previously described in Study I.
Methods of Data Analysis - We elected to use the stepwise multiple
regression procedure from the BMDP statistical software package.
This procedure sequentially tests categories of independent
(predictor) variables to determine if they are significantly
related to the criterion (outcome) variable, and then extracts that
proportion of explained variation from the criterion variable prior
to testing for further relationships among other predictor
variables. In the present design, we first entered a number of
patient demographic variables including age, race (0=black,
1=white), years of education, number of prior alcohol and drug
abuse treatments, and marital status (single, married/cohabiting,
divorced/separated); followed by our seven, ten-point ASI severity
ratings at treatment admission; followed by the number of days
spent in treatment and type of discharge from treatment
(0=unfavorable, 1=favorable). Thus, the design enabled us to see
whether our ASI measures of pre-treatment status were related to
treatment outcome, after adjusting for the contribution of
demographic differences among the patients.
Our prior work suggested that it would be important to evaluate
several different aspects of patient outcome, and that different
predictors were likely to be more important for different outcome
measures. To overcome the problems in interpreting analyses
derived from seven outcome measures we decided, a priori, to accept
variables as significant predictors only if they reached a signifi-
cant level of p < 01 on three or more of the seven outcome
measures. We had used these procedures in our earlier work and
they had the effect of eliminating spurious relationships, leaving
the-most robust and generalizable.
Results - Table 2 presents the results of the regression analyses
for the drug-dependent patients in each treatment Center. The
actual variables entered into the regression analyses and their
average correlation (r) with all seven outcome measures are pre-
sented under each treatment center. Positive correlations indicate
that higher scores on the predictor variable were related to poorer
status (greater severity) on the outcome measures.
The data indicate considerable similarity in both the nature and
extent of the predictor-criterion relationships for the drug-
dependent samples from the three Centers. There were few important
relationships between the demographic variables and the seven
outcome measures. Fewer previous alcohol and drug treatments, and
being married at the time of treatment admission, were somewhat
related to better post-treatment status in Eagleville patients,
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while no demographic variables were well related to outcome among
Philadelphia drug abuse patients.
With regard to relationships between measures of pre-treatment
problem status and follow-up outcome, the major predictors were the
severity of psychiatric, employment, and legal problems for all
three patient samples. In addition, the during-treatment measures
of treatment length and type of discharge were also significantly
and importantly related to patient status at follow-up. Collec-
tively, the full range of predictors accounted for an average of 32
to 36 per cent of criterion variance across all seven follow-up
measures.
DISCUSSION
Our first study attempted to measure the nature and extent of
changes in drug-dependent patients treated at the Philadelphia VA
Medical Center, the Carrier Clinic, and the Eagleville Hospital,
using the Addiction Severity Index (ASI).
Results of the within-group comparisons indicated significant
improvements in most of the seven criterion areas. The most
significant improvements were shown in the target areas of alcohol
and drug use, but highly significant improvements were also shown
in the areas of employment, family and psychological status. The
patients showed an 80% reduction in opiate use, a 60% reduction in
depressant use, an 83% decrease in crime days, and an 85% increase
in earned income. Fifty-two percent of the patients were drug free
(excepting alcohol and marijuana) during the 30 days preceding
follow-up. Thus, the evidence here and from other studies suggests
that the major improvements following substance abuse treatment are
in alcohol and drug use, but that there are several other areas
that show moderate to major changes. Finally, the nature and
extent of these improvements were quite similar across rather
diverse treatments and patient populations, thus strengthening the
generalizability of this conclusion.
In our second study, we attempted to use the admission data from
the ASI to predict follow-up outcomes in samples from the three
Centers. The results of the predictive analyses were quite similar
among treatment centers, indicating relatively little predictive
value for the majority of demographic variables. However, one of
our aims was to determine the types of information that are poten-
tially related to treatment outcome at the program level, since
this is the point of maximum control and the site at which' the
various interventions are planned and carried out. Thus we con-
clude that at the program level, the typical kinds of demographic
information available to the treatment staff are apparently not
well related to post-treatment outcome, regardless of the type of
treatment center or patient population.
The single best predictor of patients' overall status at follow-up
was the ASI psychiatric severity rating at treatment admission.
This ten-point, global estimate of the number and severity of a
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patient's psychiatric symptoms has been operationally defined in
prior work (McLellan et al., 1983) and has been used extensively as
a predictor of treatment outcome in alcohol, drug, and psychiatric
treatment studies. In addition, the data indicate that the
severity of patients' employment and legal problems at treatment
admission is also a robust and important indication of outcome
following treatment. These results are identical to those reported
in our prior work with male veterans; and very similar to those
shown by Sells and Simpson (1976) in their national study of drug
abuse treatment, and by DeLeon (1984) in his long-term follow-up
work with drug abuse patients in a therapeutic community setting.
Given the results from these two studies and the accumulating
literature which supports them, we conclude, first, that our
original findings regarding the effectiveness of substance abuse
treatments in a male veterans population were essentially repli-
cated and do generalize to other treatments and populations.
Second, we conclude that the usual demographic data and information
regarding the amount, duration and intensity of a patient's sub-
stance abuse problem are often the least useful for planning
treatment strategies, referring to an appropriate treatment modal-
ity, or predicting the overall outcome of treatment. Our findings
here and from other studies indicate information regarding the
pre-treatment psychiatric, employment and legal problems of these
patients is likely to be the most useful in developing the most
appropriate treatments for their alcohol and drug abuse problems.
Regardless of whether they resulted directly from the years of
chemical use, our clinical experience and a wealth of research data
suggest that chemical abuse problems rarely occur without concomi-
tant social, economic and/or psychiatric problems. Treatments that
target the reduction and elimination of the alcohol and/or drug use
without strongly addressing these ancillary problems leave the
recovering patient at significant risk for relapse and progressive
deterioration.
1From the Substance Abuse Treatment Unit of the Philadelphia VAMC,
Philadelphia, PA 19104
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TABLE 1
ADMISSION TO SIX-MONTH FOLLOW-UP COMPARISONS IN
DRUG ABUSE PATIENTS
1Multiple Regression analyses were run on seven outcome criteria. Higher
criterion scores indicated worse status. Boxed values indicate that the
predictor variable was significant (p<.01) on at least three of the seven
outcome criteria (see text for discussion).
223
The 800-COCAINE Helpline:
Survey of 500 Callers
Arnold M. Washton; Mark S. Gold; and A Carter Pottash
ABSTRACT
Five hundred cocaine users who called the 800-COCAINE helpline
received an extensive telephone interview to assess the nature,
extent and consequences of their self-reported cocaine use. The
data revealed a high incidence of dysfunctional cocaine use
associated with numerous physical, psychological, and social
problems. The typical caller was a white, middle-income male
between 25 and 40 years old with no history of drug dependency or
serious psychiatric problems. The findings are discussed with
regard to the high abuse potential of cocaine and other factors
that lead to problematic use and adverse effects.
INTRODUCTION
In response to the recent upsurge in cocaine abuse problems in the
U.S., we established a nationwide telephone helpline, 800-COCAINE,
to provide information, advice, and treatment referral. During
the first year of the helpline's operation over 400,000 calls were
received from across the U.S., sometimes at a rate of over 1,000
per day. Approximately 40% of calls are from cocaine users
themselves: the remainder are from family members, friends or
professionals seeking help or advice for someone with a cocaine
problem.
We have now conducted a survey of 500 cocaine users who called the
helpline and consented to an anonymous telephone interview. The
purpose of the survey was to formulate a demographic profile of
cocaine users and to obtain data on the nature, extent, and
consequences of their cocaine use. With the exception of an
earlier helpline survey (Washton and Tatarsky, 1984) and two
recent studies of patients entering treatment (Helfrich et al. ,
1983; Siegal 1982) there have been virtually no large studies of
problematic cocaine users. The relative absence of such studies
tends to perpetuate the popular belief that cocaine is a
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relatively harmless drug and that patterns of dysfunctional
cocaine use are uncommon.
METHODS
An extensive questionnaire was administered to 500 randomly
selected cocaine users who called 800-COCAINE during May through
July 1983, and consented to an anonymous 30-40 minute telephone
interview. In addition to demographic and drug use data, the
questionnaire included an extensive checklist of yes/no items
concerning drug-related consequences on the user's health and
psychosocial functioning. Most callers had learned of the help-
line through media broadcasts. The largest proportion of calls
(37%) came from the New York City metropolitan area. Other prime
calling areas included California (17%) and Florida (12%).
RESULTS
Our random sample of 500 cocaine users was 67% male, 33% female,
ages 22-59 years (X= 30 years); 85% were white and 15% were black
or Hispanic. Mean level of education was 14.1 years. Forty per-
cent had annual incomes over $25,000. Their preferred route of
cocaine administration was: Intranasal (IN) 61%; freebase smoking
(FB) 21%; and intravenous (IV) 18%. Estimates of weekly cocaine
use ranged from 1-32 grams per week. Frequency of cocaine usage
averaged 5.7 days per week; 48% used daily. At prices of
$100-$175 per gram, the average amount of money spent per week on
cocaine was over $637 and ranged from $100 to $3,150.
Sixty-one percent said they felt addicted to cocaine, 75% said
they had control over cocaine use. and 83% said they were unable
to refuse cocaine when it was available. Despite repeated
attempts to stop cocaine use, 67% said they were unable to stay
away from cocaine for as long as one month. Sixty-eight percent
reported using tranquilizers, marijuana, alcohol, or heroin to
reduce the stimulant effects of cocaine or to relieve the
dysphoric "crash" when cocaine effects wore off.
Over 90% reported adverse physical, psychological! and social/
financial consequences associated with their cocaine use. The
incidence of specific consequences is shown in Table 1.
Table 1
INCIDENCE OF COCAINE-RELATED CONSEQUENCES
(N=500)
Physical Effects
sleep problems
chronic fatigue
severe headaches
nasal sores, bleeding
N
410
380
300
291
Percent
82%
72%
60%
58%
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(Table 1 cont.)
chronic cough, sore throat 228 46%
nausea, vomiting 193 39%
seizure, loss of consciousness 70 14%
Physical Effects N Percent
depression
anxiety
irritability
apathy, laziness
paranoia
difficulty concentrating
memory problems
sexual disinterest
panic attacks
415 83%
416 85%
408 82%
328 66%
326 65%
323 65%
287 57%
265 53%
248 50%
Additional drug-related consequences included loss of: job (25%).
spouse (25%). friends (51%), and all monetary resources (42%).
Automobile accidents (11%), fighting and violent arguments (59%),
and cocaine-related suicide attempts (9%) were also reported. A
substantial number of callers reported stealing from work, family,
or friends (20%) and dealing cocaine (39%) in order to support
their expensive cocaine habit.
DISCUSSION
This study provides self-reported evidence of adverse physical and
psychosocial consequences of cocaine use in a sample of 500
callers to the helpline. Our findings expand an accumulating body
of data that points to the risks and dangers of cocaine use (Wetli
and Wright, 1979; Gold, 1984). A previous helpline survey of 55
cocaine users (Washton and Tatrasky, 1984) and a recent study of
136 cocaine abusers who entered treatment (Helfrich et al., 1982)
reported numerous physical, psychological, and social problems
associated with chronic cocaine abuse. In conjunction with these
earlier reports our study highlights the fact that intranasal
users are not exempt from developing a strong dependence on
cocaine or from suffering adverse effects on their health and
functioning. It is now evident that dysfunctional cocaine use can
and does occur not only in freebase and i.v. users, but in intra-
nasal users as well (Washton et al., 1983; Stone et al., 1984).
Helpline surveys and studies of treatment populations present a
somewhat skewed picture that is not necessarily representative of
all users. One would expect that dysfunctional patterns of drug
use and serious adverse effects would be more prevalent among a
sample of self-defined problematic users than among a true cross-
section of all users. For example, in a study of 85 self-defined
"social-recreational" cocaine users, Siegel (1977) reported that
occasional intranasal use had resulted in remarkably few problems
demanding clinical attention. While it is undoubtedly true that
some users exhibit controlled usage patterns and no serious
226
adverse effects, one must be careful not to conclude from such
observations that even occasional cocaine use is harmless.
Occasional use can pose subtle and accumulating risks that are
often inadequately recognized. Many "recreational" cocaine users
acquire a growing dependence on the drug without fully realizing
it. The weekend "snorter" gets accustomed to using cocaine in
order to insure a good time and eventually begins to feel incap-
able of being happy, sharp, sexy, confident, or sociable without
cocaine. The seductive and compelling effects of cocaine en-
courage the occasional user to want more of the exalted feeling
and in more varied situations. This may lead to increases in both
the dosage and frequency of use and in some cases to a switch from
snorting to more potent forms of administration, such as
freebasing. Due to progressive tolerance, continued use may lead
to a diminished euphoric response, thereby ensnaring the occasional
user into a vicious cycle of intensifying use in a futile attempt
to recapture the fleeting cocaine "high". With chronic escalating
use, not only does the euphoria diminish, but the rebound
dysphoric "crash" also intensifies and further drives continued
and escalated use. The weekend user will typically feel lethargic,
irritable, depressed and generally "hung over" on Monday mornings
leading to lateness, absenteeism, or reduced effectiveness at
work. Occasional users who have become increasingly conditioned
to cocaine's effects may sharply escalate their use if they
experience a life crisis or a particularly stressful period
because they have come to associate the drug with "feeling
better", i.e., stress relief. Cocaine seems to have a subtle
ability to delude the users into thinking that their intake of the
drug is not problematic. Legal consequences for buying or
possessing cocaine with possible ruination of job or career are
potential risks even for the occasional user. Many users resort
to dealing cocaine in order to offset the high cost of their own
cocaine habit. Legal penalties for cocaine dealing can be
extremely severe. In light of these numerous but often
unanticipated consequences, it is difficult to conclude that
occasional cocaine use is completely harmless.
Consistent with previous studies (Washton and Tatarsky, 1984;
Helfrich et al., 1982) intranasal users accounted for over half of
the present sample, indicating that "snorting" cocaine continues
to be the most popular method of self-administration. However,
smoking cocaine freebase seems to be steadily gaining in popular-
ity despite its increased risks (Siegel, 1982). Freebase is a
more volatile form of cocaine that readily lends itself to being
smoked because it has a lower melting point than the street-bought
cocaine hydrochloride. Through a simple chemical process street
cocaine is "freed" from its hydrochloride salt to yield the
freebase which is typically smoked in a glass waterpipe. As
compared to intranasal cocaine, freebase smoking results in a more
rapid and direct absorption of the drug into the bloodstream, a
quicker and more intense euphoric reaction, and increases both the
abuse potential and risk of toxic reactions. With freebase
smoking there is not only a more intense euphoria but also a more
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intense rebound dysphoria that tends to engender compulsive.
patterns of use. The sharp rise in cocaine plasma levels and the
intense euphoric "rush" with freebase smoking is nearly identical
to that with intravenous injection (Perez-Reyes et al., 1982).
Cocaine users who might never resort to i.v. use of the drug are
now turning to freebase smoking as a means of achieving the same
type of effect but without the social stigma of using needles.
Tntranasal users who have switched to freebasing report that it
leads to dramatic increase in cocaine use characterized by exag-
gerated binges, a more extreme obsession with the drug, and a
marked qualitative and quantitative difference in the euphoric
experience. The subjective effects of freebasing are described as
being more sexual, more alluring, more detached from reality, and
more blissful. The widespread distribution and sales of
freebasing pipes and other cocaine-smoking paraphernalia (Siegel,
1982) reflect the growing acceptance of this practice among users.
Cocaine use appears to promote the use and abuse of other drugs
that are usually taken to offset the negative side effects of
chronic cocaine abuse. Seventy-eight percent of the present
sample reported use of alcohol and other CNS depressants to
relieve the dysphoria "crash" or to reduce the unpleasant
stimulant effects of cocaine. Alcohol is by far the most popular
substance used for this purpose. Because alcohol or other drugs
are taken by the cocaine user not to get "high" but to self-
medicate for cocaine side effects, the user is often unaware of a
growing dependency on these substances and may eventually acquire
a second addiction. There is also an increased risk of overdose
reactions to drugs used to counteract cocaine. The strong intoxi-
cating effects of CNS depressants which would normally signal the
potential for the stimulant effects of cocaine wear off.
Similarly, auto accidents on cocaine are often due to the combined
use of cocaine and alcohol. The intoxicating effects of the
alcohol may not be felt when the cocaine user first gets behind
the wheel of the car, but may subsequently cause a blackout when
the cocaine wears off and the alcohol effects come on with full
force. Fifty-seven subjects in the present study (11%) reported a
cocaine-related automobile accident. In most of these cases it
was due to combined use of cocaine and alcohol. The role of
cocaine use in traffic accidents and fatalities is probably
underestimated to a large extent because persons stopped for
driving while intoxicated are rarely tested for the presence of
cocaine in blood or urine.
The 800-COCAINE helpline has afforded a unique opportunity to
study a large population of cocaine users that might not otherwise
be accessible for scientific or public analysis. The large and
steady volume of calls to the helpline from numerous geographical
areas across the U.S. suggests that adverse effects of cocaine use
are severe enough to cause large numbers of users to seek assis-
tance. Over 50% of cocaine users calling the helpline request a
treatment referral, but it is estimated that fewer than 20% of
these referred callers actually enter treatment. In many cases,
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the user's persistent denial of the full extent and severity of
their problem as well as their need for outside help, pose major
obstacles to entering treatment. Those who enter treatment
usually do so as a result of an immediate crisis situation, such
as the threat of job loss, marital separation, financial ruin,
legal trouble, or serious disruption to their health and function-
ing. The 800-COCAINE helpline has served to decrease some of the
obstacles to seeking help. It guarantees the anonymity of the
caller and provides a toll-free telephone number that is easy to
remember and has intuitive appeal. The helpline may encourage
some users to seek treatment before a serious crisis arises, but
to date we have no hard evidence to indicate that this is actually
occurring. Nonetheless, the helpline experience seems to have
helped to increase public awareness of cocaine problems and to
counter the long-standing myth that the drug is harmless.
With the increasing prevalence of cocaine use and intensified
usage patterns, a more complete picture of the potential consequen-
ces has begun to emerge. Cocaine is an insidious drug with a
long-standing image of being harmless and non-addictive. Recent
experience suggests that if social sanctions or medical research
failed to caution against the potential dangers, the already
widespread occurrence of dysfunctional cocaine use would continue
to rise.
FOOTNOTE
1. A longer version of this paper appeared in Psychiatric Annals,
14: 190-197, 1984, and is reprinted with permission of the
publisher Charles B. Slack, Inc., Thoroughfare, N.J.
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The Effect of Questionnaire
Design on Reported Prevalence of
Psychoactive Medication
Linda B. CottIer and Lee N. Robins
INTRODUCTION
Valid estimates of the amount of medical and non-medical drug
use In the general population are necessary to understand the
extent of drug-attributable illness. Estimates of psychoactive
medication use can be obtained through methods such as survell-
lance of patient medical records, or of pharmacy prescriptions.
Underestimates may result from surveillance of patient records
because physicians may not always document in the record the
prescriptions they write, and do not always obtain from patients
complete medication histories of prescribed and over-the-counter
medications. Pharmacologists’ records, on the other hand, may over-
estimate prescription use, since the fact that a prescription
has been filled by a pharmacist does not necessarily Indicate
Its utilization by the patient.
Estimates can also be obtained from retrospective Interview studies.
but efforts must be made to control selective and faulty recall.
Parry et al. (1970-71) demonstrated that good questionnaire design
could appreciably improve a respondent’s recall of psychoactive
drug use. In this paper, we evaluate the effect of questionnaire
design on reported prevalence of prescribed and non-prescribed
psychotherapeutic medication use. In addition, we describe the
reported indications for use of these medications.
METHODS
The data for this paper were taken from the first wave of the
St. Louis NIMH Epidemlologic Catchment Area (ECA) study, conducted
from April 1981 to March 1982. The study, aimed at determining
Incidence and prevalence rates of psychiatric disorders In the
general population, used the NIMH Diagnostic lnterview Schedule (DIS)
and Health Services Questionnaire (HSQ) (Eaton et al. 1981). The
DIS Is a structured interview which obtains Information necessary
to make over 30 of the diagnoses defined in the Diagnostic and
Statistical Manual, 3rd Edition (American Psychiatric Association
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1980). In addition to health services utilization, the HSQ elicits
Information on demographic characteristics and medication use.
Stratified cluster sampling techniques were used to select 3778
households for participation from three Mental Health Catchment
Areas in Metropolitan St. Louis. These areas were chosen because
together their 1970 population resembled the demographic composition
of the nation as a whole. After a household member completed
a screening interview which enumerated household residents over
age 18, one person per household was randomly designated to partici-
pate in the study; replacement for any reason was not allowed.
The interviewed sample was 3004 persons, representing an 80%
response rate. The interview took approximately 90 minutes and
was administered by professional Interviewers who had undergone
intensive training. Before beginning the Interview, respondents
were told that their interview was completely confidential, and
could not be Iinked to them individually. The medication utiliza-
tion section within the HSQ was Introduced by a statement explaining
that the respondent would be asked about medications taken In
the past six months, whether prescribed, over-the-counter, or
obtained from friends, relatives or neighbors. The questions were
asked In the following sequence:
1. “During the last six months, that Is, since (DATE
6 MONTHS PRIOR) have you taken any medications to help
you calm down or keep you from getting nervous or upset?”
2. “ . . . . to raise your spirits, or to help you feel less
moody or depressed?”
3. “ . . . . to help you get to sleep or stay asleep?”
4. “ . . . . help you with a drug or alcohol problem?”
5. “ . . . . for a nervous stomach?”
6. “ . . . . to give you more energy or to cut down on your appe-
tite?”
When the response was “yes”, the interviewer ascertained which
medications were used at least three times In the last six months,
and how they were obtained.
The questions just described are the indication-specific questions.
Although they are not exhaustive, it was felt they Included the
most common reasons for taking psychoactive medications. These
questions were followed by six medication-specific questions:
“In the past six months, that is, since (DATE SIX
MONTHS PRIOR) have you taken any (Elavil/Valium/
Librium/Dalmane/Thorazline/Mellarll) for any emotional
problems or problems with drugs or alcohol?”
Brand names were used because we felt respondents would be familiar
with them. However, all drugs were coded by generic name so that
similar drugs mentioned in the indication-specific questions would
be counted equally. The source from which the medication was
obtained was elicited for these drugs also, provided they were
used at least three times in the last six months.
RESULTS
Table 1 shows SIX-month prevalence rates for the six drugs asked
about by name. The rates are given for the proportion of the
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sample using each drug and whether Its use was elicited by the
indication question, or by the medication question after being
missed by the indication question. Valium was the psychoactive
drug used most among the six inquired about, followed by Librium,
ElaviI, and Dalmane. Thorazine and Mellaril were infrequently
used (by less than 0.5%). Had only the indication-specific ques-
tions been asked, the rate of Valium use would have been 5.06%.
The medication-specific question accounted for an additional 65
users, or 2.19%, which raised the esimated prevalence of Valium
use to 7.25%.
TABLE 1
SIX-month prevalence rates of
psychoactive drug use by question asked
(N=2962)
Indication- Medication- Total
specific specific
f % f % f %
Valium 150 5.06 65 2.19 215 7.25
Librium 54 1.83 23 .78 77 2.61
Elavil 33 1.11 12 .41 45 1.52
DaImane 26 .88 9 .30 35 1.18
Thorazine 7 .24 4 .14 11 .38
Mellaril 7 .24 4 .14 11 .38
(Ns varied for each drug--4 persons had missing information.)
As shown In Table 2, by asking the additional medication-specific
questions following the indication questions, prevalence rates
of psychoactive drug use increased between 35 and 57%. Reporting
of Thorazine and Mellaril, drugs used infrequently in our sample,
was especially augmented by the name-specific questions. Estimated
prevalence was Increased 43% for both Valium and Librium. On
the average, the reported prevalence increased 42% for these six
drugs. Responses to the medication-specific questions accounted
for between 26 and 36% of each drug’s total use, and on the average,
accounted for 30% of the prevalence rate for these six drugs.
TABLE 2
Increase in estimated prevalence of psychoactive
drug use attributed to asking the medication-specific questions
Thorazine
Mellaril
Valium
Librium
Elavil
Dalmane
% Increase % of
in prevalence total
57% 36%
57 36
43 30
43 30
36 27
35 26
Mean 42 30
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The responses to the indication-specific questions show that res-
pondents are able to differentiate the reasons for their drug
taking (Table 3). For example, of the 432 reports of use of
some drug “to calm down”, Valium was the most widely used of these
six drugs; it accounted for 32% of the use for this indication.
Librium was the next most prevalent. When respondents were asked
which medications were taken to help them feel less moody, Elavil
and Vallum were the most commonly used of the six, accounting
for 13% and 10% respectively of all drugs used for this problem.
Valium, DaImane, and Elavil were the drugs most often used to treat
sleep problems; Librium was the only one of the six reported to
be used for a drug or alcohol problem. These six medications
were rarely used to treat a nervous stomach. No one reported
using one of these drugs “to give more energy or decrease
appetite”. These six medications accounted for more than half
(53%) of all medications used to calm down, 30% of medications
taken to treat mood problems, and one-third of the medications
taken to Induce sleep.
TABLE 3
Selected psychoactive drugs
among all drugs used for a specific Indication
Calm Mood Sleep Drug/Alc Nervous Energy/
down problem stomach appetite
Elavil 6% 13% 8% 0 * 0
Valium 32 10 12 0 * 0
Llibrium 11 * 3 11 1 0
Dalmane * 3 9 0 0 0
Thorazine 2 2 * 0 0 0
Mellaril 2 2 2 0 * 0
% accounted
for by these
drugs 53 30 34 11 3 0
No. of
drug
uses 432 120 258 18 362 284
* less than 1%
Each drug was analyzed by the indications given for its use, with
every drug mention being counted separately. As shown in Table
4, Elavil was mentioned 75 times in response to the indication
questions. Over a third of Its use was reported for the indication
“to calm down”, and over a quarter of its use was reported for
sleep. Only 19% of its use was as an anti-depressant. Just over
half of the use of Valium and Librium was consistent with their
anxiolytic properties (i.e., to calm down). For Dalmane, two-thirds
of its use was appropriately to induce sleep; yet some persons
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reported Its use as a tranquilizer or as an anti-depressant.
Use patterns of Thorazine resembled those of Velium: the most
common reason for use was to calm down. Mellaril was used more
like Elavil, to calm down and to induce sleep predominantly.
It is noteworthy that these indication questions accounted for
as much of the use of major as minor tranquilizers, even though
“suppression of psychotic symptoms ”was not one of the indications
inquired about. The reasons for use of from 16 to 26% of each
of these drugs is not known, because their use was reported only
after the name-specific questions were asked.
The groups whose reporting was increased most by the addition
of the medication-specific questions are shown in Table 5. The
young (25-44 year olds), blacks, males, and persons with at least
eight years of education were the groups most likely to increase
recall of their medication use in response to the drug-specific
questions. Exceptions to this were found for Elavil, where reported
use was most enhanced for the 45-64 year olds, and for Valium,
where recall by both the oldest group and the young group was
strikingly enhanced by the medication question. There was no
difference in the degree of enhancement of the reporting of Librium
by race or sex.
TABLE 4
Reasons given for psychoactive drug use*
Elavil Valium Librium Dalmane Thorazine Mellaril
To calm down 35% 56% 54% 6% 47% 39%
To help mood 19 5 2 8 13 11
27 12 10 8 13To get to sleep 7 22
For a drug/
alcohol problem 0 0 2 0 0 0
For a nervous
stomach 3 1 6 0 7 6
No indication
(Med-specific) 16 26 26 24 26 22
Total mentions
of use (N) (75) (250) (89) (37) (15) (18)
% 100 100 100 100 100 100
* each of multiple indications per respondent counted
TABLE 5
Groups whose reporting was Increased most by adding
medication-specific questions
Elavil
Age 45-64 25-44 and 65+ 25-44 25-44
Race blacks blacks no diff. blacks
Sex males males no diff. females
Education >8 yrs. >8 yrs. >8 yrs. >8 yrs.
Valium Librium Dalmane
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While most of these drugs were obtained by physicians’ prescrip-
tions, some of each, except Mellaril, were obtained from friends,
relatives, or on the street. (We do not know If the original owner
got them by prescription.) We assessed whether or not the addi-
tional name-specific questions changed our estimate of the propor-
tions obtained through non-medical channels (Table 6). In the
case of each drug, these questions did elicit a higher propor-
tion of non-prescribed drug use than was obtained with the indica-
tion questions. The proportion of use which was not by personal
prescription would have been underestimated if the medication-
specific questions had not been asked.
TABLE 6
Percent non-prescribed of all reported drug use,
by indication or medication question
Elavil
Valium
Librium
Dalmane
Thorazine
Mellaril
Indication- Medication-
specific specific
3% 1 0 %
12% 25%
12% 24%
0 29%
0 25%
0 0
DISCUSSION
For six common psychoacive medications, prevalence rate estimates
were increased an average of 42% by following indication-specific
questions with name-specific questions. The drug-specific questions
accounted for 30% of the prevalence rates on the average. Increased
recall, as a result of the drug-specific question, was especially
great for blacks, males, those 24-44 years old, and for infrequently
used drugs such as Thorazine and Mellaril.
Finding a substantial average percent increase in prevalence for
these six mood drugs suggests that estimates of use of other psychoactive
drugs we did not inquire about by name probably should be approx-
imately doubled.
These findings corroborate those of Parry et al. (1970-71) that
intensive questioning appreciably increases reporting of
psychoactive drug use, especially for males and persons with more
than an eighth grade education. In a previously published paper
(CottIer and Robins 1983) we reported that women’s use of psycho-
active drugs was twice that of men’s. This ratio would have been
even greater if the name-specific questions had been eliminated.
A considerable increase in recall of medication utilization can
be expected from a simple addition of questions. Thus, careful
questionnaire design can minimize one of the disadvantages that
retrospective interview studies have long borne.
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Young Adult Marijuana Use in
Relation to Antecedent Misbehaviors
James C. Anthony
An estimated 15 to 20 percent of Americans aged 18-34 are recent
marijuana smokers (derived from Fishburne et al., 1980). The
average prevalence of daily and near-daily marijuana use is
closer to 5 or 10 percent, with male rates higher than female
rates. A profile of toxicity is not complete, but this prevalence
of daily and near-daily exposure to marijuana warrants increased
attention because of the potential public health hazard (Institute
of Medicine 1982).
Aggressiveness in early childhood and other conduct problems or
misbehaviors have been associated with later high levels of
involvement in marijuana smoking, particularly among males
(Robins 1980; Kellam et al., 1983). These early antecedents may
be modifiable factors that influence either the risk of becoming
a daily smoker or the duration of of daily smoking, or both. If
so, they have potential importance in efforts to prevent and
control the drug-using behavior , and to reduce the degree of drug
hazard.
The casual importance and modifiability of early antecedents like
childhood aggression can be thoroughly tested only with experi-
ments and quasi-experiments, including preventive trials in
community settings. This paper represents and intermediate step
in that direction, with a more modest aim: to test the strength
and nature of association between young adults' recent level
antecedent misbehaviors such as truancy and stealing. Males and
females are examined separately because previous investigators
have found sex differences in the developmental paths toward drug
use (Ensminger et al., 1982).
METHODS
In 1981, special trained lay interviewers completed 60-90 minute
interviews with 3481 adults aged 18 and over who had been sampled
for the NIMH Epidemiologic Catchment Area (ECA) household survey
in eastern Baltimore. The sample was drawn to be representative
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of the area's adult household population. The survey response
rate was 78%. The interview consisted of many standardized
socio-demographic and health-related measures, including the NIMH
Diagnostic Interview Schedule of DIS (Robins et al., 1981).
The DIS information is based mainly on what subjects report about
themselves. In this study DIS self-report data have been used to
provide measures of: (1) misbehavior before age 18; (2) age at
first non-medical drug use: and (4) DSM-III Anti-Social Personality
Disorder.
Subjects' responses to 10 DIS items on misbehavior were tallied
to produce an index of misbehavior before age 18. The DIS items
covered school misbehavior, expulsion or suspension, hookey.
fighting in and out of school, running away from home, telling
lies, stealing, intentional damage to property, and juvenile
arrests. The DIS items on school performance and early use of
alcohol or street drugs were excluded from the tally. Reliability
of the index, estimated by Cronbach's alpha, was 0.72
For this study, the index was dichotomized with 0-2 misbehaviors
forming one group, and 3-10 forming the other. This cutting
point was chosen after examining the marginal distributions of
the index for males and females, prior to cross-classification
with drug variables.
The interview included standardized questions on recent non-medical
drug use. Every subject who reported use of marijuana or other
cannabis products was asked, "During the past month, on about how
many different days did you take marijuana, hashish, [etc.] for a
non-medical reason?" The response provided the measure of
marijuana use for this paper.
The reported sample sizes indicated the number of subjects
actually interviewed. The proportions have been weighted to
account for survey sampling and non-participation factors. A
more complete description of the weights and other methods of the
survey is published elsewhere (Eaton and Kessler, in press).
The degree of association between young adults' recent marijuana
use and antecedent misbehaviors before age 18 is indexed by tau,
which may be viewed as a qualitative analogue to the coefficient
of determination for continuous data [R-squared] (Bishop et al. ,
1975). The test statistic, U-squared, is presented to test the
hypothesis of no association. It is based upon the weighted
proportions and the effective sample size for each table (not the
weighted number of persons).
RESULTS
Males. 495 males aged 18-34 completed interviews for this
study. Their responses to the non-medical drug use questions
indicated recent marijuana use by an estimated 34 percent of
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18-34 year old males living in eastern Baltimore households in
1981. An estimated 13 percent were daily or near-daily users
(based on reported 14-31 days of use during the month prior to
interview).
Table 1 indicates that among males there was an association
between recent marijuana use and the antecedent misbehaviors. As
a group, males with no recent use of marijuana were least likely
to have a history of three or more antecedent misbehaviors.
Males with 14-31 recent days of use were most likely to have a
history of the misbehaviors. There was a non-significant trend
across the three levels of recent marijuana use. The p-value
indicates the statistical significance of the association. Tau
indicates an estimated 10 percent common variance.
This association held up through a series of analyses to control
for potential confounding variables and special features of the
sample. That is, the association persisted among males with no
history of DIS-ascertained Anti-Social Personality Disorder;
among males with no history of DIS-ascertained Abuse and/or
Dependence involving opioids, cocaine, sedative-hypnotics, or
hallucinogens; and among males whose non-medical drug use did not
begin until after 17. The association also persisted when the
analysis was restricted also persisted when the analysis was
restricted to the 294 young white males in the sample.
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TABLE 1.
History of antecedent misbehavior is associated with
recent marijuana use among young adults
(Eastern Baltimore ECA Survey, 1981)
Days of Recent Marijuana Use
Young Adults, 18-34
Number of males
Proportion with history
or prior misbehavior
U-squared = 51 (df = 3)
p less than 0.001
NONE
331
31 %
Number of females 624
Percent with history
of prior misbehavior 17 %
U-squared = 76 (df = 3)
p less than 0.001
1-3
40
68 %
64
36 %
4-13 14-31
58 66
52 % 71 %
34 59
38 % 65 %
Females. 781 females aged 18-34 completed interviews for the
study. Their responses to the non-medical drug use questions
indicated recent marijuana use by an estimated 19.0 percent of
18-34 year old females living in eastern Baltimore households in
1981. An estimated 7 percent were daily or near-daily users.
Table 1 shows that for females as for males there was an associa-
tion between recent marijuana use and antecedent misbehavior
before age 18. An estimated 17 percent of females with no recent
use had a history of three or more misbehaviors, compared with 65
percent of females with 14-31 recent days of use. The data on
males indicated no trend across the three levels of recent
marijuana use, whereas the data on females suggest stepwise
increments in the percentages relative to the number of recent
days of use. The p-value indicates statistical significance of
the association. The estimated tau indicates 10 percent common
variance.
The observed association and stepwise trend persisted among young
females with no history of Anti-Social Personality Disorder;
among those with no history of Abuse and/or Dependence involving
opioids, cocaine, sedative-hypnotics, or hallucinogens; and among
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the 362 young white females in the sample. When the analysis was
restricted to young women with no reported history of non-medical
drug use prior to age 18, the association persisted but the
stepwise trend disappeared.
DISCUSSION
Based upon standard survey techniques with a sample that was
constructed to be representative of the adult household residents
of a defined area, these results provide additional evidence of
an association between the marijuana use of young males 18-34
years old and antecedent misbehaviors before age 18. The results
indicate that an association of similar strength exists for young
women as well -- at least in eastern Baltimore of 1981.
The association persisted when the analysis included control over
histories of Anti-Social Personality Disorder, Abuse and/or
Dependence involving drugs other than marijuana, and onset of
non-medical drug use prior to age 18. Thus, the association is
not solely a function of these factors. In addition, the associa-
tion was found for both white males and white females, and cannot
be explained solely in terms of white-nonwhite difference.
There is an alternative explanation for the association. Namely,
subjects who report marijuana use may provide more complete
accounts of their misbehaviors during childhood and adolescence.
Others have suggested that this may not be a major problem in
studies of this type (Robins 1974). No test of this alternative
explanation was possible here.
It was somewhat surprising to find that a history of antecedent
misbehaviors did not discriminate between levels of recent
marijuana use among the young males, even when cases of Anti-Social
Personality Disorder were taken out of the analysis. It was also
surprising to find the contrary for the young females. These
were unanticipated findings that require for developmental paths
toward drug use. Preventive intervention studies may find that
both low and high levels or marijuana involvement are affected
when early misbehaviors are modified among males, with only high
levels affected among females.
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A Prospective Twelve-Year Follow-up
of Alcoholic Women: A Prognostic
Scale for Long-Term Outcome
Elizabeth M. Smith and C. Robert Cloninger
The clinical evaluation of prognosis in alcoholic women has
become an important research priority due to the recent increase
in the prevalence of alcohol abuse by women. The search for
predictors of outcome in alcoholism has generated extensive
literature, but few data are available about alcoholic women.
The purpose of the present study was to examine the long-tern
course of alcoholism in women who were systematically
interviewed and diagnosed according to rigorous criteria at
index and to identify pre-treatment characteristics associated
with various outcomes twelve years after hospitalization. In
this paper we describe the first multivariate scale to predict
prognosis in alcoholic women.
SUBJECTS AND METHODS
Subjects: The subjects were 103 women who were consecutive
alcohol admissions to two psychiatric hospitals in the St. Louis
area, one public and one private, during 1967-68. They were
collected as part of a clinical and family study of alcoholism.
(Schuckit et al., 1969; Winokur et al., 1971).
The mean age at admission was 44 years, with a range from 18 to
67 years. The majority (76%) were white and most (65%) were
drawn from the private hospital. They were evenly divided
between lower (public hospital and ward patients) and middle to
upper socioeconomic status (private patients). The mean number
of years of problem drinking prior to admission was nine years,
with a range from one to 38 years. Seventy-five percent of
subjects had previously been hospitalized for alcohol problems.
During the hospitalization, each subject was given a structured
psychiatric interview which emphasized family history of
psychiatric illness, chronology of development of psychiatric
symptoms as well as the history of alcohol use, including the
extent and tine sequence of problem drinking, any periods of
abstinence, and consequences of alcohol abuse.
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Diagnostic Criteria: Although the original study was conducted
before all of the operational criteria were developed, the
diagnostic criteria used are essentially the same as those which
have become known as the Feighner criteria (Feighner et al.,
1972).
When a patient developed symptoms of another disorder prior to
the onset of a syndrome of alcohol abuse, that disorder was
considered primary. If the symptoms developed during or after a
period of alcohol abuse, the alcoholism was considered primary.
The subjects fell into three major diagnostic categories based
on the time course of the development of symptoms. The majority
(59%) were primary alcoholics and about one-half of this group
had a diagnosis of secondary depression. Twenty-five percent of
subjects received a diagnosis of primary affective disorder
(unipolar depression) and 7% were diagnosed as antisocial
personality. The remaining 9% received various other primary
diagnoses, including schizophrenia, hysteria, drug addiction, and
obsessional neurosis with secondary alcoholism.
Follow-up: We were able to follow up 90% of the subjects.
Three could not be located and eight refused to be interviewed,
reducing the sample from 103 to 92. Follow-up interviews were
conducted during 1979-80, approximately twelve years after
hospitalization. A structured psychiatric interview, the NIMH
Diagnostic Interview Schedule (Robins et al., 1981) was
utilized with expanded sections on alcohol and drug use, health,
work, and marital history. Detailed information was obtained on
the subject’s course since discharge from the hospital including
quantity and frequency of alcohol use, any periods of abstinence
or periods of uncomplicated social drinking, any treatment for
alcohol problems, and any consequences of alcohol abuse including
legal, marital, job or health problems.
If the subject was dead or could not be interviewed, information
was obtained from the closest available relative using the same
structured interview. Death certificates were obtained for all
subjects who died and medical and psychiatric records obtained
for those who had been hospitalized during the follow-up period.
Outcome: Subjects were classified into four outcome groups
based on the length of time during the follow-up period spent
free of alcohol-related life problems, including both social
adjustment and medical symptoms. Utilizing methods similar to
those of Schuckit and Winokur (1972), we recorded the number of
months or years during the follow-up period when the subject was
able to work, care for her family or herself, and perform other
social roles without impairment due to alcohol. During a period
of heavy drinking all problems that occurred were considered to
be alcohol-related.
This outcome scheme avoids the pitfalls of using abstinence as
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the sole outcome criterion, which in effect excludes women who
return to uncomplicated social drinking. It also utilized a
longitudinal rather than cross-sectional approach in classifying
the subjects’ behavior and functioning.
The four outcome categories are: Incapacitated - subjects had
an unremitting course with less than one year spent free of
alcohol problems. The majority of subjects in this group died
as a result of alcohol abuse. Poor - those who had at least one
full year but less than three consecutive years free of alcohol
problems. Good - those who had at least one period of three
consecutive years free of alcohol problems. This group
contained a substantial minority of episodic drinkers who had a
variable course with periodic relapses. Excellent - those who
had fairly continuous remission from alcohol problems with good
social functioning For the major part of the Follow-up period.
Predictor Variables: The number and type of predictor variables
were limited to items from the first interview and their
selection was based on prior research findings. Index
information was available In four areas: social and demographic
characteristics; familial and marital history; psychiatric
diagnosis; and alcohol and drug history and complications.
Statistical Analysis. Because of the small numbers, the poor
and incapacitated groups were combined. as were the good and
excellent groups, yielding two outcome-groups: Poor (n=47) and
Good (n=45) outcome. Discriminant Function analysis was used to
identify the index variables that distinguished good outcome
women from those with poor outcomes at twelve year follow-up.
The 32 Index variables were entered in the discriminant function
analysis with outcome as the criterion variable. The stepwise
solution method was used to select variables that minimize
Wilk’s Lambda (F For inclusion or deletion. 1.0; tolerance
level, .001). Discriminant analysis was also used to classify
good and poor outcome subjects.
As a test of the replicability of the results obtained From the
original analysts we performed a series of five discriminant
analyses, each time removing a random sample of ten subjects
from the two outcome groups.
RESULTS
Forty-nine percent of the subjects had good long-term outcomes
with an average of 7.9 years free of alcohol-related problems,
while 51% had poor outcomes with less than one year (mean =
eight months) free of problems. The mortality rate for the
located sample was 31%. With few exceptions, subjects who died
had continued to abuse alcohol and most experienced a fairly
steady downhill course with the majority of deaths the result of
alcohol-related causes including cirrhosis, accidents, and
suicide.
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Significant Predictors of Long-Term Outcome. We turn now to the
results of the discriminant analysis of the 32 index
variables. Table 1 shows the fifteen significant variables in
their order of entry into the model.
TABLE 1 VARIABLES AT ADMISSION THAT DISTINGUISHED GOOD
VERSUS POOR OUTCOME AT 12-YEAR FOLLOW-UP*
Mean Value/
Value On Percentage of
Discriminant Each Out-
Predictor Variables Function† come Group
G O O D P O O R
(N=45) (N=47)
History of Delirium Tremens (0.1) +.22 7 % 32%
Unemployed (0.1) +.52 5 % 26%
Anmission for Loss of Control (0.1) +.48 29% 55%
Antisocial Personality (0,1) +.61 0 % 13%
Psychiatrically Ill Mother (0,1) +.44 29% 37%
Problem Husband (0,1) -.29 36% 28%
Early Onset (0.1) +.51 38% 56%
Years of Education (years completed) -.51 11.7 11.4
Low Socioeconomic Status (0,1) +.59 4 0 % 60%
Never Abstained (0,1) +.28 36% 41%
Primary Diagnosis of Alcoholism (0,1) +.39 60% 64%
Age at Admission (years) -.64 41.9 41.1
Duration of Alcoholism (years) +.51 7.9 10.1
Married and Living with Husband (0.1) -.22 56% 35%
Blackouts (0,1) +.20 55% 77%
* The variables were found by diecriminant analysis (P<.0001)
and are shown in the order in which they entered. Coding of
variables is indicated in parentheses. The group means of
variables that are present (1) or absent (0) are the pro-
portion who have that factor and are listed as percentages.
† High, positive values on the discriminant function distinguish
women with poor outcomes from the others. The tabulated
values are standardized canonical discriminant coefficients
that indicate the relative weight and direction of influence
of each variable.
These variables accounted for 44% of the variance and correctly
classified 83% of the subjects according to long-ten outcome.
Subjects in the two outcome groups were classified equally well,
with 84% of those in the good outcome group and 81% in the poor
outcome group correctly classified.
Since many of these variables were highly correlated, we wanted
to identify a reduced predictive model with fewer variables.
Therefore, we selected the seven variables that were
individually most highly correlated with outcome (see Table 2).
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TABLE 2 A REDUCED PROGNOSTIC MODEL IN WHICH ALL 7 VARIABLES
ARE INDIVIDUALLY ASSOCIATED WITH OUTCOM
Unstand-
ardized- Individual
Discrim- Strength of
Prognostic inant Association
Variables
Major Predictors
Delirium Tremens
Value P
1.19 9.31 < .002
Unemployed 1.36 7.92 < .005
Antisocial Personality 1.57 6.15 <. 01
Admission for Loss of Control 0.09 6.58 <. 01
Minor Predictors
Early Onset of Alcoholism 0.54 2.84 < .09
Unmarried/Not Living with Husband 0.20 4.31 < .04
Low Socioeconomic Status 0.13 3.52 < .06
The discriminant function analysis using these seven variables
correctly classified 76% of the subjects. This reduced model
provided classification results which were almost as good
overall as the 15-variable model (76% versus 83%); however, it
was more successful in classifying subjects in the good outcome
group (89%) than in the poor outcome group (64%).
Utilizing the seven variables shown in Table 2, we developed a
prognostic scale similar to the one developed by Vaillant (1964)
in his study of schizophrenics. The first four variables which
had the highest correlation with outcome were given the greatest
weight and scored two if present. The three others, where the
strength of association was weaker, were given less weight and
scored one. If a factor was absent or questionable it was
scored zero. The prognostic scale score for an individual could
range from zero to 11.
FIGURE 1
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As shown in Figure 1, a major advantage in scaling is due to the
linear rather than dichotomous nature of the relationship
between prognostic scores and outcome. Subjects with scores of
two or less were most likely to have good outcomes, while those
with scores above four had the poorest outcomes. Subjects with
scores ranging between three and four were Fairly equally
distributed between the two outcome groups.
Using a cutting score of two on the clinical prognostic scale we
achieved a correct classification for 74% of the subjects (77%
of the poor outcome group and 71% of the good outcome group).
While there was little change in the overall prediction rate
From the discriminant analysis (74% versus 76%), there was some
loss of predictive power within the good outcome group (71%
compared to 89%), and predictive ability within the poor outcome
group Improved slightly (77% compared to 64%).
In a series of five discriminant function analyses using our
seven-variable prognostic model with a random sample of cases
from the original study population, the range of correct
classifications was from 72% to 782 of cases correctly
classified.
DISCUSSION
The findings from this study are encouraging. The prognostic
scale accurately predicted the long-term outcomes of
approximately three-fourths of the alcoholic women in our
sample. Considering the heterogeneity of the sample in terms of
diagnostic subtypes, socioeconomic status and severity of
alcoholism, as well as the relatively long (twelve year)
interval between the index interview and follow-up assessment,
the prediction rate is impressive.
The scale was derived using only a dichotomy (good or poor
outcome), but our data (see Figure 1) indicates that our
prognostic score is a linear predictor of severity of outcome;
that is, the higher the score the higher the probability of poor
outcome and the worse the severity of Incapacitation. The lower
the score the higher the probability of good outcome and the
better the social and medical adjustment. These results,
together with replicability of classifications in subsamples,
strongly support the robustness and clinical utility of the
prognostic scale.
Furthermore, in terms of the content of the scale, it is of
interest to note the similarity between our scale and the one
developed by Kammeneier and Conley (1979) for a mixed group of
men and women. Athough we were unaware of their work when our
scale was developed and thus not influenced in our selection of
variables, the general agreement is striking. In addition,
their use of a larger sample which contained males as well as
females and replication with a separate sample suggests that
some of the variables have predictive power for males as well as
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females and are fairly robust.
In examining the specific predictors, variables related to
social stability, such as enployment, marital status and
socioeconomic status, are of importance in good outcome. These
variables provide opportunity for intervention since they
include characteristics which are amenable to change.
While further work is needed, the findings provide additional
knowledge regarding prognosttc factors of importance in work
with alcoholic women. The prognostic scale provides an easily
administered, relatively objective tool to aid clinicians in
evaluating the prognosis of alcoholic women as well as
suggesting targets of intervention which might increase
treatment effectiveness.
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The Development of “Cross-
Tolerance” Between Systemic and
Spinal Morphine as a Function of
the Nociceptive Assessment Test
C. Advokat and C. B. Taylor
The spinal administration of opiates has proven beneficial for
the clinical management of both acute and chronic pain. One
unusual aspect of this treatment is the observation that spinally
injected doses which are analgesic in chronic (e.g., cancer) pain
patients are comparable to doses which are analgesic in acute
(e.g., postoperative) pain patients, even though chronic pain
patients frequently have a history of opiate medication to which
they have become tolerant. Therefore, it would be expected that
they would be "cross-tolerant" to additional opiates, regardless
of the route of administration. In fact, such "cross-tolerance"
between systemic and intrathecal (i.th.) opiates has been demon-
strated by Yaksh and his colleagues in laboratory animals, using
the nociceptive hot plate test with rats. In contrast to those
data we have found (Advokat and Tyler, Neurosci. Abstr. 8: 355:
1982) a lack of "cross-tolerance" between systemic and i.th.
morphine using the nociceptive tail flick test. We now report
that the apparent discrepancy between these previous studies is
due to the assessment test. Rats that are made tolerant to
systemic morphine and assessed on the hot plate (HP) are tolerant
to i.th. morphine on the HP; rats that are made tolerant to
systemic morphine and assessed on the tail flick (TF) are not
cross-tolerant to i.th. morphine on the TF.
Male albino rats (350-400 gm) implanted with spinal catheters
were assessed on the HP or TF after either morphine or placebo
pellet implantation. The rats were tested daily until the la-
tencies of the morphine-implanted rats returned to normal values,
at which time they were considered tolerant. They were then
examined for "cross-tolerance" by an acute injection of either
subcutaneous (1-6 mg/kg) or i.th. (2.5-3.0 ug) morphine followed
by a final test 40 min. later. The results showed that "cross-
tolerance" between the two systemic routes of administration,
subcutaneous pellets and subcutaneous injection, developed to
both the HP and the TF test. In contrast, "cross-tolerance"
between the systemic and the intrathecal route was only observed
on the HP. Morphine-implanted animals were just as analgesic as
placebo-implanted animals in their response to i.th. morphine on
the TF test.
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Therefore, the development of "cross-tolerance" between spinal
and systemic morphine is dependent on the nociceptive test. The
TF, which is a spinally mediated reflex, was not "cross-tolerant"
to spinally administered morphine; whereas the HP, which is a
supraspinally mediated behavior, was "cross-tolerant." This
dichotomy suggests that tolerance is a function of the neural
substrates that mediate both the nociceptive and pharmacological
inputs. Studies are now in progress to examine the effect of
chronic spinal morphine infusion on the development of tolerance
to the two nociceptive tests.
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Thyroid Axis Abnormalities in
Cocaine Abuse
Charles A. Dackis; Todd W. Estroff; Donald R. Sweeney;
A. L. C. Pottash; and Mark S. Gold
INTRODUCTION
Clinical manifestations of cocaine intoxication, such as
increased energy, psychomotor activation, diaphoresis,
hyperthermia, and cardiovascular arousal are remarkably similar
to hyperthyroid states. Conversely, the abrupt cessation of
cocaine abuse of ten results in symptoms resembling
hypothyroidism, such as anergia, depression, psychomotor
retardation, hypersomnia, and weight gain. Morley et al. (1980)
found that monkeys acutely and chronically exposed to
dextroamphetamine had elevated thyroid hormone (T4) and
thyroid stimulating hormone (TSH), further linking stimulant
intoxication with thyroid axis activation.
(Morley et al. 1980) were four cases of amphetamine-abusing
Also reported
patients with elevated T4 levels. Mantegazza et al. (1968)
found reduced toxicity of amphetamines in hypothyroid compared
with euthyroid rats, again suggesting a potentiation of the
thyroid axis by central stimulants. This present study is the
first report of cocaine-induced thyroid axis alterations in man.
Cocaine has well established potentiating effects on central
norepinephrine (NE) and dopamine (DA) systems in the brain
(Langer and Enero 1974: Ross and Renyi 1966). Besses et al.
(1975) suggested that DA neurons are involved in the regulation
of TSH secretion because they found that DA infusions in normal
men inhibited the TSH response
(TRH). Reichlin (1975)
to thyrotropin-releasing hormone
reported release of TRH after
hypothalamic infusion of DA and NE, but attributed the DA
effect to its conversion to NE. Serotonin was found to inhibit
TRH release, leading to the conclusion that TRH secretion is
stimulated by NE neurons and inhibited by serotonin neurons
(Reichlin 1975). Since cocaine produces numerous disruptions
in serotonin, NE and DA neuronal function (Dackis and Gold
1984), thyroid axis disruptions secondary to chronic cocaine
abuse are plausible.
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In order to assess the effects of chronic cocaine abuse on the
thyroid axis, we studied hospitalized cocaine patients with the
TRH test. This test is the most sensitive measure of thyroid
axis function (Saberi and Utiger 1975; Jackson 1982). This
test was also selected because of its wide use as a diagnostic
test for depression (Extein et al. 1982). Specific TRH testing
for depression of cocaine-abusing patients would depend upon
normal TRH test results in non-depressed cocaine abusers.
Therefore we designed this study to assess both the diagnostic
reliability of the TRH test for depression in cocaine patients,
and the effect of chronic cocaine abuse on the thyroid axis.
METHODS
We studied 17 consecutive patients admitted with cocaine abuse
by DSM III criteria, and with confirmatory plasma or urinary
cocaine titers (Kim and Cereo, 1976) demonstrated at the time
of admission to a locked hospital ward. Patients were excluded
if they met DSM III criteria for other substance abuse,
dependence, or for major affective disorders. Twenty normal
controls, similar in age and sex, and without substance abuse
or major affective illness, were also studied. Each subject
received a TRH test as previously described (Extein et al.
1982), with baseline T3 and T4 levels by radioimmunoassay.
Cocaine patients received TRH testing during their first week
of hospitalization. The TSH response to TRH (500 ug IV) was
calculated as peak minus baseline TSH ( TSH).
RESULTS
There were no significant differences in baseline T3, T4
and TSH between the two groups. However, the TSH scores of
cocaine patients (7.4 ± 3.3 uIU/ml) were significantly lower
(p <0.001, df=35, t=4.59) when compared to the controls (13.4 ±
4.2 uIU/ml). In addition, 8 of 17 cocaine patients (47%) had a
blunted TSH ( < 7 uIU/ml) (Extein et al. 1982), compared to
none of the controls (Chi Square (1) = 9.27, p<0.01).
DISCUSSION
Our data demonstrate inadequate TSH responses to TRH in
patients with cocaine abuse. This finding is consistent with
our present knowledge regarding TRH regulation by biogenic
amines. Direct hypothalamic administration of NE and DA result
in TRH release. Chronic cocaine abuse could lead to
chronically elevated TRH, down regulation of the receptors for
TRH in the anterior pituitary, and subsequent blunting of the
TSH response to TRH. This response is exquisitely sensitive to
thyroid axis changes and involved in the maintenance of
homeostasis (Saberi and Utiger 1975). Cocaine intoxication
could produce a state of compensated hyperthyroidism which is
only evident on TRH testing. (See Figure 1).
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Fig 1. Chronic cocaine abuse is hypothesized to produce
chronically elevated TRH levels through DA and NE
stimulation, with compensatory down-regulation of TRH
receptor sites. Abrupt discontinuation of cocaine would
produce a relatively hypothyroid state due to TRH
receptor subsensitivity and the lack of TRH stimulation.
While cocaine intoxication could produce thyroid axis
activation by releasing TRH, the sudden cessation of cocaine
use might result in thyroid axis inhibition due to the presence
of desensitized thyrotroph TRH receptors. Thyroid axis
inhibition at the level of the pituitary thyrotroph was found
in our cocaine patients, and could make a major contribution to
the neurovegetative symptoms associated with the cessation of
cocaine abuse. Reversal of cocaine abstinence symptoms may
depend upon the normalization of the thyroid axis and neuronal
regulatory systems.
Due to the profound blunting of the TRH test in
non-depressed cocaine abusers, this test is not suitable as a
diagnostic test for depression in these patients. In fact,
subtle mood disturbances seen after the cessation of cocaine
use may result from thyroid axis alterations. Neuroendocrine
disruptions apparently result from neurotransmitter effects of
cocaine, and represent homeostatic imbalance. Disruptions in
brain homeostasis by cocaine can be conceptualized as evidence
of “physical addiction” and may explain the profound difficulty
experienced by these patients as they attempt to remain free of
cocaine.
256
References
Besses, G.S.; Burrow, G.N.; Spaulding, S.W.; and Donabedian,
R.K. Dopamine infusion acutely inhibits the TSH and prolactin
response to TRH. J Clin Endocrinol Metab 41:985-988, 1975
Dackis, C.A., and Gold, M.S. Neurotransmitter and
neuroendocrine abnormalities associated with cocaine use.
Psychiatric Medicine, in press, 1984.
Extein, I.; Pottash, A.L.C.; Gold, M.S.; and Cowdry, R.W.
Using the protirelin test to distinguish mania from
schizophrenia. Arch Gen Psychiatry, 39:77-81, 1982.
Jackson, I. Thyrotropin-releasing hormone. N Engl J Med,
306( 3):145-155, 1982.
Kim, H.J., and Cereo, E. Interfenences by NaCl with the emit
method of analyses for drugs of abuse. Clin Chem,
22:1935-1936. 1976.
Langer, S.Z., and Enero, M.A. Cocaine: effect of in vivo
administration on synaptosomal uptake of norepinephrine. J
Pharmacol Exp Ther, 191:431, 1974.
Mantegazza, P.; Naimzada, K.M.; and Riva, M. Activity of
amphetamine in hypothyroid rats. Eur J Pharmacol, 5:10-16,
1968.
Morley, J.E.; Shafer, R.B.; Elson, M.K.; Slag, M.F.; Raleigh,
M.J., Brammer, G.L.; Yuwiler A., Hershman, J.M. Amphetamine -
induced hyperthyroxinemia. Ann Intern Med, 93:707, 1980.
Reichlin, S. Regulation of the hypophysiotropic secretions of
the brain. Arch Intern Med, 135:1350-1361, 1975.
Ross, S.B., and Renyi, A.L. Uptake of some tritiated
sympathomimetic amines by mouse brain cortex in vitro. Acta
Pharmac Tox, 24:297-309, 1966.
Saberi, M., and Utiger, R.D. Augmentation of thyrotropin
response to thyrotropin-releasing hormone following small
decreases in serum thyroid hormone concentrations. J Clin
Endocrinol Metab, 40:435, 1975.
Authors
Charles A. Dackis, M.D.
Todd W. Estroff, M.D.
Donald R. Sweeney, M.D., Ph.D.
A.L.C. Pottash, M.D.
Mark S. Gold, M.D.
Research Facilities
Fair Oaks Hospital
Summit, New Jersey 07901
257
Non-Dividing Human Lymphocytes
Have Specific Binding Sites for
Naloxone
John J. Madden; Arthur Falek; Robert M. Donahoe; Jan
Zwemer-Collins; and David A. Shafer
Human lymphocytes were obtained (courtesy of the Atlanta
Chapter of the American Red Cross) from the
leukocyte-platelet fraction of a blood plateletpheresis
procedure. After centrifugation on Ficol-Paque the
monocytes were removed from the mononuclear leukocytes by
absorption on plastic and glass wool, leaving a lymphocyte
fraction that was greater than 90% T lymphocytes and less
than 10% B and NK cells. Binding of 3H-naloxone to these
cells was measured by an equilibrium, glass filter assay
with non-radioactive naloxone as the competing ligand.
After removal of the monocytes, non-specific binding was
markedly reduced and a reproducible, saturable, competitive
binding of 3H-naloxone was found. Purified lymphocytes
from two, subjects yielded KD’s of 10.0 and 9.3 nM with a
mean of 9.7 nM. There was a high degree of cooperativity
of binding. A Hill plot of the data for each individual
produced n’s of 2.43 and 1.99 respectively for a mean value
of 2.21. While KD and n did not vary significantly
between samples, the apparent number of binding sites per
cell varied considerably, with the two cell preparations
yielding values of 6620 and 3750 sites per leukocyte
respectively (u = 5185). Whether this variance is a
product of genetic and/or environmental factors controlling
binding site expression, or whether variation in binding
site density on specific lymphocyte subpopulations is
responsible has not yet been ascertained. If the former
explanation is relevent, then individual subject variation
in binding site number may be important in defining the
differential responses of individuals to opiates. On the
other hand, if binding site density varies between
different T lymphocyte populations, then differences in
cell populations between individuals could explain the
variation in binding sites/cell found. A difference in
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binding site density between suppressor and helper T cells
might explain the selective loss of helper T cells found in
opiate addicts. Regardless of the reason for the binding
site density variation, measurement of opiate binding to
purified leukocyte population is critical to understanding
the mechanisms by which opiates alter the biological
properties and activity of the human immune system.
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Effects of Diazepam on Affective
Properties of Memories
R. E. Mann; B. A. Nicholls; C. A. Naranjo; C. W. Mueller; and
H. D. Cappell
Benzodiazepines have been shown to have reinforcing effects for
both humans and animals (Bigelow et al. 1976; Yanagita 1976). One
possible approach to understanding their reinforcing effects is
based on the drugs' therapeutically useful property of mood modi-
fication, which may serve as a functional basis for reinforcement
(e.g., Johanson and Uhlenhuth 1980). A better comprehension of
the nature of these mood-modifying effects may have important im-
plications for our understanding of the mechanisms by which these
drugs produce abuse.
Recently, it has been shown that memories which are affectively
congruent with a naturally occurring or behaviourally induced mod
state are recalled faster and more often than affectively incon-
gruent memories. Teasdale and colleages (Teasdale and Fogarty
1979; Clark and Teasdale 1982) have developed a procedure to de-
monstrate this effect. Subjects are shown a series of common
words and are asked to think of a memory (some event which they
have experienced) for each word. Subsequently, the subjects are
asked to rate the memory on affective dimensions (e.g., how happy/
unhappy the event made them feel). Memories elicited during pe-
riods when subjects are depressed (either naturally occurring or
induced) are rated as more unpleasant or unhappy than memo-
ries elicited when subjects are not depressed. The present study
examined the usefulness of such a procedure for assessing the mood-
modifying effects of diazepam.
METHOD
The subjects were sixteen male and sixteen female university stu-
dents between 19 and 32 years of age. A history was taken to ex-
clude heavy users of alcohol or drugs. All subjects received 10
mg. oral diazepam and a placebo on separate days, in a double-
blind, counterbalanced design. The task adapted from Teasdale's
work was called the cue-word task. Each time this task was per-
formed, subjects were presented with a series of twenty common
words (e.g., village, cloud). For each word, they were required
to think of a specific memory (i.e., an event which occurred to
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them in the past) which was evoked by the word. They then wrote
dam a short description of the memory, which would allow them to
recall it later, before viewing the next word in the series.
At the beginning of each session, prior to receiving drug or pla-
cebo, subjects provided measures of anxiety and verbal free recall,
in addition to performing the cue-word task. Verbal free recall
measures ware also obtained 30, 60, and 120 min. after administra-
tion of drug or placebo. The cue-word task was re-administered
(with different words) at the 60 min. test, when peak drug effects
were expected to occur (Sellers and Busto 1980). At the end of
each session (180 min. after receiving drug or placebo) subjects
rated the memories evoked by the two administrations of the cue-
word task on that day. Each memory was scored one each of six
dimensions: 1) how unhappy-happy the event made than feel when
it occurred (Happy-Then); 2) how unhappy-happy the memory makes
them feel when they think about it now (Happy-Now); 3) how un-
pleasant-pleasant the event made them feel when it occurred
(Pleasant-Then); 4) how unpleasant-pleasant the memory makes
them feel when they thihk about it now (Pleasant-Now); 5) how
anxious-relaxedthe event made them feel when it occurred (Anxious-
Then); and 6) how anxious-relaxed the memory makes them feel when
they think about it now (Anxious-Now). At the end of the second
day of testing, subjects were also asked to guess on which day
they had received the active drug and to fill out a brief drug-
liking scale.
RESULTS AND DISCUSSION
Variance analysis of the free recall data demonstrated that sub-
jects recalled significantly fewer words after administration of
diazepam than after administration of placebo. This result repli-
cates previous observations, and confirms that the dose of diaze-
pam used in the present study influenced the memory processes of
the subjects. Variance analyses of the cue-word data revealed
several drug effects on that task. Significant (p <.05) or mar-
ginally significant (.05 < p <.10) main effects of drug were
found on all of the six rating scales. In every case, memories
on the drug day were rated as more positive (i.e., happier, more
pleasant, more relaxed both then and now) than memories on the
placebo day. As well, significant or marginally significant Drug
X Sex X Trial interactions were observed for the Happy-Then,
Happy-Now, Pleasant-Then, and Pleasant-Now scales. Further anal-
yses of these interactions suggested that females were more in-
fluenced by diazepam than males. The reasons for these sex dif-
ferences are not yet known. Analyses of the drug-liking data re-
vealed no sex differences. Interestingly, subjects of both sexes
tended to dislike the effects of the drug, suggesting that the
positive effects of diazepam on affective qualities of memories
are independent of subjective enjoyment of the drug experience.
In summary, memories generated on days when diazepam was admini-
stered were given significantly more positive ratings than those
generated on placebo days. As well, these effects were more
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pronounced for females than males. For both sexes, the positive
effects of diazepam on the affective qualities of memories were
independent of self-reported liking of the drugged state. There-
sults are consistent with the known anxiolytic properties of dia-
zepam, and demonstrate that such effects occur in subjects not
selected for high anxiety levels. The present research demon-
strates the sensitivity of these measures to drug-induced mani-
pulatians of mood; the data also suggest that the cognitive and
affective changes induced by diazepam are interdependent.
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Alcoholics’ Responses to Drinking
Cues
R. E. Mann; C. X. Poulos; H. L. Kaplan; R. E. Hinson;
M. Paunil; P. J. Iversen; and H. D. Cappell
Many have suggested that conditioning processes my play a role in
tolerance to, and dependence on, alcohol and other drugs (e.g.,
Grabowski and O'Brien 1981; Wikler 1980). One model for the role
of conditioning processes in alcohol and drug influenced behavior
has been described by Siegel (1375; 1977) and others. According
to the model, drug administration elicits an unconditioned com-
pensatory response which is opposite in direction to the drug ef-
fect. Over training, the compensatory response becomes condi-
ed to enviromental stimuli which reliably precede drug ad-
ministration. After repeated pairing of drug administration with
entironmental cues, administration of the drug evokes the condi-
tional compensatory response, which counteracts some or all of
the drug's effects, resulting in tolerance. When cues associated
with drug administration are presented without drug administration,
the conditional compensatory response alone is elicited. It has
been suggested that the elicitation of compensatory responses in
the absence of the drug may contribute to the craving experienced
by alcoholics and other drug abusers. Thus, extinction of this
response may assist the alcoholic in overcoming urges to drink.
The conditional compensatory response model has received substan-
tial support from animal research. The two experiments reported
here were designed to test predictions of the model in human sub-
jects. In both experiments, alcoholics were exposed to stimuli
associated with alcohol consumption (i.e., they were exposed to,
and consumed, a nonalcoholic malt beverage which looked, smelled
and tasted like beer) and responses on several psychophysiologi-
cal and behavioral indices were measured.
EXPERIMENT 1
Twenty-four male alcoholic volunteers from a detoxification center
served as subjects. Participants more between 20 and 50 years of
age; all reported experiencing withdrawal symptoms after cessa-
tion of drinking. Subjects were led to believe that they might
be asked to consume an alcoholic beverage; otherwise they were
given a complete description of the study. After eguipment
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set-up and adjustment in a psychophysiological laboratory, each
subject was seated in a comfortable chair and the experimental
procedures began. These procedures consisted of exposing the
subject sequentially to alcohol consumption cues and water con-
sumption cues (order of presentation was counterbalanced across
subjects).
Each condition began with a 10-min. Baseline period. This was
followed by a 10-min. Cues period. For the alcohol cues condi-
tion, a tray containing liquor and beer bottles was brought into
the room; for the water cues condition, the tray contained a
pitcher of water. The 10-min. Drinking period followed. Sub-
jects were asked to drink a glass containing either 5 oz. of the
her-like malt beverage or water, respectively. At the end of
this period, the tray was removed from the room. Two 10-min.
periods (Post-Drink 1 and Post-Drink 2) followed next to allow
measurement of any responses elicited by the beverage. The
Baseline period for the second beverage began immediately after
the Post-Drink 2 period for the first beverage. Several psycho-
physiological measures, as well as measures of craving, anxiety,
verbal memory, and coding performance, here collected throughout
the study.
Variance analyses of the data revealed several significant (p <.05)
or marginally significant (.05 < p <.10) changes associated with
presentation of the alcohol cues (only some of which will be pre-
sented here). Craving scores did not differ between the water
and alcohol cues conditions in the Baseline period, but signifi-
cant elevations in craving were observed after exposure to the
alcohol cues. The mean heart rate decreased over time periods;
however, this trend was interrupted by a temporary increase after
exposure to the alcohol cues. Skin temparature also decreased
over time periods, interrupted by a temporary increase after ex-
posure to the alcohol cues. The amplitude of the T-wave in-
creased over the first three time periods; in the Post-Drink pe-
riods this increase continued in the water cues condition, while
in the alcohol cues condition the T-wave amplitude began to de-
crease.
EXPERIMENT 2
Twenty (out of a planned twenty-four) male alcoholic volunteers
have completed the second experiment. Subject population, general
design, procedures, and dependent measures were the same as those
described for Experiment 1. To examine extinction, on each of
four consecutive days subjects exposed to 10 min. Baseline,
Cues and Drinking conditions exactly like those in the alcohol
cues condition in Experiment 1. A single 10-min. Post-Drink pe-
riod was also included on each day. Additionally, half of the
subjects were exposed to three additional presentations of the
alcohol consumption cues one each day; these data will not be de-
scribed here.
Significant or marginally significant changes in response patterns
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over days for the heart rate, skin temperature, and T-wave ampli-
tude measures have been observed. On the first day the patterns
of responding very similar to those in the alcohol cues
condition of Experiment 1. However, by the fourth day, the pat-
terns of responding resemble those observed in the water cues
condition of Experiment 1.
DISCUSSION
The results of the first study revealed changes in several of the
indices after a single exposure to alcohol consumption cues, but
not after water consumption cues. These changes are consistent
with elicitation of a conditional compensatory response by the
alcohol consumption cues. The second study tested the hypothesis
that these responses will extinguish with repeated exposures to
the alcohol consumption cues. Preliminary analyses indicate that
initial exposures to the alcohol consumption cues result in changes
similar to those observed in the first experiment. However, these
changes do not persist after repeated exposures to the cues. These
data, then, support the conditioning interpretation by indicating
that extinction of the response to the alcohol cues may have occur-
red over the four days of the experiment.
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Characteristics of Drug-Dependent
Mothers Who Participate in
Developmental Outcome Studies
of Their Infants
Dianne O’Malley Regan; Theresa Matteucci; Joyce Diodati;
Karol Kaltenbach; and Loretta P. Finnegan
Family Center is a comprehensive program which provides obstet-
rical, psychosocial, and methadone maintenance for pregnant
drug-dependent women. In conjunction with this program, there
is a S-year longitudinal research project investigating the
developmental and neurological outcome of infants at periodic
intervals throughout the first five years of life. From 1980
to 1982. 67 methadone-maintained mothers enrolled in this pro-
gram agreed to have their infants evaluated at 6, 12, 18, 24,
36, and 48 months of age. Twenty-three of these mothers did
not return with their infants to be tested at 6 months of age
and thus had to be dropped from the study. To determine if
there were any salient characteristics between participants
(Group I) and non-participants (Group II). the following
maternal variables were examined: 1) number of prenatal visits,
2) continued enrollment in the program, 3) race, 4) age at
delivery, and 5) percentage of urines containing illicit drugs.
Severity of neonatal abstinence was also examined.
Mothers who participated in the follow-up study did not differ
from non-participating mothers in age at delivery. race, or
incidence of illicit drug use. There were no significant
differences found between the two groups of mothers in severity
of neonatal abstinence, both in terms of whether the infant
required pharmacotherapy or duration of infant hospitalization.
However, participating mothers were found to have more prenatal
visits (t=2.11, p <.05), and were more likely to be currently
enrolled in the program (x2=9.4, p <.01) than non-participating
mothers.
One of the major problems confronting research designed to
investigate the developmental outcome of children born to drug
dependent mothers is subject participation. These data indicate
the importance and value of integrating research within the
framework of clinical services for this population.
AUTHORS' AFFILIATION: Department of Pediatrics
Thomas Jefferson University, Philadelphia, PA
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Hypothalamic-Pituitary-Adrenal
Axis Function and Behavioral
Reactivity to Stress in Adult Rats
Administered THC in Early Life
J. A. Rosecrans; S. E. Robinson; M. K. Etkin; D. J. Mokler;
J. H. Johnson; and J. -S. Hong
The major objective of this research was to determine the long-
term effects of 9-tetrahydrocannabinol (THC) on the hypothalamic-
pituitary-adrenal-axes (HPAA) function. To accomplish this objec-
tive, rats were administered 3 dosage regimens of THC (10 mg/kg, sc)
between 30 and 50 days of age: 20, 10, and 5 doses dissolved in
emulfor vehicle were administered. Dosages were Interspaced equally
over a 20-day period and all rats received 20 dally doses of either
THC or vehicle. Dosage regimens were chosen to simulate human dosage
patterns of chronic, heavy, and occasional use. Two strains of rats
were used in this study: Sprague-Dawley (CD) and Fischer-344 (CDF).
Adult (135 days of age) CD and CDF rats were exposed to a stress-
induced analgesia paradigm (FSIA), consisting of 15 sec of 1.5 mA
foot shock. Half of the rats of each treatment (TRT) group served
as controls. Tail-flick latencies (tail-withdrawal from warm water,
55°C) were measured before and after foot-shock on day 1 in order to
evaluate the effects of acute FSIA in each TRT group. Foot shock
exposure was continued for an additional 3 daily sessions in which
latencies were measured only prior to foot-shock as a means of eval-
nating the development of conditioning to the shock (autoanalgesia).
Extinction of the conditioned response to shock was evaluated 2, 7,
14, 21, and 28 days after the last shock exposure. Tail-flick latencies
were measured with rats on the shock grid previously associated with
shock. CDF rats were sacrificed 15 min after exposure on day 28 and
plasma collected for the evaluation of HPAA function; corticosterone (CS)
and prolactin (PRL) were evaluated using RIA. CD rats and sham controls
were evaluated for an additional two weeks using classical operant
behavioral techniques.
All rats exposed to acute foot shock exhibited an analgesic response;
CDF rats were significantly more responsive to this stress. The acute
response to foot shock was also significantly facilitated by THC
10 X THC) when administered postweaning (P = 0.033; Fisher’s Exact
Probability Test). In addition, all rats developed conditioned
analgesia to foot-shock; there were few differences between TRT
groups. The most significant findings in this research were in
relation to plasma PRL levels (Table 1). ANOVA evaluations indicated
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a significant relationship between stress vs. nonstressed rats
(P < 0.0052, F=8.75) in relation to plasma CS levels, hut there were
no significant treatment interactions. An evaluation of plasma PRL
levels indicated both a group (P < 0.0008; F=13.30) and a TRT X Group
interaction (P < 0.0433; F=3.00). An interpretation of these data is
difficult at this time but it seems that the significant
interaction occurred as a result of a combination of effects of the
10 X THC and 5 X THC. Both postweaning treatments appeared to have
the effect of increasing the sensitivity of the conditioning effects
of foot shock while lowering ambient PRL levels of control rats
receiving THC in early life. Interestingly, the 20 X THC had -
little effects on any of the parameters measured. These studies
provide evidence that THC, when administered postweaning, had
potential long-term effects when such rats are exposed to stress
as adults. Rats receiving 10 X or 5 X THC over a 20-day period
seemed to be more affected in adulthood.
TABLE I: EFFECT OF VARIOUS POSTWEANING THC
DOSAGE REGIMENS ON HPAA FUNCTION.
Parameters Vehicle 5 X THC 10 X THC 20 X THC
Plasma CS
Control: 83 ± 171 134 ± 21 99 ± 52 112 ± 22
Stress: 142 ± 34 179 ± 30 215 ± 42 143 ± 41
Plasma PRL
Control: 127 ± 50 34 ± 5 33 ± 2 99 ± 54
Stress: 171 ± 44 287 ± 92 314 ± 94 118 ± 35
1Values are mean ± S.E.M. (n=6) in ng/ml plasma.
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Equi-Analgesic Dose Models for Quantitative
Physical Dependence Assessment in the
Mouse: Single Dose Suppression, Precipitated
Abstinence, and Primary Dependence
Induction Tests
William K. Schmidt
A B S T R A C T
Quantitative methods have been developed to measure the physical
dependence-producing properties of narcotic-related analgesics in
the mouse. Included are a Single Dose Suppression (SDS) test and
a Precipitated Abstinence (PA) test in morphine-dependent mice and
a Primary Dependence Induction (PDI) test in naive mice where in
equieffective dose levels of selected analgesics are maintained by
continuous minipump infusion. Major advantages include: 1) the
ability to assess dependence potential at analgetic ED50 doses, 2)
using the same species for both analgesia and dependence assess-
ment, and 3) the development of a highly reliable computer-based
method for quantitating withdrawal jumping activity in up to 64
animals simultaneously for periods from 5 min to 8 hr, then rapid-
ly analyzing the data and producing detailed reports of withdrawal
activity.
Results indicate that mu-agonist analgesics produce high levels of
dependence in all tests. Kappa-agonist analgesics produce minimal
or no dependence. Agonist/antagonist analgesics are heterogen-
eous, producing effects that are either mu-or kappa-like depending
on the drug used. Of all agonist/antagonist and kappa-agonist
analgesics, only nalbuphine, nalorphine, tifluadom, and U-50,488H
produced no abrupt abstinence withdrawal after 72 hr continuous
infusion (PDI test). Similarly, these drugs produce minimal or no
suppression of withdrawal in partly-withdrawn morphine-dependent
mice (SDS test). Analgesic-range doses of nalbuphine and nalor-
phine precipitate intense abstinence responses in non-withdrawn
morphine-dependent mice (PA test). Drugs with weaker antagonist
activity (pentazocine, butorphanol, buprenorphine) require much
larger doses to precipitate withdrawal.
These procedures offer a highly quantitative and comparatively
rapid (<1 week, all tests) assessment of the physical dependence
liability of narcotic-related analgesics with a high predicta-
bility to man.
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Adolescent Cocaine Abuse
Linda Semlitz and Mark S. Gold
INTRODUCTION
The incidence of adolescent cocaine abuse is increasing Easter
than any other drug (Kandel 1982). Surveys report that a total
of 22 million Americans (NIDA 1982) have tried cocaine and the
numbers continue to rise. According to the 1983 National
Institute of Drug Abuse (NIDA) sponsored survey of 17,000 high
school seniors, the use of marijuana and other drugs has
decreased since 1978 (American Medical News 1984). PCP rose
slightly from 2% to 3%. Daily use of marijuana has declined
from 10.7% in 1978 to 5.5% in 1983. The annual prevalence of
marijuana use decreased from 51% in 1979 to 42% in 1983.
Nearly 63% of the seniors admitted trying an illicit drug other
than marijuana at some time, down from 66% in 1982. Although
86% of the seniors said they could procure marijuana, 61% said
that they disapproved of occasional marijuana use while nearly
83% said they disapproved of regular marijuana use. In marked
contradistinction, the number of people who tried, cocaine
nearly doubled, from 9% in 1975 to 17% in 1983. Figure 1
reviews drug-taking behavior of the high school class of 1982.
(Figure 1) 3% of 1981 high school seniors used cocaine daily
in the month prior to being surveyed. (Figure 2).
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FIG 2 Thirty day prevalence of daily use of 11 types of drugs class
of 1981 (Source Johnston et al (1981). 
Drug-using youth demonstrate a variety of problem behaviors
including low self-esteem, impulsiveness, negative attitudes
toward school, and low academic aspirations. Childhood
aggression and rebelliousness predict later dysfunction.
Behavioral correlates most frequently associated with other
problem behaviors are school discipline problems, delinquent
behavior, all types of antisocial behavior and frequent use of
cigarettes, alcohol and other drugs (Narem-Heisen and Hedin,
1983). More importantly, drug use is an important cause of
mortality via motor vehicle accidents and death by suicide.
Tragically the drug-abusing group is less likely to seek help.
The belief that adolescents do not abuse cocaine because of
age, lack of access to hard drugs, or of financial
inaccessibility is not supported by objective data. Clinicians
need to be able to identify the symptoms resulting from cocaine
abuse early on in order to prevent future morbidity and
mortality. It is the purpose of this paper to profile the
typical regular cocaine user.
In response to the recent national increase in cocaine abuse
problems, Mark S. Cold, M.D., and Fair Oaks Hospital established
a national telephone helpline, 800-COCAINE, to provide
information, advice, and referral to treatment on a 24-hour per
day, 7-day per week basis. We conducted a survey of 60
adolescent cocaine abusers.
METHODS
Our subjects were 60 cocaine abusers randomly selected from
calls in June 1983 and from 30,000 callers in February 1984.
Subjects had learned of the helpline from radio and television
broadcasts stating that 800-COCAINE could be called anonymously
272
from anywhere in the United States to obtain information or
referral to treatment for a cocaine problem. Each subject
voluntarily consented to a 20-30 minute confidential telephone
interview conducted by an experienced drug abuse counselor.
Questionnaires were completed that included demographic data
drug use patterns, and negative medical and psychosocial
effect. While we have received calls from every state
callers in this sample were primarily from NY/NJ (25%),
California (20%), Illinois (12%), and Pennsylvania (8%). The
sample consisted of 28 females and 32 males with a mean age of
17 years. Fifty-four (90%) were white and 10 were black or
Hispanic.
RESULTS
The natural history of progressive cocaine abuse is rapid. The
time course between snorting their “1st line” and deterioration
in functioning leading to a call to the helpline is only 15
months, compared to 4-1/2 years in adults (Washton et al.
1984). Despite it’s cost, adolescents have access to cocaine
typically by either dealing drugs or by becoming sexually
involved with a more financially secure user. Of the 60
callers, 85% were intranasal (IN) users, 8% were freebase
smokers (FB), and 7% used cocaine intravenously (IV). While
all were self-proclaimed problem users only 48% used cocaine on
a daily basis. Among the FB and IV users. All had started
using cocaine by the intranasal route. The average caller was
a 17-year- old with 11 years of education who uses cocaine by
nasal inhalation and who views himself or herself as addicted.
At a street cost of $75-125 dollars per gram, callers reported
spending from 0-$5000, with an average of $440/month. The
average caller cited 12 of 22 negative psychiatric effects.
The adolescents were typically jittery 70%), chronically(
anxious (78%), and depressed (68%), with acute psychiatric
symptoms secondary to heavy cocaine use characterized by
delusions (35%), suspiciousness
compulsive behavior (73%).
(70%), paranoia (72%), and
Cognitive impairment included poor
concentration (65%), and memory defects (63%). 48% lost
interest in their friends and 62% lost interest in non-drug
related activity. Twenty-eight percent had active thoughts of
suicide, and 12% reported a suicide attempt.
The typical caller reported 11 of 22 possible questionnaire
items for adverse physical effects. The most commonly cited
physical symptoms included sleep difficulty (78%), chronic
fatigue (68%). runny nose (72%), and sinus problems (63%).
Intranasal users reported palpitations (65%) and nausea and
vomiting (50%). Twenty percent reported seizures.
Adolescent cocaine abusers suffered alarming social and
financial consequences. 42% deal drugs, and 35% resort to other
illicit activity to obtain cocaine. 20% have been arrested,
273
33% suffer school problems, and 18% have either been suspended,
expelled, or fired from part-time employment, 52% report a loss
of friends and 75% report fighting or violent arguments, 43%
are in debt, and 38% have stolen as a direct result of their
cocaine use. 12% of 18- and 19-year-olds suffered traffic
accidents. In spite of these consequences, 82% state that they
continue to use cocaine in order to recreate the original high.
There has been a debate for some time whether cocaine is
addicting with an assumption that non-addiction means absence
of danger. A more useful definition of addiction is compulsive
continued use in the face of obvious negative consequences. In
addition adolescents do not have the experience or judgement to
compensate for their behavior while intoxicated. Although
(67%) feel the medical consequences of cocaine use are moderate
to severe, only 10% stopped use because of such effects.
Chronic use typically leads to chronic depression, fatigue, and
irritability. Peak use of cocaine occurs at a time when youth
must make commitments to family and work roles and negotiate a
firm self -image. Drug use is an identity, life style and 24
hour/day job. Delays in psychosocial and interpersonal
development are common. Consistent with other studies (Single
et al. 1974) this study suggests that users of cocaine and
other illicit drugs are less conforming than non-users, with
resulting school problems, absenteeism, increased frequency of
delinquent acts involving interpersonal aggression, theft,
traffic violations, and other vehicle accidents and accidental
death by suicide. Unfortunately, the family is typically late
in correlating social and moral decay to drug use.
DISCUSSION
In summary, we have profiled the typical regular cocaine user
as a 17-year-old 11th grader who is chronically irritable,
depressed, estranged from family and friends, doing poorly
academically, and suffering from sleeplessness, weight loss,
rhinitis and of more concern occasionally seizures. The time
between first use and marked deterioration is 15 months.
Freebase and intravenous use was also preceded by intranasal
use. There is no specific treatment for cocaine abuse with
demonstrated long -term efficacy. The first task of treatment
is to get the patient and family to think that treatment ‘is
necessary. Frequently adolescents are pressured into treatment
with clinicians who do not know about drug use (they neglect to
tell them) and/or do not have drug abuse experience. Using
psychotherapy while the individual continues to abuse prolongs
the addictive process and provides the user with a
rationalization that he is seeking help. Psychotherapy should
occur only after substance abuse has totally stopped.
Supportive counseling, peer support groups, family education
and urine monitoring seem to be essential for treatment.
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Comparison of Physical Dependence-
Producing Mechanism Between
Barbiturates and Benzodiazepines
Yoshio Wakasa; Shin Kato; and Tomoji Yanagita
It is well known that benzodiazepines produce physical
dependence of the barbiturate type and that the withdrawal signs
of the drugs are similar to those of barbiturates in human
(Hollister 1961; Essig 1964) and in animals (Yanagita and
Takahashi 1973). Further, benzodiazepines are known to suppress
barbital withdrawal signs, indicating that they possess
cross-physical dependence property to barbiturates (Deneau 1977;
Yanagita and Takahashi 1973). Thus, benzodiazepines and
barbiturates appear to share, at least partially, some common
mechanism to produce physical dependence.
Since it is known that while benzcdiazepines act through the
benzodiazepine receptors, barbiturates do not, and that specific
benzodiazepine antagonists such as Ro15-1788 antagonize to the
central nervous system effects of benzodiazepines at the
receptor site (Darragh et al. 1981; Hunkeler et al. 1981) and
precipitate withdrawal signs in benzodiazepine-dependent animals
(McNicholas and Martin 1982; Lukas and Griffith 1982; Rosenberg
and Chiu 1982), involvement of the benzodiazepine receptors in
the physical dependence-producing mechanisms of benzodiazepines
and barbiturates were studied in the rhesus monkeys physically
dependent on diazepam or barbital.
METHODS
Route of Administration of Drugs and Dose of Ro15-1788
All drugs were administered intragastrically by gavage with
exception of pentobarbital which was administered
intramuscularly. The dose of Ro15-1788 was always 10 mg/kg.
Severity Scores of Withdrawal Signs
The severity of withdrawal signs in the monkeys physically
dependent on barbital or diazepam was scored according to the
criteria shown in Table 1.
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TABLE I SCORING SYSTEM FOR WITHDRAWAL SIGNS
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Experiment 1. The Effect of Ro15-1788 in Barbital-Dependent
Monkeys
Seven female rhesus monkeys were treated with repeated dose of
barbital 75 mg/kg once daily for first week then twice daily for
other 7 weeks. Two and a half hours after the last dose of
barbital, Ro15-1788 to 4 monkeys and carbomethylcellulose-Na
vehicle 2 ml/kg to 3 monkeys were administered by gavage and
withdrawal manifestation was observed for 3 hours.
Experiment 2. The Effect of Ro15-1788 in Barbital-Dependent and
Diazepam-Substituted Monkeys
Six female monkeys treated with barbital for total 8 weeks, 2 of
which were those used in Experiment 1, were withdrawan for about
50 hours, then received single dose of diazepam 4 mg/kg. Two
and a half hours later Ro15-1788 and the vehicle were
administered to 3 monkeys each and the changes in severity of
withdrawal signs were observed for 3 hours.
Experiment 3. The Effect of Ro15-1788 in Diazepam-Dependent
Monkeys
Six female monkeys were treated with diazepam twice daily at
doses of 8 mg/kg in the first 2 weeks then at 12 mg/kg in the
second 2 weeks. Two and a half hours later after the last dose
of diazepam single doses of Ro15-1788 and the vehicle were
administered to 4 and 2 monkeys respectively and withdrawal
manifestation was observed for 0.5 to 2 hours in the former and
for 1 week in the latter.
Experiment 4. Influence of Pentobarbital-Na Pretreatment on the
Effects of Ro15-1788 in Diazepam-Dependent Monkeys
Four monkeys used in Experiment 3 were treated further with
diazepam 12 mg/kg twice daily for 6 weeks. Two and a half hours
later after the last dose of diazepam, pentobarbital-Na 15 mg/kg
or saline were administered to 2 monkeys each, then 5 minutes
later. all monkeys received Ro15-1788 and withdrawal
manifestation was observed for 3 hours. The experiment was
repeated with further 4-week administration of diazepam and by
crossing over the animals for pentobarbital-Na and the vehicle.
RESULTS
Experiment 1. The Effect of Ro15-1788 in Barbital- Dependent
Monkeys
One monkey showed vomitings within a few minutes after
administration of Ro15-1788. No other meaningful sign was
observable by administration of Ro15-1788 or the CMC vehicle.
Experiment 2. The Effect of Ro15-1788 in Barbital-Dependent and
Diazepam-Substituted Monkeys
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Upon withdrawal of barbital for about 50 hours the monkeys
manifested such signs as apprehension, hyperirritability,
tremor, muscle rigidity, and impaired motor activity. By
administration of diazepam 4 mg/kg these withdrawal signs
attenuated or disappeared within an hour; however, the signs
exaggerated or reappeared when Ro15-1788 was administered to
them. No exaggeration or reappearance of the signs was observed
with the vehicle at least for 1 hour after administration
(Fig.1).
FIGURE 1 Diazepam 4 mg/kg was administered about
50 hours after the last dose of barbital
and 2.5 hr later, Ro15-1788 ( ) and
control (CMC) ( ) were administered to
3 monkeys each. The barbital withdrawal
signs suppressed by diazepam were pre-
cipitated by the benzodiazepine antago-
nist.
Experiment 3. The Effect of Ro15-1788 in Diazepam-Dependent
Monkeys
Within a few minutes after administration of Ro15-1788, the
monkeys began to manifest such withdrawal signs as restlessness,
lying on perch, salivation, retching, and vomiting, and
thereafter, defecation, diarrhea, muscle rigidity, tremor,
impaired motor activity, and threatening or attacking of other
monkeys. No acute withdrawal sign was observed in the vehicle
treated monkeys, but in the 7-day withdrawal observation in
these monkeys such withdrawal signs as apprehension,
hyperirritability, tremor, muscle rigidity, and impaired motor
activity were observed with grand mal convulsion on the 3rd day
of withdrawal in 1 monkey. The mean withdrawal scores at 30
minutes after administration of Ro15-1788 or vehicle were
evidently higher in the Ro15-1788 group than in the control
group (Fig.2).
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FIGURE 2 Ro15-1788 ( ) and control (CMC) ( )
were administered to respective 4 and
2 diazepam-dependent monkeys 2.5 hours
after the last diazepam dose. The
antagonist precipitated the diazepam
withdrawal signs.
Experiment 4. Influence of Pentobarbital-Na Pretreatment on the
Effects of Ro15-1788 in Diazepam-Dependent Monkeys
Precipitation tests of withdrawal signs by Ro15-1788 were
conducted following pretreatment with pentobarbital-Na or saline
in the 10th and 14th weeks of diazepam administration. In the
saline-pretreated group the withdrawal signs similar to those
observed in Experiment 3 were observed in both tests with one
case of grand mal convulsion in the 10th week test. However, in
the pentobarbital-Na pretreated group such signs as
restlessness, muscle rigidity, and impaired motor activity were
not manifested. Tremor was observed in most cases with the
severity similar to that of the saline-pretreated group, and
also vomiting and defecation were observed in 1 monkey each.
The mean withdrawal scores of the pentobarbital-Na pretreated
group were much lower than that of the control group at 0.5 and
1 hour after Ro15-1788 administration (Fig.3).
DISCUSSION
In the above experiments it has been demonstrated that the
physical dependence-producing properties of barbital are not
antagonized by Ro15-1788 but substituted by diazepam, that the
physical dependence producing properties of diazepam are
antagonized by Ro15-1788 and also substituted by pentobarbital,
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FIGURE 3 Monkeys physically dependent on diazepam
were pretreated with pentobarbital-Na
( ) or saline ( ) 2.5 hours after the
last dose of diazepam in 2 monkeys each,
and 5 minutes later, Ro15-1788 was
administered to all monkeys.
The precrpitated diazepam withdrawal
signs in the pentobarbital-pretreated
group were less severe than those of
the saline-pretreated group. Four weeks
later the test was conducted again by
crossinq over the animals for pentobar-
bital-Na and saline. The graph represents
the mean withdrawal scores of the 2 tests
(averaqe of 4 monkeys each).
and that the cross physical dependence properties of diazepam to
barbital are antagonized by the antagonist, but that of
pentobarbital to diazepam does not appear to be antagonized by
the antagonist. Thus, it become clear that the physical
dependent-producing properties of both drugs do not differ from
the other CNS effects in term of antagonism by the
benzodiazepine antagonist. These results indicate that the
benzodiazepine receptors are involved in developing physical
dependence on diazepam but not on barbital. Based on the fact
that the cross physical dependence is observable between the
barbiturates and diazepam, the sites responsible for developing
physical dependence on these drugs are assumed to be same.
Therefore, it is concluded that the sites may be located at
higher parts of the CNS than the receptor sites.
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Quantitative Determination of
LAAM and Its Metabolites in
Human Biofluids
K. Verebey; A. Depace; and S. J. Mulé
-Acetylmethadol (LAAM) is currently an investigational new drug
awaiting approval by the FDA for general use. Alternative drug
therapy of opiate dependence with LAAM is very attractive for two
main reasons. First, take-home medication is not needed due to its
long-time action; thus diversion for illicit use would be greatly
limited. Secondly, LAAM has a smooth therapeutic action elimina-
ting the daily "highs" and "lows" observed with methadone. Active
metabolite formation is responsible for the extended pharmacologi-
cal action of LAAM as contrasted with methadone which forms only
inactive metabolites. Because LAAM action depends on biotransfor-
mation to noracetylmethadol (NAM) and dinoracetylmethadol (DNAM),
individual variation in drug metabolism and disposition will sig-
nificantly influence the outcome of LAAM maintenance therapy.
The analysis of LAAM in biofluids reported in previous studies was
performed by thin layer chromatography (Henderson et al. 1977;
Misra et al. 1975; Campos-Flor and Inturrisi, 1977) by gas-liquid
chromatography (Kaiko et al. 1975; Tse and Welling 1977; Billings
et al. 1973; Lau and Henderson, 1976) by GC-MS (Sullivan et al.
1973; Jennison et al 1979) and by high-pressure liquid chromato-
graphy (Kiang et al. 1981). Most of these methods were sufficient
for research purposes but too complicated for routine analysis.
For this reason a method was developed in our laboratory with as
few steps as possible.
METHOD OF EXTRACTION
The following solutions were added to 15 ml siliconized conical
centrifuge tubes: SKF 525-A; 150 ng (the internal standard), 0.5
ml H2O, 0.5 ml serum from a subject on LAAM maintenance and 100 ml
of 50% NaOH. The tubes were mixed on a Vortex mixer and placed in
a heating block at 75°C for 15 minutes. Heating and the alkaline
environment converts LAAM metabolites into amides. This step was
used to increase extractability of the polar metabolites NAM and
DNAM. After removal from the heating block the samples were
allowed to cool and 5.0 ml of n-butyl chloride was added. The
samples were shaken for 10 minutes on an automatic shaker and cen-
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trifuged for 5 minutes at 2000 RPM. The upper layer (n-butyl
chloride) was transferred into clean test tubes and evaporated to
dryness. After reconstitution with 25 µl of ethyl acetate, 5 µl
aliquots were injected on to the capillary column.
GAS CHROMATOGRAPHY
A Hewlett Packard 5880A gas chromatograph was used with Nitrogen
detector. The column was a 25 m, 0.2 mm diameter, wall coated
OV-1 open tubular column (WCOT), made of fused flexible silica.
The mode of operation was splitless injection and cold trapping
with the split flow of 20 ml/min. The injector and detector
temperatures were: initially 190° for 30 seconds, then the temper-
ature was increased to a final value of 260° with a program rate
of 30°/minute. The carrier gas helium was flowing at 0.5 ml/min
through the column, the hydrogen at the detector was flowing at
3 ml/min and the air at 90 ml/min.
The retention times of LAAM, NAM amide and DNAM amide were 5.59
min, 10.10 min, 9.13 min respectively; SKF 525A had a retention
time of 7.16 min. Blank serum extracts had no interfering
peaks at the zones occupied by the compounds of interest.
Quantitation was performed by known standards of 5,10,20,50 and
100 ng added to 0.5 ml of blank serum with 150 ng of SKF-525A.
The standards were extracted according to the method described
for the unknown samples and analysed by gas liquid chromatography.
The standard curve was linear up to 800 ng/ml which was the high-
est concentration tested.
The nitrogen detector's absolute sensitivity for LAAM, NAM and
DNAM is 0.1 ng. However, after extraction from biological
fluids 5 ng/ml can be comfortably quantitated. The limit of
detection is approximately 1 ng/ml. Intra-run reproducibility
(n=12) as measured by the coefficient of variation for LAAM,
NAM and DNAM was 4.1,4.7, and 6.1% respectively, indicating
excellent dependability of the method.
The advantages of this method are: 1) speed, due to the single
extraction step; 2) increased recovery of NAM and DNAM, due to
the decreased polarity of the amides; 3) greater stability of
the LAAM metabolites, due to their conversion to the amide
configuration; 4) better chromatographic separation and quan-
titation because the area where the peaks migrate is free of
interfering substances; 5) low sample volume helps to reduce
the amount of blood needed for analysis, and 6) all three of the
major pharmacologically active substances can be measured
simultaneously.
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The Khat Alkaloid (-)Cathinone
Acts Like Amphetamine on
Physiological Catecholamine
Stores
Peter Kalix
In certain areas of East Africa and the Arab Peninsula, fresh
leaves of the khat bush are widely used as a stimulant. This
material is now known to contain the alkaloid (-)cathinone, a
substance that has been shown to produce amphetamine-like behav-
ioral effects. The experiments described below were carried out
in order to compare the effects of (-)cathinone and (+)amphetamine
at the cellular level.
When the effect of (-)cathinone on the efflux of radioactivity
from rabbit striatal slices prelabelled with 3H-dopamine was
examined, it was observed that low concentrations of the alkaloid
enhanced the release of label in a dose-dependent manner.
Furthermore, (-)cathinone was capable of sustaining an enhancement
of a release induced by (+)amphetamine. Preperfusion of the
tissue with cocaine, a substance that prevents the induction of
release by (+)amphetamine, inhibited the efflux increase caused
by (+)cathinone. In other experiments with dopamine-prelabelled
tissue, the alkaloid was also found to cause release from the
nucleus accumbens, a brain region that is essential for amphetamine
hypermotility. These observations suggest that (-)cathinone is a
CNS stimulant with a mechanism of action analogous to that of
amphetamine.
Since consumption of khat is associated with sympathomimetic side
effects, experiments were performed to determine whether the
releasing action of (-)cathinone observed in the CNS also occurs
in peripheral tissues. When slices of rabbit atria that had been
prelabelled with 3H-norepinephrine were superfused with solutions
of either (-)cathinone or (+)amphetamine, a rapid increase of the
efflux of radioactivity was observed. In tissue from reserpinized
animals the releasing effect of (-)cathinone, as well as of
(+)amphetamine, was characterized by rapid development of tachyphy-
laxis.
In summary, it was shown that (-)cathinone has an amphetamine-like
releasing effect both at central dopaminergic synapses and at
peripheral norepinephrine storage sites.
AUTHOR Peter Kalix, Ph. D., Dept. of Pharmacology, Univ. of Geneva, Switzerland
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Inpatient Heroin Withdrawal
With Clonidine
Hans Schanda; Otto Presslich; and Peter Hermann
Experimental (Tseng et al., 1975) and clinical (Gold et al.,
1980; Washton et al., 1980) studies pointed to the efficacy of
clonidine for the treatment of heroin withdrawal. We have been
using clonidine 1980 for the treatment of acute withdrawal
syndromes in heroin addicts and attempted from the first to
develop a clinically useful strategy for inpatient treatment.
METHODS AND POPULATION
Fifty patients (32 men, 18 women, mean age 23.7 years) entered
the study. They were all pure heroin addicts (mean duration of
opiate abuse 3.5 years). Admission to the program has to be
voluntary. A contract was made for a minimum stay of 10 days on
the unit (if necessary), with no visitors. Spot-checks of urine
were done. Six patients arrived in a state of severe withdrawal
(Kielholz stage two with perspiration, tearing, rhinorrhea,
mydriasis, severe joint and muscle pains) on the ward. They got
a single dose of 0.15 mg clonidine slowly i.v. Thereafter all
further medication was administered orally on an "as needed"
basis. Clonidine 0.075 mg (1 tablet = 0.15 mg) was given, when
withdrawal symptoms corresponded to Kielholz stage 1 (1972), and
could be repeated hourly. Our pre-study experience was that
clonidine is ineffective against insomnia. So we offered
doxepine 100 mg p.r.n. sleep throughout the hospital stay; for
the first four nights, this could be-augmented by nitrazepam 10
mg if required. Stages of withdrawal were classified clinical
according to Keilholz et al., (1972). No rating scales were
used. Liver function was performed routinely at least twice
during hospitalization. Blood pressure and pulse frequency
(supine) were taken three times a day throughout.
RESULTS AND DISCUSSION
Nine patients dropped out in the second or third day of withdrawal,
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five because of treatment failure, four because of non-cooperation
not due to non-response. Of the remaining 41 probands who
completed the study mean length of required hospitalization was
7.78 days (range = 4 to 19 days, = 2.88). Clonidine was
never required beyond 7 days (mean 5.1 days, q 1.26) (table 1).
TABLE 1
The clonidine doses required (table 2) approximate the rapid
detoxification schedule of 0.2 to 0.9 mg clonidine (daily
average 0.5 mg), proposed by Washton,  et al., (1980).
TABLE 2
Nine of our 41 patients complained of symptoms of orthostatic
hypotension, and were given a small dosage of a peripheral
vasoconstrictor (norfenefrine) as needed. Reason for this
orthostatic hypotension could of course be higher clonidine
doses. But t-test for independent samples showed no significant
differences in clonidine doses with or without a peripheral
vasoconstrictor. There was also no significant difference
between the two groups in the supine blood pressure before the
first administration of norfenefrine. No significant changes in
blood pressure and heart rate were seen in the 32 patients
without vasoconstrictor (table 3). which does not correspond
with the results of Charney, et al., (1981) and Gold, et al. ,
(1980). who reported decrease of blood-pressure under clonidine.
Maybe this is due to the use of doxepine (as sleep-medication on
an "as needed" basis) which blocks the peripheral antihyperten-
sive effect, of clonidine (uptake into peripheral adrenergic
neurons) (Briant, et al., 1973).
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Our observation and the reports of the patients show that muscle
and joint pains, muscle twitching and tremors, perspiration,
psychomotor agitation, and occasionally, anxiety attacks are
influenced by clonidine; gastro-intestinal disturbances (vomiting,
diarrhea) and especially insomnia are unaffected by clonidine.
As a consequence of this all subjects requested sleep medication
at one time or other (100 mg doxepine; for the first four 4
nights 10 mg nitrazepam). Tenacious insomnia responds well to
doxepine. Further antidepressants seem to be effective against
the depression and anhedonia, which often follow opiate withdrawal.
Mean supine heart rate and blood pressure (with 5% confidence-
intervals) during the seven clonidine days
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Withdrawal From Nicotine
Dependence Using Mecamylamine:
Comparison of Three-Week and
Six-Week Dosage Schedules
Forest S. Tennant, Jr., and Anita L. Tarver
ABSTRACT
Mecamylamine (MCL) has been shown to extinguish nicotine depend-
ence in animals and produce smoking cessation in the humans.
This study was done to determine if MCL may be more effective and
have fewer side-effects when administered at low dosages over a
six-week period than at high dosages given over a three-week per-
iod. Subjects in the high-dose, three-week group demonstrated
significantly more reduction of nicotine intake as evidenced by
self-report and presence of nicotine in urine although side-effects
were more pronounced. Although MCL’s numerous side-effects should
limit its clinical use to recalcitrant smokers who have failed
other types of treatment, its nicotine antagonist property indi-
cates it can be an effective agent to withdraw some persons from
nicotine dependence.
INTRODUCTION
The ganglionic blocker, mecamylamine (MCL), has been shown to ex-
tinguish nicotine dependence in rats and monkeys.1,2 In a pre-
liminary clinical evaluation, we found that MCL was effective in
withdrawing approximately 50% of recalcitrant nicotine-dependent
persons when administered over a three-week period.3 MCL was
initially administered in a dose of 5 to 10 mg. per day and pro-
gressively raised over a period of ten days, until the subject
experienced nicotine blockage or toxic effects. These high dos-
ages over a short period of time, however, resulted in numerous
side-effects. Reported here is a comparison of MCL given at low
dosages over a six-week period with high dosages given over a
three-week period to determine if the longer treatment period at
low dosages may be effective and have fewer side-effects.
METHODS
Nicotine-dependent volunteers who met the following criteria were
selected: smoked at least 20 (one pack) cigarettes per day: had
not been nicotine abstinent for more than one day for at least one
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year; no current history of hypertension, pregnancy, cardiovascu-
lar disease, prostate enlargement, glaucoma, or self-reported dep-
endence upon alcohol or other drugs. Subjects did not take any
prescription medication Subjects also had to have the perception
that they ware "addicted" to nicotine. Eighteen (18) persons
entered the three-week and fourteen (14) entered the six-week dos-
age regimens. Following informed consent, subjects underwent phy-
sical examination, blood pressure recording, and urine analysis
for the qualitative presence of nicotine.
Subjects in both groups attended the clinic daily for the first
five days and then two or three times per week for the period of
MCL administration. Dosage schedules for both groups are listed
in Table One. Blocking dosage was achievedwhen the subject
stated he/she cold not perceive any nicotine effect. Whenever
there was significant side-effect(s), MCL dosage was either re-
duced or held constant. Once a subject stopped smoking, they were
allowed to voluntarily continue MCL administration throughout the
duration of the assigned study period of three or six weeks.
During each clinic visit, the subject was examined for evidence of
sedation, tremor, and motor impairment, and blood pressure was re-
corded in the sitting and standing positions. A daily check list
of 24 side-effects was assessed, and the list included abdominal
cramps, blurred vision, costipation, dizziness, drowsiness, dry
mouth, dysphoria, headache, irritability, lethargy, palpitation,
photophobia, tremor, urinary hesitancy, urinary retention, and
weakness. Subjects were specifically asked on each day of attend-
ance if MCL blocked the effects of nicotine: if it "works"; helps
reduce nicotine craving, and if they wanted to continue MCL. Each
subject kept a diary of the time of day and number of cigarettes,
smoked. A urine sample was submitted by subjects every day of
attendance to be analyzed for the presence of nicotine.4
RESULTS
Both groups had similar demographic and nicotine use characteris-
tics (Table TwO). Ages ranged from 22 to 61 years. Subjects had
smoked from 7 to 49 years and, at the time of admission to the
study, smoked 20 to 80 cigarettes per day. The majority had re-
lapsed following attendance at anti-smoking programs. A number of
side effects were experienced by both groups of subjects (Table
Three). The high-dose, three-week group had significantly more
abdominal cramps, constipation, and urinary retention, while the
low-dose, six-week group had more headaches. Side-effects were
severe enough to cause almost one-half of subjects in both groups
to drop out of the study. There was no drop in systolic or dias-
tolic blood pressure in any subject greater than 15 mm Hg.
Although slightly higher percentage of three-week subjects (6;
33.3% compared to 3; 21.4%) reported they stopped smoking, the
difference was not significantly different (PNS). A significant
number of three-week compared to six-week subjects, however, re-
duced cigarette intake to less than five per day and converted
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their urine from nicotine positive to negative on at least one
urine test (Table Four). The majority of subjects in the three-
week group perceived MCL to block nicotine and reduce nicotine
craving, while only about half the six-week group felt this way.
Four of the six (66.6%) subjects in the three-week group, and the
three in the six-week group the reported total cessation of smok-
ing did so at a dose of 2.5 mg. QID (10 mg. in a 24-hour period).
Two subjects in the three-week group stopped at dosages of 40 and
50 mg. per day. Slightly more subjects in the six-week group
dropped out of treatment during the first week (33.7% compared to
10.6%; PNS). In addition, the mean retention time of 12.6 days in
the six-week group was not significantly greater than the 9.3 days
observed in the three-week group (PNS).
Two subjects in the three-week, and one in the six-week group de-
sired to take MCL past the allotted time periods of the study.
Three of the six (50.0%) subjects in the three-week group and one
of the three subjects (33.3%) in the six-week group who reported
total cessation of smoking had resumed smoking within 30 days fol-
lowing discontinuation of MCL.
DISCUSSION
This study was done to determine if low dosages of MCL given over
several weeks might be more effective and have fewer side-effects
than high dosages administered over a three-week period. Side
effects of MCL are particularly prominent in high dosages and they
produce a high drop-out rate.3 We found, however, that almost as
many subjects dropped out of the six-week, low-dosage group due to
side-effects. In addition, the low-dosage, six-week group had
fewer persons (21.4% versus 33.3%) report total smoking cessation,
although this was not a statistically significant difference. The
three-week group did have significantly more persons reduce their
cigarette intake to less than five per day and convert their urine
from nicotine positive to negative.
Better results in the three-week group appeared to be due to pro-
gressive raising of the MCL dose to achieve nicotine blockade in
the first week of treatment. Subjects in the high-dose group com-
pared to the low-dose group tended to perceive that MCL was more
effective in blocking nicotine and helping then reduce its intake.
Apparently the achievement of almost total nicotine blockade with
MCL is necessary to best retain patients in treatment and promote
nicotine abstinence.
This study was not blind to either investigators or subjects, so
data may be biased. Despite the open nature of this study, nico-
tine abstinence rates were not especially impressive, although the
subjects selected for study were chronic, recalcitrant smokers.
The majority had previously failed formal anti-smoking programs.
In addition, MCL's numerous side-effects should limit its use to
smokers who have failed other forms of nicotine dependence treat-
ment. MCL does represent a new concept in treatment of drug dep-
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endence.4,5 The antagonists disulfiram and naltrexone are cur-
rently used as maintenance agents to prevent relapse to alcohol or
opioid dependence. As a nicotine antagonist, MCL's best use
appears to be that of a withdrawal agent, although same subjects
who tolerated it well requested long-term maintenance.
TABLE ONE
DOSAGE SCHEDULES UTILIZED
*The maximum dosage given to any subject was 50 mg. in a 24 hour
period.
TABLE TWO
CHARACTERISTICS OF SUBJECTS
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Mean Use of Nicotine (Yrs.) 24.6 21.9
Mean No. Cigarettes Used
Per Day 41.9 40.6
No. Who Perceive
"Addiction" to Nicotine 18 (100%) 14 (100%)
No. Wno Awake at Night to
Smoke 9 (50.0%) 8 (57.1%)
No. Who Had Attended a
Formal Anti-Smoking
Program 11 (78.5%) 9 (64.2%)
TABLE THREE
SIDE-EFFECTS EXPERIENCED BY SUBJECTS
Side-Effect
Abdominal Cramps
Blurred Vision
Constipation
Dizziness
Drowsiness
Dry Mouth
Dysphoria
Headache
Irritable
Letargy
Palpitations
Photophobia
Tremor
Urinary Hesitancy
Weakness
Three-Week
Group N=18
10 (55.5%)
3 (16.6%)
13 (72.2%)
7 (38.8%)
8 (44.9%)
13 (72.2%)
1 ( 5.5%)
2 (11.1%)
7 (38.8%)
3 (16.6%)
1 ( 5.5%)
0 ( 0%)
1 ( 5.5%)
4 (22.2%)
5 (27.8%)
Six-week
Group N=14
3 (21.4%)
2 (14.3%)
5 (35.7%)
5 (35.7%)
7 (50.0%)
9 (64.3%)
1 ( 7.1%)
6 (42.8%)
4 (28.5%)
3 (21.4%)
2 (14.3%)
1 ( 7.1%)
1 ( 7.1%)
0 ( 0%)
7 (50.0%)
PNS
PNS
PNS
PNS
PNS
Stat
Sig.
P<.05
PNS
P<.05
PNS
PNS
PNS
PNS
P<.05
PNS
PNS
PNS
PNS
PNS
P<.05
PNS
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TABLE FOUR
RESULTS AND OUTCOMES
No. who reported smoking
cessation
No. who reported decrease
in smoking to 5 or fewer
cigarettes per day
No. who converted from
nicotine positive to
negative on one test
No. dropouts
No. who dropped out due
to side-effects* PNS
No. who dropped out due
to non-effectiveness PNS
No. who dropped out in
first week of treatment
No. who perceived MCL
blocks nicotine effects
No. who perceived MCL to
reduce nicotine craving
Three-Week
Group N=18
6 (33.3%)
12 (66.6%)
13 (72.2%)
10 (55.6%)
9 (50.0%)
1 ( 5.5%)
3 (16.6%)
16 (88.9%)
16 (88.9%)
Six-Week
Group N=14
3 (21.4%)
2 (21.4%)
4 (28.5%)
7 (50.0%)
6 (42.8%)
1 ( 7.1%)
Stat
S i g .
PNS
P<.05
P<.05
PNS
5 (25.7%) PNS
7 (50.0%) P<.05
6 (42.9%) P<.05
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Biological Evaluation of Compounds for Their
Physical Dependence Potential and Abuse
Liability. VIII. Drug Testing Program of The
Committee on Problems of Drug Dependence,
Inc. (1984)
Arthur E. Jacobson
The program of the Committee on Problems of Drug Dependence
(CPDD) on the biological evaluation of compounds for their
physical dependence potential and their abuse liability has, up
to the past few years, primarily concerned opioids. This testing
program uses procedures which are capable of determining the
biochemical and pharmacological activity of opioids and
differentiating opioid agonists, agonist-antagonists, and the
opioid antagonists. About two years ago the CPDD began to
investigate the methodology necessary for the determination of
the abuse liability of pharmacologically different classes of
compounds, the stimulants and depressants. We have now completed
the initial assessment of methodology and have enlisted, under
CPDD auspices, several laboratories to aid in the abuse liability
determination of new stimulants and depressants. During the
coming year the program will study a number of stimulants
which are scheduled for examination by the World Health
Organization in 1985.
LABORATORIES UNDER CPDD AUSPICES CONCERNED WITH OPIOIDS
Three laboratories are involved in the work on opioids. The
initial testing, in mice, for antinociceptive activity and for the
determination of a starting dose for further work in the rhesus
monkey, is done in the Medicinal Chemistry Section. LC, NIADDK, NIH
(Dr. A. E. Jacobson, with the technical assistance of M. Mattson).
The compounds which I receive from various sources are distributed
to the two other groups involved in the evaluation. These groups
are those at the Medical College of Virginia, Department of
Pharmacology (Drs. L. S. Harris, M. D. Aceto, E. L. May, R. L.
Balster and B. L. Slifer, with the technical assistance of F. T.
Grove, R. F. Jones, S. M. Tucker, W. D. Rodes and S. R. Phillips),
and at the University of Michigan Medical School, Department of
Pharmacology (Drs. J. H. Woods, G. D. Winger, F. Medzihradsky, C.
B. Smith and D. Gemerk). Evaluation of the compounds has
been described heretofore (Jacobson 1981). Modifications of these
procedures are described below.
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MODIFICATIONS IN PROCEDURES FOR EVALUATION OF OPIOIDS
The individual Annual Reports from UM and MCV will, for the
second consecutive year, be combined under a single code number
and structure. The assigned code number will be the NIH number
given to the compound at NIH. A new cumulative dosing procedure
will be used at UM in their monkey studies. This will enable
them to obtain information on the physical dependence potential
of compounds more rapidly. Single doses will he used, when
necessary, retrospectively on compounds of interest. Further, at
UM, the in vitro work using rat cerebrum membranes will be
carried out in the presence of 150 nM NaCl only. These data can
be correlated with the data previously obtained at UM through use
of their +Na/-Na ratios. That is, the binding of compounds to
the rat cerebrum membranes in the absence of sodium can be
obtained by dividing the value noted for the EC50 in the presence
of sodium by the ratio of (+)Na/(-)Na (noted in parentheses in
the Tables in my previous reports (Jacobson 1934) and in those
from UM, or in the combined Annual Report (Woods et al. 1984)).
It should be noted that the shift observed with narcotic
antagonists in the presence of sodium may only partially be due
to their opioid antagonist character. There is now evidence
(Loew 1994) that opioid receptors other than mu or delta are
involved in the binding of ligands when sodium is added. Lastly,
the electrically stimulated guinea pig ileum assay has been
discontinued to expedite the evaluation, and because the ileum
has not been found to be as predictive as the mouse vas deferens
assay.
THE ORIGIN AND TYPES OF “OPIOIDS” EXAMINED
Relatively few compounds were sent for evaluation from
pharmaceutical industry (13% total, 8% from US industry). An
additional 12% were solicited from US industry by the CPDD; these
were the antihistamines discussed below. US universities
submitted 34% of the compounds evaluated, and foreign
universities submitted 7%. The NIH submitted 22% and CPDD
requested 7% of the compounds, the latter serving as reference
samples. The remaining 5% of the compounds came from foreign
industry, in collaboration with a US university study. A
relatively large number of compounds were released for
publication; there are 61 compounds listed in the MCV Annual
Report and 50 compounds listed in the UM Report. Consolidation
in the NIDA monograph will result in a combined report on a
somewhat lower total number.
The tables 1-7 which follow contain a summary‘ of the work
completed on the released compounds; structurally similar
compounds are grouped, together. Work was done with
4,5-epoxymorphinans (tables 1 and 2), morphinans (table 3),
benzomorphans (table 4), and phenylmorphans (table 5). The
antihistamines are included among the miscellaneous compounds in
tables 6 and 7. It is of particular interest to note
endoethenooripavine-like compounds with peptide moieties in table 2.
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One of them, NIH 9835, has one of the highest affinities for the
opioid receptors in rat cerebrum membranes ever observed. Its
relatively mediocre antinociceptive activity (morphine-like) may
have been caused by the inherent in vivo instability of peptides
with all L-amino acids.
EVALUATION OF STIMULANTS AND DEPRESSANTS
This evaluation has been undertaken by Drs. J. Brady, N. Ator, R.
Griffiths, and R. J. Lamb of the Johns Hopkins University Medical
School, Drs. C. Johanson and C. R. Schuster of the University of
Chicago Medical School, Drs. R. Glennon, L. Harris, M. Aceto,
E.L. May and G.A. Patrick of the Medical College of Virginia, and
by Drs. C. Gorodetzky, R. Cone, M.E. Risner, H. E. Shannon and D.
B. Vaupel of the Addiction Research Center of the National
Institute on Drug Abuse, ADAMHA. Over the past two years a
number of depressants and stimulants have been examined and the
results have been reported at the CPDD Annual Meeting and to the
Drug Testing Program Committee of the CPDD. A complete report is
being prepared for the CPDD and for distribution to the
submitters of the compounds.
The evaluation procedure is initiated by myself at NIH, where a
CPDD number is assigned to the compound. Dr. Cone (ARC) then
determines the solubility of the compounds in the required
solvents. He also runs TLC and IR spectra for compliance with
the Good Laboratories Practice Regulations of the FDA. The
compound is initially evaluated for potency by an inverted
platform assay and in activity cage studies in rodents (Dr. L.
Harris et al., MCV) and, if the compound is in the benzodiazepine
class, their affinity to the benzodiazepine receptors in rat
brain homogenate is determined (Dr. Jacobson and M. Mattson,
NIH). The study is continued in drug discrimination and
self-injection paradigms in monkeys and in drug discrimination in
pigeons (Drs. Johanson and Schuster, Univ. of Chicago). Drug
discrimination assays in baboons and, electively, self-injection,
are done at the Johns Hopkins Univ. (Dr. Brady et al.). Dr. R.
Glennon (MCV) will aid in the evaluation of stimulants, using
drug discrimination assays in rodents.
ANTIHISTAMINES EVALUATED
The ten antihistamines which have been evaluated this year are
listed in tables 6 and 7. These are phenyltoloxamine, cyclizine,
hydroxyzine, promethazine, tripelennamine, pyrilamine,
diphenhydramine, chlorpheniramine, cimetidine, and flunixin.
Reasonable correspondence between the results from MCV and UM was
observed except for cyclizine, which will he reevaluated. Few of
the compounds showed much antinociceptive activity nor had typical
opioid patterns of action. Tripellenamine was the most potent of
the antihistamines as an antinociceptive.
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ABBREVIATIONS USED IN TABLES 1 - 7.
Antinociceptive assay (ED50, sc injection, mice) [Confidence limits
are listed in MCV/UM report]: HP = hot plate; N = Nilsen; PPQ =
phenylquinone; TF = tail flick; TFA - tail flick antagonism vs.
morphine.
I = inactive, without a reasonable dose-response relationship,
or insufficiently active for statistical analysis.
EC50 Determinations in vitro and ex vivo:
RBH (EC50 by displacement of 0.5nM 3H-etorphine) = binding
affinity, in the presence of 150mM NaCl, to rat cerebrum membrane
preparations, in nM (parenthesized number is ratio of +Na/-Na).
The EC50 of morphine, for comparison = 23.6 (1.69). NE = no
effect. NOTE: The present EC50 data cannot he directly compared
with those from my previous reports (Jacobson 1983, and previous
years) since I formerly quoted -Na values. However, the previously
stated numbers can be calculated for comparison with those which
will he utilized this year and in the future (vide supra).
GPI = electrically stimulated guinea pig ileum EC50, rounded to
one significant figure. E = x10 (parenthesized numbers are
maximum percent inhibition at EC50); bracketed letters: A =
antagonized by 10-7M naltrexone; NA = not antagonized by
naltrexone; NE = no inhibition of twitch]. NOTE: The GPI assay
is being phased out of the normal routine. These data will not
be obtained as part of the general assays. The VD assay will
continue.
VD = electrically stimulated mouse vas deferens EC50 values,
rounded to one significant figure. E = x10 (parenthesized numbers
are maximum percent inhibition at EC50); [bracketed letters: A =
antagonized by 10-7 M naltrexone; NA - not antagonized by
naltrexone; NE = no inhibition of twitch; SA = slight antagonism by
naltrexone].
Data From Monkey Colonies:
SDS = single dose suppression: NS = no suppression; CS = complete
suppression; PS = partial suppression. (Parenthesized numbers =
dose range studied, in mg/kg; if CS, then dose at which CS was
observed is noted in the parentheses). Potency comparison with
morphine [M] may be stated, in brackets.
NW = studies in non-withdrawn monkeys: PW = precipitated
withdrawal at dose levels, in mg/kg, indicated in parentheses &/or
comparison with naloxone [N], in brackets; NP = no precipitation:
SP = slight precipitation.
Other Studies:
RI - rat infusion: NS = no suppression; CS = complete suppression;
PS = partial suppression.
PPD = primary physical dependence.
SA = self-administration: NE = no effect; High = codeine-like: IN
= intermediate between saline and codeine; SE = slight effect.
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Normal monkeys: M-like = morphine-like effect.
DD = drug discrimination.
NOTE: The numbers used in the tables may be rounded. For precise
values, and details of the procedures, see the MCV/UM report in
these Proceedings.
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Evaluation of New Compounds for
Opioid Activity in Rhesus Monkey,
Rat, and Mouse (1984)
James H. Woods; Gail D. Winger; Fedor Medzihradsky;
Charles B. Smith; Debra Gmerek; and M. D. Aceto;
L. S. Harris; E. L. May; R. L. Balster; and B. L. Slifer
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
The evaluation of new compounds by the programs at the
University of Michigan and the Medical College of Virginia is
coordinated by Dr. Arthur E. Jacobson, Medicinal Chemistry
Section, NIADDK, National Institutes of Health, Bethesda, MD.
The drugs, which come originally from pharmaceutical companies,
universities, and government laboratories, are submitted to Dr.
Jacobson, who performs the mouse hot-plate and Nilsen tests.
[(Only Beta-funaltrexamine and dynorphin fragments and vaso-
pressin, tested in the Medical College of Virginia, were not
supplied by Dr. Jacobson.)] Values obtained in these tests for
some representative opioid drugs are given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information, and
(4) a recommended starting dose. Only after the evaluation is
complete and the report submitted back to Dr. Jacobson are the
chemical structure and the mouse-analgesia data released to the
evaluating laboratory.
DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression test (SDS) determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipitate
the withdrawal syndrome in nonwithdrawn (NW) morphine-dependent
monkeys. Nondependent monkeys (Normals) are used to determine
whether the acute effects of the test drug are reversible by
nalorphine or naloxone. In a primary dependence study (PDS),
non-dependent monkeys receive the test drug every six hours for
30 days to determine whether withdrawal signs will appear when
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the animals are challenged with an antagonist or when drug
administration is discontinued.
Modified procedures for the precipitated withdrawal (PPt-W) and
single dose suppression (SDS) tests were reported by Aceto and
co-workers (1977 and 1978). The PPt-W test was initiated by the
injection of a test drug 2½ hours after an injection of morphine
and the animals were observed for signs of withdrawal. The SDS
test was started approximately 15 hours after the last dose of
morphine at which time the animals were showing withdrawal
signs. The onset and duration of action of the test drug were
noted. In both tests, a vehicle control and an appropriate
positive control (naloxone 0.05 mg/kg or morphine sulfate, 3.0
mg/kg) along with 3 different treatments (doses) of a test
compound were randomly allocated to the 5 monkeys of a group.
Occasionally 4 monkeys comprised a group and 2 doses of test
compound were studied. Usually, 3 or 4 groups per compound were
used. All drugs were given subcutaneously or (1 ml/kg) intrave-
nously (1-2 ml) and the vehicle used is indicated for each
compound. The observer was "blind" with regard to the treatment
given. A minimum t-week washout and recuperation period between
tests was allowed. In the primary physical dependence (PPD)
test, the animals of a group received the drug every 4-6 hr for
30-50 days. They were placed In abrupt withdrawal and challenged
with naloxone periodically and were observed for signs of
physical dependence.
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TABLE 1
MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated for
analgesic activity by Dr. Arthur E. Jacobson. Shown below are comparative data (ED 50mg/kg ) (95%
Confidence Interval) from Hot Platea-c and Nilsend assays.
TABLE 1 Continued
No antinociceptive activity in hot plate assay: Phenobarbital, amborbital, diazepam,
meprobamate, mescaline, oxazepam, flurazepam.
Chloropromazine HCl 1.1 (0.9-1.5)
3.2 (2.4-4.2)
a) Eddy and Leimbach (1953); b) Jacobson and May (1965); c) Atwell and Jacobson (1978)
d) Perrine. Atwell, Tice, Jacobson and May (1972).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug
to maintain responding in monkeys trained to self-inject codeine.
Each of at least three monkeys was studied with saline as a nega-
tive control and a number of doses of the test compound until a
maximum rate of responding was obtained or until, in the absence
of evidence of a reinforcing effect, directly observable changes
in behavior were produced by the compound.
The schedule of intravenous drug delivery was a fixed-ratio 30;
when a light above a lever was illuminated, the 30th response
produced a five-second intravenous drug injection accompanied by
another light that was illuminated during drug delivery. After
each injection, a ten-minute timeout condition was in effect
during which responses had no scheduled consequence and neither
light was illuminated. Each of the two daily sessions consisted
of 13 injections or 130 minutes, whichever occurred first.
Other details of the procedure and initial findings with a
variety of narcotics are given in previous reports (Woods, 1977;
1980).
Doses of the drugs are typically described in terms of moles/kg/
injection (inj), to facilitate direct comparisons among drugs.
Duplicate observations of codeine (7.5 x 10 mol/kg/inj; 0.32
mg/kg/inj) and of saline were obtained for each monkey. A
saline substitution was conducted before and after the series of
observations on a test drug; the control rates of codeine-
reinforced responding were obtained by a random sampling of two
sessions between the drug- substitution sessions. These data
are represented in the following graphs with individual symbols
for each of the monkeys; each symbol is the mean of duplicate
observations for a given dose in each monkey. There are two
additional types of averaged data presented. The closed circles
indicate the averaged data for observations on the subset of
monkeys used to study each drug under each of the experimental
conditions. The open circles indicate the codeine and saline
rates of responding of 20 monkeys studied under the same
conditions. The brackets indicate ± 3 standard errors of the
codeine mean, and ± 3 standard errors of the saline mean for the
group of 20 monkeys. In all cases, the rates of responding
given are those calculated during only the fixed-ratio portion
of each session.
Intravenous self-administration studies, at MCV, were carried out
as described previously (Slifer and Balster, 19831. Adult male
rhesus monkeys were prepared with chronic intravenous catheters
which were protected by a vest and restraining arm arrangement.
They were trained to lever press under a fixed-ratio 10 schedule
for intravenous cocaine hydrochloride during daily one-hour
sessions. Injections were 1.0 ml delivered over 10 sec. When
responding was stable, test solutions were substituted for four
days. Between each substitution the subjects were returned to
cocaine for at least three days. The vehicle for each test drug
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(usually 0.9% saline) was also substituted for four days. The
data from the last three days of each substitution was used in
the data analyses. A dose was considered for function as a
reinforcer In a particular subject if the mean for the three
days exceeded the vehicle mean and the ranges did not overlap.
Cocaine baseline injection rates were determined for each
subject from the average of the three-day means preceding each
dose substitution for each drug or drug pair tested.
RAT-INFUSION
The rat-infusion method was reported by Teiger (1974) and
certain modifications were indicated as follows. Semi-restrained
male Sprague-Dawley rats were medicated by continuous infusion
through indwelling, intraperitoneal cannula for 6 days with the
drugs. Rats were anesthetized and each was fitted with a spe-
cially prepared cannula which was passed subcutaneously from the
nape of the neck to the lateral side of the lower abdomen and
then inserted in the peritoneal cavity. The cannula was anchored
at both ends with silk sutures and attached to a flowthrough, swi-
vel mechanism which allowed the animal to move about in the cage
and eat and drink normally. The swivel was connected to a
syringe which was attached to a syringe pump. Animals received
7 to 10 ml of solution every 24 hours.
In the substitution for morphine (SM) test, the animals first
received morphine (50 mg/kg/24 hr on the first day, 100 mg/kg/24
hr on the second day, and 200 mg/kg/24 hr from days 3-6). Then,
a test drug was substituted for 2 days. The morphine controls
received an infusion of water. The animals were observed for
changes in body weight and for behavioral-withdrawal signs for ½
hour at 6,24,48,72 and/or 96 hours after stopping the infusion
of morphine.
In the primary physical dependence (PPD) study, the rats received
test compound for 6 days and then were placed in abrupt withdrawal
and observed as above.
MOUSE TESTS
Three mouse tests were used in the laboratory at the Medical
College of Virginia to provide a preliminary estimate of the
potency and profile of activity of each test compound. The tests
were the tail-flick agonist (TF) and the morphine antagonist (TF
vs MI tests and the phenylquinone (PPQ) test (Dewey et al. ,
1970; Dewey and Harris, 1971). Reference-standard data for
these tests are shown in Table II. In addition, Dr. Jacobson
provided us with estimated starting doses. These doses are
based on results obtained from the mouse hot plate (HP) (Eddy
and Leimbach, 1953; Jacobson and May, 1965; Atwell and Jacobson,
19781 and Nilsen (N) (Perrine et al., 1972) tests from his
laboratory. Reference data for these tests are shown in Table
I.
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TABLE II
Comparative Data-ED50 mg/kg s.c. (95% C.L.) of Selected
Standards in Three House Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick Phenylquinone
Pentazocine
Test Antagonism Test Test
15% 18 1.65
at 10.0 (12.4-26) (1.6-2.5)
Cyclazocine 17%
at 1.0a
0.03 0.011
(0.2-0.78) (0.0046-0.03)
Nalorphine.HCL None at 2.6 0.6
10.0 (0.69-9.75) (O.25-1.44)
Naloxone.HCL None at 0.035 No Activity
10.0 (0.010-0.93)
Naltrexone.HCL None at 0.007 No Activity
10.0 (0.002-0.02)
Morphine Sulfate 5.8 (5.7-5.9) - - - 0.23 (0.20-0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in reaction time was seen.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay were described in the 1978 ANNUAL
REPORT (Swain et al., 1978). Briefly, aliquots of a membrane
preparation from rat cerebrum were incubated with 3H-etorphine
in the absence and presence of 150 mM NaCl, end in the presence
of different concentrations of the drug under investigation.
Stereospecific, i.e., opiate receptor related, interaction of
3H-etorphine was determined as the difference in binding obtained
in the presence of an appropriate excess of dextrorphan and
levorphanol, respectively. The potency of the drugs in inhibit-
ing the stereospecific binding of 3H-etorphine was determined
from log-probit plots of the data. It should be noted that since
April, 1982, the concentration of 3H-etorphine in the binding
assay was reduced from 3.0 nM to 0.5 nM, a concentration approach-
ing the KD of the radiolabeled opiate. This change was implemen-
ted in order to let the determined EC50 approximate the true Ki
of a given drug. However, due to the different concentration of
the radiolabeled ligand, the EC50s determined since April, 1982
are lower than those obtained previously. For the purpose of
reference, Table III contains EC50 values of representative
opiates determined in binding assays using 0.5 nM 3H-etorphine.
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TABLE III
EC50 of representative opiates in displacing
0.5 nM 3H-etorphine in a membrane preparation from rat cerebrum
EC50 (nM)
Compound -NaCl +NaCl +Na/-Na
UM 911 14.6 28.3 1.94
Morphine 14.0 23.6 1.69
Dextrorphan 6180 9820 1.59
UM 1071R 1.14 1.55 1.36
Ketazocine 10.7 14.1 1.32
Ethylketazocine 5.22 6.60 1.26
(-)SKF 10047 4.09 3.93 0.96
Etorphine 0.47 0.37 0.79
(-)Cyclazocine 0.85 0.53 0.63
Naltrexone 1.43 0.63 0.44
NOTE: Binding data for these and other compounds, determined in
binding assays using 3.0 nM 3H-etorphine, are included in the
1978 and 1981 ANNUAL REPORTS.
INHIBITION OF TWITCH OF ISOLATED SMOOTH MUSCLE PREPARATIONS
In the past, submitted drugs have been evaluated on two smooth
muscle preparations, the details of which were described in the
1978 ANNUAL REPORT (Swain et al, 1978). Shown in the following
pages are the EC50's for the tested drug alone, for the drug in
the presence of naltrexone (a pure opioid antagonist which is
more effective against so-called "mu" agonists than against so-
called "kappa" agonists), and for the drug in the presence of UM
979 (an antagonist which appears to be more effective against
"kappa" than against "mu" drugs) (Smith, 1978). The maximum
depression of the electrically induced twitch in each of the
preparations is also indicated. The concentrations of both
naltrexone and UM 979 used in tests of antagonism are always
10-7 M for the guinea pig ileum and always 10-8 M for the mouse
vas deferens. Recently, the drug evaluation procedure has been
modified. The guinea-pig ileal preparation has not proven to be
reliable and may give false positive results. Therefore, the
preparation is only used as a supplementary assay. Drugs are
still evaluated on the mouse vas deferens as described previously.
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There have been small additional modifications in procedure.
First, naltrexone, 10-7 M, is the only antagonist used. Second,
the ability of naltrexone, in an equimolar concentration, to
reverse the inhibition of the twitch by active drugs, is assessed.
Finally, the ability of each drug to reverse the inhibition of
the twitch produced by a maximally effective concentration of
morphine is measured in order to determine whether the unknown
drug has antagonistic activity.
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year and the individual tests which were per-
formed are shown in Table IV. Also shown are dates of Annual
Reports in which results are reported of earlier tests on those
compounds conducted at Michigan. [Those also performed at the
Medical College of Virginia are so indicated (MCV)].
The compounds which were evaluated at the Medical College of
Virginia during the past year and the tests performed are shown
in Table V. Those also performed at the University of Michigan
are so Indicated (UM).
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NIH
9450
9830
9831
9833
9835
9842
9886
9887
9888
9922
9929
9930
9938
9941
9942
9945
9969
9970
9974
9989
9998
10002
10010
10016
10018
-
-
-
-
-
-
-
-
+
-
-
-
+
-
-
-
-
+
-
-
+
-
-
-
-
MCV
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
-  -  -  -
1982 1982 - -
1982 1982 - -
-  -  -  -
-  -  -  -
-  -  -  -
1982 1982 - -
+ - + -
- - - -
- - - -
- - - -
- - - -
1983 1983 - -
1982 - 1982 -
1982 1982 1982 - -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1369
1371
1379
1383
1385
UM
1305
1295
1296
1297
1299
1352
1285
1286
1287
1320
1311
1312
1321
1331
1332
1327
1346
1357
1361
-
MCV
-
4233
4234
4243
4259
4260
4002
4269
4283
4284
4286
4291
4292
4295
4299
4276
-
4309
4316
4318
-
CHEMICAL CLASS AND/OR
GENERIC NAME SDS NW N SA
benzomorphan
dihydromorphine
dihydromorphine
morphine-peptide
morphine-peptide
morphinan
phenylmorphan
phenylmorphan
phenylmorphan
phenylpiperdine
morphine
naltrexone
benzomorphan
naphthylamine
naphthylamine
phenylmorphan
isoquinoline
isoquinoline
morphinan
morphinan
morphinan
naloxone oxime
morphinan
morphinan
morphinan
- - - -
- - - -
GPI MVD BIND
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
+
+
-
+
+
1983
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
+
+
+
+
+
+
+
PDS
+
+
+
TABLE IV
SUMMARY OF TESTS PERFORMED (UK)
NIH
10021
10121
10146
10147
10148
10149
10157
10159
10160
10163
10169
10170
10172
10173
10174
10175
10186
10187
10188
10189
10249
10292
10293
10294
UM
1388
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MCV
4405
4338
4339
4341
4342
4343
4339
4350
4351
4352
4361
4362
4367
4368
4363
4364
4375
4376
4377
4378
-
4396
4397
4398
CHEMICAL CLASS AND/OR
GENERIC NAME
phenylmorphan 1982 -
phenyltoloxamine + -
imidazole + -
naltrexone +  +
naloxone +  +
naltrexone +  +
benzomorphan + -
benzomorphan + -
benzomorphan + -
oxymorphone + -
cyclizine + -
promethazine + -
benzomorphan + -
benzomorphan + -
hydroxyzine + -
diphenhydramine + -
tripelennanine + -
naltrexone - +
naloxone -  +
oxymorphone + -
normetazocine + -
ethylamine - -
ethylamine - -
ethylamine - -
SDS NW N
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SA GPI
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
MVD BIND
-  +
-  -
+  -
+  +
+  +
+  +
+  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  -
+  -
+  -
+  -
PDS
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MCV
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
TABLE IV Continued
SUMMARY OF TESTS PERFORMED
NIH
8359
8509
8683
8791
8805
8848
9344
9736
9938
9969
9970
10021
10068
10069
10070
10071
10111
10121
UM
1321
1346
1357
1388
MCV
4385
4232
4403
4336
4387
4348
4104
4196
4269
4291
4292
4405
4236
4327
4328
4329
4337
4338
CHEMICAL CLASS AND/OR MOUSE
GENERIC NAME TF TFvsM PPQ
Nalbuphine
Phenylmorphan
Meptazinol
Butorphanol
Buprenorphine
Ethylketocyclazocine
Doxpicomine
Morphinan
6,7-Benzomorphan
Benzooctahydroiso-
quinoline
Benzooctahydroiso-
quinoline
Phenylmorphan
14-Hydroxydihydro-
morphinone
14-Hydroxydihydro-
m o r p h i n o n e
14-Hydroxydihydro-
morphinone
14-Hydroxydihydro-
morphinone
14-Hydroxydihydro-
morphinone
Phenyltoloxamine
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
HP
+
+
+
+
+
+
+
+
+
-
-
+
+_
+
+
+
+
+
RAT
N SM PPD
- - -
- - -
- - -
- - -
- - -
- - +
- - +
+ - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
+ - +
MONKEY
SDS PPt-W PPD UM
+ - -
+ - -
+ + -
+ - -
+ a + -
-  -  -
-  -  -
-  -  +
+ - - +
+ - - +
+ - - +
+ - - +
+ + -
+ + -
+ - -
+ - -
-  -  -
+(3 studies) +
TABLE V
SUMMARY OF TESTS PERFORMED (MCV)
NIH N
10142 - -  - - - -
10144 - -  -
10146 + -  -
10147
UM MCV
4365
4366
4339
4341
- -  - - - -
10148 4342
- -  - - - -
10149 4343
- -  - - - -
10156 - -  -
10157 - -  -
10158 - -  -
10159 - -  -
10160 - -  - - - -
10163
4345
4349
4346
4350
4351
4352
- -  - - - -
10164 4347
- -  -
10169 4361 +- -  -
10170 4362 + -  -
10171 4369 - -  - - -
10172 4367 - -  - - - -
10173 4368 - -  - - -
10174 4363 - -  -
10175 4364
CHEMICAL CLASS AND/OR MOUSE
GENERIC NAME TF TFvsM PPQ HP
RAT
SM PPD
6,7-Benzomorphan
6,7-Benzomorphan
Imidazoimidazole
14-Hydroxydlhydro-
morphine
14-Hydroxydlhydro-
morphine
14-Hydroxyepoxy-
morphinan
6,7-Benzomorphan
6,7-Benzomorphan
6,7-Benzomorphan
6,7-Benzomorphan
6.7-Benzomorphan
14-Hydroxydihydro-
morphine
14-Hydroxydlhydro-
morphine
Cyclizine
Promethazine
Epoxyphenylmorphan
Epoxyphenylmorphan
6,7-Benzomorphan
Hydroxyzine
Diphenhydramine
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
-  +
+  +
+  +
+  +
+  +
MONKEY
SDS PPt-W PPD
+ - -
+ - -
+ + -
+ - -
+ (2 studies)
+ - -
-
-
+ - -
- -  - + - -
UM
+
+
+
+
+
+
+
+
+
+
+
+
+
+
TABLE V Continued
SUMMARY OF TESTS PERFORMED (MCV)
R A T
NIH SM PPD
10186 - -  - + -
10187
UM MCV
4375
4376
-  - -  -  -
10188 4377
- -  - -  -  -
10189 4378
- -  - -  -  -
10215 4380 - -  - +  -  -
10216 4381 - -  - +  -  -
10224 4393 - -  - -  -  -
10248 4379 -  - +  -  -
10250 4384 - -  - +  -  -
10292 4396 - -  - +  -  -
10293 4397 - -  - +  -  -
10294 4398 - -  - +  -  -
10303 4353 - - - +  -  -
10304 4354 - - +  -  -
10306 4356 - - - +  -  -
10307 4357 - - +  -  -
10308 4358 - - - +  -  -
10309 4370 - - - +  -  -
10311 4394
+  +  -
10316 4395
CHEMICAL CLASS AND/OR
GENERIC NAME TF TFvsM
Tripelennamine +
14-Hydroxydihydro-
morphinone +
14-Hydroxydihydro-
morphinone +
14-Hydroxydihydro-
morphinone +
Chlorpheniramine +
Cimetidine +
Epoxyphenylmorphan +
Pyrilamine +
Flunixin +
Phenylcyclohexene +
Phenylcyclohexene +
Phenylcyclohexene +
Dynorphin (1-13)
Dynorphin (1-10)-amide -
Dynorphin (1-6)
alpha-Neo-Endorphin -
Vasopressin
Dynorphin (1-8)
14-Hydroxydihydro-
morphine +
(+)-Thebaine +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
MOUSE
PPQ HP
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
+  +
- -
- -
- -
- -
- -
- -
+  +
+  +
(MCV)
N
+
+
+
+
SDS
+
MONKEY
PPt-W PPD UM
+
+
+
+
+
+
+
-  -
-  -
-  -
-  -
-  -
-  -
-  -
-  - +  -  -
TABLE V Continued
SUMMARY OF TESTS PERFORMED
TABLE V Continued
SUMMARY OF TESTS PERFORMED (MCV)
CHEMICAL CLASS AND/OR MOUSE RAT MONKEY
NIH UM MCV GENERIC NAME TF TFvsM PPQ HP N SM PPD SDS PPt-W PPD UM
10323 4372 beta-Funaltrexamine - - - - - + - - + -
10332 4415 14-Hydroxydihydro-
morphine + + + - - - - - - -
b Also, special 9-and 19-hr SDS studies were carried out.
The following Report on Individual Compounds presents the 1984
combined evaluation data from the testing facilities of the
Medical College of Virginia (MCV) and the University of Michigan
(UM). NIH numbers only are used.
Certain data come only from one laboratory. Thus, the hotplate
and Nilsen data come from Dr. Jacobson's laboratory at the NIH,
while the rat infusion and other antinociceptive data come from
MCV. The quinea pig ileum, rat vas deferens, and binding data
come from UM. The monkey data is labeled separately as to its
origin.
We hope this new format will make these annual reports easier to
reference and more useful.
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REPORT OR INDIVIDUAL COMPOUNDS
1984
NIH 8359, 10274 Nalbuphine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: approx. 13.0
TF: 10-22% at 1.0,
10.0 & 30.0
TF vs M: 20 % @ 1.0, 63% @
10.0, 69% @ 30.0 &
46% @ 60.0
PPQ: 0% at 1.0, 23% #
10.0 & 63% @ 30.0
DEPENDENCE EVALUATION IN RHESUS MONKEYS (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2 O
2 10.0
2 5.0
1 2.5
2 3.0
2 1 ml/kg
NIH 8359 (10274) substituted briefly (90 min) for morphine at the
highest dose. Some suppression of withdrawal signs was seen at
the lower doses. The compound could not be completely evaluated
because drug supply was exhausted. It is recommended that addi-
tional studies be conducted.
NIH 8509, 9889 (+)-5-(m -Hydroxyphenyl)-2-methylmorphan
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.35 (0.28-0.45)
TF: 4.8 (1.5-15.5)
TF vs M: 0% @ 1.0; 18% @
30.0
PPQ: 0.5 (0.3-0.9)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H2O
4 8.0
3 4.0
3 2.0
4 3.0
4 1 ml/kg
NIH 8509 (9889) substituted completely for morphine in 3/4 animals
at the highest dose and in all 3 at the next lower dose. The drug
acted promptly and had a duration of action of about 90 min.
Morphine's duration of action was at least 2½ hours.
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NIH 8683 m-(3-Ethyl-1-methylhexahydro-1H-azepin-3-yl)phenol
hydrochloride (Metazinol hydrochloride)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 5.3 (4.0-7.1)
TF: 12.8 (5.8-28.3)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1.6 (0.5-5.1)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3
3
3.2
0.8
2 0.2
3 3.0
3 1 ml/kg
This drug did not substitute for morphine at any of the doses
tested. Tremors were noted in some of the animals receiving the 2
higher doses.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) H 2O
2 6.4
4 3.2
3 0.8
2 0.2
4 0.05
4 1 ml/kg
NIH 8683 precipitated dose-related withdrawal. Onset of action
was prompt and duration was approximately 1 hr. The drug is about
1/150-1/200 as potent as naloxone.
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DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3 0.5
3 0.05
3 0.05 3.0
3 1 ml/kg
The drug did not substitute for morphine and may have exacerbated
withdrawal.
NIH 8791, 10275 Butorphanol Tartrate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: approx. 0.78
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: Inactive 0 1.0,
10.0 & 30.0
NIH 8805, 10276 Buprenorphine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.035 (0.028-0.045)
0.14 (0.09-0.23)a
TF vs M: 1.0 (0.3-3.3)
PPQ: 0.016 (0.005-0.042)
aBiphasic curve: 58% @ 1.0; 30%
@ 10.0
Naloxone AD 50 vs the TF ED 80 of
NIH 10276: 0.15 (0.06-0.36)
Naloxone AD 50 vs PPQ ED 80 of
NIH 10271: 0.06 (0.025-0.15)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
(Regular 15-hr withdrawal, SDS)
9
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc)
1 0 64
H2O
3 0.32
4 0.16
5 0.08
5 0.02
3 0.005
3 0.0016
9 3.0
1 ml/kg
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NIH 8805, 10276 Continued
In the dose range of 0.005-0.64 mg/kg, NIH 8805 (10276)
significantly alleviated many withdrawal signs during. the first
hour. The drug also reduced the number of withdrawal signs at
0.02 and 0.005 mg/kg during the first 2½ hours. In both cases,
however, the drug did not completely substitute for morphine.
(Special 9-hr withdrawal, SDS)
No. Animals
3
Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
0.32
3 0.08
3 0.02
3 3.0
3 1 ml/kg
NIH 8805 (10276) did not substitute for morphine in any of the
doses tested.
(Special 19-hr withdrawal, SDS)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc)
3 0.32
0.08
H&l (PPt-W)
3
3
3
0.02
3.0
3 1 ml/kg
NIH 8805 (10276) partially suppressed withdrawal at the 2 lower
doses. In the 19-hour withdrawal test, even morphine did not
alleviate the sign vocalizes when the abdomen was palpated and
only partially reduced the incidence of many other signs.
(PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) H 2O
3 0.32
3 0.08
3 0.02
3 0.05
3 1 ml/kg
NIH 8805 (10276) precipitated withdrawal in a dose-related manner.
Onset of action was prompt and duration of action was more than 2½
hours. Naloxone duration of action is about 1½ hours. At the 2
highest doses, some animals were still vocalizing after abdominal
palpation (after morphine at noon and four hours later). The drug
appeared to be an irreversible antagonist.
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NIH 8848, 10165 2-Cyclopropylmethyl-5-ethyl-8-oxo-9- alpha-methyl-6,-
7-benzomorphan methanesulfonate (Ethylketocyclazocine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.09 (0.07-0.12)
TF: 0.4 (0.1-1.0)
TF vs M: Inactive @ 1.0
10.0 & 30.0
PPQ: 0.04 (0.02-0.1)
AD 50 for naloxone vs NIH 10165
in TF: 0.1 (0.04-0.25)
AD 50 for naloxone vs NIH 10165
in PPQ: 0.2 (0.04-1.6)
RAT INFUSION (PPD)
As shown in the figure and table ethylketocyclazocine did not pro-
duce signs of dependence expressed as either
or behavioral-withdrawal signs when infused
body-weight changes
continuously for 6
days at a dose schedule approximately ¼ that of morphine.
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NIH 8848, 10165 Continued
NIH 9344 (-)-3-[(Dimethylamino)( m-dioxan-5-yl)methyl]pyridine
hydrochloride (Doxpicomine)
3.0 & 10.0
repeat 17.9 (10.2-28.0)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 6.4 (2.8-14.6)
MOUSE ANALGESIA, ED50 (mg/kg)
TF: Inactive @ 1.0,
RAT INFUSION (PPD)
NIH 9344 produced a degree of primary physical dependence at all
three dose schedules tested. According to the body weight changes,
the degree of dependence which developed was the same at all 3
doses but not as great as that noted for morphine (see figure).
Regarding withdrawal signs, there was a dose-related increase at
24 and 72 hours (see table).
330
NIH 9344 Continued
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NIH 9450 2,5-Dimethyl-2'-hydroxy-9- alpha-isopentyl-6,7-benzomorphan
methanesulfonate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 14.1 (11.7-17.0)
Nilsen: 19.7 (13.4-29.0)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 361 nM in absence of 150 mM NaCl
EC50 of 622 nM in presence of 150 mM NaCl
Sodium response ratio = 1.72
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
EC50
19.0 nM
1.0 nM
Maximum Response
23.2
30.2
no reversal
complete reversal
NIH 9450 is an oploid antagonist without significant agonist
action in the mouse vas deferens. It is unusual in the binding
assay because it has a sodium response ratio that is associated
with agonist action.
NIH 9736 N-Cyclobutylmethyl-3-hydroxy-6-methylene-8- beta-
methylmorphinan
MOUSE ANALGESIA ED50 (mg/kg)
Hot Plate:
Nilsen: 1.3 (0.73-2.4)
TF: 8% @ 0.1; 48% @
1.0; 12% @ 10.0 @
8% @ 30
TF vs M: 0% @ 0.01; 48% @
0.1; 44% @ 1.0;
54% @ 10.0 & 61%
@ 30.0
PPQ: 0.02 (0.002-0.18)
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NIH 9736 Continued
DEPENDENCE EVALUATION IN RHESUS MONKEYS - PPD (MCV)
Five monkeys were given NIH 9736 every 6 hours. The drug was dis-
solved in H2O and given in a volume of 0.25-2 ml/kg. The starting
dose was 1.0 mg/kg and it was gradually raised to 13.0 mg/kg by
day 12. Salivation and jaw and body sag were noted in some mon-
keys early in the study and slowing was noted in all the monkeys.
Restlessness, wet-dog shakes, vocalizing and scratching were also
noted frequently during this period. On day 15, abrupt withdrawal
was initiated but no withdrawal syndrome was observed. The study
was resumed at 17.0 mg/kg on day 16 but seizures were noted at
this dose; the dose was lowered to 12.0 mg/kg on the same day.
During this period the signs of slowing, vocalizing, restlessness,
wet-dog shakes and scratching were seen. Bleeding was noted at
the sites of injection on day 18 and on day 23 ulcers developed at
these sites. One male monkey developed severe genital swelling.
The study was terminated. No withdrawal syndrome was seen after
abrupt and precipitated withdrawal (2.0 mg/kg naloxone). Body
weights remained essentially unchanged throughout the study.
Despite the fact that NIH 9736 showed little evidence of producing
physical dependence, the study had to be terminated early due to
the development of skin ulcers. Thus, definitive conclusions
regarding the physical-dependence liability of this compound
cannot be made.
NIH 9830 Ethyl 6,14-endoetheno-7,8-dihydromorphine-7- beta-
carboxylate hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.04 (0.03-0.06)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 18.4 nM in absence of 150 mM NaCl
EC50 of 10.1 nM in presence of 150 mM NaCl
Sodium response ratio q 0.55
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 62.0 nM 89.3
After naltrexone 2.0 nM 86.1
Equimolar concentration
with naltrexone reversal
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NIH 9830 Continued
EC50 Maximum Response
Equimolar concentration
with morphine no reversal
SUMMARY
NIH 9830 appears to be a morphine-like agonist upon the mouse vas
deferens. It does not differ significantly from morphine either
in potency or efficacy. It was as potent in the binding assay as
morphine, but NIH 9830 has a smaller sodium response ratio.
NIH 9831 Ethyl 6,14-endoetheno-7.8-dihydromorphine-7-alpha-
carboxylate hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.35 (0.27-0.47)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 27 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 1.04 uM 34.2
After naltrexone
Equimolar concentration
3.13 uM 69.0
with naltrexone
Equimolar concentration.
marked reversal
with morphine no reversal
SUMMARY
NIH 9831 was a morphine-like agonist upon the isolated mouse vas
deferens preparation. It is less potent than morphine, but
equally efficacious. It was comparable in potency to morphine in
the binding assay.
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NIH 9833 N-(6,14-Endoetheno-7,8-dihydromorphlne-7- alpha-carbonyl)-
L-phenylalanyl-L-leucine ethyl ester hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.83 (0.61-1.1)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.58 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
1.16 nM
3.52 nM
86.8
95.4
slight reversal
no reversal
SUMMARY
NIH 9833 appeared to be a morphine-like agonist which is equi-
effective and about 100 times more potent than morphine. NIH 9833
was also much more potent than morphine in the binding assay.
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NIH 9835 N-(6,14-Endoetheno-7,8-dihydromorphine-7- alpha-carbonyl)-
L-glycyl-L-phenylalanyl-L-leucine ethyl ester hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 1.1 (0.75-1.5)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.0187 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
21.8 nM
13.7 nM
64.1
48.9
reversal
reversal
The ability of NIH 9835, 10-7 M, to antagonize responses to morphine was
evaluated.
EC50 Maximum Response
Morphine
Morphine plus 9835
SUMMARY
370 nM 85.3
4.61 uM 66.8
NIH 9835 has agonistic action which does not seem to be morphine-
like. This drug does have significant opiate antagonistic activity
similar to that seen with naltrexone in the vas deferens preparation.
NIH 9835 displaces etorphine with an extraordinary potency; it may
be a "pure" narcotic of high potency.
336
NIH 9938 (±)-5,9-alpha-Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,
7-benzomorphan hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 8.3 (6.0-11.4)
TF: 3.3 (1.5-7.3)
TF vs M: 0% @ 1.0 & 30.0
PPQ: 2.6 (1.0-7.9)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H2O
1 12.0
2 9.0
2 6.0
3 3.0
3 3.0
3 1 ml/kg
In the dose range tested, NIH 9938 did not substitute for morphine.
The monkey receiving the highest dose developed convulsions within
30 minutes. A pentobarbital injection terminated these convulsions.
NIH 9842 (-)-N-Methyl-3,4-methylenedioxy-6-oxomorphinan
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 6.3 (4.3-9.2)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 570 nH in absence of 150 mM NaCl
EC50 of 658 nM in presence of 150 mM NaCl
Sodium response ratio = 1.15
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NIH 9842 Continued
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 11.6 uM 66.4
After naltrexone 21.3 uM 66.7
Equimolar concentration
with naltrexone no reversal
Equimolar concentration
with morphine no reversal
SUMMARY
NIH 9842 appears to be devoid of either opiate agonistic or
antagonistic activity upon the mouse vas deferens preparation.
It, however, displaced etorpine at high concentrations. This is
an unusual discrepancy.
NIH 9886 [(-)-(m)-Hydroxyphenyl]-2-n -pentylmorphan hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: inactive
Nilsen: inactive
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 523 nM in absence of 150 mM NaCl
EC50 of 155 nM in presence of 150 mM NaCl
Sodium response ratio = 0.3
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
Equimolar concentration
after naltrexone
Equimolar concentration
with morphine
EC50
0.41 nM
0.64 nM
Maximum Response
29.4
32.6
no reversal
complete reversal
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NIH 9886 Continued
SUMMARY
NIH 9886 appears to be an opiate antagonist upon the mouse vas
deferens preparation. NIH 9886 low sodium response ratio is
associated with narcotic antagonist action. This compound may be
a "pure" antagonist with less potency than naltrexone.
NIH 9887 (-)-N-Hexyl-5-(m-hydroxyphenyl)-morphan hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: inactive
Nilsen: inactive
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 117 nM in absence of 150 mM NaCl
EC50 of 150 nM in presence of 150 nM NaCl
Sodium response ratio q 1.28
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
0.47 nM 36.1
0.54 nM 28.8
with naltrexone
Equimolar concentration
no reversal
with morphine
SUMMARY
complete reversal
NIH 9887 appears to be an opiate antagonist upon the mouse vas
deferens preparation without significant agonist actions. NIH
9887 was less potent than naltrexone in the binding assay with a
smaller sodium response ratio. This compound may be a "pure"
antagonist.
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NIH 9888 (+)-5-(m-Hydroxyphenyl)morphan hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate:
Nilsen:
no dose response
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 232 nM In absence of 150 mM NaCl
EC50 of 263 nM in presence of 150 mM NaCl
Sodium response ratio = 1.13
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 689 nM 97.4
After naltrexone 51 uM 95.2
After UM 979 12 uM 86.7
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 2.58 uM 88.4
After naltrexone 11.9 uM 76.4
After UM 979 7.23 uM 64.1
SUMMARY
NIH 9888 appears to be a morphine-like agonist upon both smooth
muscle preparations. It was considerally less potent than morphine
in all assays.
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NIH 9922 3-(1,2-alpha,4-alpha,5-beta-Tetramethyl-4- beta-
piperidinyl)-m-phenol,Z-2-butenedioic acid salt
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.4 (1.7-3.3)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 84 nM in absence of 150 mM NaCl
EC50 of 141 nM in presence of 150 mM NaCl
Sodium response ratio = 1.67
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
EC50
8.55 nM
33.6 nM
Maximum Response
65.2
39.3
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
marked reversal
slight reversal
NIH 9922 has both opioid agonistic
the mouse vas deferens preparation.
and antagonistic actions upon
NIH 9929, 0001 Morphine
MOUSE ANALGESIA, ED50 mg/kg)
Hot Plate: 1.0 (0.7-1.3)
Nilsen: 1.5 (1.1-2.0)
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NIH 9929, 0001 Continued
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 50.6 nM in absence of 150 mM NaCl
EC50 of 51.3 nM in presence of 150 mM NaCl
Sodium response ratio = 1.01
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 418 nM 61.8
After naltrexone 23.7 uM 62.5
After UM 979 no inhibition
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 418 nM 100
After naltrexone 3.1 uM 98.2
After UM 979 3.4 uM 98.2
SUMMARY
NIH 9929 has opiate agonist action in each preparation; it is
slightly less potent in each assay than morphine.
NIH 9930, 8503 Naltrexone hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: no dose response
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 2.63 nM in absence of 150 mM NaCl
EC50 of 0.97 nM in presence of 150 mM NaCl
Sodium response ratio = 0.37
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NIH 9930 8503 Continued
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 1.92 nM 30.2
After naltrexone 3.34 uM 56.7
After UM 979 227 uM 54.4
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 4.9 nM 14.4
After naltrexone 11.3 nM 21.1
After UM 979 completely
blocked at 10-8 M
SUMMARY
NIH 9930 appears to have opiate agonist activity upon both smooth
muscle preparations in addition to other pharmacological effects.
The binding data suggest that it will have antagonist activity at
slightly higher doses in vivo than naltrexone. Thus, the compound
will probably be a strong mixed narcotic agonist-antagonist.
NIH 9938 5,9-alpha-Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 8.3 (6.0-11.4)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 108 nM in absence of 150 mM NaCl
EC50 of 188 nM in presence of 150 mM NaCl
Sodium response ratio = 1.74
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NIH 9938 Continued
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 1.28 uM 93.9
After naltrexone 4.77 uM 82.7
After UM 979 3.75 uM 83.3
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
SUMMARY
EC50 Maximum Response
687 nM 95.3
3.13 uM 96.0
2.58 uM 96.0
NIH 9938 appears to be a narcotic agonist that is less potent than
morphine on the basis of comparison to morphine in these assays.
NIH 9941 (-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-
phenyl-2-naphthylamine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 13.1 (9.9-17.3)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9941 failed to significantly displace tritiated etorphine up to
a concentration of 6000 nM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
3.81 nM
4.39 nM
39.4
40.7
no reversal
slight reversal
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NIH 9941 Continued
SUMMARY
NIH 9941 is devoid of morphine-like agonistic activity. Although
in high concentrations it might have very slight antagonistic
activity in the vas deferens, it failed to displace etorphine even
in high concentrations. Therefore, it is unlikely to have signifi-
cant narcotic activity in these preparations.
NIH 9942 (+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-
phenyl-2-naphthylamine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 40% @
50, 30% @ 100
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9942 failed to significantly displace tritiated etorphine up
to a concentration of 6000 nM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
3.77 nM
3.80 nM
31.5
38.9
no reversal
50% reversal
NIH 9942 is devoid of morphine-like, agonistic activity, but does
have some antagonistic activity upon the mouse vas deferens pre-
parations. It fails to displace etorphine even in high concentra-
tions.
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NIH 9945 2,9-alpha-5-Dimethyl-5-( m-methoxyphenyl)morphan
hydrobromide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 50% @
50 (90% dead @
100)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9945 failed to displace significantly tritiated etorphine up
to a concentration of 6000 nM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
Maximum Response
no inhibition
no inhibition
no inhibition
no inhibition
NIH 9945 appears to be devoid of opiate activity in these prepara-
tions.
NIH 9969 cis-1,2,3,4,4a,5,6,1Ob-Octahydro-3-methyl-lOb-propylbenz-
[f]isoquinoline-9-ol hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 9.0 (6.8-12.0)
TF: 8.8 (3.1-24.8)
TF vs M: Inactive @ 1.0 &
30.0
PPQ: 1.5 (0.5-4.7)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
A dose of 5.6 mg/kg NIH 9969 produced complete suppression of
withdrawal. Lower doses (1.0 and 3.0 mg/kg) had little effect on
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NIH 9969 Continued
withdrawal. In the non-dependent monkey, 10 mg/kg NIH 9969
produced pupil dilation, decreased movement and scratching that
were reversed to some extent by 1.7 mg/kg naloxone.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Morphine (mg/kg/sc)Dose (mg/kg/sc) H 2O
2 12.0
3 8.0
2 4.0
3 3.0
3 1 ml/kg
At the highest doses, NIH 9969 substituted completely for morphine.
The onset of action was prompt and duration of action was approxi-
mately 7 hours. Morphine also acted promptly and the duration was
2-3 hours. At the intermediate dose, NIH 9969 substituted com-
pletely and briefly in 1 of 3 monkeys for approximately 1 hour.
Partial substitution was observed in 1 of 2 monkeys receiving the
lowest dose. Approximately ¼ as potent as morphine.
NIH 9970 cis-1,2,3,4,4a,5,6,10b-Octhydro-3,10b-dimethylbenz[f]-
isoquinolin-9-ol butanedioate (1:1) salt
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.6 (1.9-3.7)
TF: 2.7 (1.0-7.4)
TF vs M: Inactive @ 1.0 &
30.0
PPQ: 1.4 (0.5-3.6)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 1455 nM in absence of 150 mM NaCl
EC50 of 1354 nM in presence of 150 mM NaCl
Sodium response ratio = 0.93
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
At no concentration did NIH 9970 cause an inhibition of the twitch.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 209 nM 60.0
After naltrexone 27.5 nM 32.0
After UM 979 110 nM 47.4
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NIH 9970 Continued
SUMMARY
In the binding assay NIH 9970 was not very potent, and it appeared
to lack opiate agonist activity upon either smooth muscle prepara-
tion.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc)
1 24.0
1 18.0
3 12.0
6 6.0
3 3.0
3 1.5
6 3.0
6
H 2 O
1 ml/kg
Severe ataxia and tremors were seen at the highest dose. The drug
did not substitute completely for morphine but it partially sup-
pressed the total number of withdrawal signs especially in the
dose range of 3.0-12.0 mg/kg.
NIH 9974 (-)-N-Allyl-4-hydroxymorphinan-6-one
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 1.8 (1.5-2.2)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 114 nM in absence of 150 mM NaCl
EC50 of 223 nM in presence of 150 mM NaCl
Sodium response ratio = 1.96
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NIH 9974 Continued
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
671.62 nM 96.2
6.45 uM 98.4
with naltrexone
Equimolar concentration
marked reversal
with morphine
SUMMARY
no reversal
NIH 9974 is a morphine-like agonist upon the mouse vas deferens
preparation. It Is as efficacious but slightly less potent than
morphine on this preparation. It is also less potent than morphine
in the binding assay, but has a slightly higher sodium response
ratio.
NIH 9989 (-)-N-Methylmorphinan d-tartrate
MOUSE ANALGESIA; ED50 (mg/kg)
Hot Plate: 2.3 (1.7-3.2)
Nilsen: 2.5 (1.7-3.7)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 375 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Maximum ResponseEC50
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
3.02 nM
1.53 nM
65.0
39.8
partial reversal
complete reversal
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NIH 9989 Continued
SUMMARY
NIH 9989 is an opiate drug with mixed agonist-antagonist activity upon t
isolated mouse vas deferens preparation.
NIH 9998 (-)-4,14,Dihydroxy-N-methylmorphinan
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.83 (0.60-1.14)
Nilsen: 1.7 (1.2-2.4)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 108 nM in absence of 150 mM NaCl
EC50 of 115 nM in presence of 150 mM NaCl
Sodium response ratio = 1.06
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Only at concentration of 10-6 M did NIH 9998 cause a slight (less
than 10%) inhibition of the twitch. This response was completely
blocked by naltrexone and UM 979.
SUMMARY
NIH 9998 appears to have a very slight opiate-like activity on the
guinea-pig ileal preparation and it is somewhat less potent in the
binding assay than morphine.
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NIH 10002 6-Desoxy-6-isonitrosonaloxone (naloxone oxime)
Hot Plate:
Nilsen:
MOUSE ANALGESIA, ED50 (mg/kg)
inactive
inactive
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 150 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
EC50
1.96 uM
0.10 uM
Maximum Response
44.9
4.4
no reversal
complete reversal
NIH 10002 is a morphine antagonist upon the isolated mouse
deferens preparation.
NIH 10010 (-)-N-Allylmorphinan-6-one hydrochloride
vas
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.9 (2.1-3.9)
Nilsen: 1.8 (1.3-2.7)
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NIH 10010 Continued
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 320 nM in presence of 150 mM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 186.0 nM 91.9
After naltrexone 15.6 uM 77.0
Equimolar concentration
with naltrexone complete reversal
Equimolar concentration
with morphine no reversal
SUMMARY
NIH 10010 appears to be a morphine-like agonist upon the mouse vas
deferens. It does not differ significantly from morphine either
in potency or efficacy in this preparation. It was significantly
less potent than morphine in the binding assay.
NIH 10016 (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10.6 (8.0-14.0)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 78 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
123 nM
164 nM
Maximum Response
36.0
24.8
reversal
reversal
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NIH 10016 Continued
SUMMARY
NIH 10016 is much less potent and efficacious than morphine. It
appears to have both agonistic and antagonistic properties. It is
slightly less potent than morphine and considerably less potent
than naltrexone in the binding assay.
NIH 10018 (-)-3,4-Dimethoxy-N-(2-phenethyl)-morphinan-6-one
hydrobromide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.14 (0.10-0.18)
Nilsen: 0.02 (0.017-0.035)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.75 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
56.1 nM
145 nM
96.0
96.2
nearly complete
reversal
no reversal
NIH 10018 appears to be a pure opioid agonist upon the mouse vas
deferens. It is more potent and equally efficacious when compared
to morphine. In the binding assay, it was more potent than
morphine.
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NIH 10021 9-alpha-Acetoxy-2-methyl-5-( m-acetoxy)phenylmorphan
hydrobromide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.0 (1.4-2.8)
TF: 7.3 (3.6-14.7)
TF vs M: Inactive @ 30.0,
10.0 & 1.0
PPQ: 2.0 (1.4-2.8)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 3523 nM in absence of 150 mM NaCl
EC50 of 4246 nM in presence of 150 mM HaCl
Sodium response ratio = 1.20
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
2.88 nM
2.04 nM
25.7
33.2
no reversal
partial reversal
NIH 10021 appears devoid of opioid agonistic activity but might
have slight activity as an antagonist in the vas deferens. It is
of very low potency in displacing etorphine in the binding assay.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kq/sc) Morphine (mg/kg/sc) H 2O
2 10.0
2 5.0
2 1.0
2 3.0
2 1 ml/kg
NIH 10021 substituted completely for morphine at the 2 higher
doses. Partial substitution was observed at the lowest dose.
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NIH 10068 6-beta-(beta-Carboxyallyl)-naltrex-6- alpha-ol-gamma-
Tactone-14-acetate
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc)
2 0.05
2 0.0125
1 0.003
2
2
Morphine (mg/kg/sc) Lactic Acid
& H2O
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0.08 (0.04-0.2)
PPQ: Inactive @ 0.1,
1.0, 10.0 @ 30.0
3.0
1 ml/kg
This compound did not substltute for morphine at any of the doses
tested. One monkey receiving the highest dose was given morphine
because the animal developed severe tremors.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc)
2 0.2
2 0.1
2 0.05
2 0.0125
3 0.05
3
Lactic Acid
@ H2O
1 ml/kg
At doses of 0.0125 or more, NIH 10068 precipitated withdrawal;
drug acted promptly and the duration of action was at least one
hour longer than that of naloxone. The potency is about that of
naloxone.
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NIH 10069 6-beta-(beta-Carboxyallyl)-naltrex-6-alpha-ol-gamma-
lactone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0.1 (0.08-0.2)
PPQ: 20% @ 1.0, 20% @
10.0 & 29% @ 30.0
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) DMSO & H2O
5 0.1
2 0.025
1 0.006
2
2 3.0 1 ml/kg
The compound did not substitute for morphine. Instead, it appeared
to exacerbate withdrawal at the highest dose.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) DMSO & H2O
2 1.6
3
2
0.4
0.1
1 0.025
3 0.05
3 1 ml/kg
The drug promptly precipitated withdrawal at the 2 higher doses.
The duration of action Is at least 1 hour longer than that of
naloxone but the potency is about 1/10.
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NIH 10070 6-beta-(beta-Carboxyallyl)-oxymorphon-6- alpha-ol-gamma-
lactone-14-acetate
HOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 4.1 (2.8-6.0)
TF: 8.5 (4.5-15.7)
TF vs M: 4% @ 1.0, 8% @
10.0 & 20% @ 30.0
PPQ: 2.0 (1.2-3.3)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) Lactic Acid
& H2O
2 12.0
2
5
6.0
3.0
2
2
In the dose range studied, the drug
phine. Drug supply was exhausted.
3.0
1 ml/kg
did not substitute for mor-
NIH 10071 6-beta-(beta-Carboxyallyl)-oxymorphon-6- alpha-ol-gamma-
lactone acetic acid salt
MOUSE ANALGESIA, ED50 (mg)
Hot Plate: 2.6 (1.8-3.6)
TF: 8.9 (3.7-21.5)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 0.9 (0.3-3.0)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
3
2 4.0
1 2.0
3
1 ml/kg
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1 16.0
8.0
3.0
4
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NIH 10071 Continued
At the highest dose, the drug substituted completely for morphine.
It acted promptly and the animal did not require the noon
injection of morphine. It substituted for morphine in 2/3 animals
at the 8.0 mg/kg dose. Potency is about 1/2 - 1/3 that of
morphine. Drug supply was exhausted.
NIH 10111 Naloxone-6-spirohydantoin(6- beta-oxo)
NIH 10121, 10197 Phenyltoloxamine dihydrogen citrate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20.0 & 0.0
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 8 30.0
PPQ: 23% @ 1.0, 17% @
10.0 & 23% @ 30.0
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 40.5 (27.5-59.6)
Nilsen: 40% @ 80
TF: 1 Inactive @ 1.O,
10.0 & 30.0
2 Inactive @ 1.0,
10.0 & 30.0
TF vs M: 1 Inactive @ 1.0,
10.0 & 30.0
2 31% @ 0.3, 35% @
1.0, 31% @ 3.0,
37% @ 10.0 & 34%
@ 30.0
PPQ: 1 1.3 (0.3-6.4)
2 20% @ 1.0, 25% @
10.0 & 50% @ 30.0
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10121 failed to produce marked narcotic agonist or antagonist
actions at 5.6, 10 and 30 mg/kg s.c. Further assay was discontin-
ued due to the elicitation of a convulsion upon handling at the
highest dose.
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NIH 10121, 10197 Continued
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV)
STUDY 1 (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc)
2 30.0
5 20.0
5 10.0
5 3.0
H 2O
1 ml/kg
At the highest dose, NIH 10121 suppressed withdrawal partially in
both monkeys. The drug also partially suppressed withdrawal signs
in some monkeys at the 2 lower doses. It acted promptly and the
duration of action was at least 2½ hours. Head tremors were noted
at the highest dose. Further studies are recommended.
Study 2 (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H2O
1 30.0
3 20.0
1 10.0
2 3.0
2 1 ml/kg
We have confirmed the results reported earlier. NIH 10121 substi-
tuted partially for morphine at 30.0 and 20.0 mg/kg. One monkey
receiving the highest dose had convulsions and was given pentobar-
bitol, 65.0 mg.
Study 3 (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1 16.0
4 8.0
3 4.0
3 1.0
1 0.25
7 3.0
7 1 ml/kg
NIH 10197 partially suppressed withdrawal signs at 0.25-8.0 mg/kg
during the first hour. In this dose range the number of signs was
suppressed by 50%. Partial suppression does not imply that the
drug has morphine-like properties.
359
NIH 10121, 10197 Continued
RAT INFUSION (SM)
At 50.0 and 100.00 mg/kg/24 hr, NIH 10121 did not substitute
completely for morphine in morphine-dependent rats. (See figure
and table).
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NIH 10142 2-Cyclopropylmethyl-3- beta,5-dimethyl-2'-hydroxy-6,-
7-benzomorphan Hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.4 (1.9-3.2)
TF: 3.0 (1.0-8.7) 7.9
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 0.2 (0.1-0.6) 3.6
Naloxone vs NIH 10142 in PPQ AD
50: 0.1 (0.05-0.2)
NIH 10144 3-beta-Allyl-2,3-alpha,5-trimethyl-6,7-benzomorphan
hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 3.7 (2.7-5.2)
TF: 19% @ 10.0 & 55%
30.0 & 100% @ 60.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 7.0 (3.5-13.7)
1.8
NIH 10146 2,3,5,6-Tetrahydro-6-methylene-7-(2,4-dichlorophenyl)-
imidazo[1,2-a]imidazole
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 6.3 (4.7-8.3)
Nilsen: 24.3 (19.7-30.0)
TF: 10% @ 1.0, 25% @
10%, 19% @ 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 2.6 (0.8-8.8)
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
EC50 Maximum Response
6.03 uH 89.8
4.46 uM 90.7
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NIH 10146 Continued
EC50 Maximum Response
Equimolar concentration
with naltrexone no reversal
Equimolar concentration
with morphine no reversal
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Neither 3 nor 10 mg/kg NIH 10146 produced typical narcotic agonist
or antagonist action. Because the higher dose produced preconvul-
sive signs in both monkeys, further assay was discontinued.
SUMMARY
NIH 10146 is devoid of opiate agonistic or antagonistic activity.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kq/sc) dil HCL
3 6.0
& H2O
3 3.0
3 3.0
3 1 ml/kg
This drug did not substitute for morphine and may have exacerbated
withdrawal. Tremors were noted at both doses.
NIH 10147 6-beta-Oxido-6-methylene naltrexone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate:
TF:
20% @ 50
Inactive @ 1.0,
10.0 & 30.0
0.007 (0.003-
0.197)
Inactive @ 0.1,
1.0, 10.0 & 17%
@ 30
TF vs M:
PPQ:
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING INHIBITION
OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 10147 was insoluble and EC50's could not be obtained with
these preparations.
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NIH 10147 Continued
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10147 at 0.1 mg/kg increased the severity of withdrawal signs
in the withdrawn monkey. In the non-withdrawn, dependent monkeys,
mild withdrawal signs were produced by 0.003 mg/kg, and increased
in severity as dose was increased to a maximum of 0.1 mg/kg. It
was one third as potent as naloxone in precipitating withdrawal,
and had a duration of action of 24 hours.
SUMMARY
This compound is a potent long-acting narcotic antagonist. It is
slightly more potent than cyclazocine or WIN 44,441 in precipitat-
ing withdrawal. It has a very long duration of action since the
monkeys' response to morphine was attentuated even at 24 hrs
subsequent to 0.1 mg/kg s.c.
NIH 10148 6-beta-Oxido-6-methylene naloxone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive
TF:
TF vs M:
PPQ:
Inactive @ 1.0,
3.0, 10.0 & 30.0
0.003 (0.001-
0.011)
27% @ 0.3, 12% @
30.0
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING INHIBITION
OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 10148 was insoluble and EC50's for these preparations could
not be obtained.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY
NIH 10148 at a dose of 0.1 mg/kg increased the severity of withdraw-
al in the withdrawn monkey. In the dependent, non-withdrawn mon-
key, 0.01 mg/kg produced a very mild withdrawal. Increasing doses
produced increasing withdrawal signs; 0.06 mg/kg produced severe
withdrawal that lasted less than six hours.
SUMMARY
NIH 10148 is a potent (one third the potency of naloxone) narcotic
antagonist of relatively short duration of action.
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NIH 10149 6-alpha-(beta-Carboxyallyl)-naltrex-6- beta-ol-gamma-
lactone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 230% @ 20
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0.15 (0.05-0.47)
Text Inactive @ 1.0,
10.0 & 30.0
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING INHIBITION
OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 10149 was insoluble and EC50's for these preparations could
not be obtained.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
At a dose of 0.1 mg/kg, NIH 10149 produced an increased withdrawal
severity in the withdrawn monkeys. A dose-dependent increase in
withdrawal severity was produced by 0.3, 1.0, and 1.8 mg/kg in the
non withdrawn monkeys.
SUMMARY
NIH 10149 has narcotic antagonist properties similar to those of
naloxone in in vivo preparations. It is approximately 50 times
less potent naloxone and has a long duration of action.
NIH 10156 2'-Hydroxy-5~methyl-9- alpha-(3-methyl)butyl-2-pentyl-6,
7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 100.0
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 9% @ 1.9, 17% @
10.0 & 20% @ 30.0
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NIH 10156 Continued
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mq/kg/sc) Morphine (mg/kg/sc) H 2O
2 16.0
2 8.0
2 4.0
2 3.0
2 1 ml/kg
In the dose range tested, NIH 10156 did not substitute for mor-
phine. Restlessness and tremors were seen at the highest dose and
the drug appeared to suppress retching. Drug supply was exhausted.
NIH 10157 2'-Hydroxy-5-methyl-9- alpha-(3-methyl)butyl-2-phenethy-
1-6,7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate:
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 46% @ 3.0, 39%
@ 10 0 & 55% @
30.0a
aPropylene glycol controls also
active with 43% inhibition.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 10157 did not inhibit the twitch in concentrations of 10 nm to
10 uM and did not reverse the effects of a maximally effective
concentration of morphine.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10157 at 5.6 and 10.0 mg/kg had no apparent effects in withdrawn
monkeys. Drug supply depleted.
SUMMARY
NIH 10157 has no apparent narcotic agonist or antagonist effects
in these preparations.
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NIH 10158 2'-Hydroxy-5-methyl-9- alpha-(3-methyl)butyl-2-propyl-
6,7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: No dose response
TF: Inactive @ 1.0.
TF vs M:
PPQ:
10.0 & 30.0
14.8 (9.1-24.0)
7.0 (3.1-16.1)
a Naloxone inactive vs NIH
10158 in PPQ test up to 20.0
mg/kg.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
2 5.0
2
2
2.5
3.0
2 1 ml/kg
In the dose range tested, NIH 10158 did not substitute for mor-
phine. Morphine was given to both monkeys receiving the highest
dose after 90 minutes because of severe tremors.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) H2O
a
2 5.0
2 1.25
2 1.25 0.05
2 1 ml/kg
The drug did not precipitate withdrawal at the doses tested. At
the highest dose, severe. tremors were noted. Drug supply was
exhausted.
aIn some studies the drug was suspended and the volume given was 2
ml/kg.
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NIH 10159 2-Allyl-2'-hydroxy-5-methyl-9- alpha-(3-methyl)butyl-6,
7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 40% @ 50
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 11.2 (4.4-29.0)
PPQ: 10.3 (5.5-19.9)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10159 at doses of 1.7-5.6 mg/kg did not alter markedly signs
of narcotic withdrawal. At the highest dose, preconvulsive signs
were observed. This dose failed to elicit withdrawal in the non
withdrawn dependent monkey.
NIH 10160 2-Cyclopropylmethyl-2'-hydroxy-5-methyl-9- alpha-(3-
methyl)butyl-6,7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 50
convulsions)
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 5.5 (3.2-9.5) 2.3
PPQ: 14.4 (10.9-9.1)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10160 had little effect in the withdrawn monkey at 3.0 mg/kg,
and produced preconvulsive signs at 10.0 mg/kg.
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NIH 10163 6-beta-Oxido-6-methylene oxymorphone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.17 (0.13-0.22)
TF: 0.3 (0.1-0.7)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 0.02 (0.005-0.05)
Naloxone vs NIH 10163 in TF AD
50
0.01 (0.003-0.004)
Naloxone vs NIH 10163 in PPQ AD
50 0.24 (0.1-0.7)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
This compound suppressed abstinence completely in withdrawn
dependent monkeys. It was 6 times more potent than morphine and
had a shorter duration of action.
NIH 10164 6-alpha-(beta-Carboxyallyl)-oxymorphon-6- beta-ol-gamma-
lactone
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.6 (1.9-3.7)
TF: 5.2 (3.3-8.0)
PPQ: 2.4 (1.2-4.9)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) Propylene
2 10.0
glycol & H2O
2 5.0
2 2.5
2 3.0
2 1 ml/kg
In the dose range studied, NIH 10164 did not substitute for
morphine. Muscle spasms were noted in one monkey receiving the
highest dose. Drug supply was exhausted.
NIH 10165 - See NIH 8848
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NIH 10169 1-Diphenylmethyl-4-methylpiperazine hydrochloride
(Cyclizine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 50% @ 50
Nilsen: 23.9 (20.3-28.1)
Inactive @ 1.0 &
10.0; 21% @ 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1 7.4 (3.7-14.9)
2 29.6 (13.7-67.4)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
This drug suppressed partially the signs of narcotic abstinence at
10 mg/kg. Lower doses were inactive; 30 mg/kg produced strong
preconvulsive signs soon after administration and convulsions upon
handling at 30 minutes.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV)
Study 1 (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1 20.0
3 10.0
3 5.0
3 3.0
3 1 ml/kg
This drug did not substitute for morphine. At the 2 higher doses,
severe tremors, stereotyped head movements, and excitation were
noted.
Study 2 (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
2 20.0
2 10.0
1 5.0
2 3.0
1 1 ml/kg
The results of this study confirmed those reported earlier. NIH
10169 did not substitute for morphine. However, at the highest
dose after 2 hours, the monkeys did not vocalize when their
abdomens were palpated and these muscles were relaxed. Also, at
the 2 higher doses tremors were noted.
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NIH 10170 N,N-alpha-Trimethyl-1-OH-phenothiazine-10-ethanamine
hydrochloride (Promethazine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 30
Nilsen: 12% @ 20
TF: 7-15% @ 1.0,
10.0 & 30.0
TF vs M: 1 4.7 (1.7-13.6)
2 26% @ 1.0, 30%
@ 10.0 & 0% @
30.0
PPQ: 1.7 (0.6-4.8)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
At doses from 5-18 mg/kg, this compound failed to suppress absti-
nence. It, over this dose range, induced pupil dilation, incoor-
dination, and ataxia. At the highest dose, mild tremor was ob-
served.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
4 20.0
5 10.0
3 5.0
5 3.0
5 1 ml/kg
The drug produced dose-related reduction of many withdrawal signs
such as rigid abdomen, vocalizes when abdomen palpated, retching
and wet-dog shakes. The drug nearly substituted for morphine
briefly. Tremors, slowing and ataxia were also observed.
NIH 10171 2,3,4,5,6,6a-Hexahydro-8-hydroxy-1H-411b-methanobenzo-
furo[3,2]azocine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate:
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
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NIH 10172 2-Ethyl-2'-hydroxy-5-methyl-9- alpha-(3-methyl)butyl-6,
7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 20
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0% @ 1.0, & 10.0;
22% @ 30.0
PPQ: Inactive @ 1.0,
10.0 & 30.0
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10172 at doses of 5.6, 10, and 17 mg/kg had no effect on the
withdrawal signs in physically dependent, withdrawn rhesus
monkeys. At the two higher doses, mild to marked tremors were
observed.
NIH 10173 2-n -Butyl-2'-hydroxy-5-methyl-9- alpha-(3-methyl)butyl-6,
7-benzomorphan oxalate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 80
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 10% @ 3.0, 55% @
10.0 & 39% @
30.0
PPQ: 27.3 (13.3-56.0)
Used 1.5% methylcellulose
suspension as vehicle.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
This compound was studied with a vehicle of 60% emulphor, 20% weak
HCl, 20% ethanol. It was heated as well. No effect upon absti-
nence signs were observed over the dose range of 5-15 mg/kg;
tremor was observed at 10 and 15 mg/kg. Drug supply was depleted,
preventing a full characterization of effects.
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TF:
10.0 @ 30.0
47% @ 10.0, &
0% @ 20.0
37% @ 10.0 8 43%
30.0
NIH 10174 2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazi-
nyl]ethanol hydrochloride (Hydroxyzine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive
Inactive @ 1.0,
TF vs M:
PPQ: @ 1.0, 3% @ 3.0,
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10174 was given to withdrawn rhesus monkeys In doses of 5.6,
10, 30, 100 mg/kg. Abstinence was not affected at any dose. At
the highest dose, prolonged intention tremors, rigidity and slight
ataxia were observed.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals
3
4
4
3
2
7
7
Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
30.0
20.0
16.0
8.0
4.0
3.0
1 ml/kg
NIH 10174 substituted partially for morphine at all the doses
tested during the first 90 minutes. At the highest dose, 1/3 and
at 8.0 mg/kg 4/4 animals did not vocalize when their abdomens were
palpated. In addition, the abdominal muscles were relaxed. Some
suppression of retching and coughing was also evident. The drug
did produce ataxia, slowing and drowsiness at the 3 higher doses.
Partial substitution does not necessarily imply that the drug is
morphine-like.
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NIH 10175 2-Diphenylmethoxy-N,N-dimethylethanamine hydrochloride
(Diphenhydramine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate:
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 5.2 (2.5-12.0)
14.8 (4.1-53.1)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
This compound was studied over a 5-30 mg/kg range of doses.
Slight suppression of abstinence signs was observed; at no dose
was there complete suppression.
preconvulsive signs were observed.
At 10 and 30 mg/kg, tremor and
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals
3
1
3
2
2
5
5
Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
14.0
10.0
7.0
5.0
3.5
3.0
1 ml/kg
NIH, 10175 did not substitute for morphine at any of the doses
tested. The incidence of tremors was higher at doses of 7.0, 10.0
and 14.0 mg/kg.
NIH 10186 N,N-Dimethyl-N'-2-pyridinyl-1,2-ethanediamine hydrochlo-
ride (Tripelennamine)
MOUSE ANALGESIA, ED50 (mg/kg)
3.9 (1.9-7.9)Hot Plate:
TF: 0% @ 1.0, 0% @
10.0 & 45% @
30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1.3 (0.4-3.7)
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NIH 10186 Continued
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Doses of 1.7, 3.0 and 10.0 mg/kg of NIH 10186 were administered to
withdrawn rhesus monkeys. The intermediate dose produced slight
suppression of morphine withdrawal. The highest dose produced
preconvulsive signs in one monkey (no abstinence suppression),
some intention tremor In a second monkey, followed (2-3 hours) by
mild suppression of abstinence.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3 4.0
3 1.0
1 0.25
3 3.0
3 1 ml/kg
NIH 10186 did not substitute for morphine at 0.25-4.0 mg/kg. At
the highest dose, the drug may have exacerbated withdrawal; the
incidence of retching and vomiting was increased.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) H 2O
2 8.0
1 6.0
3 2.0
2
3
0.5
0.05
3 1 ml/kg
One of the 2 animals receiving the highest dose had convulsions.
Pentobarbital (30 mg, i.p.) was given. Salivation, retching,
wet-dog shakes; tremors,
in the other animal.
restlessness and fighting were observed
The abdominal muscles were relaxed and this
animal did not vocalize when palpated. The animal showed behavior
suggesting . hallucinations. The drug acted promptly and' the
duration of action was about 90 minutes. At the lower doses,
(tremors at 6.0, and restlessness, fighting, and wet dogs at 2.0)
few signs were seen.
signs of withdrawal.
The drug elicited some but not all of the
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NIH 10187 Naltrexone-0-methyloxime
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 40% @ 50
Nilsen: 37% @ 50
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0.08 (0.02-0.3)
PPQ: 3.9 (0.8-20.5)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Doses of 0.01, 0.03 and 0.056 mg/kg NIH 10187 produced increas-
ingly severe withdrawal signs in the dependent, non-withdrawn
monkey. The duration. of the withdrawal following 0.03 mg/kg was
two hours. This drug is approximately one half as potent as
naloxone as a narcotic antagonist in this preparation.
NIH 10188 Naloxone-0-methyloxime
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 50.0
Nilsen: Inactive
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 1.9 (0.4-7.8)
PPQ: Inactive @ 1.0,
10.0 & 30.0
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Doses of 0.03, 0.1 and 0.3 mg/kg of NIH 10186 produced morphine
withdrawal signs of increasing severity in the morphine-dependent,
non-withdrawn rhesus monkey. The effects of 0.1 mg/kg lasted
approximately 60 min, while those of 0.3 mg/kg lasted at least
three hours. This drug is about 10 times less potent than nalo-
xone.
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NIH 10189 Oxymorphone-0-methyloxime
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.22 (0.20-0.24)
TF: 0.08 (0.02-0.3)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 0.24 (0.01-0.05)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Doses of NIH 10189, from 0.003 mg/kg, which produced no effect, to
0.1 mg/kg, which produced nearly complete suppression of withdraw-
al, were evaluated in the 14-hour morphine-deprived, dependent
monkeys. The duration of suppression by the highest dose tested
was approximately 2 hours. This drug is approximately 100 times
more potent than morphine in this test.
GESIA, ED50 (mg/kg)
10% @ 100.0
Inactive 0 1.0,
10.0 & 30.0
12% @ 1.0, 16% @
10.0 & 19% @
30.0
9% @ 1.0, 22% @
10.0 & 11% @
30.0
NIH 10197 - See NIH 10121
NIH 10215 gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridine-propana-
mine maleate (Chlorpheniramine)
MOUSE ANAL
Hot Plate:
TF:
TF vs M:
PPQ:
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1 8.0
3 4.0
2 1.0
2 0.25
3 3.0
2 1 ml/kg
NIH 10215 did not substitute for morphine in the dose range of
0.25-8.0 mg/kg. Dose related tremors and myoclonic jerks in one
animal at 4.0 mg/kg were observed.
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NIH 10216 N-Cyano-N'-methyl-N"-[2-[[(5-methyl-1H-imidiazol-4-yl)
methyl]thio]ethyl]guanidine(Cimetidine)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 100.0
TF: Inactive @ 1.0,
10.0 and 30.0
TF vs M: Inactive @ 1.0,
10.0 and 30.0
PPQ: Inactive @ 1.0,
10.0 and 30.0
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc)
1 30.0
3 15.0
3 10.0
3 5.0
4 3.0
4
Propylene
Glycol & H2O
1 mg/kg
In the dose range of 5.0-30.0 mg/kg, NIH 10216 did not substitute
for morphine.
NIH 10224 2,3,4,9b-Tetrahydro-8-hydroxy-2-methyl-1H-1,4a-propano-
benzofuro[2,3c]azine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 50.0
convulsions @
60.0
TF: 15% @ 30.0
TF vs M: 6% @ 1.0, 21% @
10.0, 53% @ 30.0
& 62% @ 60.0
PPQ: 0% @ 10.0, 8% @
3.0, 34% @ 10.0
& 49% @ 30.0
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NIH 10248 Pyrilamine Maleate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 32.8 (28.3-38.1)
Nilsen: 17.7 (12.8-38.1)
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1 13.1 (5.7-30.0)
2 70,6 (39.6-130.1)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3 16.0
4 8.0
3 2.0
1 0.25
4 1.0
4 1 ml/kg
In the dose range of 0.25-16.0 mg/kg, NIH 10248 did not substitute
for morphine. Some tremors were noted at the highest dose. Some
suppression of withdrawal signs was observed during the first
hour.
NIH 10249 N-(2,3-Epoxypropyl)normetazocine
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: inactive
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
Administration of 1.0, 3.0 and 5.6 mg/kg NIH 10249 to the with-
drawn monkey produced little, if any, change in withdrawal signs.
At the highest dose, one monkey showed some abdominal relaxation,
but also exhibited stretching and an increase in respiration.
This drug does not appear to have marked narcotic agonist or
antagonist properties.
water with heating.)
(Vehicle used: Emulphor, ethanol, and
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NIH 10250 Flunixin Meglumine
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive
TF: Inactive @ 1.0,
10.0 & 30.0
TF vs M: 0-16% @ 1.0,
10.0 & 30.0
PPQ: 17-56% @ 1.0,
10.0 & 30.0
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1 40.0
1 20.0
4 10.0
3 5.0
3 2.5
5 3.0
5 1 ml/kg
NIH 10250 suppressed the total number of withdrawal signs at the 2
higher doses during the first hour. However, it did not substitute
completely for morphine.
NIH 10274 - See NIH 8359
NIH 10275 - See NIH 8791
NIH 10276 - See NIH 8805
NIH 10292 (±)-2-[1-( m-Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 5.2 (3.4-7.9)
TF: 6% @ 1.O, 7% @
10.0, 39% @ 30.0
& 34% @ 60.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 4.3 (2.2-8.6)
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NIH 10292 Continued
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
EC50
2.37 uM
4.69 uM
Maximum Response
54.7
51.2
no reversal
no reversal
SUMMARY
NIH 10292 failed to have significant narcotic activity in these
preparations.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3 10.0
3 2.5
2 0.625
3 3.0
3 1 ml/kg
In a preliminary study, a monkey receiving a cumulative dose of 40
mg/kg in 1 hour developed convulsions and died in spite of the
fact that pentobarbital (35 mg i.p.) was given. The drug did not
substitute for morphine at any of the doses tested.
NIH 10293 (-)-2-[1-(m-Methoxyphenyl-2-cyclohexen-l-yl)]-N,N-dimet-
hyl ethylamine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
4.3 (2.8-6.6)Hot Plate:
jumping, ataxia
& clonic con-
vulsions
TF: 63% @ 60.0, 36%
@ 30.0, 0% @
10.0 & 3% @ 1.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 3.0 (1.3-6.8)
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NIH 10293 Continued
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 1100 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
Equimolar concentration
with naltrexone
Equimolar concentration
with morphine
SUMMARY
EC50
106 nM
91 nM
Maximum Response
25.3
24.5
no reversal
no reversal
NIH 10293 does not appear to have either opiate agonistic or
antagonistic activity upon the isolated mouse vas deferens prepa-
ration nor does it displace etorphine at low concentrations.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
1
1
10.0
5.0
2 2.5
1 O.625
2 3.0
2 1 ml/kg
At the highest doses, the animal showed severe myoclonic jerks
which were treated with pentobarbital (15.0 mg i.p.). The drug
did not substitute for morphine.
NIH 10294 (+)-2-[1-( m-Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 6.0 (4.5-7.9)
TF: 1 % @ 1.0 & 31%
@ 30.0
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1.8 (0.6-5.6)
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NIH 10294 Continued
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 10294 failed to displace tritiated etorphine in concentrations
up to 6000 nM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone
After naltrexone
Equimolar concentration
74.9 nM 22.1
137 nM 17.4
with naltrexone
Equimolar concentration
no reversal
with morphine
SUMMARY
no reversal
NIH 10294 appears to be devoid of significant morphine-like
agonistic or antagonistic activity upon the isolated mouse vas
deferens preparation. NIH 10294 did not have significant activity
in the binding assay.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) H 2O
3 5.0
2 2.5
3 0.625
3 3.0
3
NIH 10294 did not substitute for morphine
0.625-5.0 mg/kg. At the 2 higher doses,
exacerbate withdrawal.
1 ml/kg
in the dose range of
the drug appeared to
NIH 10303 Dynorphin-(1-13): H-Thr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-
Pro-Lys-Leu-Lys-OH
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/iv) Morphine (mg/kg/sc) H 2O
2 0.5
5 0.25
5 0.125
3 0.062
6 1.0
6 2 ml/kg
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NIH 10303 Continued
Dynorphin-(1-13) at 0.5, 0.25 and 0.125 mg/kg i.v. suppressed
withdrawal signs in a dose-related manner within 30 minutes. The
effects were waning by 90 minutes.
NIH 10304 Dynorphin-(1-10) Amide
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/iv) Morphine (mg/kg/sc) Saline
4 0.5
4 0.25
3 3.0
3 2 ml/kg
Dynorphin-(1-10) amide suppressed withdrawal signs at 0.5 mg/kg
i.v.
NIH 10306 Dynorphin-(1-6)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/iv) Morphine (mg/kg/sc) Saline
4 0.5
4 0.25
3
3 3.0 2 ml/kg
Dynorphin-(1-6) did not suppress withdrawal signs in morphine-
dependent monkeys at either 0.5 or 0.25 mg/kg i.v.
NIH 10307 alpha-Neo-Endorphin
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/iv) Morphine (mg/kg/sc) Saline
4 0.5
4 0.25
3 3.0
3 2 ml/kg
alpha-Neo-Endorphin did not suppress withdrawal signs at either
0.25%- or 0.5 mg/kg i.v.
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NIH 10308 Vasopressin tannate (Pitressin)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (units/sc) Morphine (mg/kg/sc) H 2O
4 20
4 10
3 3.0
3 1 ml/kg
Pitressin did not substitute for morphine. This substance may
have produced more retching than that seen in the control animals
at approximately 3 units/kg.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (PPt-W)
No. Animals Dose (units/se)
2 80
3 40
4 20
2
2
Naloxone (mg/kg/sc) H 2O
0.05
In doses up to approximately
precipitate withdrawal in these
NIH 10309 Dynorphin-(1-8)
DEPENDENCE EVALUATION IN RHESUS
25 units/kg pitression did not
dependent monkeys.
MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/iv)
3 0.5
2 0.25
3
2
Morphine (mg/kg/sc) Saline
3.0
1 ml/kg
2 ml/kg
Dynorphin-(1-8) did not substitute for morphine at 0.5 and 0.25
mg/kg i.v.
NIH 10311 Z-6-Carbethoxymethylene-6beta-oxide naltrexone
PPQ:
10.0 & 30.0
TF vs M:
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive @ 20.0
& 50.0
Nilsen: Inactive
TF: 16% @ 30.0, 17%
@ 10.0, 6% @
1.0
0.3 (0.1-1.0)
Inactive @ 1.0
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NIH 10311 Continued
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) Tween 80
& H2O
3 0.1
3 0.01
3 0.001
4 3.0
4 1 ml/kg
The monkey receiving 1.0 mg/kg in the preliminary study was given
morphine (2 x 3.0 mg/kg) to terminate withdrawal. The animal was
still vocalizing when palpated 21 hours later in spite of receiving
regularly scheduled doses of morphine every 6 hours. The drug did
not substitute for morphine at any of the doses tested.
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) Tween 80
& H2O
3 0.1
2 0.02
1 0.01
1 0.001
3 0.05
3 1 ml/kg
Dose-related precipitated withdrawal was observed.The onset of
action was rapid and the duration of action much longer than that
of naloxone (60-90 min). The animal receiving the highest dose
was still vocalizing 1/2 hour after the noon injection of
morphine.
NIH 10316 (+)-Thebaine
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 8.4 (5.8-12.1)
Nilsen: 10.9 (7.7-15.5)
TF: 11.2 (4.8-26.3)
TF vs M: Inactive @ 1.0,
10.0 & 30.0
PPQ: 1.9 (0.4-7.8)
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NIH 10316 Continued
DEPENDENCE EVALUATION IN RHESUS MONKEYS (MCV) (SDS)
No. Animals Dose (mg/kg/sc) Morphine (mg/kg/sc) Tween 80
& H2O
3 12.0
2 3.0
2 0.75
3 3.0
2 1 ml/kg
NIH 10316 did not substitute for morphine at 0.75-12.0 mg/kg.
Drug supply exhausted.
NIH 10323 beta-Funaltrexamine( beta-FNA)
DEPENDENCE EVALUATION IN RHESUS MONKEYS (PPt-W)
No. Animals Dose (mg/kg/sc) Naloxone (mg/kg/sc) H 2O
5 3.0
3 10.0
3 0.05
3 1 ml/kg
beta-Funaltrexamine precipitated withdrawal in a dose-related
manner. The drug produced a full withdrawal syndrome with a rapid
onset of action and long duration (> 30 hr). Because we did not
want the animals to remain in withdrawal an excessive period of
time, they were given. morphine after 2 1/2 hrs to terminate
withdrawal. The monkeys continued to show signs of withdrawal at
the high dose up to 30 hr in spite of the fact that morphine was
given regularly every 6 hr.
SPECIAL RAT INFUSION STUDY
As shown in the table, the rats receiving the highest dose of
beta-FNA (5.0 mg/kg/24 hr) in combination with morphine failed to
show behavioral signs of withdrawal at 24, 48, 72, or 96 hr after
abrupt withdrawal was inititated. The lower dose (1.0 mg/kg/24
hr) was partially effective in blocking the development of this
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NIH 10323 Continued
syndrome, i.e., compared with
differences were calculated at
the vehicle controls. Significant
24 and 48 hr. However, the with-
that observed with the morphinedrawal was not as intense as
controls. The controls receiving only beta-FNA did not show a
withdrawal syndrome at any time. Regarding weight loss, the
morphine controls lost nearly 20% of their body weight within 24
hours after abrupt withdrawal was inititated (Fig. 1) and were
slowly regaining weight thereafter. Those animals receiving
either dose of beta-FNA in combination with morphine lost approxi-
mately half that amount. The beta-FNA controls and vehicle
controls behaved similarly and continued to gain weight throughout
the entire study. Since this drug is a selective mu antagonist,
these results indicate that weight loss may not be associated
exclusively with the mu receptor.
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NIH 10332 6-Deoxy-6-fluoro-7,8-dihydro-l4-hydroxymorphine
hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
TF: 0.3 (0.2-0.4)
PPQ:
2.5
0.03 (0.02-0.5)
2.4
Naloxone AD 50 in TF: 0.07
(0.04-0.13)
Naloxone AD 50 in PPQ: 0.11
(0.03-0.3)
SELF-ADMINISTRATION STUDIES - MCV
Intravenous self-administration studies were carried out as
described previously (Slifer and Balster, 1983). Adult male
rhesus monkeys were prepared with chronic intravenous catheters
which were protected by a vest and restraining arm arrangement.
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SELF-ADMINISTRATION STUDIES Continued
They were trained to lever press under a fixed-ratio 10 schedule
for intravenous cocaine hydrochloride during daily one-hour
sessions. Injections were 1.0 ml delivered over 10 sec. When
responding was stable, test solutions were substituted for four
days. Between each substitution the subjects were returned to
cocaine for at least three days. The vehicle for each test drug
(usually 0.9% saline) was also substituted for four days. The
data from the last three days of each substitution was used in the
data analyses. A dose was considered to function as a reinforcer
In a particular subject if the mean for the three days exceeded
the vehicle mean and the ranges did not overlap. Cocaine baseline
injection rates were determined for each subject from the average
of the three-day means preceding each dose substitution for each
drug or drug pair tested.
Five compounds (NIH 7410, 7569, 7571, 8509 and 9802) were evaluated
this year. The results are shown in the accompanying tables.
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NIH 7410 alpha-metazocine:
Levometazocine:
(+)-2,5,9-alpha-trimethyl-1'hydroxy-6,7-benzomorphan HCl
NIH 7569 (-)-2,5,9-alpha-trimethyl-2-'hydroxy-6,7-benzomorphan HBr
NIH 7571 alpha-(+I-netazocine: (+)-2,5,9-alpha-trimethyl-2'-hydroxy-6,7-benzomorphan HBr
SELF-ADMINISTRATION
Drug Dose (mg/kg/inj) Mean # of Injectiona
#Self-Administering
Testedc
Cocaine·HCl 50
Range of Meansb
45.7 37.8 - 51.2 3/3
Saline -- 9.0 5.9 - 11.7 --
NIH 7410·HCl 3 33.2 11.7 - 62.3 1/3
10 71.2 11.3 - 145.0 2/3
30 63.2 38.0 - 112.7 3/3
100 65.0 57.3 - 74.0 3/3
NIH 7569·HBr 1 20.9 8.0 - 23.3 2/3
3 26.7 12.7 - 35.0 1/3
10 43.3 13.30 - 103.3 1/3
30 73.0 22.0 - 161.3 2/3
NIH 7571·HBr 3 8.8 3.7 - 14.0 0/3
10 13.3 9.0 - 19.7 1/3
30 12.8 8.7 - 18.0 0/3
100 31.9 3.3 - 56.3 2/3
aMean number of injections per 1-hr session over last 3 days of each 4-day substitution for 3 subjects.
bRange of 3-day means for the individual subjects tested with each treatment.
cSubjects were considered to self-administer a dose when the range of injection rates for that dose did not
overlap the range of injection rates for saline.
Conclusion: NIH 7410 and NIH 7569 were self-administered above control levels at least at one dose in each
of the subjects tested. NIH 7571 was self-administered at 100 mg/kg/inj in 2 of the 3 subjects. Limited
supplies precluded further testing of NIH 7571.
NIH 9882 and 8500 (-)-5-(m -Hydroxyphenyl)-2-methylmorphan hydrochloride
NIH 8509 (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
INTRAVENOUS SELF-ADMINISTRATION
Drug Dose (mg/kg/inj) # of Subjects Mean # of Injections
a Range of Meansb
#Self-Adminstering
#Tested
Cocaine·HCl 30 or 50 5 57.8 32.3 - 97.0 5/5
Saline -- 5 8.9 3.3 - 20.3 --
NIH 9882 1 1 12.7 -- 0/1
3 4 26.0 7.0 - 52.3 3/4
10 4 37.6 12.3 - 71.0 2/4
3 0 4 45.3 8.0 - 87.0 4/4
100 2 25.4 21.3 - 29.5 2/2
NIH 8509 1 1 17.0 -- 0/1
3 3 39.5 3.3 - 70.3 2/3
10 4 53.7 1.3 - 117.0 3/4
30 4 48.9 14.0 - 74.3 3/4
100 1 47.3 -- 1/0
aMean number of injections per 1-hr session over last 3 days of each 4-day substition for all subjects
tested with each treatment.
bRange of 3-day means for the various subjects tested with each treatment.
cSubjects were considered to self-administer a dose when the range of injection rates for that dose did
not overlap the range of injection rates for saline.
Conclusion: Both NIH 9682 and NIH 8509 were self-administered above control values at least at one dose
in each subject tested.
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mouse analgesia, 329
397
2-Cyclopropylmethyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-
benzomorphan oxalate (NIH 10160, MCV 4351)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 367
mouse analgesia, 367
Dalmane
prevalence of use, 231-237
Despiramine
treatment for withdrawal from cocaine dependence, 159-163
6-Desoxy-6-fluoro-7,8-dihydro-14-hydroxymorphine hydrochloride
(NIH 10332, HCV 4415)
mouse analgesia, 388
self-administration, 388-389
6-Desoxy-6-isonitrosonaloxone (naloxone oxime, NIH 10002,
HCV 4309, UM 1371)
biological evaluation for dependence liability, 304
depression of smooth muscle twitch, 351
displacement of stereospeclfic 3H-etorphine binding, 351
mouse analgesia, 351
Detoxification
assessment and extinction of conditioned withdrawal-like
responses in an integrated treatment, 202-210
use of methadone dose increases in, 178-184, 197-201
Dexoxadrol
binding to the phencyclidine receptor, 95
Dextrorphan
displacement of stereospecific 3H-etorphine binding, 163
Diazepam
behavioral disruption in humans, 71
clinical profile and therapeutic benefits of dependence,
212-216
effectiveness in the control of neonatal abstinence, 158
effects on affective properties of memories, 260-265
effects on psychophysical thresholds, reaction times in
baboons, 69
evaluation for anxiolytic/anorectic activity in drug dis-
crimination studies, 79-80
preference comparison to oxazepam in humans, 97-98
prevalence of use, 231-237
use as adjunct medication in outpatient methadone detoxifi-
cation; 191-196
1,1-Dicyclohexyl-3-(2-piperidyl)cyclopentane
evaluation in batrachotoxin and phencyclidine binding assays
and by drug discrimination, 90-96
Diethylpropion
anorectic efficacy, neurotoxicity, drug discrimination and
self-administration, 76-81
self-administration studies in humans, 72
Dihydromorphinone hydrochloride (NIH 0123)
mouse analgesia, 321
(-)-4,14,Dihydroxy-N-methylmorphinan (NIH 9998, UM 1369)
biological evaluation for dependence liability, 305
depression of smooth muscle twitch, 350
398
displacement of stereospeciflc 3H-etorphine binding, 350
mouse analgesia, 350
(-)-3,4-Dimethoxy-N-(2-phenethyl)-morphlnan-6-one hydrobromide
(NIH 10018, UM 1385)
biological evaluation for dependence liability, 305
depression of smooth muscle twitch, 353
displacement of stereospecific 3H-etorphine binding, 353
mouse analgesia, 353
(-)-3-[(Dimethylamlno)( m -dioxan-5-yl)methyl]pyridine hydrochlo-
ride (Doxpicomine, NIH 9344, MCV 4104, UM 1126)
biological evaluation for dependence liability, 307
dependence studies in rats, 330
mouse analgesia, 330
2,5-Dimethyl-2’-hydroxy-9 -isopentyl-6,7-benzomorphan methane-
sulfonate (NIH 9450, MCV 4276, UM 1305)
biological evaluation for dependence liability, 306
depression of smooth muscle twitch, 330
displacement of stereospecific 3H-etorphine binding, 330
mouse analgesia, 332
(±)-5,9 -Dimethyl-2’-hydroxy-2-(4-methylpentyl)-6,7-benzomorphan
hydrochloride (NIH 9938, MCV 4269, UM 1321)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 337
depression of smooth muscle twitch, 344
displacement of stereospeciflc 3H-etorphlne binding, 343
mouse analgesia, 337, 343
2,9 -Dimethyl-5-(m -methoxyphenyl)morphan hydrobromide (NIH 9945,
MCV 4286, UM 1327
biological evaluation for dependence liability, 306
depression of smooth muscle twitch, 346
displacement of stereospecific 3H-etorphine binding, 346
mouse analgesia, 346
N,N-Dimethyl-N’-2-pyridinyl-1,2-ethanediamine hydrochloride
(Tripelennamine, NIH 10186, MCV 4375)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 374
mouse analgesia, 373
(-)-trans-N,N-Dimethyl-l,2,3,4,-tetrahydro-4-methyl-4-phenyl-2-
naphthylamine hydrochloride (NIH 9941, MCV 4283, UM 1331)
biological evaluation for dependence liability, 307
depression of smooth muscle twitch, 344
displacement of stereospecific 3H-etorphlne binding, 344
mouse analgesia, 344
(+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-
naphthylamlne (NIH 9942, MCV 4284, UM 1332)
biological evaluation for dependence liability, 307
depression of smooth muscle twitch, 345
displacement of stereospecific 3H-etorphine binding, 345
mouse analgesia, 345
Dinoracetylmethadol
quantitation in serum, 283-285
Diphenhydramine (NIH 10175, MCV 4364)
See 2-Diphenylmethoxy-N,N-dimethylethanamine hydrochloride
399
1,1-Diphenyl-3-(2-piperidyl)cyclopentane
evaluation in batrachotoxin and phencyclidine binding
assays and by drug discrimination, 90-96
2-Diphenylmethoxy-N,N-dimethylethanamine hydrochloride (Diphenhy-
dramine, NIH 10175, HCV 4364)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 373
mouse analgesia, 373
1-Diphenylmethyl-4-methylpiperazine hydrochloride (Cyclizine,
NIH 10169, HCV 4361)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 369
mouse analgesia, 369
Doxepin
use as adjunct medication in outpatient methadone detoxifi-
cation, 191-196
Doxpicomine (NIH 9344, MCV 4104, UM 1126)
See (-)-3-[(Dimethylamino)( m -dioxan-5-yl)methyl]pyridine
hydrochloride
Drug abuse
commonalities with gambling, 59-60
Drug dependence
characteristics of dependent mothers who participated in
developmental outcome studies of their infants, 266
Dynorphin-(1-6) (NIH 10306, MCV 4356)
dependence studies in monkeys, 383
Dynorphin-(1-8) (NIH 10309, 4370)
dependence studies in monkeys, 384
Dynorphin-(1-13): H-Thr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-
Lye-Leu-Lys-OH (NIH 10303, MCV 4353)
dependence studies in monkeys, 382
Dynorphin-(1-10) amide (NIH 10304, MCV 4354)
dependence studies in monkeys, 383
Elavil
prevalence of use, 231-237
N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-L-glycyl-L-
phenylalanyl-L-leucine ethyl ester hydrochloride (NIH 9835,
UM 1299)
biological evaluation for dependence liability, 304
depression of smooth muscle twitch, 336
displacement of stereospecific 3H-etorphine binding, 336
mouse analgesia, 336
N-(6,14-Endoetheno-7,8-dihydromorphlne-7 -carbonyl)-L-phenyla-
lanyl-L-leucine-ethyl ester hydrochloride (NIH 9833, UM 1297)
biological evaluation for dependence liability, 304
depression of smooth muscle twitch, 335
displacement of stereospecific 3H-etorphine binding, 335
mouse analgesia, 335
Endogenous opioids
effects on release of luteinizing hormone-releasing hor-
mone, 15
regulation of reproductive endocrinology, 15
400
-Endorphin
-endorphin-like immunoreactivity in human centenarians,
52-53
, 306
N-(2,3-Epoxypropyl)normetazocine (NIH 10249)
biological evaluation for dependence liability
dependence studies in monkeys, 378
mouse analgesia, 378
Estradiol
effect of marihuana smoke on levels in women, 24-31
Estrogens
role in feminization in men with alcohol-induced cirrhosis,
32-41
Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate hydro-
chloride (NIH 9831, UM 1296)
biological evaluation for dependence liability, 304
depression of smooth muscle twitch, 334
displacement of stereospecific 3H-etorphine binding, 334
mouse analgesia, 334
Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate hydro-
chloride (NIH 9830, UM 1295)
biological evaluation for dependence liability, 304
depression of smooth muscle twitch, 333
displacement of stereospecific 3H-etorphine binding, 333
mouse analgesla, 333
2-Ethyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-benzomorphan
oxalate (NIH 10172, MCV 4367)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 371
mouse analgesla, 371
Ethylketocyclazocine (NIH 8848, NIH 10165, MCV 4348, UM 975)
See (2-Cyclopropylmethyl-5-ethyl-8-oxo-9 -methyl-6,7-
benzomorphan methanesulfonate
m -(3-Ethyl-1-methylhexahydro-1H-azepin-3-yl)phenol hydrochloride
(Heptazinol hydrochloride, NIH 8683, MCV 4403, UM 888)
biological evaluation for dependence liability, 307
dependence studies in monkeys, 326
mouse analgesia, 326
Etorphine
displacement of stereospecific 3H-etorphine binding, 316
Feminization
occurrence in men with alcohol-induced cirrhosis, 32-41
Fencamfamine
behavioral properties, 54-56
Fenfluramine
anorectic efficacy, neurotoxicity, drug discrimination and
self administration, 76-81
Flunixin meglumine (NIH 10250, MCV 4384)
analgesic efficacy compared to meperidine, 145-150
biological evaluation for dependence liability, 308
dependence studies in monkeys, 379
mouse analgesia, 379
-FNA
See -Funaltrexamlne
401
Food deprivation
effects on self-administration of cocaine, 125-131
-Funaltrexamine ( -FNA, NIH 10323, MCV 4372)
effects in drug naive and morphine-dependent monkeys,
99-205
dependence studies in monkeys, 386
dependence studies in rats, 386
Gambling
commonalities with drug abuse, 59-60
Glucose
abuse liability, 60
Gonadotropin releasing hormone
effects on luteinizing hormone secretion in tetrahydrocan-
nabinol-treated rats, 42-51
Halazepam
evaluation for anxiolytic/anorectic activity in drug discri-
mination studies, 79-80
Heroin
relative potency to morphine, 11
treatment of withdrawal with clonidine, 288-290
2,3,4,5,6,6a-Hexahydro-8-hydroxy-1H-411b-methanobenzofuro[3,2]-
azocine hydrochloride (NIH 10171, MCV 4369)
biological evaluation for dependence liability, 306
mouse analgesia, 370
(-)-n -Hexyl-5-(m -hydroxyphenyl)morphan hydrochloride (NIH 9887,
MCV 4234, UM 1286)
biological evaluation for dependence liability, 306
depression of smooth muscle twitch, 339
displacement of stereospecific 3H-etorphine binding, 339
mouse analgesia, 339
Hydrocodone
metabolism in humans, dog, rats, guinea pigs and rabbits,
53-54
Hydromorphone
drug discrimination in methadone maintenance patients,
151-157
metabolism in humans, dog, rats, guinea pigs and rabbits,
53-54
2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-pentyl-6,7-benzomorphan
oxalate (NIH 10156, MCV 4345)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 365
mouse analgesia, 364
2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-phenethyl-6,7-benzomor-
phan oxalate (NIH 10157, MCV 4349)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 365
depression of smooth muscle twitch, 365
mouse analgesia, 365
2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-propyl-6,7-benzomorphan
oxalate (NIH 10158, MCV 4346)
biological evaluation for dependence liability, 306
402
dependence studies in monkeys, 366
mouse analgesia, 366
(+)-5-( m -Hydroxyphenyl)-2-methylmorphan (NIH 8509, NIH 9889,
MCV 4232, UM 810)
biological evaluation for dependence liability, 306
dependence studies in monkeys, 325
mouse analgesia, 325
self-administratron by monkeys, 391
(-)-5-( m -Hydroxyphenyl)-2-methylmorphan hydrochloride (NIH 8508,
NIH 9882)
self-administration by monkeys, 391
(+)-5-(m -Hydroxyphenyl)morphan hydrochloride (NIH 9888, MCV 4234,
UM 1287)
biological evaluation for dependence liability, 306
depression of smooth muscle twitch, 340
displacement of stereospecific 3H-etorphine binding, 340
mouse analgesia, 340
(-)-(m -Hydroxyphenyl)-2- n-pentylmorphan hydrochloride (NIH 9886,
MCV 4233, UM 1285)
biological evaluation for dependence liability, 306
depression of smooth muscle twitch, 338
displacement of stereospecific 3H-etorphine binding, 338
mouse analgesia, 338
Hydroxyzine (NIH 10174, MCV 4363)
See 2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-
piperazinyl]ethoxy]ethanol hydrochloride
Hypogonadism
occurrence in men with alcohol-induced cirrhosis, 32-41
J. Michael Morrison Award
outstanding achievement in science administration, 1
Ketazocine
displacement of stereospecific 3H-etorphine binding, 316
Khat
See (-)-Cathinone
Ketocyclazocine
pharmacologic and behavioral effects in humans, 61-64
L A A M
See 1- -Acetylmethadol
Librium
prevalence of use, 231-237
Levorphanol tartrate (NIH 4590)
mouse analgesia, 311
Loperamide
pupillary effects, 57-58
Lorazepam
in pentobarbital-lorazepam discrimination in baboons and
rats, 68-69
Luteinizing hormone
effects of marihuana smoking on release in women, 24-31
effects of naloxone and morphine on serum levels, 16-19
effects of 9-tetrahydrocannabinol on secretion in rats,
42-51
Luteinizing hormone-releasing hormone
alteration of release by opiates, 14-15
403
Lymphocytes
specific binding sites for naloxone, 258-259
Marihuana smoking.
effects on luteinizing hormone, estradiol, progesterone and
prolactin release in women, 24-31
effects on naloxone-induced release of luteinizing hormone,
24-31
use in relation to antecedent misbehaviors, 238-244
Mazindol
anorectic efficacy, neurotoxicity, drug discrimination and
self-administration, 76-81
MCV 4002 (NIH 8503, NIH 9930, UM 1312)
MCV 4104 (NIH 9344, UM 1126)
MCV 4196 (NIH 9736, UM 1224)
MCV 4232 (NIH 8509, NIH 9889, UM 810)
MCV 4233 (NIH 9886, UM 1285)
MCV 4234 (NIH 9887, UM 1286)
MCV 4243 (NIH 9888, UM 1287)
MCV 4259 (NIH 9922, UM 1320)
MCV 4260 (NIH 0001, NIH 9929, UM 1311)
MCV 4269 (NIH 9938, UM 1321)
MCV 4276 (NIH 9450, UM 1305)
MCV 4283 (NIH 9941, UM 1331)
MCV 4284 (NIH 9942, UM 1332)
MCV 4286 (NIH 9945, UM 1327)
MCV 4291 (NIH 9969, UM 1346)
MCV 4292 (NIH 9970, UM 1357)
See Naltrexone hydrochloride
See (-)-3-[(Dimethylamino)(
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8
See (+)-5-(
See (-)-(
See (-)-
See (+)-5-(
See 3-(1,2
See Morphine
See (+)-5,9
See 2,5-Dimethyl-2’-hydroxy-9 -isopentyl-6,7-benzomorphan
See (-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
See
See 2,9 -Dimethyl-5-( m -methoxyphenyl)morphan hydrobromide
See cis-1,2,3,4,4a,5,6,10b-Octahydro-3-methyl-10b-
See
m -dioxan-5-yl)methyl]pyridine
hydrochloride (Doxpicomine)
-methylmor-
phinan
m -hydroxyphenyl)-2-methylmorphan
m -Hydroxyphenyl)-2-n-pentylmorphan hydrochloride
n-Hexyl-5-(m -hydroxyphenyl)morphan hydrochloride
m -Hydroxyphenyl)morphan hydrochloride
,4 ,5 -Tetramethyl-4 -piperidinyl)- m -phenol,Z-
2-butenedioic acid salt
-Dimethyl-2’-hydroxy-2-(4-methylpentyl)-
6,7-benzomorphan hydrochloride
methanesulfonate
4-phenyl-2-naphthylamine hydrochloride
(+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
propylbenz[f]isoquinoline-9-ol hydrochloride
cis-1,2,3,4,4a,5,6,10b-Octahydro-3,10b-
dimethylbenz[f]isoquinolin-9-ol butanedioate (1:1) salt
404
MCV 4295
MCV 4299
MCV 4309
MCV 4316
MCV 4318
MCV 4326
MCV 4327
MCV 328
MCV 4329
MCV 4337
MCV 4338
MCV 4339
MCV 4341
MCV 4342
MCV 4343
MCV 4345 (NIH 10156)
MCV 4346 (NIH 10158)
MCV 4347 (NIH 10164)
MCV 4348 (NIH 8848, NIH 10165, UM 975)
MCV 4349 (NIH 10157)
MCV 4350 (NIH 10159)
MCV 4351 (NIH 10160)
(NIH 9974, UM 1361)
See (-)-N-Allyl-4-hydroxymorphinan-6-one
(NIH 9989, UM 1364)
See (-)-N-Methylmorphinan d-tartrate
(NIH 10002, UM 1371)
See 6-Desoxy-6-isonitroaonaloxone (naloxone oxime)
(NIH 10010, UM 1379)
See (-)-N-Allylmorphinan-6-one hydrochloride
(NIH 10016, UM 1383)
See (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
(NIH 10068)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone-14-
acetate
(NIH 10069)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone
(NIH 10070)
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone-14-
acetate
(NIH 10071)
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone
acetic acid salt
(NIH 10111)
See Naloxone-6-spirohydantoin (6 -oxo)
(NIH 10121, NIH 10197, MCV 4373)
See Phenyltoloxamine dihydrogen citrate
(NIH 10146)
See 2,3,5,6-Tetrahydro-6-methylene-7-(2,4-dichlorophenyl)-
imidazo[1,2a]imidazole
(NIH 10147)
See 6 -Oxide-6-methylene naltrexone
(NIH 10148)
See 6 -Oxide-6-methylene naloxone
(NIH 10149)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone
See 2’-Hydroxy~5-methyl-9 -(3-methyl)butyl-2-pentyl-6,7-
benzomorphan oxalate
See 2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-propyl-6,7-
benzomorphan oxalate
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone
See 2-Cyclopropylmethyl-5-ethyl-8-oxo-9 -methyl-6,7-
benzomorphan methadesulfonate (Ethylketocyclazocine)
See 2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-phenethyl-
6,7-benxomorphan oxalate
See 2-Allyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-
benzomorphan oxalate
See 2-Cyclopropylmethyl-2’-hydroxy-5-methyl-9
(3-methyl)butyl-6,7-benzomorphan oxalate
405
MCV 4352
See
MCV 4353
See
MCV 4354
See
MCV 4356
See
MCV 4357
(NIH 10163)
6 -Oxide-6-methylene oxymorphone
(NIH 10303)
Dynorphin-(1-13): H-Thr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-
Arg-Pro-Lys-Leu-Lys-OH
(NIH 10304)
Dynorphin-(1-10) amide
(NIH 10306)
Dynorphin-(1-6)
(NIH 10307)
-Neo-endorphinSee
MCV 4358 (NIH 10308)
See
MCV 4361
See
MCV 4362
See
MCV 4363
See
MCV 4364
See
MCV 4365
See
MCV 4366
See
MCV 4367
See
MCV 4368
See
MCV 4369
See
MCV 4370
See
MCV 4372
See
MCV 4373
See
MCV 4375
See
MCV 4376
See
MCV 4377
See
Vasopressin tannate (Pitressin)
(NIH 10169)
1-Diphenylmethyl-4-methylpiperazine hydrochloride
(Cyclizine)
(NIH 10170)
N,N, -Trimethyl-1-OH-phenothiazine-10-ethanamine hydro-
chloride (Promethazine)
(NIH 10174)
2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-
piperazinyl]ethoxy]ethanol hydrochloride (Hydroxyzine)
(NIH 10175)
2-Diphenylmethoxy-N,N-dimethylethanamine hydrochloride
(Diphenhydramine)
(NIH 10142)
2-Cyclopropylmethyl-3 ,5-dimethyl-2’-hydroxy-6,7-benzo-
morphan hydrochloride
(NIH 10144)
3 -Allyl-2,3 ,5-trimethyl-6,7-benzomorphan hydrochloride
(NIH 10172)
2-Ethyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-ben-
zomorphan oxalate
(NIH 10173)
2-n -Butyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-
benzomorphan oxalate
(NIH 10171)
2,3,4,5,6,6a-Hexahydro-8-hydroxy-1H-411b-methanobenzofu-
ro[3,2]azocine hydrochloride
(NIH 10309)
Dynorphin-(1-8)
(NIH 10323)
-Funaltrexamlne
(NIH 10121, NIH 10197, MCV 4338)
Phenyltoloxamine dihydrogen citrate
(NIH 10186)
N,N-Dimethyl-N’-2-pyridinyl-1,2-ethanediamine hydro-
chloride (Tripelennamine)
(NIH 10187)
Naltrexone-O-methyloxime
(NIH 10188)
Naloxone-O-methyloxime
406
MCV 4378 (NIH 10189)
MCV 4379 (NIH 10248)
MCV 4380 (NIH 10215)
MCV 4381 (NIH 10216)
MCV 4384 (NIH 10205)
MCV 4385 (NIH 8359, NIH 10274, UM 686)
MCV 4386 (NIH 8791, NIH 10275, UM 941)
MCV 4387 (NIH 8805, NIH 10276, UM 952)
MCV 4393 (NIH 10224)
See Oxymorphone-O-methyloxime
See Pyrilamine maleate
See -(4-Chlorophenyl)-N,N-dimethyl-2-pyridine-propana-
mine maleate (Chlorpheniramine)
See N-Cyano-N’methyl-N”-[2-[[(5-methyl-1H-imidiazol-4-
yl)methyl]thio]ethyl]guanidine (Cimetidine)
See Flunixin meglumine
See Nalbuphine hydrochloride
See Butorphanol tartrate
See Buprenorphine hydrochloride
See 2,3,4,9b-Tetrahydro-8-hydroxy-2-methyl-1H-1,4a-
propanobenzofuro[2,3c]azine hydrochloride
MCV 4394 (NIH 10311)
See Z-6-Carbethoxymethylene-6 -oxide naltrexone
MCV 4395 (NIH 10316)
See (+)-Thebaine
MCV 4396 (NIH 10292)
See (±)-2-[1-(m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
MCV 4397 (NIH 10293)
See (-)-2-(1-( m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
MCV 4398 (NIH 10294)
See (+)-2-[1-( m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
MCV 4403 (NIH 8683, UM 888)
See m -(3-Ethyl-1-methylhexahydro-1H-azepin-3-yl)phenol
hydrochloride (Meptazinol hydrochloride)
MCV 4405 (NIH 10021, UM 1388)
See 9 -Acetoxy-2-methyl-5-( m -acetoxy)phenylmorphan hydro-
bromide
MCV 4415 (NIH 10322)
See 6-Desoxy-6-fluoro-7,8-dihydro-14-hydroxymorphine hydro-
chloride
Mecamylamine
use in withdrawal from nicotine dependence, 291-297
Mellaril
prevalence of use, 231-237
Memory
effects of diazepam on, 260-262
Meperidine (NIH 5521)
comparison of analgesic efficacy with flunixin meglumine,
145-150
mouse analgesia, 311
407
Meptazinol hydrochloride (NIH 8683, MCV 4403, UM 888)
evaluation in cancer patients with postoperative pain,
138-144
See also m -(3-Ethyl-l-methylhexahydro-1H-azepin-3-yl)phenol
hydrochloride
-(±)-Metazocine (NIH 7410)
See (±)-2,5,9 -Trimethyl-1’-hydroxy-6,7-benzomorphan hydro-
chloride
-(-)-Metazocine (NIH 7569)
See (-)-2,5,9 -Trimethyl-2’-hydroxy-6,7-benzomorphan hydro-
chloride
-(+)-Metazocine (NIH 7571)
See (+)-2,5,9 -Trimethyl-2’-hydroxy-6,6-benzomorphan hydro-
chloride
Methadone
detoxification, effects of diazepam and doxepin as adjunct
medications, 191-196
drug discrimination in methadone maintenance patients,
151-157
effect of dose increase during detoxification, 197-201
effects on cigarette smoking, 70
use of contigent methadone dose Increases in detoxification
patients, 178-184
Methadone challenge
a technique for assessing degree of opioid tolerance, 73
treatment intervention trials, 73
(±)-2-[1-(m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-dimethyl
ethylamine hydrochloride (NIH 10292, MCV 4396)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 380
depression of smooth muscle twitch, 380
mouse analgesia, 379
(-)-2-[1-(m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-dimethyl
ethylamine hydrochloride (NIH 10293, MCV 4397)
biological evaluation for dependence liability, 308
depression of smooth muscle twitch, 381
displacement of stereospecific 3H-etorphine binding, 381
mouse analgesia, 380
(+)-2-[1-( m -Methoxyphenyl)-2-cyclohexen-l-yl]-N,N-dimethyl
ethylamine hydrochloride (NIH 10294, MCV 4398)
biological evaluation for dependence liabilities, 308
dependence studies in monkeys, 382
depression of smooth muscle twitch, 382
displacement of stereospecific 3H-etorphine binding, 382
mouse analgesia, 381
3-Methyl-3- m -hydroxyphenylpiperidines
synthesis, resolution, receptor binding and analgesic pro-
perties, 82-89
(-)-N-Methyl-3,4-methylenedioxy-6-oxomorphinan (NIH 9842, UM 1352)
biological evaluation for dependence liabilites, 305
depression of smooth muscle twitch, 338
displacement of stereospecific 3H-etorphine binding, 337
mouse analgesia, 337
408
(-)-N-Methylmorphinan d-tartrate
biological evaluation for dependence liability, 305
depression of smooth muscle twitch, 349
displacement of stereospecific 3H-etorphine binding, 349
mouse analgesia, 349
Hethyphenidate
anorectic efficacy, neurotoxicity, drug discrimination and
self administration, 76-81
Metopon
relative potency to morphine, 10
Morphine (NIH 0001, NIH 9929, MCV 4260, UM 1311)
biological evaluation for dependence liability, 304
development of cross tolerance between systemic and spinal
administration, 252-253
depression of smooth muscle twitch, 341
displacement of stereospecific 3H-etorphine binding, 316, 34
effect on release of luteinizing hormone-releasing hormone,
15
effects on serum luteinizing hormone levels, 16-21
evaluation in cancer patients with postoperative pain, 138-
144
mouse analgesia, 311, 315, 341
pharmacologic and behavioral effects in humans, 61-64
pregestational influences, 19-22
pupillary effects, a neuronal model, 57-58
relative potency to heroin, 11
relative potency to metopon, 10
self-administration in baboons, 67
Nalbuphine (NIH 8359, NIH 10274, MCV 4385, UM 686)
biological evaluation for dependence liability, 303
dependence studies in monkeys, 325
mouse analgesia, 325
quantitative methods for measuring physical dependence pro-
ducing properties in the mouse, 269-270
self administration in baboons, 67
Nalorphine (NIH 2105)
mouse analgesia, 312, 315
quantitative methods for measuring physical dependence pro-
ducing properties in the mouse, 269-270
Naloxone (NIH 7890)
binding sites in non-dividing human lymphocytes, 258-259
effect on release of luteinizing hormone-releasing hormone,
15
effects on serum luteinizing hormone levels, 16-19
drug discrimination in methadone maintenance patients,
151-157
metabolism in humans, dogs, rats, guinea pigs and rabbits,
53-54
mouse analgesia, 312, 315
pharmacologic and behavioral effects in humans, 61-64
self administration in baboons, 67
stimulated release of luteinizing hormone, effect of mari-
huana smoke on, 24-31
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Naloxone-O-methyloxime (NIH 10188, MCV 4377)
biological evaluation for dependence liability, 304
dependence studies in monkeys, 375
mouse analgesia, 375
Naloxone oxime (NIH 10002, MCV 4309, UM 1371)
See 6-Desoxy-6-isonitrosonaloxone
Naloxone-6-spirohydantoin(6 -oxo) (NIH 10111, MCV 4337)
biological evaluation for dependence liability, 303
mouse analgesia, 358
Naltrexone (NIH 8503, NIH 9930, MCV 4002, UM 1312)
biological evaluation for dependence liability, 304
depression of smooth muscle twitsch, 343
displacement of stereospecific 3H-etorphine binding, 316, 342
metabolism in humans, dogs, rats, guinea pigs and rabbits,
53-54
mouse analgesia, 312, 315, 342
use in addicted physicians and business executives, 185-
190
Naltrexone-O-methyloxime (NIH 10187, MCV 4376)
biological evaluation for dependence liability, 304
dependence studies in monkeys, 375
mouse analgesia, 375
Nathan B. Eddy Memorial Award Lecture
the analgesic connection, 4-13
-Neo-endorphin (NIH 10307, MCV 4357)
dependence studies in monkeys, 383
Nicotine
adversive properties and subjective dysphoria, 61
use of mecamylamine for withdrawal, 291-297
NIH 0001 (NIH 9929, MCV 4260, UM 1311)
See Morphine
NIH 0002
See Codeine phosphate
NIH 0123
See Dihydromorphinone hydrochloride
NIH 2105
See Nalorphine hydrochloride
NIH 4590
See Levorphanol tartrate
NIH 5221
See Meperidine hydrochloride
NIH 7410 ( -(±)-metazocine)
See (±)-2,5,9 -Trimethyl-1’-hydroxy-6,7-benzomorphan hydro-
bromide
NIH 7569 ( -(-)-metazocine)
See (-)-2,5,9 -Trimethyl-2’-hydroxy-6,7-benzormophan hydro-
hydrobromide
NIH 7511 ( -(+)-metazocine)
See (+)-2,5,9 -Trimethyl-2’-hydroxy-6,7-benzomorphan hydro-
bromide
NIH 7890
See Naloxone hydrochloride
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NIH 7958
See Pentazocine
NIH 7981
See Cyclazocine
NIH 8359 (NIH 10274, MCV 4385, UM 686)
See Nalbuphine hydrochloride
NIH 8503 (NIH 9930, MCV 4002, UM 1312)
See Naltrexone hydrochloride
NIH 8508 (NIH 9882)
See (-)-5-(m -Hydroxyphenyl)-2-methylmorphan hydrochloride
NIH 8509 (NIH 9889, MCV 4232, UM 810)
See (+)-5-(m -Hydroxyphenyl)-2-methylmorphan
NIH 8683 (MCV 4403, UM 888)
See m -(3-Ethyl-1-methylhexahyrdo-1H-azepin-3-yl)phenol
hydrochloride (Meptazinol hydrochloride)
NIH 8791 (NIH 10275, MCV 4386, UM 941)
See Butorphanol tartrate
NIH 8805 (NIH 10276, MCV 4387, UM 952)
See Buprenorphine hydrochloride
NIH 8848 (NIH 10165, MCV 4348, UM 975)
See 2-Cyclopropylmethyl-5-ethyl-8-oxo-9 -methyl-6,7-
benzomorphan methanesulfonate (Ethylketocyclazocine)
NIH 9344 (MCV 4104, UM 1126)
See (-)-3-[(Dimethylamino)(m -dioxan-5-yl)methyl]pyridine
hydrochloride (Doxpicomine)
NIH 9450 (MCV 4276, UM 1305)
See 2,5-Dimethyl-2’-hydroxy-9 -isopentyl-6,7-benzomorphan
methanesulfonate
NIH 9736 (MCV 4196, UM 1224)
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8 -methylmor-
phinan
NIH 9830 (UM 1295)
See Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate
hydrochloride
NIH 9831 (UM 1296)
See Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate
hydrochloride
NIH 9833 (UM 1297)
See N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-L-
phenylalanyl-L-leucine ethyl ester hydrochloride
NIH 9835 (UM 1299)
See N-6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-L-
glycyl-L-phenylalanyl-L-leucine ethyl ester hydrochloride
NIH 9842 (UM 1352)
See (-)-N-Methyl-3,4-methylenedioxy-6-oxomorphinan
NIH 9882 (NIH 8509)
See (-)-5-( m -Hydroxyphenyl)-2-methylmorphan hydrochloride
NIH 9886 (HCV 4233, UM 1285)
See (-)-(m -Hydroxyphenyl)-2- n-pentyImorphan hydrochloride
NIH 9887 (MCV 4234, UM 1286)
See (-)-n -Hexyl-5-( m -hydroxyphenyl)morphan hydrochloride
NIH 9888 (HCV 4243, UM 1287)
See (+)-5-(m -Hydroxyphenyl)morphan hydrochloride
411
NIH 9889
See
NIH 9922
See
NIH 9929
See
NIH 9930
See
NIH 9938
See
NIH 9941
See
NIH 9942
See
NIH 9945
See
NIH 9969
See
(NIH 8509, MCV 4232, UM 810)
(+)-5-(m -Hydroxyphenyl)-2-methylmorphan
(MCV 4259, UM 1320)
3-(1,2 ,4 ,5 -Tetramethyl-4 -piperidinyl)-m -phenol,Z-
2-butenedioic acid salt
(NIH 0001, MCV 4260, UM 1311)
Morphine
(NIH 8503, MCV 4002, UM 1312)
Naltrexone hydrochloride
(MCV 4269, UM 1321)
(+)-5,9 -Dimethyl-2’-hydroxy-2-(4-methylpentyl)-
6,7-benzomorphan hydrochloride
(MCV 4283, UM 1331)
NIH 9970
See
NIH 9974
See
NIH 9989
See
NIH 9998
See
(-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
(MCV 4284, UM 1332)
(+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
(MCV 4286, UM 1327)
2,9 -Dimethyl-5-(m -methoxyphenyl)morphan hydrobromide
(MCV 4291, UM 1346)
cis-1,2,3,4,4a,5,6,10b-Octahydro-3-methyl-10b-
propylbenz[f]isoquinoline-9-ol hydrochloride
(MCV 4292, UM 1357)
cis-1,2,3,4,4a,5,6,10b-Octahydro-3,10b-
dimethylbenz[f]isoquinolin-9-ol butanedioate (1:1) salt
(MCV 4295; UM 1361)
(-)-N-Allyl-4-hydroxymorphinan-6-one
(MCV 4299, UM 1364)
(-)-N-Methylmorphinan d-tartrate
(UM 1369)
(-)-4,14-Dihydroxy-N-methylmorphinan
NIH 10002 (MCV 4309, UM 1371)
See 6-Desoxy-6-isonitrosonaloxone (naloxone oxime)
NIH 10010 (MCV 4316, UM 1379)
See ( )-N-Allylmorphinan-6-one hydrochloride
NIH 10016 (MCV 4318, UM 1383)
See (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
NIH 10018 (UM 1385)
See (-)-3,4-Dimethoxy-N-(2-phenethyl)-morphinan-6-one
hydrobromide
NIH 10021 (MCV 4405, UM 1388)
See 9 -Acetoxy-2-methyl-5-( m -acetoxy)phenylmorphan hydro-
bromide
NIH 10068 (MCV 4326)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone-14-
acetate
NIH 10069 (MCV 4327)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone
NIH 10070 (MCV 4328)
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone-14-
acetate
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NIH 10071 (MCV 4329)
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone
acetic acid salt
NIH 10111 (MCV 4337)
See Naloxone-6-spirohydantoin (6 -oxo)
NIH 10121 (NIH 10197, MCV 4338, MCV 4373)
See Phenyltoloxamine dihydrogen citrate
NIH 10142 (MCV 4365)
See 2-Cyclopropylmethyl-3 ,5-dimethyl-2’-hydroxy-6,7-benzo-
morphan hydrochloride
NIH 10144 (MCV 4366)
See 3 -Allyl-2,3 ,5-trimethyl-6,7-benzomorphan hydrochloride
NIH 10146 (MCV 4339)
See 2,3,5,6-Tetrahydro-6-methylene-7-(2,4-dichlorophenyl)-
imidazo[1,2a]imidazole
NIH 10147 (MCV 4341)
See 6 -Oxide-6-methylene naltrexone
NIH 10148 (MCV 4342)
See 6 -Oxide-6-methylene naloxone
NIH 10149 (MCV 4343)
See 6 -( -Carboxyallyl)-naltrex-6 -ol- -lactone
NIH 10156 (MCV 4345)
See 2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-penty1-6,7-
benzomorphan oxalate
NIH 10157 (MCV 4349)
See 2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-phenethyl-6,7-
benzomorphan oxalate
NIH 10158 (MCV 4346)
See 2’-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-propyl-6,7-
benzomorphan oxalate
NIH 10159 (MCV 4350)
See 2-Allyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-
benzomorphan oxalate
NIH 10160 (MCV 4351)
See 2-Cyclopropylmethyl-2’-hydroxy-5-methyl-9
(3-methyl)butyl-6,7-benzomorphan oxalate
NIH 10163 (MCV 4352)
See 6 -Oxido-6-methylene oxymorphone
NIH 10164 (MCV 4347)
See 6 -( -Carboxyallyl)-oxymorphon-6 -ol- -lactone
NIH 10165 (NIH 8848, MCV 4348, UM 975)
See 2-Cyclopropylmethyl-5-ethyl-8-oxo-9 -methyl-6,7-benzo-
morphan methanesulfonate (Ethylketocyclazocine)
NIH 10169 (MCV 4361)
See 1-Diphenylmethyl-4-methylpiperazine hydrochloride
(Cyclizine)
NIH 10170 (MCV 4362)
See N,N, -Trimethyl-1-OH-phenothiazine-10-ethanamine hydro-
chloride (Promethazine)
NIH 10171 (MCV 4369)
See 2,3,4,5,6,6a-Hexahydro-8-hydroxy-1H-411b-methanobenzofu-
ro[3,2]azocine hydrochloride
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NIH 10172 (MCV 4367)
See 2-Ethyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-ben-
zomorphan oxalate
NIH 10173 (MCV 4368)
See 2-n -Butyl-2’-hydroxy-5-methyl-9 -(3-methyl)butyl-6,7-
benzomorphan oxalate
NIH 10174 (MCV 4363)
See 2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-
piperazlnyl]ethoxy]ethanol hydrochloride (Hydroxyzine)
NIH 10175 (MCV 4364)
See 2-Diphenylmethoxy-N,N-dimethylethanamine hydrochloride
(Diphenhydramine)
NIH 10186 (MCV 4375)
See N,N-Dimethyl-N’-2-pyridinyl-1,2-ethanediamine hydro-
chloride (Tripelennamine)
NIH 10187 (MCV 4376)
See Naltrexone-O-methyloxime
NIH 10188 (MCV 4377)
See Naloxone-O-methyloxime
NIH 10189 (MCV 4378)
See Oxymorphone-O-methyloxlme
NIH 10197 (NIH 10121, MCV 4338, MCV 4373)
See Phenyltoloxamine dihydrogen citrate
NIH 10215 (MCV 4380)
See -(4-Chlorophenyl)-N,N-dimethyl-2-pyridine-propana-
mine maleate (Chlorpheniramine)
NIH 10216 (MCV 4381)
See N-Cyano-N’methyl-N”-[2-[[(5-methyl-1H-imidiazol-4-
yl)methyl]thio]ethyl]guanidine (Cimetidine)
NIH 10224 (MCV 4393)
See 2,3,4,9b-Tetrahydro-8-hydroxy-2-methyl-1H-1,4a-
propanobenzofuro[2,3c]azine hydrochloride
NIH 10248 (MCV 4379)
See Pyrilamine Maleate
NIH 10249
See N-(2,3-Epoxypropyl)normetazocine
NIH 10250 (MCV 4384)
See Flunixin Meglumine
NIH 10274 (NIH 8359, MCV 4384, UM 686)
See Nalbuphine hydrochloride
NIH 10275 (NIH 8791, MCV 4386, UM 941)
See Butorphanol tartrate
NIH 10276 (NIH 8805, MCV 4387, UM 952)
See Buprenorphine hydrochloride
NIH 10292 (MCV 4396)
See (+)-2-(1-( m -Hethoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
NIH 10293 (MCV 4397)
See (-)-2-(1-(m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
NIH 10294 (MCV 4398)
See (+)-2-(1-( m -Methoxyphenyl)-2-cyclohexen-1-yl]-N,N-
dimethyl ethylamine hydrochloride
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NIH 10303
See
NIH 10304
See
NIH 10306
See
NIH 10307
See
NIH 10308
See
NIH 10309
See
NIH 10311
See
NIH 10316
See
NIH 10323
See
NIH 10322
(MCV 4353)
Dynorphin-(1-13): H-Thr-Gly-Cly-Phe-Leu-Arg-Arg-Ile-
Arg-Pro-Lys-Leu-Lys-OH
(MCV 4354)
Dynorphin-(1-10) Amide
(MCV 4356)
Dynorphin-(1-6)
(MCV 4357)
-Neo-Endorphin
(MCV 4358)
Vasopressin tannate (Pitressin)
(MCV 4370)
Dynorphin-(1-8)
(MCV 4394)
Z-6-Carbethoxymethylene-6 -oxide naltrexone
(MCV 4395)
(+)-Thebaine
(MCV 4372)
-Funaltrexamine( -FNA)
(MCV 4415)
6-Desoxy-6-fluoro-7,8-dihydro-14-hydroxymorphine hydro-
quantitation in serum, 283-285
cis-1,2,3,4,4a,5,6,10b-Octahydro-3,10b-dimethylbenz[f]isoquino-
lin-9-ol butanedioate (1:1) salt (NIH 9970, MCV 4292, UM 1357)
biological evaluation for dependence liability, 307
dependence studies in monkeys, 348
depression of smooth muscle twitch, 347
displacement of stereospecific 3H-etorphine binding, 347
mouse analgesia, 347
See
chloride
Noracetylmethadol
cis-1,2,3,4,4a,5,6,10b-Octahydro-3-methyl-10b-propylbenz[f]iso-
quinoline-9-ol-hydrochloride
biological evaluation for dependence liability, 307
dependence studies in monkeys, 346-347
mouse analgesia, 346
Opiate dependence
assessment and extinction of conditioned withdrawal-like
responses in an integrated treatment, 202-210
Oxazepam
behavioral disruption in humans, 71
preference comparison to diazepam in humans, 97-98
6 -Oxide-6-methylene naloxone
biological evaluation for dependence liability, 303
dependence studies in monkeys, 363
depression of smooth muscle twitch, 363
mouse analgesia, 363
6- -Oxide-6-methylene naltrexone (NIH 10147, MCV 4341)
biological evaluation for dependence liability, 303
dependence studies in monkeys, 363
depresson of smooth muscle twitch, 362
mouse analgesia, 362
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6 -Oxide-6-methylene oxymorphine (NIH 10163, MCV 4352)
biological evaluation for dependence liability, 303
dependence studies in monkeys, 368
mouse analgesia, 368
Oxycodone
metabolism in humans, dogs, rats, guinea pigs and rabbits,
53-54
Oxymorphone
metabolism in humans, dogs, rats, guinea pigs and rabbits,
53-54
Oxymorphone-O-methyloxime (NIH 10189, MCV 4378
biological evaluation for dependence liability, 304
dependence studies in monkeys, 376
mouse analgesia, 376
Paregoric
effectiveness in the control of neonatal abstinence, 158
Pentazocine (NIH 7958)
mouse analgesia, 312, 315
quantitative methods for measuring physical dependence pro-
ducing properties in the mouse, 269-270
self-administration in baboons, 67
Pentobarbital
assessment of abuse liability in humans, 106-110
in pentobarbital-lorazepam discrimination in baboons and
rats, 68-69
Phenmetrazine
anorectic efficacy, neurotoxicity, drug discrimination and
self-administration, 76-81
Phenobarbital
effectiveness in the control of neonatal abstinence, 158
Phenylpropanolamine
anorectic efficacy, neurotoxicity, drug discrimination and
self-administration, 76-81
Phenyltoloxamine dihydrogen citrate (NIH 10121, NIH 10197,
MCV 4338, MCV 4373)
biological evaluation for dependence liability, 307
dependence studies in monkeys, 358-359
dependence studies in rats, 360
mouse analgesia, 358
Physical dependence
mechanisms for barbiturates and benzodiazepines, 276-282
Pitressin
See Vasopressin tannate
PK 9084
in pentobarbital-lorazepam discrimination in baboons and
rats, 68-69
Platelet serotonin transporter
measurement in cocaine patients, 164-169
Progesterone
effects of marihuana smoke on levels in women, 24-31
Prolactin
effects of marihuana smoke on levels in women, 24-31
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effects of 9-tetrahydrocannabinol on secretion in rats,
42-51
levels in stressed rats treated with 9-tetrahydrocannabi-
nol, 267-268
Pyribenzamine
impact of Talwin Nx on pyribenzamines’s pattern of abuse
with Talwin, 170-177
Pyrilamine maleate (NIH 10248, MCV 4379)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 378
mouse analgesia, 378
Questionnaire design
effect on reported prevalence of prescribed and non-pre-
scribed psychotherapeutic medication use, 231-237
Ro15-1788
investigation of physical dependence producing mechanisms
of barbiturates and benzodiazeplnes, 276-282
Stress
effect of 9-tetrahydrocannabinol on neuroendocrine and
behavioral reactivity to stress, 267-268
Talwin Nx
impact on street patterns of abuse of Talwin and pyribenza-
mine combinations, 170-177
Temazepam
evaluation for anxiolytic/anorectic activity in drug dis-
crimination studies, 79-80
9-Tetrahydrocannabinol
behavioral dependence in monkeys, 111-117
effects on neuroendorcrine and behavioral reactivity to
stress, 267-268
effects on reproductive neuroendocrine function in the fe-
male, 42-512,
3,4,9b-Tetrahydro-8-hydroxy-2-methyl-1H-1,4a-propanobenzofuro-
[2,3c]azine hydrochloride (NIH 10224, MCV 4393)
biological evaluation for dependence liability, 306
mouse analgesia, 377
2,3,5,6-Tetrahydro-6-methylene-7-(2,4-dichlorophenyl)-imidazo-
[1,2a]imadazole (NIH 10146, MCV 4339)
biological evaluation for dependence liability, 307
dependence studies in monkeys, 362
depression of smooth muscle twitch, 361-362
mouse analgesia, 361
3-(1.2 ,4 ,5 -Tetramethyl-4 -piperidinyl)- m -phenol,Z-2-
butenedioic acid salt (NIH 9922, MCV 4259, UM 1320)
biological evaluation for dependence liability, 307
depression of smooth muscle twitch, 341
displacement of stereospecific 3H-etorphlne binding, 341
mouse analgesia, 341
(+)-Thebaine (NIH 10316, MCV 4395)
dependence studies in monkeys, 386
mouse analgesia, 385
Thorazine
prevalence of use, 231-237
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Thyroid
abnormalities in cocaine abuse, 254-257
Triazolam
assessment of abuse liability in humans, 106-110
in pentobarbital-lorazepam discrimination in baboons and
rats, 68-69
effects on psychophysical thresholds, reaction times in
baboons, 69
Trifluadom
quantitative methods for measuring physical dependence pro-
ducing properties in the mouse, 269-270
(±)-2,5,9 -Trimethyl-1’-hydroxy-6,7-benzomorphan hydrochloride
(NIH 7410, -(±)-metazocine)
self administration by monkeys, 390
(-)-2,5,9 -Trimethyl-2’-hydroxy-6,7-benzomorphan hydrobromide
(NIH 7569, -(-)-metazocine)
mouse analgesia, 311
self administration by monkeys, 390
(+)-2,5,9 -Trimethyl-2’-hydroxy-6,7-benzomorphan hydrobromide
(NIH 7571, -(+)-metazocine)
self administration by monkeys, 390
N,N- -Trimethyl-1-hydroxy-phenothiazine-10-ethanamine hydrochloride
(Promethazine NIH 10170, MCV 4362)
biological evaluation for dependence liability, 308
dependence studies in monkeys, 370
mouse analgesia, 370
Tripelennamine (NIH 10186, MCV 4375)
See N,N-Dimethyl-N’-2-pyridinyl-1,2-ethanedlamine hydro-
chloride
U-50,488H
UM 686 (NIH 8359, NIH 10274, MCV 4385)
UM 810 (NIH 8509, NIH 9889, MCV 4232)
UM 888 NIH 8683, MCV 4403)
UM 911
UM 941 (NIH 8791, NIH 10275, MCV 4386)
UM 95flNIH 8805, NIH 10276, MCV 4387)
UM 975 NIH 8848, NIH 10165, MCV 4348)
UM 1071R
UM 1126 (NIH 9344, MCV 4104)
quantitative methods for measuring physical dependence pro-
ducing properties in the mouse, 269-270
See Nalbuphine hydrochloride
See (+)-5-(m -Hydroxyphenyl)-2-methylmorphan
See m-(3-Ethyl-1-methylhexahydro-1H-azepin-3-yl)phenol
hydrochloride (Meptazinol hydrochloride)
displacement of stereospecific 3H-etorphine binding, 316
See (-)-3-[(Dimethylamino)( m -dioxan-5-yl)methylpyridine
hydrochloride (Doxpicomine)
displacement of stereospecific 3H-etorphine binding, 316
See Butorphanol tartrate
See Buprenorphine hydrochloride
See 2-Cyclopropylmethyl-5-ethyl-8-oxo-9 -methyl,6-7-
benzomorphan methanesulfonate (Ethylketocyclazocine)
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UM 1224 (NIH 9736, MCV 4196)
UM 1285 (NIH 9886, MCV 4233)
UM 1286 (NIH 9887, MCV 4234)
UM 1287 (NIH 9888, MCV 4243)
UM 1295 (NIH 9830)
UM 1296 (NIH 9831)
UM 1297 (NIH 9833)
UM 1299 (NIH 9835)
UM 1305 (NIH 9450, MCV 4276)
UM 1311 (NIH 0001, NIH 9929, MCV 4260)
UM 1312 (NIH 8503, NIH 9930, MCV 4002)
UM 1320 (NIH 9922, MCV 4259)
UM 1321 (NIH 9938, MCV 4269)
UM 1327 (NIH 9945, MCV 4286)
UM 1331 (NIH 9941, MCV 4283)
UM 1332 (NIH 9942, MCV 4284)
UM 1346 (NIH 9969, MCV 4291)
UM 1352 (NIH 9842)
UM 1357 (NIH 9970, MCV 4292)
UM 1361 (NIH 9974, MCV 4295)
UM 1364 (NIH 9989, MCV 4299)
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8 -methylmor-
phinan
See (-)-(m -Hydroxyphenyl)-2- n-pentylmorphan hydrochloride
See (-)-n -Hexyl-5-(m -hydroxyphenyl)morphan hydrochloride
See (+)-5-(m -Hydroxyphenyl)morphan hydrochloride
See Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate
hydrochloride
See Ethyl-6,14-endoetheno-7,8-dihydromorphine-7 -carboxylate
hydrochloride
See N-(16,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-L-
phenylalanyl-L-leucine-ethyl ester hydrochloride
See N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-L-
glycyl-L-phenylalanyl-L-leucine ethyl ester hydrochloride
See 2,5-Dimethyl-2’-hydroxy-9 -isopentyl-6,7-benzomorphan
methanesulfonate
See Morphine
See Naltrexone hydrochloride
See 3-(1,2 ,4 ,5 -Tetramethyl-4 -piperldinyl)-m -phenol,Z-
2-butenedioic acid salt
See (+)-5,9 -Dimethyl-2’-hydroxy-2-(4-methylpentyl)-
6,7-benzomorphan hydrochloride
See 2,9 -Dimethyl-5-(m -methoxyphenyl)morphan hydrobromide
See (-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
See (+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
See cis-1,2,3,4,4a,5,6,10b-Octahydro-3-methyl-10b-
propylbenz[f]isoquinoline-9-ol hydrochloride
See (-)-N-Methyl-3,4-methylenedioxy-6-oxomorphinan
See cis -1,2,3,4,4a,5,6,10b-Octahydro-3-10b-
dimethylbenz[f]isoquinolin-9-ol butanedioate (1:1) salt
See (-)-N-Allyl-4-hydroxymorphinan-6-one
See (-)-N-Methylmorphinan d-tartrate
419
UM 1369 (NIH 9998)
See (-)-4,14-Dihydroxy-N-methylmorphinan
UM 1371 (NIH 10002, MCV 4309)
See 6-Desoxy-6-isonitrosonaloxone (naloxone oxime)
UM 1379 (NIH 10010, MCV 4316)
See (-)-N-Allylmorphinan-6-one hydrochloride
UM 1383 (NIH 10016, MCV 4318)
See (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
UM 1385 (NIH 10018)
See (-)-3,4-Dimethoxy-N-(2-phenethyl)-morphinan-6-one
hydrobromide
UM 1388 (NIH 10021, MCV 4405)
See 9 -Acetoxy-2-methyl-5-( m -acetoxy)-phenylmorphan hydro-
bromide
Valium
See Diazepam
Vasopressin tannate (Pitressin, NIH 10308, MCV 4358)
dependence studies in monkeys, 384
Zopiclone
in pentobarbital-lorazepam discrimination in baboons and
rats, 68-69
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